introduct
acut
bacteri
conjunct
abc
one
commonli
ocular
diseas
children
examin
pediatrician
outpati
depart
sinc
treatment
usual
empir
prior
cultur
normal
taken
virul
factor
involv
process
often
unidentifi
object
determin
incid
isol
pathogen
conjunctiv
exud
cultur
examin
antibiot
suscept
efficaci
therapi
manag
confirm
abc
children
method
conjunctiv
swab
collect
children
age
month
year
old
attend
diagnosi
abc
children
hospit
period
bacteria
identifi
classic
microbiolog
method
antimicrobi
suscept
perform
accord
nccl
guidelin
result
cultur
ocular
specimen
posit
total
bacteria
isol
frequent
isol
bacteria
haemophilu
influenza
streptococcu
pneumonia
staphylococcu
coagulas
neg
cn
staphylococcu
aureu
follow
streptococcu
viridan
variou
gram
neg
bacteria
moraxella
catarrhali
haemophilu
spp
patient
develop
mix
cultur
two
type
bacteria
among
isol
pneumonia
test
resist
penicillin
gentamicin
gm
tobramycin
tob
respect
resist
ampicillin
recov
h
influenza
aureu
cn
strain
aminoglycosid
show
higher
resist
gm
tob
cn
isol
comparison
aureu
gm
tob
h
influenza
strain
gm
tob
respect
isol
sensit
chloramphenicol
ciprofloxacin
conclus
main
pathogen
caus
abc
h
influenza
pneumonia
chloramphenicol
ciprofloxacin
show
favor
vitro
activ
major
pathogen
resist
rate
indic
need
continu
surveil
motor
studi
pertussi
adult
infant
bulgarian
popul
role
pcr
diagnosi
panaiotov
v
levterova
ivanov
kantardjiev
n
vladimirova
v
voinova
e
kazarova
sofia
bg
pertussi
continu
import
vaccin
prevent
diseas
long
last
tradit
bulgaria
pertussi
prevent
year
wholecel
pertussi
vaccin
administ
infant
high
vaccin
coverag
achiev
maintain
pertussi
morbid
decreas
dramat
pertussi
continu
occur
among
differ
age
make
specif
diagnosi
pertussi
patient
clinic
evid
infect
one
mani
challeng
present
bordetella
pertussi
year
pertussi
diagnosi
bulgaria
routin
done
use
two
classic
lab
method
direct
fluoresc
antibodi
test
pertussisagglutin
antibodi
test
recent
elisa
method
introduc
research
purpos
object
describ
pcr
diagnosi
b
pertussi
countri
present
first
result
assay
pertussi
suspect
patient
compar
result
pcr
diagnosi
direct
fluoresc
antibodi
test
patient
assess
role
mycoplasma
pneumonia
chlamidia
pneumonia
caus
infant
respiratori
infect
misdiagnos
gener
practition
pertussi
infect
result
nasopharyng
swab
collect
infant
pertussi
symptom
contact
adult
sampl
test
pcr
pcr
perform
insert
element
b
pertussi
sampl
found
posit
b
pertussi
pcr
two
posit
pneumonia
sampl
test
compar
two
method
pcr
direct
fluoresc
antibodi
test
vaccin
statu
patient
clinic
data
analys
conclus
first
result
b
pertussi
pcr
assay
present
pertussi
continu
circul
bulgaria
even
achiev
high
vaccin
coverag
infant
children
pcr
rapid
simplifi
laboratori
diagnosi
pertussi
serolog
immunofluoresc
cultur
compar
studi
need
aim
better
evalu
role
pcr
diagnosi
molecular
epidemiolog
respiratori
syncyti
viru
infect
univers
hospit
kuala
lumpur
malaysia
use
specif
primer
rsv
group
random
amplif
polymorph
dna
rapd
techniqu
perform
simpl
method
observ
genet
divers
isol
rsv
result
thirti
npa
sampl
posit
rsv
use
dif
assay
sampl
posit
tissu
cultur
peak
month
month
octob
januari
year
seminest
pcr
rsv
isol
reveal
case
rsv
group
remain
three
case
rsv
group
b
rapd
result
suggest
may
five
main
subgroup
studi
period
conclus
studi
confirm
rsv
group
domin
group
may
virul
malaysian
context
similar
studi
part
world
intragroup
variat
occur
throughout
durat
studi
variat
may
consider
effect
effici
transmiss
virul
restrict
analysi
studi
done
order
compar
isol
object
studi
find
use
part
global
initi
toward
vaccin
develop
object
determin
epidemiolog
characterist
ie
occurr
respiratori
syncyti
viru
rsv
infect
croatian
children
acut
respiratori
tract
infect
method
virolog
depart
croatian
nation
institut
public
health
cniph
test
nasopharyng
secret
obtain
patient
hospit
two
zagreb
hospit
acut
respiratori
infect
demonstr
viru
isol
cell
cultur
andor
detect
monoclon
antibodi
direct
immunofluoresc
assay
result
often
viru
demonstr
rsv
respiratori
virus
adeno
parainfluenza
influenza
shown
consider
less
commonli
viral
infect
could
demonstr
patient
bronchiol
rsv
demonstr
common
caus
also
proven
common
caus
agent
infect
children
age
month
bronchiol
less
commonli
pneumonia
diagnos
link
rsv
age
group
hand
rsv
demonstr
children
diagnos
upper
respiratori
tract
infect
urti
show
presenc
major
rsv
infect
winter
month
ie
novemb
june
conclus
rsv
common
caus
lower
respiratori
tract
infect
croatian
infant
young
children
annual
outbreak
occur
winter
season
onset
mostli
novemb
human
metapneumoviru
infect
among
children
hospitalis
acut
respiratori
ill
taiwan
cy
lin
js
lin
changhua
tw
object
understand
associ
human
metapneumoviru
hmpv
acut
respiratori
infect
ri
among
hospit
children
taiwan
conduct
studi
method
februari
august
consecut
nasopharyng
aspir
npa
collect
children
hospit
acut
ri
submit
virolog
laboratori
rapid
detect
respiratori
syncyti
viru
rsv
antigen
retrospect
analys
hmpv
extract
nucleic
acid
frozen
npa
rsv
first
detect
amplifi
rsvspecif
fusion
f
nucleocapsid
n
gene
respect
use
revers
transcriptionpolymeras
chain
reaction
rtpcr
extract
subsequ
detect
hmpv
amplifi
hmpvspecif
f
n
gene
respect
use
nest
rtpcr
multipl
sampl
cours
ill
submit
either
one
virusposit
sampl
first
choic
one
virusneg
sampl
second
choic
includ
analysi
decreas
statist
bia
result
npa
collect
hospit
children
acut
ri
examin
howev
npa
success
detect
rsv
hmpv
rtpcr
age
patient
rang
year
posit
rate
rsv
hmpv
npa
n
n
respect
npa
neg
rsv
hmpv
found
n
sampl
npa
posit
virus
infect
rate
hmpv
significantli
relat
month
recruit
p
pearson
chisquar
test
peak
rate
may
june
respect
accord
clinic
diagnosi
sampl
pneumonia
bronchiol
bronchiti
brochopneumonia
arbitrarili
defin
lower
ri
otherwis
upper
ri
recogn
n
among
npa
neg
rsv
lower
ri
significantli
associ
hmpv
compar
upper
ri
p
fisher
exact
test
conclus
preliminari
studi
disclos
hmpv
play
role
taiwanes
children
acut
ri
compar
rate
infect
report
western
countri
hmpv
infect
children
may
season
prefer
shown
studi
though
longer
period
evalu
remain
necessari
rare
coinfect
rsv
hmpv
children
acut
ri
impli
import
hmpv
detect
especi
npa
neg
rsv
acut
cmv
infect
paediatr
popul
p
koudouni
pagkal
g
triantafil
p
rozi
serr
gr
object
aim
studi
laboratori
confirm
acut
cmv
infect
children
hospit
attend
outpati
depart
sign
symptom
suggest
recent
cmv
infect
method
blood
sampl
taken
children
boy
girl
age
month
year
symptom
suggest
recent
cmv
infect
juli
decemb
test
detect
cmv
antibodi
igm
igg
microparticl
enzym
immunoassay
axsym
abbott
enzym
link
fluoresc
assay
use
method
confirm
igm
posit
test
also
test
iggavid
use
supplementari
mean
exclus
recent
primari
infect
less
month
vida
biomerieux
result
total
children
examin
group
found
posit
igm
igg
antibodi
group
ii
found
posit
igm
antibodi
group
iii
found
posit
igg
antibodi
children
nt
expos
diseas
igmigg
group
children
use
cmvavid
test
acut
infect
exclud
children
fact
also
confirm
second
antibodi
detect
test
group
ii
children
exclud
way
child
acut
infect
confirm
test
confirm
group
iii
old
infect
found
cmv
avid
test
conclus
result
give
us
indic
inform
incid
cmv
infect
hospit
chronolog
period
refer
studi
show
use
confirm
test
necessari
sever
case
especi
unclear
clinic
laboratori
find
pattern
nasopharyng
microflora
preschool
children
recurr
respiratori
tract
infect
u
kosikowska
koronaglowniak
r
lo
biernasiuk
malm
lublin
pl
object
respiratori
tract
infect
predominantli
viral
etiolog
common
communityacquir
infect
young
children
complic
bacteri
infect
usual
endogen
origin
mucou
membran
nasopharynx
known
import
reservoir
opportunist
potenti
pathogen
bacteria
aim
present
studi
compar
nasopharyng
microflora
two
group
preschool
children
without
recurr
respiratori
tract
infect
method
nasal
throat
specimen
obtain
children
age
year
cotton
swab
immedi
place
onto
appropri
nonselect
blood
agar
select
media
haemophilu
chocol
agar
chapman
agar
mcconkey
agar
sabouraud
agar
plate
incub
appropri
atmospher
without
increas
co
concentr
hr
isol
microorgan
identifi
basi
routin
method
macroscop
microscop
biochem
assay
rapid
commerci
latex
test
slidex
staphkit
slidex
pneumokit
biomerieux
result
preval
potenti
pathogen
bacteria
typic
nasopharynx
staphylococcu
aureu
streptococcu
pneumonia
moraxella
catarrhali
haemophilu
influenza
also
yeastlik
fungi
candida
sp
mostli
c
albican
similar
group
children
howev
nasopharynx
children
recurr
respiratori
tract
infect
sever
opportunist
bacteria
belong
enterobacteriacea
escherichia
coli
citrobact
freundii
nonfer
rod
pseudomona
putida
agrobacterium
radiobact
acinetobact
lwoffii
found
also
bacteria
slimeproduc
bacillu
sp
streptomycet
isol
group
children
conclus
obtain
data
suggest
young
children
recurr
respiratori
tract
infect
predispos
nasopharynx
colon
sever
opportunist
bacteri
speci
gramneg
rod
even
unusu
microorgan
eg
slimeproduc
bacillu
sp
streptomycet
object
establish
correl
antimicrobi
resist
pneumonia
h
influenza
isol
children
upper
respiratori
tract
infect
urti
paulo
brazil
histori
antimicrobi
use
andor
vaccin
method
sampl
one
per
patient
select
patient
year
old
subject
diagnos
urti
posit
cultur
result
least
one
select
pathogen
pneumonia
h
influenza
clinic
data
relat
age
gender
diagnosi
sampl
describ
pneumonia
isol
test
penicillin
anoth
five
antimicrobi
minimum
inhibitori
concentr
mic
etest
methodolog
interpret
criteria
use
describ
nccl
document
h
influenza
isol
test
betalactamas
product
chromogen
cephalosporin
method
logist
regress
perform
investig
correl
pneumonia
intermedi
high
penicillin
resist
previou
antimicrobi
use
pneumococc
vaccin
procedur
done
betalactamaseposit
h
influenza
previou
antimicrobi
use
vaccin
h
influenza
type
b
hib
result
patient
pneumonia
isol
inform
previou
antibiot
use
pneumococc
vaccin
patient
h
influenza
isol
inform
previou
antibiot
use
vaccin
h
influenza
correl
presenc
penicillinresist
pneumonia
previou
antibiot
use
p
vaccin
pneumococci
p
similarli
correl
found
presenc
betalactamaseproduc
h
influenza
previou
antibiot
use
p
hib
vaccin
p
conclus
correl
found
antibiot
use
respect
vaccin
pneumonia
hib
relat
resist
characterist
penicillin
resist
betalactamas
product
respect
howev
among
possibl
bia
influenc
result
vaccin
pathogen
still
low
studi
popul
possibl
compar
resist
previou
antimicrobi
use
drug
class
alon
median
age
patient
scv
differ
distinctli
median
age
patient
ncv
year
rang
vs
year
rang
persist
scv
could
demonstr
scvposit
patient
subsequ
microbiolog
investig
studi
period
antibiot
prophylaxi
trimethoprimsulfamethoxazol
could
elicit
scvposit
patient
scv
isol
resist
trimethoprimsulfamethoxazol
high
resist
rate
also
document
ciprofloxacin
gentamicin
analysi
underli
auxotroph
reveal
predomin
thymidin
depend
scv
isol
scv
show
known
friedegg
pinpoint
morpholog
strain
exhibit
mucou
phenotyp
previous
observ
conclus
present
data
show
aureu
scv
isol
frequent
repeatedli
airway
cf
patient
investig
requir
illumin
genet
background
pathogen
role
aureu
phenotyp
persist
infect
stenotrophomona
maltophilia
sm
isol
airway
secret
children
cystic
fibrosi
cf
increas
preval
last
year
aim
studi
determin
trend
preval
resist
choic
antibiot
patient
materi
method
review
retrospect
clinic
demograph
laboratori
data
patient
attend
hospit
least
one
year
period
sputum
deep
throat
specimen
cultur
identif
isol
made
api
identif
system
biomerieux
franc
antibiot
resist
determin
etest
strip
ab
biodisk
sweden
result
sm
harbour
patient
femal
male
chronic
infect
remain
one
posit
cultur
sm
mean
age
isol
sm
year
yearli
incid
rate
sm
acquisit
yearli
preval
respect
sensit
ticarcillinclavulan
acid
well
cotrimoxazol
respect
conclus
yearli
preval
incid
rate
sm
cf
patient
show
trend
resist
ticarcillin
clavulan
acid
gradual
increas
object
highli
transmiss
epidem
strain
pseudomona
aeruginosa
widespread
among
cystic
fibrosi
patient
attend
clinic
liverpool
unit
kingdom
studi
emerg
clonal
variant
liverpool
epidem
strain
le
time
chronic
infect
patient
method
forti
le
isol
seven
patient
type
macrorestrict
analysi
spei
xbaidigest
dna
puls
field
gel
electrophoresi
pfge
total
isol
patient
studi
collect
three
differ
time
colonis
macrorestrict
fragment
pattern
compar
first
le
collect
isol
clonal
variant
band
differ
control
strain
isol
test
posit
pcr
assay
specif
le
result
pfge
analysi
spei
xbai
digest
reveal
clonal
variant
le
respect
overal
good
correl
spei
xbai
fragment
pattern
howev
digest
spei
discriminatori
studi
patient
clonal
variant
le
rang
variant
ident
fragment
pattern
isol
common
isol
one
patient
least
two
variant
also
common
detect
three
patient
emerg
clonal
variant
individu
patient
appear
occur
random
persist
throughout
studi
period
correl
clonal
variant
phenotyp
antibiot
sensit
pattern
isol
conclus
clonal
variant
le
common
detect
patient
studi
confirm
genom
divers
evolut
clonal
lineag
indic
subtl
band
shift
macrorestrict
fragment
pattern
common
chronic
infect
cystic
fibrosi
patient
vitro
effect
submic
antibiot
antigen
structur
pseudomona
aeruginosa
strain
isol
patient
cystic
fibrosi
j
vrane
b
beden
tjesicdrinkov
n
jarzadavila
zagreb
hr
object
pseudomona
aeruginosa
lead
pathogen
respons
morbid
mortal
patient
cystic
fibrosi
cf
primari
reason
reduc
surviv
age
differ
molecul
respons
p
aeruginosa
virul
includ
lipopolysaccharid
lp
cellular
compon
suppress
modul
p
aeruginosa
virul
factor
may
altern
strategi
treatment
lung
infect
cf
aim
studi
examin
influenc
subminim
inhibitori
concentr
submic
ceftazidim
ciprofloxacin
lp
structur
p
aeruginosa
strain
isol
patient
cf
method
total
strain
isol
sputa
patient
cf
use
serotyp
base
detect
heat
stabl
lp
bacteri
surfac
antigen
oantigen
perform
slide
agglutin
test
use
ospecif
polyclon
sera
suspens
live
bacteri
isol
examin
accord
intern
antigen
type
system
serotyp
perform
exposur
strain
mic
antibiot
result
slide
agglutin
test
polyclon
diagnost
sera
show
nine
strain
typabl
six
strain
polyagglutin
three
strain
nontyp
two
strain
autoagglutin
exposur
strain
exponenti
phase
growth
submic
antibiot
signific
differ
typeabl
strain
observ
treatment
submic
ceftazidim
ciprofloxacin
result
alter
polysaccharid
structur
typabl
strain
nine
monoagglutin
strain
seven
strain
becom
autoagglutin
exposur
mic
ceftazidim
two
strain
becom
polyagglutin
suggest
loss
oantigen
determin
lp
polyagglutin
observ
frequent
exposur
strain
mic
ciprofloxacin
five
nine
strain
nontyp
strain
becom
autoagglutin
polyagglutin
depend
concentr
antibiot
conclus
result
studi
shown
antigen
structur
p
aeruginosa
strain
isol
sputa
patient
cf
significantli
chang
vitro
exposur
submic
ceftazidim
ciprofloxacin
due
loss
oantigen
determin
object
asymptomat
colonis
pneumocysti
jirovecii
pc
recent
demonstr
immunocompet
patient
mainli
subject
differ
pulmonari
diseas
crosssect
studi
shown
healthi
adult
frequent
serum
antibodi
pneumocysti
primari
contact
usual
occur
earli
age
howev
dynam
humor
immun
respons
pathogen
still
remain
unknown
object
studi
evalu
dynam
antibodi
respons
p
jirovecii
patient
cystic
fibrosi
cf
method
popul
cohort
studi
includ
total
consecut
patient
cf
attend
special
unit
may
juli
patient
follow
everi
six
month
one
year
visit
respiratori
serum
sampl
collect
pc
evalu
method
nest
pcr
perform
respiratori
sampl
detect
presenc
pc
colon
serum
specimen
assay
total
igaigmigg
antibodi
pneumocysti
antigen
western
blot
wb
commerci
monoclon
antibodi
moab
human
pc
compon
dako
glostrup
denmark
use
posit
control
presenc
immunoreact
band
kda
molecular
weight
moab
interpret
posit
result
result
mean
age
cf
patient
year
rang
male
pc
carriag
found
cf
patient
baselin
followup
pc
colonis
observ
initi
pcrneg
subject
wb
posit
baselin
patient
cf
followup
serolog
dynam
follow
among
initi
wbposit
subject
remain
posit
case
serorevers
observ
wb
becam
neg
among
initi
wbneg
subject
seroconvers
observ
case
remain
persist
neg
conclus
high
rate
pneumocysti
exposit
patient
cystic
fibrosi
contrari
previou
belief
result
show
first
time
serolog
respons
p
jirovecii
perman
presenc
specif
antibodi
could
result
repeat
exposur
pathogen
studi
support
grant
fi
de
salud
themat
network
joint
research
nosocomi
infect
paediatr
patient
renko
kinnula
uhari
oulu
fin
background
aim
evalu
incid
nosocomi
infect
occur
within
day
care
paediatr
infect
ward
oulu
univers
hospit
method
discharg
hospit
data
clinic
diagnosi
aetiolog
infect
number
patient
room
whether
child
got
nosocomi
infect
hospit
stay
regist
two
week
child
discharg
parent
fill
questionnair
concern
whether
child
becam
ill
discharg
result
data
patient
patient
treat
singl
patient
room
common
diagnos
obstruct
bronchiti
gastroenter
case
twentythre
got
nosocomi
infect
stay
ward
gastroenter
parent
patient
return
questionnair
children
taken
ill
discharg
within
hour
cough
common
symptom
taken
ill
day
discharg
diarrhoea
taken
ill
within
first
hour
figur
children
got
nosocomi
infect
younger
patient
mean
year
vs
other
p
durat
hospit
care
longer
mean
vs
day
p
conclus
due
short
hospit
care
children
report
get
nosocomi
infect
stay
yet
children
discharg
ward
taken
ill
within
hour
virus
caus
gastroenter
seem
difficult
prevent
spread
respiratori
virus
plasma
level
ngml
day
surgeri
n
random
two
group
igmenrich
immunoglobulin
prepar
pentaglobin
biotest
pharma
gmbh
germani
administr
patient
studi
group
n
addit
standard
treatment
day
surgeri
mlkg
day
patient
control
group
n
receiv
standard
treatment
patient
group
compar
sever
initi
condit
age
cpb
time
pct
blood
plasma
concentr
measur
day
surgeri
immunoluminometr
method
pct
lia
brahm
aktiengesellschaft
gmbh
germani
postop
infect
rate
analys
group
data
compar
mannwhitney
utest
pvalu
consid
statist
signific
result
none
patient
exhibit
sign
infect
surgeri
patient
pct
blood
plasma
level
less
ngml
day
surgeri
n
smooth
postop
period
rate
postop
infecti
complic
significantli
lower
studi
group
vs
p
two
death
control
group
occur
due
sepsi
n
periton
n
postop
pct
level
significantli
higher
control
group
observ
period
see
tabl
data
express
median
ngml
percentil
conclus
high
pct
level
day
surgeri
associ
infecti
complic
pct
monitor
allow
select
patient
system
bacteri
inflamm
cpb
earli
postop
administr
igmenrich
immunoglobulin
effect
prevent
infecti
complic
patient
cardiac
surgeri
clinic
characterist
rotaviru
enter
adenoviru
astroviru
infect
among
hospitalis
children
hungari
object
aim
studi
determin
preval
sever
clinic
characterist
viral
gastroenter
caus
astroviru
hastv
rotaviru
rv
enter
adenoviru
ead
result
hospit
among
children
baranya
counti
hungari
method
stool
specimen
collect
may
may
children
hospit
gastroenter
sampl
test
hastv
rv
ead
hastv
detect
revers
transcriptasepolymeras
chain
reaction
rv
ead
identifi
latex
agglutin
test
demograph
clinic
data
collect
enrol
children
clinic
symptom
sever
ill
determin
result
period
children
hospit
acut
gastroenter
enrol
mean
age
month
rang
day
month
hastv
rv
ead
detect
enrol
children
rv
detect
ead
hastv
collect
stool
sampl
common
clinic
present
rv
infect
children
combin
diarrhoea
vomit
fever
children
hastv
ead
infect
diarrhoea
alon
characterist
respect
children
infect
either
viru
diarrhoea
last
day
episod
per
day
vomit
episod
last
day
fever
base
vesikari
sever
score
system
rv
infect
children
moder
sever
infect
score
children
ead
hastv
rather
mild
diseas
score
p
conclus
clinic
present
gastroenter
rv
hastv
ead
similar
diarrhoea
common
manifest
follow
vomit
andor
fever
rv
infect
patient
sever
ill
children
infect
ead
hastv
base
epidemiolog
clinic
data
conclud
enter
virus
signific
burden
diseas
base
upon
hospit
childhood
gastroenter
baranya
counti
hungari
background
neonat
gut
normal
becom
colonis
varieti
bacteri
speci
howev
surgic
intervent
nutrit
depriv
antibiot
therapi
devast
normal
gastrointestin
gi
ecosystem
may
contribut
risk
bacteri
transloc
bt
intervent
use
probiot
bacteria
prebiot
carbohydr
propos
reduc
problem
studi
look
abil
probiot
bacteria
colonis
abnorm
gut
object
demonstr
persist
probiot
bacteria
demonstr
biolog
effect
use
short
chain
fatti
acid
profil
method
convent
cultur
stool
stoma
fluid
perform
hors
blood
neomycin
blood
agar
macconkey
agar
extend
cultur
perform
use
rogosa
agar
lactobacillu
spp
beeren
agar
bifidobacterium
spp
short
chain
fatti
acid
scfa
analysi
perform
ga
liquid
chromatographi
chromatographi
isol
lactobacilli
genotyp
use
random
amplif
polymorph
dna
rapd
use
primer
eubacteri
primer
follow
gel
electrophoresi
result
routin
bacteri
cultur
specimen
yield
coagulas
neg
staphylococci
cn
enterococci
coliform
gram
posit
bacilli
isol
specimen
extend
cultur
specimen
gram
posit
bacilli
isol
occas
short
chain
fatti
acid
scfa
analysi
show
patient
sampl
demonstr
scfa
profil
similar
healthi
breastf
infant
one
patient
studi
longitudin
chang
diet
along
administr
probiot
result
chang
fatti
acid
profil
predominantli
octano
acid
proprion
acid
rapd
analysi
show
lactobacillu
indistinguish
probiot
strain
could
isol
faec
one
patient
throughout
period
probiot
administr
conclus
pilot
studi
confirm
potenti
scfa
analysi
detect
chang
result
pre
probiot
dietari
supplement
rapd
method
use
success
discrimin
lactobacillu
spp
investig
work
need
done
area
particular
resolut
rapd
whether
dnabas
methodolog
eg
fish
may
improv
detect
specif
probiot
strain
allow
greater
understand
effect
detect
scfa
analysi
children
urinari
pathogen
oneyear
survey
greek
hospit
antimicrobi
suscept
urinari
pathogen
comparison
paediatr
paediatr
surgic
unit
e
iosifidi
e
farmaki
c
antachopoulo
sofian
e
roilid
thessaloniki
gr
object
urinari
tract
infect
uti
usual
treat
empir
result
urin
cultur
avail
period
evalu
antimicrobi
suscept
caus
microorgan
warrant
due
emerg
bacteri
resist
purpos
studi
review
current
antimicrobi
suscept
pattern
pathogen
caus
uti
compar
paediatr
pu
paediatr
surgic
psu
tertiari
care
hospit
method
retrospect
analysi
microbiolog
record
bacteri
isol
urin
cultur
children
uti
admit
two
pu
one
psu
hippokr
hospit
identif
suscept
test
perform
use
vitek
autom
system
biomerieux
franc
result
total
isol
review
children
distribut
escherichia
coli
e
coli
vari
significantli
pu
psu
vs
p
suscept
rate
e
coli
vari
p
among
isol
pu
psu
amikacin
vs
ampicillin
vs
trimethoprimsulfamethoxazol
st
vs
cefalothin
vs
ceftazidim
taz
vs
respect
hand
signific
differ
pu
psu
cefoxitin
amoxicillinclavulan
vs
nitrofurantoin
vs
ciprofloxacin
cip
vs
addit
e
coli
isol
pu
psu
phenotyp
extendedspectrum
alactamas
esbl
produc
common
pathogen
pseudomona
aeruginosa
psa
klebsiella
pneumonia
kpn
enterobact
cloaca
ecl
psa
isol
suscept
taz
piperacillintazobactam
ticarcillin
imipenem
imi
depart
suscept
rate
kpn
ecl
patient
pu
significantli
higher
psu
p
taz
st
differ
imi
cip
conclus
resist
e
coli
isol
pu
particularli
psu
common
antimicrobi
presenc
esblproduc
strain
concern
increas
resist
rate
common
isol
psu
patient
highlight
continu
evalu
antimicrobi
suscept
pattern
uropathogen
necessari
ascertain
optim
empir
therapi
preval
vagin
pathogen
childhood
adolesc
r
kourkouli
baka
e
kouskouni
athen
gr
object
microbiolog
femal
genit
tract
complex
entiti
alway
found
dynam
situat
children
adolesc
normal
flora
easili
defin
purpos
studi
assess
preval
pathogen
vagin
cultur
obtain
children
present
hospit
method
januari
octob
examin
vagin
cultur
equal
number
symptomat
nonsexu
activ
young
girl
mean
age
year
rang
year
vagin
secret
inocul
onto
cultur
plate
incub
aerob
anaerob
condit
h
respect
isol
identif
suscept
antibiot
carri
standard
condit
use
vitek
system
atb
express
biomerieux
franc
detect
mycoplasma
homini
specimen
inocul
dna
agar
incub
anaerob
condit
h
wherea
ureaplasma
urealyticum
identifi
ureas
product
use
urea
broth
result
result
show
young
girl
posit
cultur
neg
cultur
pathogen
case
growth
plate
whatsoev
posit
cultur
isol
pathogen
anaerob
bacteria
streptococci
ureaplasma
urealyticum
gramneg
rod
gardnerella
vaginali
staphylococci
mycoplasma
homini
conclus
distinguish
pathogen
isol
nonpathogen
one
simpl
task
children
adolesc
clinic
microbiolog
infect
volum
supplement
commonli
isol
pathogen
anaerob
bacteria
streptococci
preval
ureaplasma
urealyticum
studi
group
high
sinc
result
indic
involv
ureaplasma
urealyticum
young
girl
vulvovagin
routin
examin
pathogen
suggest
fever
infant
less
three
month
age
christodoulaki
f
barabouti
v
makri
athanasopoulo
e
kataki
e
balomenaki
chania
gr
object
manag
febril
infant
younger
month
age
difficult
challeng
pediatrician
rel
high
preval
seriou
bacteri
infect
purpos
studi
evalu
clinic
characterist
manag
infecti
outcom
febril
infant
age
month
method
review
case
febril
infant
rectal
temperatur
day
old
admit
hospit
period
infant
consid
low
risk
seriou
bacteri
infect
met
follow
rochest
criteria
appear
well
previous
healthi
focal
infect
white
blood
cell
wbc
count
band
form
count
mm
wbc
per
high
power
field
microscop
examin
urin
sediment
wbc
per
high
power
field
microscop
examin
stool
smear
diarrhoea
remain
infant
classifi
high
risk
group
seriou
bacteri
infect
defin
posit
cultur
blood
urin
cerebrospin
fluid
stool
aspir
specimen
result
infant
studi
boy
girl
infant
classifi
low
risk
group
high
risk
group
overal
incid
seriou
bacteri
infect
patient
infant
urinari
tract
infect
bacteraemia
mening
bacteri
enter
pneumonia
antibiot
administ
infant
mean
durat
hospit
day
infant
good
outcom
except
one
infant
mening
transfer
intens
care
unit
refractori
seizur
infant
low
risk
group
seriou
infect
compar
infant
high
risk
group
p
none
infant
low
risk
group
bacteraemia
conclus
infant
younger
three
month
age
fever
meet
low
risk
criteria
unlik
seriou
bacteri
infect
probabl
form
basi
well
found
decis
manag
individu
febril
infant
object
frequenc
rel
enlarg
new
born
toddler
respiratori
system
infect
accompani
morphofunct
alter
excretori
renal
system
andor
supraren
gland
draw
attent
knowledg
structur
particular
system
becom
risk
factor
prognost
infect
evolut
known
morphogenesi
system
incomplet
moment
birth
continu
long
time
post
partum
propos
evalu
morphodifferenti
function
structur
respiratori
renal
excretori
order
know
potenti
evolut
andor
extens
inflammatori
process
method
lung
kidney
fragment
harvest
new
born
toddler
deceas
cardiorespiratori
insuffici
fix
use
formaldehyd
ph
section
made
paraffin
inclus
color
van
gieson
ri
pa
stain
result
serial
section
analysi
new
born
lung
notic
presenc
termin
bag
synonym
pulmonari
alveoli
entoblast
origin
line
cylindr
epithelium
cubic
section
realiz
new
born
kidney
notic
structur
heterogen
renal
cortex
due
presenc
pf
intermediari
stage
genesi
excretori
uniti
metanephro
extracellular
matrix
surround
renal
corpuscl
partial
differenti
found
enlarg
heparinsulf
proteoglycan
quantiti
conclus
identif
new
born
lung
kidney
function
structur
still
differenti
show
organ
reaction
instabl
sourc
infecti
aggress
influenc
sever
earlyonset
infect
dynam
chang
serum
gastrin
concentr
fullterm
preterm
neonat
significantli
higher
infect
prematur
without
symptom
second
determin
mean
sgc
fullterm
infect
neonat
alimentari
tract
disord
lower
p
fullterm
neonat
without
disord
conclus
dynam
chang
serum
gastrin
concentr
cours
sever
earlyonset
neonat
infect
observ
first
month
life
fullterm
preterm
newborn
indic
function
alimentari
tract
disord
object
infect
caus
gram
flora
major
caus
morbid
patient
haematolog
condit
associ
neutropenia
although
vancomycin
often
indic
infect
associ
infusionrel
reaction
renal
toxic
studi
evalu
efficaci
toler
linezolid
first
member
new
class
antibacteri
agent
oxazolidinon
treatment
infecti
complic
oncohematolog
patient
method
retrospect
analysi
base
data
paediatr
patient
age
mo
haematolog
condit
linezolid
mgkg
bid
administ
intraven
infus
alway
compon
combin
antibacteri
therapi
ceftazidim
cefepim
carbapenem
without
amikacin
indic
antibacteri
therapi
includ
fever
unknown
origin
neutropen
patient
soft
tissu
infect
mucos
enterocol
cathet
relat
infect
pneumonia
osteomyel
urinari
tract
infect
subhepat
abscess
microbiolog
sampl
taken
start
therapi
repeat
day
treatment
result
posit
result
total
cours
linezolid
deliv
mean
durat
therapi
day
day
clinic
respons
therapi
observ
cours
includ
complet
resolut
symptom
cours
erad
gram
organ
patient
mix
fungal
bacteri
infect
cours
clinic
respons
achiev
empir
therapi
cours
cours
document
gram
infect
erad
complet
resolut
symptom
achiev
improv
cours
patient
switch
linezolid
follow
ineffect
vancomycin
therapi
cours
linezolid
therapi
discontinu
due
exacerb
cytopenia
child
acquir
sever
aplast
anemia
conclus
first
studi
assess
efficaci
toler
linezolid
children
infecti
complic
oncohematolog
diseas
linezolid
highli
effect
use
compon
empir
therapi
febril
neutropenia
haematolog
toxic
linezolid
low
even
baselin
suppress
hemopoiesi
present
allow
full
complianc
treatment
schedul
clinic
microbiolog
infect
volum
supplement
amoxicillin
ciprofloxacin
increas
ddd
mainli
explain
rise
cefuroxim
share
total
oral
drug
iv
drug
decreas
pd
total
antibiot
consumpt
slightli
increas
pd
versu
pd
broad
spectrum
antibiot
use
decreas
ddd
pd
mainli
due
decreas
ac
ceftriaxon
went
pd
conclus
antibiot
use
analysi
show
adher
new
cap
guidelin
chang
ceftriaxon
ac
cefuroxim
penicillin
prescript
pattern
oral
drug
increas
iv
antibiot
decreas
broad
spectrum
drug
decreas
narrow
spectrum
one
increas
data
provid
interest
inform
feedback
hospit
physician
encourag
implement
concert
guidelin
determin
underand
overus
antibiot
primari
care
patient
acut
otiti
media
object
netherland
antibiot
prescrib
rate
acut
otiti
media
aom
low
compar
countri
public
suggest
relat
declin
antibiot
use
rise
complic
respiratori
tract
infect
therefor
import
studi
overprescript
also
underprescript
antibiot
clinic
factor
associ
phenomena
thu
studi
undertaken
assess
appropri
antibiot
treatment
aom
low
prescrib
countri
like
netherland
assess
clinic
patient
characterist
caus
underand
overprescrib
antibiot
case
aom
method
four
week
winter
dutch
gp
middl
region
netherland
includ
patient
acut
ear
complaint
regist
patient
demograph
clinic
present
sign
symptom
sever
ill
whether
thought
patient
expect
antibiot
treatment
diagnosi
manag
use
key
issu
current
guidelin
aom
benchmark
assess
appropri
antibiot
prescrib
case
aom
addit
assess
associ
clinic
patient
characterist
underor
overprescrib
antibiot
case
aom
result
seven
ten
patient
acut
ear
complaint
antibiot
treatment
accord
guidelin
consult
antibiot
indic
prescrib
underprescrib
antibiot
indic
prescrib
overprescrib
lower
gp
assess
sever
ill
worsen
sinc
previou
contact
durat
symptom
prior
consult
short
patient
one
inflamm
sign
underprescrib
occur
gp
assess
high
sever
ill
patient
cough
gp
thought
patient
expect
antibiot
gp
prescrib
often
antibiot
without
indic
overprescrib
conclus
incorrect
interpret
sign
symptom
perceiv
expect
patient
correl
incorrect
antibiot
manag
acut
otiti
media
clarithromycin
good
altern
tetracyclin
treatment
mediterranean
spot
fever
children
randomis
trial
e
n
oz
b
font
md
ferrer
sanfeliu
f
segura
sabadel
e
background
vitro
vivo
studi
demonstr
high
efficaci
doxycyclin
treatment
msf
howev
conveni
anoth
altern
avail
patient
allerg
tetracyclin
pregnant
children
year
base
good
result
vitro
consid
interest
evalu
clinic
efficaci
clarithromycin
treatment
msf
method
random
therapeut
studi
group
receiv
clarithromycin
h
day
adult
h
day
children
group
b
receiv
treatment
choic
doxycyclin
h
day
adult
doxycyclin
h
day
josamycin
h
day
children
inclus
criteria
patient
compat
clinic
msf
presenc
primari
lesion
tach
noir
posit
serolog
r
conorii
exclus
criteria
patient
receiv
effect
antibiot
treatment
whose
symptom
appear
day
enrol
studi
result
random
patient
exclud
patient
group
group
b
patient
evalu
male
mean
age
year
year
patient
present
fever
exanthema
present
case
tach
noir
observ
case
diagnosi
confirm
serolog
case
patient
receiv
clarithromycin
group
doxycyclin
josamycin
group
b
interv
onset
symptom
start
treatment
day
group
day
group
b
p
ns
time
taken
disappear
fever
treatment
day
group
vs
day
group
b
p
ns
symptom
disappear
day
group
vs
day
group
b
p
ns
advers
reaction
treatment
relaps
either
group
conclus
clarithromycin
could
consid
altern
treatment
msf
object
mani
question
remain
unansw
fate
antibiot
resist
abr
drugfre
environ
examin
fit
cost
express
five
abrcod
mobil
genet
element
absenc
drug
select
method
plasmid
transposon
ice
element
separ
introduc
rifr
rifampicinresist
deriv
recent
porcin
isol
insert
site
identifi
use
pcr
dna
sequenc
fit
cost
abr
element
assess
vitro
pairwis
growth
competit
vivo
monitor
number
cfug
faec
regularli
day
follow
inocul
six
sevenweek
old
organ
piglet
cfu
bacteria
recov
plate
onto
macconkey
agar
contain
rifampicin
retent
abr
element
monitor
replic
onto
agar
contain
appropri
antibiot
isol
express
expect
resist
profil
characteris
pcr
dna
sequenc
result
insert
cryptic
dna
sequenc
adjac
rhsd
gene
insert
site
kb
away
independ
insert
made
previou
studi
found
enhanc
host
fit
insert
describ
effect
fit
vitro
vivo
plasmid
fit
cost
per
gener
vitro
recov
rate
pig
gut
plasmidfre
strain
p
similarli
plasmid
without
vitro
fit
cost
effect
fit
vivo
p
plasmid
larg
fit
cost
vitro
also
recov
lower
rate
vivo
p
ice
element
neutral
effect
fit
vitro
vivo
abr
elementcarri
strain
recov
anim
retain
resist
relev
antibiot
except
three
isol
lost
resist
ampicillin
tetracyclin
kanamycin
isol
retain
plasmid
includ
intact
wildtyp
resist
gene
promot
sequenc
indic
gene
silenc
conclus
fit
impact
exert
upon
e
coli
rifr
carriag
abr
element
variabl
depend
element
also
absent
advantag
sometim
confer
appear
depend
insert
site
silenc
resist
gene
encod
occur
vivo
develop
protein
base
test
multipl
antibioticresist
salmonella
typhimurium
gel
electrophoresi
hplcmass
spectrometri
result
number
protein
detect
gel
deriv
control
cultur
significantli
p
reduc
follow
treatment
ciprofloxacin
ngml
mean
sd
respect
howev
increas
express
p
cell
envelop
protein
detect
greatest
increas
express
fold
p
observ
atpa
atpb
atpc
atph
protein
sub
unit
synthas
proton
pump
complex
increas
express
protein
includ
outer
membran
channel
protein
tolc
organ
solvent
toler
protein
imp
outer
membran
protein
ompa
porin
ompb
also
observ
analysi
cell
envelop
proteom
provid
complet
assess
identif
score
suggest
increas
express
mani
protein
includ
acra
acrb
conclus
synthas
proton
pump
complex
provid
motiv
forc
efflux
activ
may
modul
membran
potenti
porin
select
molecular
influx
present
possibl
target
protein
complex
mar
express
outer
membran
protein
phospholipas
increas
treatment
fluoroquinolon
may
provid
altern
target
molecular
epidemiolog
mechan
resist
sever
antimicrobi
agent
sporad
salmonella
spp
strain
caus
acut
gastroenter
cuba
object
determin
antimicrobi
suscept
molecular
mechan
resist
salmonella
spp
strain
caus
acut
gastroenter
cuba
determin
potenti
dissemin
resist
clone
method
total
salmonella
strain
isol
fece
patient
acut
gastroenter
isol
differ
region
cuba
receiv
process
laboratori
clinic
microbiolog
hospit
barcelona
antimicrobi
suscept
antibiot
ampicillin
amoxicillinclavulan
acid
nalidix
acid
tetracyclin
trimethoprimsulphametoxazol
chloramphenicol
gentamicin
ciprofloxacin
spectinomycin
determin
use
agar
dilut
method
molecular
mechan
resist
sever
antimicrobi
agent
detect
pcr
chloramphenicol
acetyl
transferas
activ
colorimetr
assay
analysi
molecular
epidemiolog
perform
puls
field
gel
electrophoresi
use
low
frequenc
restrict
enzym
xbai
result
twentytwo
strain
present
resist
multirresist
serotyp
typhimurium
phagetyp
frequent
present
similar
genet
profil
pfge
high
level
resist
tetracyclin
spectinomycin
ampicillin
chloramphenicol
found
resist
tetracyclin
associ
tet
g
tet
gene
resist
ampicillin
due
presenc
blactamas
mainli
carb
type
flor
gene
main
mechan
resist
chloramphenicol
among
suscept
strain
six
belong
serotyp
agona
epidemiolog
relat
conclus
presenc
two
main
clone
detect
cuba
widespread
dissemin
multiresist
clone
salmonella
enterica
serotyp
typhimurium
dt
antimicrobi
suscept
clone
salmonella
enterica
serotyp
agona
two
separ
region
countri
molecular
characteris
antibiot
resist
clinic
isol
pseudomona
putida
horii
shiba
h
muramatsu
takeshita
maekawa
hamamatsu
nagoya
jp
object
infect
caus
pseudomona
putida
mostli
report
compromis
patient
newborn
cancer
patient
recent
emerg
resist
carbapenem
antibiot
report
present
studi
examin
suscept
character
resist
betalactam
fluoroquinolon
clinic
isol
p
putida
method
six
clinic
isol
p
putida
differ
patient
pseudomona
aeruginosa
use
isol
show
differ
pulsedfield
gel
electrophoresi
genotyp
mic
determin
agar
dilut
method
describ
nation
committe
clinic
laboratori
standard
detect
metallobetalactamas
gene
carri
polymeras
chain
reaction
amplif
outer
membran
protein
profil
character
sdspage
nucleotid
sequenc
quinolon
resistancedetemin
region
qrdr
gyra
gyrb
parc
gene
determin
isol
p
putida
p
aeruginosa
result
five
p
putida
isol
show
resist
betalactam
includ
ampicillin
mgl
ceftazidim
mgl
carbapenem
mgl
imipenem
meropenem
four
isol
show
high
resist
fluoroquinolon
mgl
includ
norfloxacin
levofloxacin
sparfloxacin
gatifloxacin
pazufloxacin
mic
rang
sitafloxacin
mgl
four
isol
resist
betalactam
fluoroquinolon
also
show
minocyclin
resist
mgl
one
isol
suscept
betalactam
fluoroquinolon
carbapenemresist
isol
gene
one
isol
highli
resist
carbapenem
mgl
except
sitafloxacin
mgl
sdspage
show
reduc
product
protein
band
identifi
oprd
amino
acid
sequenc
specif
mutat
confer
fluoroquinolon
resist
found
qrdr
gyra
gyrb
parc
p
putida
isol
conclus
five
isol
p
putida
resist
carbapenem
acquisit
metallobatalactamas
gene
result
suggest
reduc
product
oprd
associ
incres
mic
carbapenem
four
isol
show
resist
fluoroquinolon
except
sitafloxacin
combin
amino
acid
alter
qrdr
gyra
gyrb
parc
porin
express
among
clinic
isol
escherichia
coli
show
ampchyperproduct
phenotyp
object
juneaugust
armrl
receiv
carbapenemresist
isol
k
pneumonia
separ
patient
liver
icu
london
tertiari
care
hospit
investig
two
isol
blood
cultur
one
bronchial
wash
one
wound
swab
patient
clinic
infect
treat
broadspectrum
antibiot
includ
colistin
one
patient
bacteraemia
die
shortli
begin
treatment
attribut
mortal
sought
defin
resist
mechan
isol
method
isol
compar
pfge
xbaidigest
genom
dna
analys
bionumer
softwar
mic
determin
interpret
accord
bsac
guidelin
isol
screen
betalactamas
gene
includ
known
carbapenemas
pcr
imipenem
hydrolysi
investig
spectrophotometri
isoelectr
focus
ief
perform
visualis
betalactamas
outer
membran
profil
examin
sdspage
analysi
result
four
isol
similar
pfge
repres
singl
strain
antibiogram
complex
resist
evid
ertapenem
mic
mgl
less
mark
meropenem
mic
mgl
imipenem
mgl
mic
unaffect
edta
carbapenemas
activ
gene
detect
spectrophotometri
pcr
respect
resist
cephalosporin
test
includ
cefepim
mic
mgl
reduc
significantli
clavulan
isol
also
highli
resist
cefoxitin
mic
mgl
isol
resist
gentamicin
tobramycin
ciprofloxacin
suscept
colistin
show
borderlin
suscept
amikacin
mic
mgl
two
betalactamas
appar
ief
consist
group
blactxm
allel
detect
pcr
blashv
also
detect
neither
ief
pcr
yield
evid
ampc
product
sdspage
show
loss
major
outer
membran
protein
omp
conclus
imperm
associ
omp
loss
combin
product
group
ctxm
enzym
appear
underli
complex
pattern
betalactam
resist
k
pneumonia
strain
howev
lack
potenti
cephalosporin
clavulan
unusu
ctxm
produc
klebsiella
carbapenem
resist
limit
treatment
option
resist
variant
pose
signific
clinic
problem
characteris
multiresist
mutat
strain
pseudomona
aeruginosa
icu
patient
b
henrichfreis
wiegand
b
wiedemann
bonn
object
hypermut
common
featur
p
aeruginosa
cystic
fibrosi
patient
chronic
infect
littl
known
mutat
strain
patient
acut
infect
among
hypermut
seem
rare
aim
studi
character
molecular
alter
respons
mutat
phenotyp
ii
investig
mutationmedi
resist
multiresist
mutat
strain
p
aeruginosa
icu
patient
method
multiresist
p
aeruginosa
strain
isol
wound
swab
old
patient
ic
unit
german
hospit
strain
show
resist
levofloxacin
piperacillin
intermedi
resist
imipenem
ceftazidim
gentamicin
hypermut
detect
disk
diffus
test
mutat
frequenc
determin
select
rifampicin
agar
mismatch
repair
system
gene
mut
mutl
uvrd
amplifi
sequenc
effluxpump
overexpress
detect
test
levofloxacin
mic
without
effluxpump
inhibitor
mexr
code
repressor
mexaboprm
operon
qrdr
gyra
parc
amplifi
sequenc
result
mutat
rate
strain
sequenc
mismatch
repair
system
gene
reveal
bp
delet
mutl
result
frameshift
levofloxacin
mic
reduc
mgl
mgl
presenc
indic
effluxpump
overexpress
alter
type
ii
topoisomeras
mexr
n
insert
detect
two
chang
gyra
one
chang
parc
found
conclus
first
genet
characteris
multiresist
mutat
strain
p
aeruginosa
icu
patient
acut
infect
new
mutat
mutl
p
aeruginosa
respons
mutat
phenotyp
found
mutat
phenotyp
confer
select
advantag
stress
environ
one
could
consid
coselect
mutat
mutationmedi
resist
phenotyp
strain
work
necessari
understand
underli
mechan
evolutionari
process
strain
patient
acut
infect
novel
class
integron
contain
aada
aminoglycosid
resist
gene
cassett
result
vivo
homolog
recombin
cano
de
benito
jm
j
ero
santand
e
object
describ
new
variant
aada
gene
encod
resist
aminoglycosid
result
sequenc
reassort
gene
cassett
method
total
clinic
isol
yersinia
enterocolitica
collect
differ
patient
area
analys
presenc
class
integron
identif
suscept
test
perform
microscan
walkaway
system
dade
behr
suscept
chloramphenicol
nalidix
acid
tetracyclin
kanamycin
streptomycin
spectinomycin
determin
diskdiffus
strain
screen
pcr
use
primer
specif
gene
gene
cassett
identifi
sequenc
pcr
product
integron
variabl
region
obtain
primer
result
sixti
enterocolitica
isol
show
presenc
integron
could
group
two
cluster
bp
isol
bp
isol
accord
two
pattern
obtain
amplif
variabl
region
sequenc
bp
product
reveal
presenc
new
aada
gene
cassett
sequenc
mosaic
built
piec
isol
resist
streptomycin
spectinomycin
chloramphenicol
suscept
gentamicin
tobramycin
amikacin
kanamycin
conclus
new
aada
gene
describ
enlarg
report
exampl
integron
contain
gene
cassett
furthermor
nucleotid
sequenc
analysi
reveal
new
gene
variant
produc
natur
exchang
mechan
probabl
mediat
homolog
recombin
sulfamethoxazol
resist
gene
uropathogen
e
coli
j
shchepetova
k
truusalu
e
sepp
mikelsaar
tartu
est
increas
antimicrobi
resist
among
e
coli
ec
caus
urinari
tract
infect
uti
seriou
worldwid
problem
treatment
cotrimoxazol
st
combin
sulfamethoxazol
sulfa
trimetoprim
often
prevent
recurr
uti
ruti
sensit
antibiot
consecut
ruti
isol
usual
detect
diskdiffus
etest
alway
reflect
presenc
resist
gene
sulfa
resist
enterobacteria
aris
acquisit
two
addit
gene
suli
sulii
encod
dihydroptero
synthetas
gene
locat
differ
type
mobil
element
suli
associ
type
integron
sulii
nonconjug
plasmid
howev
data
preval
sulfa
resist
gene
integron
communityacquir
ec
strain
isol
children
ruti
one
put
reason
ruti
may
lie
nonaccord
phenoand
genotyp
result
antibiot
suscept
determin
result
noneffici
antimicrobi
treatment
aim
studi
determin
preval
sulfa
resist
gene
suli
sulii
among
ec
caus
ruti
children
materi
method
altogeth
consecut
ec
isol
ruti
patient
tartu
univers
children
hospit
chang
antibiot
resist
st
appli
ec
resist
sulfa
detect
etest
bio
mereux
dna
extract
use
qiaamp
dna
mini
kit
qiagen
suli
sulii
gene
detect
pcr
polymeras
chain
reaction
result
ec
isol
resist
sulfa
mic
mgl
int
present
ec
isol
suli
andor
sulii
gene
detect
resist
ec
isol
three
differ
combin
gene
found
isol
contain
suli
sulii
isol
suli
isol
sulii
gene
among
phenotyp
sensit
ec
strain
isol
mic
mgl
carri
suli
sulii
gene
strain
mic
mgl
contain
three
gene
conclus
studi
demonstr
resist
gene
sulfa
suli
sulii
wide
distribut
ec
strain
children
ruti
half
ruti
caus
strain
carri
integron
provid
capabl
obtain
multiresist
detect
sulfa
gene
ec
might
import
prevent
ruti
plasmid
transfer
klebsiella
pneumonia
escherichia
coli
c
struve
ka
krogfelt
copenhagen
dk
object
increas
number
gastrointestin
infect
rapid
increas
antibiot
bacteri
resist
make
investig
antibiot
resist
develop
intestin
colon
import
issu
object
investig
klebsiella
pneumonia
strain
abil
conjug
escherichia
coli
vitro
vivo
characteris
transconjug
plasmid
profil
restrict
fragment
analysi
method
donor
k
pneumonia
atcc
strain
multiresist
mucoid
strain
contain
three
larg
plasmid
kbp
two
small
one
kbp
recipi
e
coli
strepr
rifr
vitro
conjug
perform
solid
liquid
media
wherea
vivo
conjug
perform
colonis
larg
intestin
streptomycinampicillin
treat
mice
transconjug
isol
vitro
vivo
experi
combin
plasmid
purif
purifi
larg
plasmid
way
allow
follow
restrict
cut
plasmid
profil
restrict
fragment
analysi
use
characteris
transconjug
obtain
experi
result
vitro
conjug
k
pneumonia
e
coli
show
transfer
either
plasmid
depend
condit
k
pneumonia
use
colonis
larg
intestin
shown
k
pneumonia
transfer
one
plasmid
contain
antibiot
resist
gene
indigen
e
coli
strain
mice
coinfect
k
pneumonia
laboratori
e
coli
strain
seen
k
pneumonia
transfer
plasmid
antibiot
resist
e
coli
laboratori
strain
indigen
e
coli
newli
acquir
plasmid
test
conjug
abil
seen
obtain
conjug
plasmid
k
pneumonia
furthermor
plasmid
characteris
restrict
fragment
analysi
confirm
transconjug
plasmid
ident
plasmid
origin
donor
k
pneumonia
atcc
conclus
k
pneumonia
atcc
contain
conjug
plasmid
conjug
occur
high
frequenc
vivo
vitro
type
plasmid
conjug
depend
environment
condit
accuraci
microscan
walkaway
system
identifi
p
aeruginosa
strain
carri
class
integron
mic
cefepim
higher
ceftazidim
e
ugald
ab
campoesquisabel
cano
j
calvomont
j
ero
l
santand
e
object
mic
cefepim
fep
p
aeruginosa
usual
similar
ceftazidim
caz
isol
express
efflux
pump
contain
oxa
enzym
may
present
mic
fep
higher
caz
studi
evalu
microscan
walkaway
system
wa
detect
p
aeruginosa
isol
follow
phenotyp
caz
suscept
fep
intermedi
caz
fep
resist
r
cazi
fepr
presenc
class
integron
isol
also
investig
method
may
sept
p
aeruginosa
isol
one
per
patient
r
fep
caz
first
strain
r
caz
fep
evalu
mic
fep
caz
determin
refer
microdilut
nccl
guidelin
clinic
categori
obtain
wa
organ
previous
indic
phenotyp
compar
obtain
refer
method
class
integron
detect
pcr
use
primer
specif
type
integras
gene
primer
specif
conserv
region
class
integron
gene
cassett
identifi
sequenc
amplicon
obtain
two
differ
isol
integron
type
found
result
follow
phenotyp
cazfep
number
isol
identifi
wa
system
refer
microdilut
confirm
isol
suscept
caz
fep
wa
correctli
identifi
isol
sensit
refer
microdilut
confirm
higher
suscept
caz
fep
isol
detect
wa
specif
isol
wa
caus
major
fals
resist
error
caz
fep
phenotyp
cazfep
isol
recogn
wa
ii
n
ri
n
rr
n
class
integron
identifi
isol
bp
integron
code
oxa
protein
share
highest
aminoacid
ident
group
ii
oxa
enzym
bp
integron
code
pcr
fail
amplifi
integron
conserv
region
conclus
wa
system
specif
poorli
sensit
recognit
p
aeruginosa
suscept
caz
fep
centr
phenotyp
often
associ
presenc
integron
code
oxa
enzym
nonbetalactamas
mediat
betalactam
resist
stenotrophomona
maltophilia
v
gould
miller
ra
howe
avison
bristol
uk
object
stenotrophomona
maltophilia
import
emerg
gramneg
nosocomi
pathogen
caus
bacteraemia
respiratori
tract
colonis
organspecif
infect
isol
potenti
mutat
multidrug
resist
mdr
link
overexpress
efflux
pump
smedef
betalactam
resist
thought
due
betalactamas
overexpress
sinc
smedef
pump
betalactam
method
betalactam
resist
mutant
maltophilia
isol
select
use
either
ceftazidim
meropenem
mic
variou
class
antimicrobi
agent
determin
etest
use
mullerhinton
agar
betalactamas
induct
attempt
use
cefoxitin
challeng
mgl
h
specif
betalactamas
assay
perform
use
nitrocefin
without
edta
mm
rna
extract
rtpcr
smee
smef
use
kit
quiagen
result
parent
isol
one
high
level
meropenemresist
mic
one
high
level
ceftazidim
resist
mutant
mic
select
parent
isol
one
high
level
meropenem
resist
mutant
select
mic
betalactamas
assay
absenc
induc
reveal
none
mutant
overexpress
betalactamas
inde
unlik
parent
strain
betalactamas
express
mutant
induc
condit
test
mic
class
antimicrobi
reveal
increas
mic
fluoroquinolon
betalactam
resist
mutant
rtpcr
confirm
smedef
overexpress
mutant
conclus
data
suggest
betalactam
resist
part
mdr
phenotyp
maltophilia
mutant
mechan
involv
appear
alter
drug
accumul
rate
sinc
betalactam
induc
abl
reach
concentr
high
enough
stimul
betalactamas
express
mechan
like
effluxpump
mediat
suggest
exist
previous
uncharacteris
efflux
pump
maltophilia
first
complet
sequenc
penicillinbind
protein
genu
aeromona
object
member
genu
aeromona
human
pathogen
caus
sever
infect
especi
immunocompromis
patient
patient
sever
underli
diseas
antibiot
resist
increas
problem
effect
therapeut
strategi
import
understand
mechansim
resist
betalactam
antibiot
known
bind
inhibit
pbp
lead
disturb
peptidoglycan
metabol
littl
inform
pbp
aeromona
veronii
eight
pbp
differ
molecular
mass
identifi
insert
mutant
aeromona
overexpress
betalactamas
disrupt
within
one
two
differ
gene
partial
sequenc
gene
product
assign
function
ddcarboxypeptidas
identifi
complet
sequenc
one
inactiv
gene
encod
ddcarboxypeptidas
homolog
differ
speci
order
creat
basi
studi
cell
wall
metabol
betalactamas
induct
method
purifi
genom
dna
one
insert
mutant
digest
ecori
sali
dnafrag
ligat
equal
linear
vector
transform
e
coli
select
coloni
investig
recombin
plasmid
correct
insert
sequenc
determin
use
primer
walk
strategi
result
sequenc
fragment
code
open
read
frame
amino
acid
calcul
mw
kda
mw
good
agreement
mw
e
coli
vibrio
shewanella
mw
rang
kda
deduc
protein
show
homolog
differ
speci
bifunct
enzym
ddcarboxypeptidas
ddendopeptidas
function
characterist
activesit
fingerprint
pbp
locat
sequenc
conclus
first
complet
sequenc
pbp
genu
aeromona
disrupt
pbpgene
lead
overexpress
betalactamas
aeromona
veronii
result
start
point
studi
role
pbp
peptidoglycan
metabol
betalactamas
induct
aeromona
veronii
metronidazol
resist
nimposit
nimneg
b
fragili
strain
sever
passag
metronidazol
contain
columbia
agar
plate
r
schaumann
petzold
ac
rodloff
leipzig
object
recent
data
show
emerg
b
fragili
strain
resist
fluoroquinolon
part
antimicrobi
agent
aim
present
studi
investig
induc
metronidazol
mtr
resist
b
fragili
strain
method
b
fragili
strain
includ
nimposit
refer
strain
one
atcc
strain
mic
valu
mtr
determin
etest
analys
nimgen
ad
pcr
bacteri
suspens
incub
supplement
columbia
agar
plate
contain
mtr
twice
micvalu
specif
strain
test
incub
anaerob
condit
h
incub
grow
bacteria
harvest
cultiv
thereaft
incub
time
mic
procedur
repeat
increas
antibiot
concentr
result
micvalu
confirm
etest
result
micvalu
mtr
four
nimposit
refer
strain
rang
mgl
three
clinic
isol
b
fragili
strain
show
micvalu
mgl
strain
nimgen
detect
pcr
b
fragili
atcc
strain
nimneg
micvalu
mgl
clinic
isol
b
fragili
also
nimneg
micvalu
rang
mgl
nimposit
refer
strain
show
passag
micvalu
mgl
mtr
sever
passag
mtr
contain
agar
b
fragili
strain
includ
atcc
strain
exhibit
mic
valu
mgl
conclus
mtr
resist
select
nimposit
b
fragili
strain
also
nimneg
strain
suggest
mechan
nim
involv
mtr
resist
find
underscor
import
suscept
test
anaerob
even
routin
laboratori
dissemin
nitroimidazol
resist
determin
among
gramneg
anaerob
bacteria
greec
object
surveil
incid
nitroimidazol
resist
nim
determin
among
gramneg
anaerob
clinic
isol
greec
materi
method
total
gramneg
anaerob
bacteria
collect
eight
hospit
athen
greec
test
metronidazol
resist
use
etest
method
brucella
blood
agar
plate
incub
chellab
anaerob
chamber
perform
hour
interpret
result
accord
nccl
guidelin
qualiti
control
strain
b
fragili
b
thetaiotaomicron
use
strain
mic
mgl
screen
nim
gene
pcr
use
nim
nim
set
primer
pcr
product
stain
ethidium
bromid
document
uv
illumin
sequenc
perform
abi
genet
analyz
use
bigdy
termin
kit
blast
search
programm
nation
center
biotechnolog
inform
use
search
gene
bank
signific
align
result
total
isol
mic
mgl
detect
four
bacteroid
fragili
group
eight
prevotella
spp
one
bacteroid
spp
nonfragili
three
miscellan
three
three
two
one
seven
strain
mic
mgl
higher
respect
eight
strain
posit
pcr
bp
amplicon
three
metronidazol
mic
mgl
lower
current
nccl
breakpoint
dna
sequenc
reveal
one
two
two
three
strain
harbour
nima
nimc
nimd
nime
gene
respect
strain
detect
harbour
nimb
gene
particular
relationship
detect
regard
speci
mic
distribut
nim
gene
class
conclus
nitroimidazol
resist
determin
detect
among
metronidazol
resist
suscept
gramneg
anaerob
bacteria
greec
studi
confirm
widespread
occurr
nim
gene
demonstr
silent
nim
gene
detect
pcr
metronidazol
suscept
isolatesmemb
hellen
studi
group
gramneg
anaerob
bacteria
avlami
c
koutsiakarouz
c
kontoukastelan
pangali
e
papafranga
e
trikagrafako
h
malamoulada
vogiatzi
morpholog
chang
clostridium
difficil
exposur
metronidazol
r
alonso
l
j
n
e
cercenado
e
bouza
madrid
e
background
report
high
preval
metronidazol
mtz
resist
clostridium
difficil
institut
resist
mtz
seem
heterogen
unstabl
observ
morpholog
alter
strain
grow
presenc
metronidazol
object
aim
studi
character
morpholog
chang
studi
stabil
alter
phenotyp
mtz
remov
method
select
total
isol
resist
metronidazol
mic
mgl
c
difficil
atcc
also
includ
control
brain
heart
infus
broth
tube
bhi
prepar
mgl
mtz
brucella
plate
without
antibiot
also
use
bacteri
morpholog
evalu
microscopi
gramstain
also
plate
coloni
volum
ml
mcfarland
cultur
use
inocul
bhi
tube
broth
incub
anaerob
chamber
day
everi
two
day
cultur
screen
microscopi
serial
passag
perform
brucella
plate
without
antibiot
plate
incub
condit
observ
day
result
atcc
c
difficil
strain
abl
grow
presenc
mtz
concentr
gram
stain
mtzresist
c
difficil
strain
grown
presenc
assay
mtz
concentr
reveal
gramposit
coccoid
form
coexist
first
typic
gramposit
bacillari
form
becam
progress
predomin
dayperiod
subcultur
antibiot
bhi
tube
brucella
plate
render
coloni
atyp
white
appear
round
shape
coloni
revert
progress
typic
c
difficil
phenotyp
day
incub
freemtz
brucella
plate
show
characterist
pleomorph
yellowgreen
ground
glass
appear
gram
stain
revert
phenotyp
show
typic
sporeform
gramposit
bacilli
conclus
presenc
mtz
induc
morpholog
chang
c
difficil
easili
revert
antibioticfre
medium
similar
phenomenon
describ
anoth
genu
helicobact
pylori
relat
decreas
intracellular
atp
level
although
studi
need
explain
phenomenon
c
difficil
report
gene
system
identif
characteris
multipl
antibiot
resist
mar
e
coli
associ
alter
express
acrabtolc
drug
efflux
pump
n
matthiessen
p
heisig
hamburg
object
increas
preval
bacteri
resist
antibiot
worldwid
problem
therapi
infecti
diseas
among
three
basic
mechan
lead
antibiot
resist
ie
alter
target
inactiv
drug
reduc
accumul
drug
target
site
latter
becom
import
resistancemechan
due
follow
reason
abund
mechan
detect
gramneg
gramposit
bacteria
ii
often
mediat
multi
drug
resist
mdr
broad
rang
unrel
drug
class
iii
favor
acquisit
addit
mechan
resist
frequent
mdr
achiev
one
sever
mutat
result
deregul
mdr
efflux
pump
express
major
multidrug
efflux
pump
ecoli
acrabtolc
constitut
express
tripartit
complex
consist
rndtype
transport
acrb
membran
fusion
protein
acra
outer
membran
channel
tolc
express
acrab
regul
local
repressor
acrr
known
global
regul
system
marrab
soxr
rob
sinc
mutat
inactiv
acrr
global
regul
like
marr
may
result
acrab
overexpress
detect
resist
mutat
requir
extens
sequenc
addit
suscept
test
use
differ
antibiot
method
thu
report
gene
system
develop
sens
alter
express
acrabtolc
efflux
pump
caus
induct
andor
mutationdelet
local
andor
global
regul
briefli
luciferas
gene
luc
firefli
photinu
pyrali
report
gene
fuse
promotor
pacrab
modifi
pcr
techniqu
soe
insert
plasmid
result
firefli
luciferas
report
advantag
due
high
sensit
background
activ
wide
rang
applic
eas
use
cost
effici
alter
express
acrab
either
due
presenc
inductor
mutat
marr
could
detect
increas
luciferas
activ
report
gene
system
conclus
thu
newli
develop
report
gene
system
use
identifi
acrr
mutant
quantifi
alter
express
acrab
operon
moreov
use
tool
studi
differ
environment
condit
express
screen
inductor
inhibitor
acrabtolc
efflux
pump
express
mrna
efflux
pump
protein
pseudomona
aeruginosa
strain
cystic
fibrosi
patient
relat
antibiot
resist
islam
h
oh
jalal
ciofu
n
hoibi
b
wretlind
stockholm
copenhagen
dk
object
multidrug
efflux
system
play
promin
role
resist
sever
antibiot
pseudomona
aeruginosa
date
differ
mdr
efflux
system
character
p
aeruginosa
mexaboprm
mexcdoprj
mexefoprn
mexxyoprm
mexjkoprm
mexvwoprm
mexhiopmd
aim
present
investig
discern
extent
overexpress
efflux
pump
contribut
antimicrobi
resist
particular
interest
quinolon
aminoglycosid
resist
p
aeruginosa
strain
cfpatient
method
twenti
pseudomona
aeruginosa
isol
collect
six
cystic
fibrosi
cf
patient
age
isol
isol
cf
center
copenhagen
denmark
studi
mic
norfloxacin
ciprofloxacin
amikacin
tobramycin
tetracyclin
ceftazidim
piperacillin
tazobactam
meropenem
imipenem
determin
use
etest
rel
express
mrna
four
efflux
pump
protein
determin
realtim
pcr
correl
suscept
two
fluoroquinolon
seven
antimicrobi
agent
result
strain
consid
hyperproduc
mrna
pump
protein
cdna
level
strain
mexi
mrna
overproduct
strain
seem
achiev
clinic
relev
level
resist
quinolon
correl
decreas
suscept
aminoglycosid
mexb
overproduct
strain
mediat
signific
quinolon
resist
seem
decreas
suscept
antimicrobi
highlevel
overexpress
mexd
affect
quinolon
suscept
clear
correl
alter
strain
nfxb
regul
mexcdoprj
mexd
mrna
hyperproduct
seen
mexf
mrna
express
high
level
correl
resist
quinolon
imipenem
conclus
elev
product
mrna
four
efflux
pump
test
correl
decreas
suscept
quinolon
also
antimicrobi
includ
penem
aminoglycosid
betalactam
public
health
surveil
geograph
inform
system
background
intern
circumpolar
surveil
ic
system
conduct
populationbas
surveil
invas
bacteri
diseas
greenland
gn
northern
canada
n
northern
sweden
n
swe
us
arctic
alaska
ak
method
isol
patient
invas
diseas
caus
haemophilu
influenza
hi
neisseria
meningitidi
nm
group
streptococcu
ga
group
b
streptococcu
gb
forward
refer
laboratori
alaska
alaska
canada
canada
greenland
sweden
confirm
serotyp
clinic
demograph
inform
collect
use
standard
surveil
form
data
report
preliminari
result
total
number
report
case
hi
nm
ga
gb
crude
annual
rate
invas
diseas
per
popul
vari
countri
organ
tabl
ak
nativ
n
aborigin
peopl
consist
higher
rate
diseas
except
gb
n
nonaborigin
hi
case
serotyp
hib
ak
case
rate
n
case
rate
age
rang
year
hib
diseas
occur
person
year
age
ak
n
thirtythre
hi
case
serotyp
hia
ak
case
rate
n
case
rate
hia
case
report
ak
date
rate
ak
respect
n
hia
case
report
year
rate
respect
case
fatal
ratio
higher
ak
n
gn
invas
diseas
caus
hi
ak
n
nm
ak
n
gn
conclus
aborigin
peopl
ak
n
high
rate
invas
bacteri
diseas
caus
hi
nm
ga
gb
overal
rate
nm
diseas
higher
gn
ak
n
n
swe
case
invas
hib
diseas
continu
occur
children
year
age
rate
hia
appear
elev
n
trend
merit
surveil
object
laboratori
surveil
salmonella
itali
high
level
integr
among
involv
institut
repres
enternet
system
coordin
istituto
superior
di
concern
notif
human
case
food
item
environment
sampl
entervet
network
coordin
istituto
zooprofilattico
sperimental
dell
venezi
collect
inform
isol
anim
food
anim
origin
method
network
use
harmonis
microbiolog
method
share
databas
data
salmonella
serotyp
phagetyp
antimicrobi
resist
collect
epidemiolog
inform
year
network
collect
analyz
data
human
isol
isol
anim
food
environ
human
isol
repres
typhimurium
st
enteritidi
subdivis
within
phagetyp
becom
necessari
elucid
outbreak
investig
sinc
phagetyp
epidemiolog
import
predomin
enteritidi
phagetyp
typhimurium
phagetyp
common
phagetyp
among
human
anim
isol
molecular
type
may
import
subtyp
tool
isol
belong
phagetyp
pulsedfield
gel
electrophoresi
analysi
consid
gold
standard
method
result
accur
analysi
enternet
entervet
databas
allow
us
detect
increas
preval
typhimurium
non
phagetyp
nt
atyp
monophas
strain
defin
human
case
veterinari
sampl
st
nt
account
st
isol
human
period
st
isol
sampl
swine
origin
resist
ampicillin
streptomycin
sulphonamid
tetracyclin
typic
profil
found
high
percentag
human
swine
strain
pfge
show
profil
restrict
part
human
swine
st
nt
isol
conclus
italian
surveil
integr
network
salmonella
repres
import
databas
studi
salmonella
infect
epidemiolog
epidemiolog
data
togeth
serotyp
phagetyp
molecular
type
salmonella
isol
human
anim
sourc
provid
inform
better
estim
risk
factor
human
infect
background
crimeancongo
haemorrhag
fever
cchf
potenti
fatal
viral
infect
caus
tickborn
viru
nosocomi
outbreak
high
mortal
among
hospit
staff
document
sporad
case
occur
health
care
worker
hcw
iran
infect
cchf
viru
follow
contact
one
suspect
case
cchf
one
die
systanbaluchestan
southeast
iran
isfahan
centr
iran
provinc
endem
area
cchf
infect
iran
hcw
two
provinc
frequent
contact
cchf
case
materi
method
pretest
selfadminist
questionnair
fill
hcw
work
admit
ward
hospit
systanbaluchestan
isfahan
provinc
iran
collect
data
analys
determin
level
abstract
knowledg
attitud
staff
distinguish
predict
factor
knowledg
attitud
result
hcw
good
knowledg
cchf
show
accept
attitud
toward
diseas
knowledg
directli
associ
attitud
p
higher
job
rank
better
knowledg
p
higher
attitud
p
common
use
sourc
data
cchf
poster
pamphlet
among
hcw
use
poster
pamphlet
higher
knowledg
p
signific
differ
seen
among
differ
sex
job
provinc
group
use
poster
pamphlet
common
type
contact
cchf
patient
intact
skin
blood
contact
enrol
hcw
percutan
contact
cchf
case
work
systanbaluchestan
provinc
accompani
higher
risk
contact
cchf
case
p
conclus
conclud
enrol
hcw
systanbaluchestan
isfahan
provinc
iran
accept
knowledg
attitud
improv
knowledg
via
poster
pamphlet
could
effect
modal
set
health
author
pay
attent
systanbaluchestan
provinc
provid
suffici
effect
univers
protect
lower
nosocomi
transmiss
risk
cchf
hcw
area
seropreval
rubella
among
puerpera
area
northeastern
itali
serolog
evid
suscept
rubella
infect
found
proport
suscept
women
vari
across
differ
age
yr
yr
p
ns
nation
group
italian
p
ns
correct
retest
pregnanc
occur
case
among
suscept
women
pregnant
least
two
child
acut
infect
pregnanc
diagnos
conclus
studi
prenat
screen
rate
rubella
puerpera
unsatisfactori
moreov
proport
nearli
suscept
pregnant
women
result
high
risk
rubella
infect
pregnanc
correl
found
age
nation
rubella
suscept
besid
half
rubella
suscept
puerpera
one
child
result
also
suggest
need
improv
postpartum
vaccin
implement
spatial
distribut
registri
base
casecontrol
analysi
campylobact
infect
denmark
denmark
ethelberg
j
simonsen
p
gernersmidt
kep
olsen
k
copenhagen
dk
object
examin
potenti
environment
sourc
contribut
campylobact
infect
denmark
use
geograph
analys
method
analys
avail
inform
place
live
regist
laboratori
confirm
domest
acquir
case
campylobacteriosi
denmark
period
year
studi
perform
registerbas
case
control
studi
control
case
select
nation
popul
regist
individu
match
age
gender
counti
resid
total
case
compar
control
variabl
relat
geographi
address
live
analys
logist
regress
result
three
factor
independ
associ
increas
risk
infect
type
hous
rel
onefamili
hous
decreas
odd
hous
typic
citi
increas
odd
hous
typic
rural
area
live
area
low
popul
densiti
assess
count
peopl
live
km
squar
surround
case
control
subject
children
larg
respons
increas
odd
ratio
associ
area
low
popul
densiti
municip
resid
adjust
type
hous
popul
densiti
odd
live
differ
municip
denmark
vari
p
appar
order
lowhigh
risk
municip
visual
map
conclus
largest
studi
far
made
geographi
type
hous
campylobact
case
found
children
live
nonurban
area
increas
risk
campylobact
infect
assumpt
risk
food
ie
fresh
chicken
particular
equal
distribut
across
countri
result
indic
exposur
via
anim
environ
sourc
substanti
proport
sporad
infect
campylobact
among
children
countrysid
furthermor
contamin
drink
water
like
explan
find
vari
risk
municip
sinc
peopl
differ
municip
differ
water
supplier
denmark
use
spatial
analysi
survey
h
influenza
pneumonia
isol
children
urban
area
southeastern
brazil
object
french
guiana
tuberculosi
tb
incid
appear
great
mani
problem
prevent
effect
tb
control
region
one
way
improv
tb
control
increas
casefind
rate
therefor
proport
case
treat
identif
popul
risk
tuberculosi
aim
studi
present
determin
vulner
index
popul
live
iledecayenn
tuberculosi
order
produc
risk
map
tuberculosi
method
geograph
inform
system
gi
tool
allow
organ
analyz
data
referenc
spatial
ie
data
tie
physic
locat
mani
type
data
spatial
aspect
includ
epidemiolog
studi
digit
map
ign
satellit
imag
includ
gi
cartograph
base
addit
data
use
assess
degre
insalubr
urban
area
includ
well
demograph
data
influenc
transmiss
rate
differ
layer
crosslink
assess
vulner
index
popul
cartographi
tuberculosi
case
combin
vulner
map
order
adjust
model
risk
map
tuberculosi
result
distribut
tb
case
report
januari
decemb
monitor
gp
use
home
locat
patient
vulner
index
popul
deriv
qualit
analysi
urban
landscap
socioeconom
data
use
gi
geostatist
tool
crosslink
variabl
habitat
typolog
deriv
air
photo
interpret
popul
densiti
type
urban
sewerag
system
inde
indic
exist
sociospati
inequ
map
tuberculosi
risk
among
popul
establish
coupl
cartographi
tuberculosi
case
cartographi
vulner
conclus
framework
allow
reveal
transmiss
pattern
tuberculosi
iledecayenn
provid
support
develop
health
polici
programm
french
guiana
also
offer
uniqu
opportun
dispos
impress
environmenthealth
databas
serv
region
health
author
health
planif
forecast
khaydarov
ra
khaydarov
tashkent
uzb
accord
announc
ministri
public
health
republ
uzbekistan
qualiti
portabl
water
main
reason
infecti
diseas
aral
sea
region
fresh
water
resourc
limit
unevenli
distribut
drink
water
often
contain
extraordinari
larg
number
pathogen
bacteria
water
disinfect
method
present
work
base
destruct
impact
low
concentr
metal
ion
bacteria
water
disinfect
process
alloy
electrod
place
water
bodi
current
appli
electrod
caus
releas
metal
ion
metal
ion
bind
bacteri
cell
wall
caus
disrupt
lyse
efficaci
use
differ
metal
ion
ag
cu
au
combin
within
limit
current
drink
water
regul
kill
typhoidparatyphoid
legionella
pneumophila
salmonella
v
cholera
etc
examin
cultiv
cultur
enrich
test
bacteria
perform
follow
standard
method
examin
water
wastewat
american
public
health
associ
evalu
disinfect
test
carri
variou
independ
lab
univers
period
shown
depend
bacteria
kill
time
metal
ion
concentr
differ
initi
bacteria
concentr
cful
influenc
differ
ion
cl
fe
fe
concentr
disinfect
process
best
disinfect
obtain
use
alloy
silvercoppergold
composit
concentr
metal
ratio
respect
aral
sea
region
uzbekistan
water
disinfect
devic
base
develop
method
instal
sever
hundr
manual
water
pump
allow
decreas
communityacquir
infecti
diseas
region
heczey
g
prinz
budapest
hun
object
hungari
statist
data
infect
endocard
ie
unknown
therefor
prospect
studi
conduct
goal
investig
determin
common
pathogen
predispos
factor
affect
valv
mean
time
first
symptom
establish
diagnosi
incid
vascular
phenomena
percentag
surgeri
need
total
inhospit
mortal
elek
test
case
indic
toxin
product
sensit
number
antibiot
ampicillin
penicillin
erythromycin
gentamicin
piperacillin
cefuroxim
determin
kirbybau
disc
diffus
method
except
penicillin
ampicillin
resist
one
patient
antibiot
test
sensit
patient
treat
penicillin
gentamicin
parenter
surviv
without
complic
conclus
nontoxigen
c
diphtheria
infecti
pathogen
detect
coryneform
bacteria
blood
longer
dismiss
contamin
must
investig
failur
recognis
pathogen
delay
final
diagnosi
initi
appropri
chemotherapi
speci
identif
import
mortal
differ
differ
biotyp
import
organ
emerg
pathogen
underestim
aerococcu
urina
rare
detect
pathogen
infect
endocard
slani
p
pavlik
j
cerni
freiberg
brno
cz
object
aerococcu
urina
rare
report
pathogen
possibl
due
difficulti
identif
organ
urina
gramposit
coccu
grow
pair
cluster
alphahemolyt
coloni
blood
agar
characterist
urina
often
misidentifi
streptococcu
enterococcu
staphylococcu
addit
also
report
sever
case
blood
cultur
neg
infect
due
urina
infect
mild
seriou
one
endocard
septicemia
occur
best
knowledg
total
number
thirteen
case
infect
endocard
includ
eight
fatal
case
describ
world
literatur
far
object
antimicrobi
resist
campylobact
becom
subject
great
concern
resist
strain
commonli
found
sampl
human
anim
origin
c
jejuni
atcc
confirm
suitabl
qualiti
control
qc
strain
campylobact
howev
far
tent
rang
minim
inhibitori
concentr
mic
strain
avail
studi
broth
microdilut
method
vetmic
tm
valid
c
jejuni
manufactur
method
guidelin
vetmic
tm
campplat
sva
sweden
modifi
standard
size
inoculum
method
nephelomet
coloni
count
use
measur
inoculum
densiti
inoculum
size
determin
bovin
intestin
isol
repeatedli
qc
strain
use
preincub
direct
inocul
qc
strain
test
independ
vetmic
tm
procedur
use
preincub
broth
time
direct
inocul
result
correl
detect
coloni
count
mcfarland
level
nephelomet
conclud
standard
inoculum
size
could
base
bacteria
commonli
use
method
howev
notic
grow
campylobact
brucella
broth
hour
yield
consist
approxim
cfuml
mean
cell
densiti
bovin
isol
cfuml
standard
deviat
sd
campylobact
preincub
broth
n
direct
inocul
mean
cell
densiti
cfuml
sd
n
cell
densiti
qc
strain
cfuml
sd
n
cfuml
sd
n
respect
preincub
broth
yield
accur
target
inoculum
size
cfuml
vetmic
tm
result
qc
strain
erythromycin
nalixid
acid
oxytetracyclin
gentamicin
method
within
tent
qc
rang
given
nccl
slight
differ
could
seen
distribut
result
method
base
result
set
qc
limit
mgl
ampicillin
mgl
enrofloxacin
use
laboratori
modifi
method
result
suggest
modifi
broth
microdilut
method
present
reliabl
reproduc
test
antimicrobi
resist
c
jejuni
conclus
earli
presumpt
report
salmonella
achiev
posit
ldc
profil
confirmatori
serolog
h
isol
chromogen
media
also
media
utilis
hydrogen
sulphid
discriminatori
charact
comparison
three
clostridium
difficil
toxin
assay
c
difficil
gdhantigen
eia
c
difficil
gdhpcr
bacteri
cultur
cytotox
assay
diagnosi
c
difficileassoci
diarrhoea
k
sach
g
ackermann
ac
rodloff
leipzig
object
clostridium
difficileassoci
diarrhoea
cdad
remain
lead
caus
nosocomialacquir
diarrhoea
prolong
hospit
stay
diagnost
therapeut
procedur
due
cdad
caus
addit
cost
present
studi
aim
assess
valu
differ
assay
detect
c
difficil
infect
among
patient
nosokomi
diarrhoea
among
stool
posit
toxigen
cultur
posit
three
toxin
assay
posit
tox
tox
ab
tox
ab
faecal
cytotoxin
tox
ab
none
three
test
among
specimen
posit
tox
ab
neg
cultur
one
patient
posit
stool
cultur
ten
day
conclus
tox
ab
sensit
highli
specif
assay
detect
c
difficil
toxin
faecal
specimen
moreov
compar
detect
method
tox
ab
particularli
fast
easi
perform
ad
benefit
detect
toxin
new
approach
laboratori
diagnost
infecti
gastroenter
object
detect
major
virul
gene
clonal
divers
phage
type
antibiot
suscept
evolut
escherichia
coli
strain
isol
patient
gastroenter
catalunya
last
year
method
main
virul
gene
e
coli
character
classic
pcr
specif
primer
phageencod
cytotoxin
gene
shiga
toxin
specif
intimin
plasmid
ehxa
gene
enterohemolysin
also
studi
chromosom
encod
eae
intimin
gene
plasmid
encod
gene
plasmid
serotyp
confirm
multiplex
pcr
detect
somat
antigen
gene
flagellar
antigen
gene
epidemiolog
subtyp
perform
puls
field
electrophoresi
pfge
method
cleaveg
agaroseembed
total
genom
dna
achiev
xbai
phage
type
strain
carri
enterobacteri
depart
carlo
iii
health
institut
sensit
strain
assay
antibiot
use
kirbybau
method
result
pcr
show
isol
harbour
gene
wherea
carri
gene
strain
carri
gene
specif
gene
plasmid
enterohemolysin
well
somat
flagellar
antigen
detect
strain
conclus
base
result
sourc
contamin
raw
chicken
import
protect
public
contamin
raw
chicken
investig
sourc
contamin
chicken
farm
level
outbreak
gastroenter
due
aeromona
hydrophila
carev
tandara
p
rizvan
z
baris
k
sisko
kraljev
e
borzic
split
hr
object
goal
report
outbreak
aeromona
hydrophila
gastrointestin
infect
due
consumpt
contamin
water
rural
area
dalmatia
counti
croatia
report
warn
diagnost
difficulti
import
find
aeromona
water
human
stool
sampl
method
epidemiologist
person
interview
symptomat
asymptomat
villag
four
human
stool
diseas
analys
salmonella
spp
shigella
spp
yersinia
spp
vibrio
spp
campylobact
spp
rota
adenovirus
intestin
protozoa
helmint
egg
six
water
sampl
examin
bacteriolog
virolog
parasitolog
result
diseas
drink
water
local
drink
water
distribut
system
pipelin
distant
water
sourc
main
symptom
abdomin
pain
wateri
diarrhoea
tired
patient
recov
complet
hr
treat
symptomat
person
control
group
nt
drink
water
allal
stool
sampl
neg
virus
parasit
bacteri
pathogen
result
water
analys
neg
virus
intestin
parasit
bacteriolog
analys
first
water
sampl
show
number
aerob
mesophil
psychrophil
bacteria
per
ml
higher
standard
hydrophila
isol
cefsulodin
irgasan
novobiocin
cin
agar
ml
analysi
last
two
stool
sampl
includ
addit
test
pink
coloni
cin
agar
transfer
kligler
iron
agar
incub
oxydas
catalas
test
posit
api
bbl
crystal
confirm
isol
hydrophila
stool
water
isol
show
suscept
pattern
antibiot
resist
amoxicillin
cefazolin
first
confirm
isol
bacteria
caus
outbreak
counti
clean
chlorin
connect
new
water
sourc
water
sampl
accord
standard
new
case
conclus
ident
biochem
antimicrobi
suscept
pattern
human
water
strain
posit
clinic
find
epidemiolog
data
show
us
small
outbreak
due
hydrophila
conclus
support
neg
test
pathogen
real
preval
pathogen
still
unknown
probabl
underestim
antimicrobi
resist
molecular
type
salmonella
isol
food
object
studi
clonal
relationship
antimicrobi
resist
show
strain
differ
serotyp
salmonella
spp
isol
food
human
consumpt
oneyear
period
method
antimicrobi
suscept
antibiot
determin
disk
diffus
salmonella
spp
isol
submit
lnrsse
spanish
region
follow
distribut
serotyp
enteritidi
n
typhimurium
n
serotyp
n
molecular
epidemiolog
enteritidi
typhimurium
serotyp
investig
use
pfge
computer
numer
analysi
data
phage
type
also
perform
result
analysi
carri
strain
without
epidemiolog
link
analyz
enteritidi
strain
n
mainli
egg
deriv
poultri
deriv
detect
phage
type
pt
predomin
identifi
pulsetyp
similar
genet
rang
emerg
frequent
clone
analyz
typhimurium
strain
n
sausag
cold
meat
pig
deriv
poultri
deriv
detect
dt
predomin
identifi
pulsetyp
similar
genet
rang
emerg
frequent
clone
antimicrobi
resist
rate
nccl
strain
enteritidi
typhimurium
differ
serotyp
n
respect
ampicillin
spectinomycin
streptomycin
gentamicin
tobramycin
amikacin
netilmicin
nalidix
acid
tetracyclin
sulphonamid
trimethoprimsulphamethoxazol
cloramphenicol
sever
pseudomembran
coliti
mimick
acut
abdomen
elderli
patient
l
legout
l
bernard
gasselin
assal
p
rohner
p
hoffmey
genev
ch
pari
f
background
pseudomembran
coliti
life
threaten
complic
broad
spectrum
antibiot
therapi
caus
clostridium
difficil
frequenc
pseudomembran
coliti
potenti
fatal
outcom
underestim
especi
elderli
patient
patient
method
report
case
pseudomembran
coliti
elderli
patient
adynam
ileu
mimick
acut
abdomen
c
difficil
identifi
toxin
cultur
plain
film
abdomen
ct
perform
patient
result
femal
median
age
yearsrang
admit
hospit
pneumonia
n
osteomyel
n
diarrhoea
n
elect
orthopaed
surgeri
n
receiv
betalactamin
n
clindamycin
n
comorbid
lupu
n
diabet
mellitu
n
cancer
n
renal
chronic
failur
n
fever
n
bad
gener
condit
n
cramp
abdomin
pain
n
follow
acut
abdomin
n
diarrhoea
present
begin
medic
histori
patient
biolog
exam
found
whitecel
count
gl
neutrophil
polynuclear
count
gl
platelet
count
gl
creactiv
protein
mgl
lmoll
urea
mmoll
liver
test
chest
xray
normal
plain
film
abdomen
show
megacolon
n
abdomen
ct
suspect
volvulu
caecum
n
diverticul
n
found
wall
thicken
transvers
colon
n
ascit
n
perfor
patient
abdomin
laparoscop
explor
day
treatment
metronidazol
outcom
fatal
patient
due
heart
failur
discuss
conclus
diagnosi
pseudomembran
coliti
must
evoc
elderli
patient
especi
histori
antibiot
therapi
even
short
cours
exampl
periop
prophylaxi
found
cramp
abdomin
pain
associ
high
white
cell
count
gl
surgic
treatment
requir
overal
mortal
increas
characteris
campylobact
jejunicoli
strain
isol
serbia
montenegro
addit
lack
evid
data
relat
serotyp
distribut
geograph
area
also
gb
associ
strain
method
studi
character
strain
thermophil
campylobact
isol
patient
gb
strain
thermophil
campylobact
isol
patient
diarrhoea
ni
strain
collect
institut
immunobiolog
virolog
torlak
belgrad
strain
presumpt
identifi
campylobact
differenti
speci
level
combin
biotyp
test
use
pcrbase
rflp
test
hs
serotyp
perform
use
passiv
hemagglutin
test
use
erythrocyt
sensit
heat
extract
antigen
antisera
conclus
tgc
expandedbroadspectrum
iv
glycylcyclin
activ
gramposit
gramneg
anaerob
pathogen
includ
strain
resist
commonli
use
antibiot
tgc
met
statist
criteria
noninferior
compar
imici
appear
safe
effecaci
treatment
hospit
patient
ciai
object
purpos
studi
appli
pcr
base
procedur
assess
stabil
pathogen
specif
nucleic
acid
sequenc
present
frozen
archiv
faecal
sampl
english
infecti
intestin
diseas
iid
method
faecal
sampl
collect
case
control
part
iid
studi
store
frozen
suspens
eight
year
sampl
select
archiv
either
cryptosporidium
giardia
salmonella
campylobact
enteroaggreg
escherichia
coli
eaggec
patient
one
bacterium
found
patient
ppb
mean
exacerbationsyear
compar
patient
nonpb
patient
stratifi
accord
sever
copd
moder
sever
sever
sever
copd
group
patient
ppb
nonpb
sever
copd
group
patient
mean
exacerbationsyear
respect
higher
frequenc
colonis
current
smoker
compar
exsmok
neither
whole
group
stratifi
sever
conclus
stabl
copd
patient
spontan
produc
sputum
pathogen
bacteria
correl
colonis
current
smoke
patient
colonis
increas
number
sever
exacerb
even
stratifi
sever
copd
suggest
presenc
bacteria
clinic
relev
next
step
perform
intervent
studi
aim
reduc
colonis
benefit
question
object
studi
identifi
predictor
pneumonia
could
contribut
identif
patient
need
antibiot
treatment
may
lead
reduct
antibiot
prescrib
group
patient
nonpneumon
lrti
method
prospect
studi
consecut
outpati
lrti
patient
characterist
regist
chest
xray
taken
blood
sampl
drawn
measur
creactiv
protein
crp
leukocyt
pneumonia
defin
transient
infiltr
chest
xray
result
pneumonia
found
patient
pneumon
patient
older
median
age
year
compar
year
nonpneumon
patient
differ
occurr
cough
dyspnoea
chest
pain
auscult
abnorm
sputum
product
less
common
pneumon
compar
nonpneumon
patient
vs
p
median
crp
higher
pneumon
patient
mgl
vs
mgl
p
median
leukocyt
count
vs
p
signific
differ
median
temperatur
group
vs
median
respiratori
frequenc
higher
vs
p
oxygen
satur
lower
vs
p
pneumon
patient
conclus
pneumon
patient
differ
nonpneumon
patient
older
present
less
often
product
cough
respiratori
frequenc
higher
oxygen
satur
lower
promis
predictor
found
measur
crp
found
higher
pneumon
patient
pointofcaretest
crp
avail
use
primari
care
may
guid
gener
practition
identifi
patient
lrti
need
antibiot
treatment
materi
method
epidemiolog
record
commun
outbreak
legionellosi
report
depart
health
generalitat
catalonia
million
inhabit
spain
exclud
nosocomi
origin
period
studi
epidem
outbreak
consid
appear
two
epidemiologicallyrel
case
legionellosi
descript
variabl
record
outbreak
compar
analysi
made
outbreak
occur
occur
occur
period
occur
v
test
use
compar
qualit
variabl
result
nineti
outbreak
studi
origin
determin
sole
epidemiolog
data
epidemiolog
data
molecular
biolog
origin
could
determin
remain
outbreak
cool
tower
involv
outbreak
annual
evolut
number
outbreak
progress
greater
clear
increas
onward
outbreak
occur
period
juneoctob
total
number
peopl
affect
outbreak
median
number
affect
per
outbreak
rang
averag
age
affect
year
sd
hospit
requir
case
peopl
die
global
casefat
rate
outbreak
period
smaller
averag
age
patient
higher
outbreak
detect
later
casefat
rate
significantli
higher
period
period
ii
versu
period
diagnost
method
use
bcye
serolog
wherea
outbreak
period
ii
diagnos
urinari
antigen
test
conclus
catalonia
number
size
ld
outbreak
risen
clearli
present
howev
begin
outbreak
detect
sooner
case
fatal
rate
fallen
significantli
use
sensit
diagnost
test
legionella
rapid
establish
appropri
treatment
may
explain
result
high
preval
rhinoviru
lower
respiratori
tract
specimen
object
aim
studi
improv
etiolog
diagnost
accuraci
patient
sever
communityacquir
pneumonia
scap
use
invas
procedur
ip
method
period
patient
show
clinic
radiolog
characterist
sever
cap
fail
respond
antimicrobi
therapi
studi
male
femal
mean
age
year
rang
age
year
admit
either
pneumolog
depart
intens
care
unit
icu
sever
pneumonia
defin
clinic
criteria
determin
accord
fine
score
class
iv
v
conjunct
initi
routin
serolog
microbiolog
diagnost
test
blood
urin
sputum
avail
bronchoalveolar
lavag
bal
transthorac
fine
needl
agoaspir
ttfna
perform
identifi
respons
infect
pathogen
granulocyt
bacteri
cultur
cutoff
cfuml
defin
infecti
pneumonia
result
patient
enrol
present
noninfecti
lung
diseas
mimick
cap
final
differenti
diagnos
lung
carcinoma
ard
boop
cell
lung
lymphoma
drug
parenchym
damag
wegen
granulomatosi
unknown
diagnosi
granulocyt
bal
rule
infecti
pneumonia
remain
patient
malign
overlap
infecti
pneumonia
mean
invas
procedur
etiolog
diagnosi
achiev
case
tuberculosi
isol
case
therapeut
treatment
modifi
case
conclus
invas
procedur
significantli
improv
diagnost
accuraci
patient
scap
establish
differenti
diagnosi
noninfecti
unusu
infecti
pneumonia
mimick
scap
though
routin
use
ip
substanti
impact
etiolog
diagnosi
decis
influenc
chang
therapeut
strategi
select
number
case
implement
ip
prove
safe
effect
mean
reduc
therapeut
failur
scap
identif
unsuspect
resist
pathogen
would
otherwis
unattain
patient
surviv
reduc
unexpect
find
pertussi
rdna
sequenc
bronchoalveolar
lavag
fluid
immunocompromis
patient
endem
set
dudman
jonassen
steinbakk
n
object
immun
infant
reduc
preval
pertussi
norway
howev
epidem
whoop
cough
start
spread
older
children
adolesc
throughout
countri
pertussi
notifi
diseas
total
case
report
diagnosi
diseas
made
isol
b
pertussi
detect
pcr
respiratori
secret
well
use
serolog
method
elisa
laboratori
paper
report
result
differ
method
use
describ
case
pertussi
found
unexpectedli
method
case
pertussi
includ
januari
octob
posit
rate
calcul
accord
differ
laboratori
method
case
pertussi
detect
bronchoalveolar
lavag
fluid
medic
record
obtain
result
total
number
patient
diagnos
pertussi
observ
period
patient
organ
could
found
two
differ
specimen
sampl
found
posit
serolog
method
sampl
found
pcr
posit
cultur
sampl
b
pertussi
could
isol
nasopharyng
secret
one
case
bacteria
isol
blood
cultur
addit
one
case
detect
bronchoalveolar
lavag
fluid
patient
suffer
chronic
lymphat
leukaemia
admit
hospit
fever
dyspnoea
dri
cough
diagnos
interstiti
pneumonia
rdna
sequenc
perform
directli
cultur
neg
bronchoalveolar
prospect
studi
perform
compris
hospit
adult
patient
commun
acquir
pneumonia
cap
chlamydia
pneumonia
cp
caus
cap
detect
n
singl
caus
n
diagnosi
made
serolog
eia
mif
assay
mean
age
patient
cp
pneumonia
n
x
year
n
male
clinic
laboratori
radiograph
find
analys
compar
control
group
patient
bacteri
etiolog
cap
n
analysi
radiograph
chang
prior
admiss
hospit
patient
chlamydia
pneumonia
pneumonia
reveal
half
interstiti
infiltr
v
p
remain
alveolar
mix
infiltr
besid
domin
diffus
extens
chang
patient
cp
pneumonia
lobar
segment
extens
infiltr
lung
v
p
pleural
effus
found
v
p
patient
cp
pneumonia
hilar
adenopathi
v
p
partial
regress
chang
found
contra
later
progress
v
p
infiltr
frequent
lower
lobe
either
left
right
v
p
order
increas
percentag
patient
cp
pneumonia
would
initi
treat
adequ
antimicrobi
therapi
multifactor
regress
discrimin
factor
analys
done
base
result
obtain
follow
postul
diagnost
algorithm
make
exact
diagnosi
chlamydia
pneumonia
pneumonia
surveil
probabl
bacteri
pneumonia
children
less
year
old
two
geograph
area
argentina
preval
mycoplasma
pneumonia
hospitalis
children
lower
respiratori
infect
commun
acquir
pneumonia
cap
extrapulmonari
symptom
provid
epidemiolog
data
season
distribut
annual
incid
mycoplasma
pneumonia
infect
materi
method
total
patient
year
old
symptom
sign
compat
cap
enrol
period
thorax
radiographi
pair
sera
obtain
patient
cours
ill
monitor
uniformli
specif
igg
igm
antibodi
measur
enzym
link
immunosorb
assay
remel
usa
immunocard
base
igm
eia
meridian
franc
children
divid
three
age
group
group
year
old
group
b
year
group
c
year
serum
crp
concentr
also
determin
nephelometri
sampl
older
age
comorbid
common
sinc
report
least
one
frequenc
follow
previou
hospit
admitt
last
year
copd
diabet
mellitu
smoker
previou
episod
pneumonia
malign
immunosuppress
chronic
heart
failur
cerebrovascular
diseas
hepatopathi
alcohol
nephropathi
other
antibiot
alreadi
taken
admiss
penicillin
macrolid
quinolon
cephalosporin
data
proper
influenza
andor
pneumococc
vaccin
use
medic
manag
patient
anteced
vaccin
acknowledg
subject
studi
subject
particip
clinic
trial
cap
mean
median
modal
length
hospit
stay
cap
episod
day
respect
five
per
cent
subject
enter
icu
correspond
mean
median
modal
stay
day
respect
fine
variabl
properli
record
subject
whose
distribut
broken
tabl
conclus
occup
rate
hospit
admit
adult
cap
bedsyear
male
predomin
clear
trend
age
disbal
patient
least
year
old
subject
alreadi
take
antibiot
admit
subject
admit
hospit
low
fine
score
iiii
hypoxemia
occur
hospit
differ
diagnost
microbiolog
workup
patient
admit
hospit
communityacquir
pneumonia
spain
e
jl
c
r
j
garau
behalf
nacer
group
object
process
microbiolog
sampl
known
yield
differ
result
depend
mani
extern
factor
logist
natur
sought
assess
differ
microbiolog
workup
patient
communityacquir
pneumonia
cap
admit
spanish
hospit
conclus
microbiolog
confirm
obtain
patient
diagnost
perform
vari
consider
among
centr
mean
min
max
larg
differ
observ
among
hospit
number
qualiti
diagnost
microbiolog
procedur
done
global
adult
patient
cap
admit
hospit
blood
cultur
done
rang
besid
centr
lower
proport
blood
cultur
seem
also
done
frequent
wrong
time
fact
blood
drawn
start
antibiot
therapi
episod
therefor
proper
blood
sampl
microbiolog
process
occur
success
obtain
sputa
patient
also
divers
even
provid
sputum
microbiolog
exam
consider
proport
done
antibiot
treatment
mean
proport
sputa
obtain
properli
obtain
clinic
present
communityacquir
pneumonia
adult
admit
hospit
spain
jl
j
ruiz
je
r
j
garau
behalf
nacer
group
object
assess
frequenc
classic
sign
symptom
acut
pneumonia
larg
seri
adult
patient
communityacquir
pneumonia
cap
requir
hospit
admiss
method
retrospect
review
hospit
chart
patient
admit
hospit
diagnosi
cap
period
geograph
scatter
hospit
spain
patient
admit
novemb
octob
includ
data
avail
patient
result
fever
defin
axillari
temperatur
present
subject
presenc
decreas
patient
high
risk
fine
score
group
ivv
compar
low
risk
fine
score
group
iiii
vs
p
leukocytosi
present
sputa
purul
abrupt
onset
record
hypoxemia
occur
hypotens
mechan
ventil
need
subject
base
result
estim
probabl
classic
associ
fever
leukocytosi
purul
sputum
abrupt
onset
typic
classic
pneumococc
pneumonia
would
taken
place
adult
patient
cap
admit
hospit
chest
xray
film
case
unilater
monolobar
predomin
alveolar
pattern
occur
interstiti
pleural
effus
present
cavit
conclus
real
practic
classic
clinic
present
bacteri
pneumonia
fit
well
present
patient
cap
admit
hospit
isol
sign
symptom
good
sensibl
predictor
admiss
hospit
cap
subject
expect
present
classic
pneumococc
present
alveolar
chest
xray
pattern
predomin
experi
pleural
effus
uncommon
sinc
occur
one
tenth
subject
proport
patient
bodi
temperatur
decreas
fine
store
increas
object
acut
lower
respiratori
tract
infect
lrti
elderli
great
concern
gener
practition
sinc
cours
often
complic
classif
lowor
high
risk
may
improv
medic
care
henc
reduc
unnecessari
treatment
target
monitor
therapi
effici
object
develop
predict
rule
hospit
death
elderli
primari
care
patient
lrti
method
develop
predict
rule
retrospect
analys
easili
obtain
medic
data
episod
physicianattend
lrti
includ
pneumonia
acut
bronchiti
exacerb
copd
patient
year
age
characterist
identifi
predict
hospitalis
mortal
subsequ
develop
predict
rule
use
logist
regress
result
hospit
death
day
occur
episod
caus
mortal
increas
age
male
gender
hospit
month
prior
diagnosi
heart
failur
diabet
use
oral
glucocorticoid
use
antibiot
prior
month
diagnosi
pneumonia
exacerb
copd
predictor
hospit
death
patient
point
chanc
uncompl
cours
patient
point
chanc
hospit
death
conclus
predict
rule
discern
elderli
patient
high
low
risk
hospit
death
classif
risk
group
help
gener
practition
adjust
prevent
therapeut
decis
expect
prognosi
might
lead
fewer
complic
lower
cost
object
mycoplasma
pneumonia
mp
etiolog
agent
respons
communityacquir
pneumonia
case
pneumonia
due
mp
label
atyp
pneumonia
infect
mp
may
detect
part
respiratori
system
effect
well
recogn
document
respect
diagnosi
treatment
promin
structur
featur
mp
lack
cell
wall
shown
surfaceexpos
polypeptid
elicit
immunogen
respons
particular
involv
attach
organel
mp
attach
organel
compos
complex
polypeptid
cytadhesin
protein
major
role
due
high
immunogen
paradigm
util
definit
antigen
serodiagnost
system
way
produc
either
recombinantor
peptidebas
antigen
similar
natur
modifi
extract
procedur
membran
protein
employ
method
mp
cell
expos
nonion
deterg
triton
deterg
appli
separ
membran
extract
insolubl
protein
temperaturedepend
way
antigen
activ
reveal
extract
test
elisa
character
sera
util
detect
system
specif
igg
igm
iga
result
insolubl
phase
triton
extract
compris
singl
kda
polypeptid
shown
sdspage
solubl
phase
extract
well
current
use
antigen
seromp
test
shown
multipl
band
comparison
elisa
three
prepar
reveal
antigen
activ
insolubl
extract
compar
current
assay
result
repeat
igg
igm
iga
mean
major
antigen
activ
insolubl
fraction
may
attribut
kda
polypeptid
conclus
current
observ
support
previou
work
indic
size
polypeptid
deterg
extract
associ
attach
organel
show
antigen
potenti
kda
extract
modifi
procedur
reveal
compar
activ
current
assay
find
identifi
kda
polypeptid
appropri
candid
use
diagnost
test
nowaday
legionella
known
common
water
bacteria
abil
caus
outbreak
epidem
legionnair
diseas
pontiac
fever
time
intens
travel
peopl
laboratori
must
capabl
type
environment
human
isol
give
clear
answer
sourc
infect
bulgaria
data
concern
typescop
l
pneumophila
strain
circul
potabl
water
present
result
pilot
studi
type
l
pneumophila
lp
strain
isol
water
sampl
three
geograph
differ
bulgarian
region
isol
strain
subject
character
use
serogroup
specif
techniqu
monoclon
antibodi
amplifi
fragment
length
polymorf
aflp
type
method
water
sampl
collect
build
locat
one
west
two
east
bulgarian
region
reveal
presenc
varieti
l
pneumophila
isol
total
twenti
six
lp
strain
isol
predomin
serogroup
lp
serogroup
also
isol
belong
lp
serogroup
lp
serogroup
lp
serogroup
cocontamin
water
sampl
differ
lp
serogroup
observ
frequent
lp
serogroup
monoclon
subtyp
knoxvil
allentown
obtain
aflp
profil
show
good
discriminatori
power
result
pilot
studi
point
lp
serogroup
rare
find
potabl
water
consid
past
base
restrict
studi
one
town
lp
serogroup
isol
first
time
countri
studi
necess
use
complex
method
clear
epidemiolog
type
demonstr
result
show
extens
studi
need
give
clear
pictur
environment
distribut
lp
type
bulgarian
water
compar
lp
type
environment
sourc
clinic
case
legionnair
diseas
method
record
hospit
pneumonia
patient
screen
mi
result
antibiot
treatment
record
mi
select
year
evalu
presenc
clinic
signific
pathogen
time
mi
begin
accord
pathogen
sensit
sn
antibiot
real
result
mi
interpret
util
sn
avail
within
day
begin
accord
sn
mi
interpret
nonutilis
pathogen
identifi
sn
avail
day
begin
discrep
sn
real
clinic
effect
determin
case
utilis
nonutilis
mi
also
evalu
number
mi
need
determin
sn
formula
number
need
screen
nn
use
calcul
number
mi
sn
need
prevent
one
case
ineffect
cost
total
number
mi
compar
buy
cost
secondlin
antibiot
gener
cephalosporin
vancomycin
carbapenem
cours
treatment
cost
associ
ineffect
first
cours
calcul
result
case
pneumonia
etiolog
signific
pathogen
identifi
probe
mean
mi
done
get
one
sn
case
utilis
nonutilis
mi
effect
respect
base
figur
nn
calcul
demonstr
mi
sn
need
prevent
one
case
ineffect
total
number
mi
need
prevent
one
case
ineffect
multipli
cost
mi
significantli
less
buy
cost
secondlin
antibiot
conclus
mi
significantli
increas
effect
pneumonia
hospit
investig
perform
direct
buy
cost
secondlin
antibiot
higher
cost
mi
increas
effect
mi
necessari
reduc
number
mi
without
pathogen
mi
wrong
sn
mi
use
physician
select
set
cost
structur
evalu
econom
effect
mi
may
requir
calcul
full
cost
associ
ineffect
outcom
nonhospit
pneumonia
depend
prehospit
tactic
patient
first
applic
medic
aid
vertkin
naumov
moscow
ru
aim
elabor
introduct
evalu
effect
clinic
recommend
treat
patient
nonhospit
pneumonia
prehospit
stage
method
research
carri
patient
commun
acquir
pneumonia
cap
patient
divid
group
patient
diagnos
cap
number
case
confirm
hospit
ii
tactic
treat
cap
prehospit
stage
correspond
clinic
recommend
iii
patient
confirm
cap
diagnosi
prehospit
treatment
correspond
clinic
recommend
patient
group
compar
result
prehospit
stage
clinic
pictur
evalu
patient
averag
underestim
clinic
pictur
caus
hyper
diagnost
cap
prehospit
stage
wherea
hospit
absenc
characterist
complaint
physic
sign
cap
allow
evalu
situat
adequ
chang
diagnosi
prehospit
stage
patient
group
ii
clinic
criteria
cap
accompani
document
concomit
diseas
reveal
anamnesi
data
previou
treatment
collect
adequ
treatment
cap
carri
antibacteri
drug
administ
case
risk
unfavor
termin
known
evalu
case
hospit
one
third
patient
nonprofil
besid
index
preday
lethal
came
gener
lethal
came
group
group
iii
patient
symptom
cap
allow
evalu
degre
diseas
sever
correctli
administ
therapi
antibiot
amoxicillin
phlemoxin
solutab
case
nonsever
pneumonia
ceftriaxon
case
sever
pneumonia
carri
correct
sort
patient
preday
lethal
came
gener
lethal
came
group
time
group
iii
patient
stay
hospit
came
day
group
ii
patient
came
day
p
moreov
necess
antibacteri
therapi
chang
group
iii
hospit
occur
observ
wherea
group
ii
happen
case
comparison
bacteriolog
betalactamas
product
tonsil
adenoid
surfac
core
flora
object
adenoidectomi
tonsillectomi
indic
children
recurr
persist
symptom
infect
hypertrophi
among
frequent
oper
perform
children
studi
carri
investig
microbi
surfac
core
flora
tonsil
adenoid
method
core
surfac
cultur
taken
tonsil
adenoid
patient
time
surgeri
tonsillectomi
adenoidectomi
patient
age
rang
year
mean
age
year
specimen
inocul
onto
sheep
blood
chocol
emb
agar
haemophilu
medium
biomerieuxfr
anaerob
bacteria
core
sampl
inocul
onto
anaerob
blood
agar
incub
genbagana
pocket
biomerieuxfr
anaerob
plate
examin
hour
aerob
organ
identifi
convent
method
anaerob
organ
identifi
vitek
ani
biomerieuxfr
system
chocol
agar
haemophilu
medium
haem
also
compar
haemophilu
influenza
identif
result
one
hundr
thirti
three
aerob
bacteri
isol
recov
surfac
tonsil
core
tonsil
surfac
adenoid
core
adenoid
eight
anaerob
bacteria
identifi
core
tonsil
core
adenoid
frequent
isol
microorgan
alphahaemolyt
streptococci
neisseria
spp
h
influenza
betalactamas
produc
bacteria
blpb
found
patient
frequent
blpb
staphylococcu
aureu
isol
h
influenza
isol
neisseria
spp
isol
potenti
pathogen
microorgan
betahaemolyt
streptococci
aureu
h
influenza
pneumonia
isol
patient
conclus
studi
demonstr
polymicrobi
aerobicanaerob
flora
adenoid
tonsil
close
relationship
bacteriolog
tonsil
adenoid
core
surfac
flora
could
find
statist
differ
bacteriolog
blpb
tonsil
adenoid
core
surfac
flora
haem
chocol
agar
also
found
similar
h
influenza
h
parainfluenza
statist
differ
found
microbi
colon
laryngectomi
stoma
villar
vidal
e
eraso
l
madariaga
c
marco
acha
j
aguirr
g
bizkaia
e
object
investig
microbi
colon
stoma
laryngectomi
patient
patient
method
nineteen
consecut
patient
previous
undergon
laryngectomi
recruit
odontolog
clinic
univers
swab
taken
laryngectomi
stoma
site
microbiolog
cultur
isol
perform
follow
standard
procedur
columbia
agar
candida
chromogen
agar
plate
franc
identif
isol
done
catalas
product
detect
differenti
growth
mannitolsalt
agar
slidex
staph
plu
latex
reagent
id
staph
slidex
mrsa
detect
test
use
evalu
methicillin
resist
result
despit
clinic
sign
infect
patient
carrier
potenti
pathogen
microorgan
staphylococcu
aureu
detect
stoma
patient
methicillinresist
aureu
mrsa
isol
staphylococcu
epidermidi
isol
three
patient
staphylococcu
xylosu
isol
stoma
patient
also
colon
aureu
candida
albican
yeast
speci
isol
clinic
specimen
conclus
found
high
incid
colon
staphylococci
laryngectomi
stoma
clinic
sign
infect
microorgan
could
potenti
sourc
superfici
deep
infect
epidemiolog
peritonsillar
abscess
diseas
northern
ireland
result
patient
confirm
peritonsillar
abscess
treat
inpati
account
per
year
popul
hospit
catchment
area
mean
age
year
rang
sixtynin
patient
male
mean
length
hospit
stay
day
needl
aspir
swab
pu
throat
swab
blood
submit
microbi
cultur
cultur
yield
greatest
needl
aspir
similar
even
prior
antibiot
exposur
although
rel
frequenc
pathogen
differ
group
receiv
prior
antibiot
betahaemolyt
streptococci
common
isol
howev
varieti
pathogen
implic
throat
swab
blood
cultur
typic
unhelp
result
cultur
sensit
affect
individu
patient
treatment
review
sensit
demonstr
frequent
resist
isol
group
betahaemolyt
streptococci
macrolid
antibiot
heterophil
antibodi
test
routin
reveal
epsteinbarr
viru
infecti
mononucleosi
preval
popul
conclus
support
view
aspir
pu
peritonsillar
abscess
period
cultur
guid
empir
antibiot
manag
sinc
perform
cultur
everi
case
may
unnecessari
patient
taken
antibiot
prior
aspir
may
includ
surveil
singledos
azithromycin
microspher
versu
threeday
azithromycin
treatment
group
betahaemolyt
streptococc
gabh
pharyngitistonsil
adult
adolesc
object
antibiot
therapi
gabh
pharyng
recommend
earlier
symptom
resolut
prevent
complic
reduc
spread
diseas
azithromycin
mg
qd
day
effect
treatment
document
gabh
pharyng
adult
novel
microspher
formul
azithromycin
make
possibl
administ
full
cours
therapi
singl
dose
maintain
toler
optim
complianc
object
studi
test
hypothesi
singl
g
dose
azithromycin
microspher
bacteriolog
noninferior
day
azithromycin
mg
qd
day
use
treat
adult
adolesc
gabh
pharyngitistonsil
method
phase
iii
multicentr
random
doubleblind
doubledummi
trial
conduct
north
america
europ
india
primari
endpoint
bacteriolog
respons
test
cure
toc
day
bacteriolog
per
protocol
bpp
popul
secondari
endpoint
clinic
respons
toc
safeti
result
five
hundr
ninetyeight
subject
enrol
studi
treat
subject
includ
bpp
popul
bacteriolog
erad
achiev
subject
azithromycin
microspher
azithromycin
group
respect
toc
ci
longterm
follow
lftu
day
bacteriolog
recurr
observ
subject
azithromycinmicrospher
group
compar
subject
azithromycin
group
clinic
cure
observ
subject
azithromycin
microspher
group
azithromycin
group
treatment
well
toler
advers
event
mild
moder
intens
frequent
advers
event
ae
diarrhoealoos
stool
occur
treatment
group
subject
either
group
discontinu
treatment
due
treatmentrel
ae
conclus
singl
g
dose
azithromycin
microspher
effect
well
toler
day
azithromycin
mg
qd
treat
gabh
pharyng
adult
adolesc
predict
prognosi
effect
antibiot
treatment
rhinosinus
background
deal
patient
suspect
rhinosinus
famili
physician
reli
mainli
histori
physic
examin
plain
radiograph
yet
evid
valu
inform
manag
spars
aim
studi
examin
whether
patient
suspect
rhinosinus
ill
durat
andor
effect
antibiot
treatment
predict
basi
clinic
symptomssign
radiolog
method
particip
patient
suspect
rhinosinus
particip
rct
compar
amoxicillin
placebo
mean
cox
regress
assess
associ
presenc
baselin
rhinosinus
symptom
sign
abnorm
radiograph
subsequ
ill
cours
test
interact
investig
whether
presenc
baselin
symptomssign
could
predict
benefici
effect
antibiot
treatment
result
poor
gener
condit
hazard
ratio
reduc
product
hr
baselin
independ
associ
prolong
cours
none
classic
sinusitislik
symptom
abnorm
radiographi
prognost
valu
prognosi
also
remain
unchang
whether
patient
treat
antibiot
regardless
baselin
symptom
conclus
repres
group
patient
suspect
acut
rhinosinus
fp
neither
presenc
sinus
symptomssign
abnorm
radiograph
provid
inform
regard
prognosi
effect
amoxicillin
treatment
patient
felt
poorli
baselin
nt
feel
abl
work
need
time
recov
could
influenc
amoxicillin
effect
moxifloxacin
clarithromycin
chlamydi
gene
express
treatmentrefractori
persist
chlamydia
pneumonia
infect
j
rupp
v
wobb
maass
beck
object
chlamydia
pneumonia
caus
chronic
infect
relat
asthma
bronchial
atherosclerosi
chronic
infect
erad
shortterm
antimicrobi
treatment
due
nonrepl
persist
state
c
pneumonia
surviv
continu
synthes
mrna
presenc
antibiot
unknown
antibiot
modifi
gene
express
profil
persist
chlamydia
clinic
relev
manner
therefor
analys
differenti
express
select
gene
presenc
moxifloxacin
clarithromycin
activ
acut
chlamydi
infect
use
model
chlamydi
persist
peripher
blood
monocyt
pbmc
method
persist
infect
c
pneumonia
initi
pbmc
establish
methodolog
infect
cell
continu
expos
moxifloxacin
lgml
clarithromycin
lgml
kept
antibioticfre
medium
differenti
gene
express
select
c
pneumonia
target
gene
type
iii
secret
lcrd
yscl
yscn
inclus
membran
inca
incc
amino
acid
metabol
tyrb
glya
quantit
analys
h
infect
rtpcr
use
lightcycl
system
result
antibioticfre
medium
gene
express
level
vari
individu
time
gene
analys
howev
target
gene
show
upregul
mrna
peak
h
exposur
moxifloxacin
less
promin
clarithromycin
conclus
initi
expect
reduc
transcript
level
persist
c
pneumonia
ad
antibiot
prove
wrong
surprisingli
clear
upregul
gene
express
moxifloxacin
rather
indic
gener
regulatori
effect
drug
pathogen
first
demonstr
chlamydia
persist
state
complet
inert
show
reaction
antibiot
investig
whether
protein
synthesi
upregul
parallel
potenti
clinic
relev
find
regard
host
cell
respons
cours
infect
remain
analys
vivo
model
studi
provid
basi
applic
valid
risk
score
safe
reduc
rate
hospit
admiss
patient
communityacquir
pneumonia
present
emerg
depart
object
patient
receiv
diagnosi
commun
acquir
pneumonia
cap
hospit
emerg
depart
ed
need
care
evalu
treat
inor
outpati
pneumonia
score
index
psi
valid
score
predict
short
term
risk
death
patient
cap
could
therefor
assist
decid
whether
singl
patient
cap
need
hospit
method
implement
computerbas
critic
decis
pathway
manag
patient
cap
base
psi
score
dedic
softwar
gesporex
briefli
adult
age
year
provision
diagnosi
cap
elig
inclus
studi
patient
receiv
written
inform
diagnosi
pneumonia
treatment
plan
cap
defin
presenc
new
pulmonari
infiltr
chest
rx
symptom
consist
pneumonia
includ
cough
dyspnea
chang
sputum
pleurit
chest
pain
psi
score
calcul
patient
meet
elig
criteria
patient
score
point
lower
recommend
outpati
treatment
wherea
higher
score
recommend
hospit
admiss
psi
score
use
guid
admiss
decis
supersed
clinic
judgment
followup
consist
two
visit
within
day
month
discharg
hospit
result
protocol
appli
consecut
patient
cap
present
ed
compar
previou
year
detect
signific
reduct
p
ci
rate
admiss
hospit
patient
cap
moreov
length
stay
hospit
show
trend
toward
reduct
day
protocol
implement
day
month
follow
detect
rehospit
patient
treat
outpati
rate
cure
similar
protocol
implement
conclus
estim
applic
critic
pathway
gener
potenti
save
euro
one
year
interestingli
studi
end
trend
toward
reduct
admiss
rate
cap
patient
maintain
thu
suggest
use
psi
score
enter
clinic
practic
persist
benefici
effect
clinic
safe
costeffect
manag
cap
patient
adult
communityacquir
pneumonia
evalu
antibiotherapi
propos
emerg
depart
analysi
impact
train
l
piglion
v
blanc
l
lerousseau
rafidiniaina
c
rotomondo
antib
f
evalu
qualiti
adult
communityacquir
pneumonia
cap
probabilist
antibiotherapi
within
emerg
depart
influenc
target
train
prescript
method
studi
took
place
medium
size
gener
hospit
file
relat
patient
admit
diagnosi
cap
hospit
review
prospect
way
local
committe
independ
expert
first
halfyear
first
halfyear
compar
two
period
prescrib
physician
train
educ
session
base
guidelin
pneumonia
care
french
societi
infecti
diseas
spilf
three
major
qualiti
indic
use
initi
molecul
select
dosag
time
first
dose
cost
antibiotherapi
calcul
result
file
select
group
well
match
age
sex
fine
score
inadequ
initi
molecul
select
decreas
ns
inadequ
dosag
decreas
ns
time
first
dose
hour
group
prescript
amoxicillin
increas
expens
fluoroquinolon
cephalosporin
macrolid
prescript
remain
stabl
antibiotherapi
cost
decreas
fold
ratio
p
conclus
work
demonstr
even
dosag
error
rare
antibiot
therapi
alway
earli
mediocr
adhes
recommend
regard
choic
molecul
intervent
even
though
result
obtain
target
train
modest
encourag
increas
use
guidelin
recommend
antibiotherapi
lead
signific
cost
gain
develop
differ
educ
strategi
essenti
applic
good
medic
practic
better
patient
manag
moment
admit
emerg
depart
moraxella
catarrhali
replac
nasopharynx
asymptomat
children
sulikowska
p
grzesiowski
w
hryniewicz
warsaw
pl
object
aim
studi
analys
use
phenotyp
molecular
method
dynam
nasopharyng
carriag
moraxella
catarrhali
asymptomat
children
sampl
two
time
point
interv
method
children
orphanag
day
care
centr
dcc
examin
twice
first
winter
follow
spring
clinic
data
inform
sex
age
socioeconom
statu
respiratori
tract
infect
antibiot
treatment
within
prior
sampl
collect
questionnair
nasopharyng
swab
process
catarrhali
identifi
standard
procedur
blactamas
product
determin
use
nitrocefin
test
pulsedfield
gel
electrophoresi
pfge
bcuidigest
catarrhali
dna
perform
determin
related
among
isol
clinic
microbiolog
infect
volum
supplement
result
altogeth
catarrhali
isol
identifi
deriv
children
orphanag
dcc
thirti
children
orphanag
dcc
colonis
winter
orphanag
dcc
spring
fourteen
children
orphanag
dcc
colonis
catarrhali
winter
spring
one
child
colonis
strain
first
second
sampl
case
catarrhali
isol
differ
point
year
child
unrel
isol
catarrhali
blactamas
produc
conclus
colonis
nasopharynx
catarrhali
repres
dynam
process
bacteria
acquir
elimin
reacquir
period
month
longterm
colon
month
involv
investig
children
haemophilu
influenzaeisol
highli
vaccin
popul
b
ndahl
mainz
object
character
invas
noninvas
haemophilu
influenza
hi
strain
done
sinc
implement
gener
vaccin
hi
type
b
germani
method
invas
isol
acquir
popul
base
nationwid
surveil
use
detect
system
colon
noninvas
isol
isol
nasopharyng
aspir
hospit
children
acut
respiratori
diseas
result
total
invas
isol
collect
could
evalu
strain
noncapsul
n
frequent
capsular
type
type
b
n
follow
type
f
n
e
n
n
type
c
detect
increas
nonbisol
observ
period
capsul
hi
detect
pcr
agglutin
n
vs
n
frequent
biotyp
type
n
follow
type
ii
n
type
iii
n
small
proport
isol
produc
betalactamas
n
period
noninvas
colon
hi
isol
strain
one
capsular
type
e
noncapsul
hi
type
b
could
detect
frequent
biotyp
type
ii
n
follow
type
n
iii
n
four
isol
produc
betalactamas
conclus
haemophilu
influenza
type
b
colon
invas
pathogen
almost
disappear
germani
replac
observ
invas
colon
hiisol
rare
produc
betalactamas
object
simkania
negevensi
environment
chlamydialik
intracellular
bacterium
shown
report
associ
respiratori
infect
infant
adult
data
avail
preval
negevensi
antibodi
infect
finland
develop
microimmunofluoresc
mif
method
measur
negevensi
antibodi
test
pair
sera
obtain
finnish
children
infecti
episod
use
method
method
serum
sampl
children
screen
igg
iga
igm
antibodi
inhous
mif
test
util
urografin
purifi
formalin
bacteria
negevensi
atcc
strain
antigen
incub
time
overnight
patient
three
sera
middl
serum
sampl
select
pair
sera
avail
last
serum
select
screen
negevensi
posit
screen
titer
test
pair
sera
three
sera
presenc
igm
antibodi
remov
igg
antibodi
gullsorb
reagent
fourfold
titer
rise
igg
iga
pair
sera
consid
diagnost
acut
infect
result
preval
negevensi
antibodi
igg
iga
igm
acut
negevensi
infect
diagnos
altogeth
children
six
case
igg
seroconvers
case
presenc
igm
antibodi
conclus
negevensi
antibodi
demonstr
first
time
finnish
children
serolog
diagnosi
acut
negevensi
infect
obtain
children
studi
use
eg
direct
demonstr
negevensi
cultur
pcr
clinic
sampl
need
elucid
pathogenet
signific
clinic
pictur
associ
bacterium
mif
method
develop
studi
seem
suitabl
measur
negevensi
antibodi
seem
crossreact
chlamydia
pneumonia
antibodi
use
test
object
describ
failur
clarithromycin
treatment
pulmonari
nocardia
nova
infect
despit
vitro
suscept
macrolid
patient
method
male
diabet
mellitu
non
hodgkin
lymphoma
chemotherapi
chronic
adren
replac
therapi
due
lymphomat
infiltr
adren
present
persist
cough
previou
month
weakli
acid
fast
bacilii
detect
sputum
treatment
ethambutol
rifampin
clarithromycin
given
presum
mott
infect
although
patient
report
strict
complianc
drug
therapi
three
week
neither
symptomat
radiograph
improv
note
nocardia
spp
isol
sputum
cultur
dna
extract
bacteri
coloni
fragment
encompass
gene
pcramplifi
subsequ
digest
bsteii
haeiii
endonucleas
bacteri
dna
also
pcramplifi
use
primer
pair
specif
conserv
region
rrna
nucleotid
sequenc
result
amplicon
establish
analys
use
blast
softwar
result
pcrrflp
analysi
reveal
restrict
pattern
compat
n
nova
identif
ultim
confirm
n
nova
homolog
base
blast
analysi
bacteria
rrna
sequenc
isol
sensit
erythromycin
patient
receiv
trimethoprim
sulfamethoxazol
gradual
clinic
radiolog
improv
three
month
followup
remain
well
conclus
nocardia
nova
may
account
nocardia
isol
identifi
n
asteroid
n
nova
strain
previous
note
suscept
ampicillin
cephalosporin
erythromycin
macrolid
suggest
altern
sulfonamid
nonrespond
allergi
sulfa
appar
dispar
vitro
suscept
macrolid
clinic
failur
warrant
cautiou
use
antibiot
n
nova
infect
sequenc
base
identif
allow
accur
separ
n
nova
relat
speci
background
although
antimicrobi
resist
r
rate
among
pneumonia
spn
h
influenza
hi
increas
significantli
countri
last
year
studi
brazil
report
rel
low
r
rate
among
pathogen
analys
suscept
pattern
spn
hi
brazil
year
signific
trend
method
spn
hi
collect
mainli
respiratori
tract
bloodstream
infect
suscept
test
nccl
broth
microdilut
method
drug
result
analys
year
result
result
summar
conclus
r
pen
increas
markedli
among
spn
year
r
ts
also
escal
eri
cli
tet
significantli
decreas
among
spn
strain
r
antimicrobi
test
remain
stabl
among
hi
yeartoyear
variat
r
newer
fluoroquinolon
detect
chl
show
excel
spectrum
pathogen
object
determin
potenc
gemifloxacin
gemi
test
pneumonia
spn
year
evalu
gemi
compar
current
market
fluoroquinolon
fq
also
made
includ
mechan
resist
r
method
six
year
period
total
spn
isol
collect
medic
centr
three
contin
test
antimicrobi
suscept
use
refer
nccl
broth
microdilut
method
interpret
criteria
antimicrobi
agent
test
includ
five
fq
gemi
ciprofloxacin
cipro
levofloxacin
levo
gatifloxacin
gati
moxifloxacin
moxi
analysi
quinolon
resist
determin
region
qrdr
perform
fqr
strain
levo
mic
mgl
result
activ
gemi
spn
six
year
period
shown
tabl
six
year
rank
order
potenc
mgl
fq
gemi
moxi
gati
levo
cipro
fq
median
modal
potenc
remain
stabl
monitor
interv
spn
isol
cipro
mic
valu
mgl
rang
detect
trend
toward
increas
r
across
region
common
qrdr
mutat
among
strain
cipro
levo
mic
valu
mgl
gyra
parc
pare
isol
gemi
maintain
potent
activ
valu
mgl
mic
rang
mgl
conclus
among
fq
test
gemi
clearli
potent
agent
remain
valuabl
candid
treat
multidrug
r
spn
increasingli
observ
respiratorytract
pathogen
studi
year
fqr
increas
significantli
rate
gemi
remain
unrel
increas
r
among
betalactam
macrolid
antimicrobi
conclus
signific
rate
betalactamas
product
h
influenza
detect
preval
penicillin
intermediateresist
pneumonia
high
common
compar
previou
year
empir
therapi
penicillin
alon
low
dose
avoid
popul
amoxicillin
would
still
appropri
treat
pneumococc
infect
despit
penicillin
resist
would
coamoxiclav
evid
emerg
nonvaccin
type
caus
invas
pneumococc
diseas
spain
object
pneumonia
sp
import
caus
morbid
mortal
children
adult
vaccin
reduc
carriag
prevent
diseas
nationwid
point
preval
studi
institut
area
spain
collect
sp
isol
one
week
februari
isol
sent
central
laboratori
suscept
test
serotyp
studi
analyz
distribut
serotyp
resist
antimicrobi
sp
isol
children
adult
method
total
sp
isol
identifi
suscept
test
perform
broth
microdilut
method
cationadjust
muellerhinton
broth
lyse
hors
blood
follow
nccl
guidelin
serotyp
perform
standard
method
isol
belong
adult
children
origin
respiratori
tract
blood
ear
conjunctiva
csf
steril
fluid
miscellan
penicillin
resist
ir
erythromycin
resist
total
isol
nontyp
exclud
analysi
frequent
serotyp
st
st
frequent
among
penicillinresist
strain
st
among
suscept
strain
frequent
st
invas
isol
blood
csf
children
adult
respect
among
invas
isol
correspond
st
includ
vaccin
st
includ
vaccin
frequent
nonvaccin
st
total
sp
isol
adult
belong
st
frequent
isol
children
consid
sp
isol
origin
estim
coverag
vaccin
children
adult
estim
coverag
vaccin
adult
consid
invas
isol
estim
coverag
vaccin
children
adult
estim
coverag
vaccin
adult
conclus
result
confirm
high
rate
resist
sp
penicillin
erythromycin
spread
adult
st
frequent
isol
children
evid
emerg
nonvaccin
type
caus
invas
pneumococc
diseas
moder
coverag
pneumococc
vaccin
object
determin
incid
invas
pneumococc
infect
ipi
patient
group
recommend
receiv
pneumococc
polysaccarid
vaccin
well
outcom
ill
method
laboratori
perform
blood
cerebrospin
fluid
csf
cultur
submit
data
isol
streptococcu
pneumonia
blood
csf
inform
vital
statu
comorbid
denomin
data
person
risk
obtain
popul
inform
system
nation
hospit
discharg
registri
cancer
registri
nation
social
insur
institut
nation
infecti
diseas
registri
patient
nation
ident
code
use
link
databas
first
episod
ipi
includ
analysi
result
total
episod
ipi
identifi
incid
case
per
popul
highest
incid
ipi
seen
patient
haematolog
malign
per
popul
organ
bone
marrow
transplant
male
age
chronic
obstruct
pulmonari
diseas
person
hiv
overal
casefat
proport
cfp
day
posit
cultur
respect
day
cfp
rang
differ
age
group
patient
age
significantli
higher
men
women
vs
p
patient
nonhematolog
malign
alcohol
highest
cfp
day
respect
patient
hematolog
malign
cfp
among
healthi
adult
age
year
adult
age
year
case
underli
condit
recommend
incid
outcom
ipi
vari
consider
differ
patient
group
howev
patient
group
highest
rate
ipi
alway
highest
risk
death
overal
mortal
associ
ipi
nearli
twice
high
day
infect
compar
first
week
suggest
contribut
preexist
ill
longterm
sequela
among
nonelderli
adult
high
preval
underli
condit
recommend
emphas
import
vaccin
group
highest
risk
diseas
death
use
prognost
score
system
pneumonia
sever
index
psi
ewig
score
communityacquir
bacteraem
pneumococc
pneumonia
object
predict
score
system
cap
develop
heterogen
group
cap
none
evalu
pneumonia
caus
singl
pathogen
streptococcu
pneumonia
common
caus
cap
common
caus
fatal
pneumonia
prospect
studi
accuraci
three
score
system
psi
ewig
score
predict
need
icutreat
death
due
communityacquir
bacteraem
pneumococc
pneumonia
bpp
method
adult
patient
n
invas
pneumococc
diseas
ipd
xray
verifi
pneumonia
karolinska
danderyd
hospit
stockholm
sweden
includ
patient
treat
dpt
infecti
diseas
patient
dpt
od
sever
score
calcul
accord
origin
public
independ
prognost
import
differ
variabl
analys
multipl
regress
analys
result
psi
iii
presenc
major
minor
risk
factor
ewig
score
high
sensit
somewhat
less
good
specif
predict
fatal
outcom
tabl
area
receiv
oper
characterist
curv
predict
death
three
test
death
rate
patient
treat
significantli
lower
rate
treat
od
vs
p
also
within
sever
score
strata
mortal
lower
among
patient
treat
od
fatal
psiscor
ivv
od
vs
p
factor
explain
differ
found
multipl
regress
analys
conclus
scoresystem
use
predict
need
icucar
risk
death
due
bpp
psi
sensit
score
easi
use
death
rate
time
higher
patient
treat
od
compar
treat
despit
sever
score
illustr
comparison
mortal
differ
patient
materi
must
interpret
caution
even
analysi
base
calcul
sever
diseas
preval
intern
clone
among
invas
isol
portug
serrano
j
melocristino
ramirez
lisbon
p
object
evalu
preval
intern
clone
recogn
pneumococc
molecular
epidemiolog
network
pmen
among
invas
isol
portug
method
collect
invas
isol
portug
describ
recent
serrano
et
al
invas
streptococcu
pneumonia
portug
implic
vaccin
antimicrobi
therapi
clin
microbiol
infect
character
use
combin
macrorestrict
profil
use
smai
puls
field
gel
electrophoresi
pfge
multilocu
sequenc
type
serotyp
preval
overal
decreas
rank
order
total
strain
recov
children
year
old
result
combin
pfge
data
sequenc
type
st
isol
abl
identifi
genet
lineag
major
strain
found
st
includ
novel
st
correspond
differ
lineag
eburst
analysi
clone
current
recogn
pmen
found
repres
among
collect
clone
group
singl
pfge
cluster
includ
n
isol
express
serotyp
addit
isol
belong
cluster
clone
isol
express
serotyp
belong
either
one
clone
serotyp
isol
n
belong
cluster
clone
clone
account
major
n
serotyp
isol
sinc
cluster
includ
clone
encompass
strain
total
strain
express
serotyp
belong
pmen
clone
among
serotyp
strain
clone
account
n
isol
clone
n
n
account
isol
pmen
clone
account
penicillin
nonsuscept
pn
strain
includ
resist
isol
well
major
strain
resist
erythromycin
result
total
patient
diseas
episod
isol
includ
mean
age
yr
yr
children
male
clinic
spectrum
includ
occult
bacteraemia
uncompl
pneumonia
complic
pneumonia
mening
septic
shock
septic
arthriti
mastoid
nosocomi
bacteraemia
isol
penicillin
nonsuscept
mic
lgml
nine
children
die
underli
diseas
total
serotyp
found
three
predomin
serotyp
includ
found
serotyp
account
isol
patient
pneumonia
serotyp
isol
present
resist
penicillin
serotyp
pfge
type
identifi
two
genotyp
isol
fourteen
isol
genotyp
serotyp
isol
genotyp
serotyp
caus
pneumonia
conclus
pneumonia
occult
bacteraemia
two
common
present
three
three
major
serotyp
rel
cluster
two
genotyp
identifi
one
clone
associ
serotyp
pneumonia
introduct
patient
pneumonia
resist
treatment
prove
common
problem
chest
hospit
pneumocysti
jiroveci
pj
alway
thought
opportunist
pathogen
case
potenti
especi
tcellrel
immunodefici
even
aidsdiseas
appar
report
case
pjp
without
associ
aidsdiseas
chest
hospit
object
aim
studi
investig
frequenc
diagnost
procedur
cours
outcom
pjp
without
associ
aidsdiseas
hospit
method
retrospect
studi
evalu
hospit
patient
present
pneumonia
januari
august
hospit
identif
case
pjp
base
upon
discharg
diagnosi
well
microbiolog
databas
confirm
pj
bronchoalveolar
lavag
immunofluorescencetest
ift
andor
pcr
result
diagnosi
pjp
without
associ
aidsdiseas
could
made
patient
hospit
proven
pneumonia
patient
treat
immunosuppress
medic
prior
admiss
indic
pulmonari
fibrosi
copd
cerebr
edema
respect
substanti
decreas
cell
case
establish
diagnosi
pjp
pjpcr
use
bronchoalveolar
lavag
materi
necessari
case
case
pjift
prove
falselyneg
sever
hypoxemia
could
success
bridg
noninvas
ventil
patient
l
patient
ventil
invas
mortalityr
patient
see
tabl
detail
conclus
pjp
import
differenti
diagnosi
time
sever
pulmonari
complic
immunodefici
patient
abl
confirm
high
mortal
rate
pjppatient
without
associ
aidsdiseas
publish
literatur
expect
pjpcr
superior
pjift
therefor
perform
routin
basi
diagnos
pjp
noninvas
ventil
demonstr
worthwhil
therapeut
option
bridg
sever
hypoxemia
patient
pjp
introduct
idiopath
interstiti
pneumonia
iip
one
sever
pulmonari
diseas
initi
chronic
inflamm
lead
parenchym
fibrosi
common
characterist
process
infecti
agent
possibl
caus
initi
inflamm
prove
pneumocysti
jirovecii
pj
mediat
inflammatori
respons
increas
permeabl
alveolocapillari
membran
caus
diffus
alveolar
damag
therefor
pulmonari
carriag
pj
could
play
role
pathogenesi
diseas
howev
molecular
epidemiolog
pj
kind
patient
still
unknown
object
studi
preval
molecular
epidemiolog
pj
carrier
iip
patient
patient
method
studi
includ
consecut
patient
final
diagnosi
iip
dna
isol
bronchoalveolar
lavag
oropharyng
wash
sampl
nest
pcr
protocol
use
analys
presenc
pj
polymorph
mt
lsu
rrna
region
studi
direct
sequenc
touchdownpcr
protocol
follow
rflp
acci
haeiii
assay
determin
mutat
dhp
gene
introduct
pneumocysti
jirovecii
carrier
may
exist
among
cystic
fibrosi
cf
patient
due
underli
pulmonari
diseas
role
natur
histori
diseas
poorli
understood
preval
molecular
epidemiolog
patient
still
remain
unknown
moreov
knowledg
p
jiroveci
genotyp
distribut
may
help
understand
epidemiolog
pathogen
object
describ
preval
genotyp
distribut
p
jirovecii
popul
cf
spanish
patient
method
crosssect
studi
perform
cf
patient
includ
lung
transplant
recipi
p
jirovecii
identifi
nest
pcr
mt
lsu
rrna
gene
respiratori
sampl
sputum
oropharyng
wash
genotyp
analys
direct
sequenc
posit
result
overal
preval
p
jirovecii
colon
among
cf
patient
preval
lung
transplant
recipi
higher
non
transplant
cf
patient
polymorph
predomin
also
genotyp
identifi
one
case
found
mix
genotyp
colonis
higher
cf
patient
year
old
besid
patient
receiv
prophylaxi
cotrimoxazol
azithromycin
colon
p
jirovecii
none
develop
pneumocysti
pneumonia
pcp
year
followup
analysi
show
concord
colon
statu
brother
group
conclus
high
preval
p
jirovecii
carrier
among
cf
patient
spain
data
suggest
chemoprophylaxi
cotrimoxazol
azithromycin
may
prevent
pcp
avoid
colon
concord
observ
among
brother
support
idea
common
sourc
infect
persontoperson
transmiss
studi
partial
support
acut
leukaemia
blood
stemcel
transplant
recipi
episod
commun
acquir
neutropenia
diagnosi
pneumonia
bacteriem
aetiolog
diagnosi
establish
episod
bacteri
aetiolog
predomin
n
follow
fungal
n
frequent
bacteria
pseudomona
aeruginosa
n
streptococcu
pneumonia
n
legionella
pneumophila
n
fusobacterium
nucleatum
n
aetiolog
invas
mycosi
aspergillosi
n
definit
n
probabl
n
possibl
n
pneumocysti
jiroveci
n
diagnost
yield
blood
cultur
tc
diagnost
use
global
mortal
day
patient
neutropenia
presenc
neutropenia
p
rr
bacteraemia
p
rr
multilobar
extens
p
rr
associ
sever
clinic
featur
first
hour
presenc
initi
respiratori
failur
independ
factor
advers
outcom
select
multivari
analysi
p
rr
conclus
incid
pneumonia
cancer
patient
high
aetiolog
eestablish
one
half
episod
bacteria
frequent
aetiolog
p
aeruginosa
frequent
speci
aspergillu
spp
make
one
third
episod
mortal
pneumonia
patient
high
associ
initi
respiratori
failur
treatment
start
empir
ceftriaxon
gd
plu
amikacin
gd
modifi
accord
antimicrobi
suscept
pattern
continu
month
result
nocardia
speci
isol
consecut
nine
patient
six
nine
patient
predispos
factor
identifi
common
predispos
factor
includ
receiv
immunosuppress
therapi
cadaver
kidney
transplant
diabet
mellitu
system
lupu
erythematosu
clinic
syndrom
nocardi
infect
seen
pulmonari
infect
three
patient
cerebr
infect
five
patient
dissemin
infect
one
patient
previous
healthi
patient
develop
cerebr
nocardiosi
due
nocardia
farcinica
initi
antibiot
use
appropri
four
nine
patient
howev
two
four
patient
experienc
relaps
one
relaps
die
diseas
overal
mortal
patient
two
case
death
due
nocardia
infect
conclus
despit
rel
rariti
nocardia
import
caus
infect
especi
patient
predispos
factor
use
imipenem
meropenem
combin
amikacin
suggest
initi
therapi
seriou
nocardia
infect
durat
therapi
protract
month
prevent
relaps
background
maltophilia
nonfer
gramneg
bacteria
often
associ
seriou
ventilatorassoci
pneumonia
sought
determin
characterist
maltophilia
lung
infect
cancer
patient
lowsuspicion
maltophilia
infect
method
maltophilia
respiratori
sampl
evalu
retrospect
patient
establish
risk
maltophilia
infect
critic
care
unit
ccu
stay
mechan
ventil
mv
neutropenia
anc
cellsll
hiv
infect
underli
structur
lung
diseas
exclud
result
patient
median
age
year
male
patient
sever
lymphocytopenia
cellsll
apach
ii
score
hematolog
malign
acut
leukaemia
fourteen
bmt
recipi
receiv
allogen
graft
treat
chronic
graftversushost
diseas
cgvhd
system
corticosteroid
mg
daili
prednisolon
equival
dose
infect
occur
day
rang
day
bmt
patient
refractori
advanc
cancer
diabet
mellitu
copd
twentythre
patient
nosocomi
infect
none
either
prior
maltophilia
orointestin
genitourinari
tract
colon
concomit
maltophilia
bacteraemia
cough
common
n
dyspnea
fever
occur
patient
respect
thirtythre
patient
present
pneumonia
receiv
broadspectrum
system
antibiot
day
maltophilia
n
suscept
trimethoprimsulfamethoxazol
ticarcillinclavulan
acid
n
fifteen
patient
need
hospit
hospit
patient
requir
ccu
admiss
mv
day
eight
death
attribut
maltophilia
pneumonia
presenc
young
age
vs
year
p
prolong
hospit
vs
day
p
high
apach
ii
score
vs
p
associ
increas
mortal
univari
analysi
presenc
acut
leukaemia
apach
ii
score
mv
ccu
stay
cgvhd
poor
predictor
outcom
stepwis
logist
regress
analysi
later
emerg
signific
prognost
death
conclus
maltophilia
pneumonia
seriou
lung
infect
nonneutropen
nonccu
patient
cancer
usual
interstiti
pneumonia
associ
cytomegaloviru
infect
percutan
translumin
coronari
angioplasti
falaga
rizo
tsiodra
betsou
p
fouka
michalopoulo
athen
gr
background
ventil
associ
pneumonia
due
cmv
larg
unexpect
probabl
underestim
diagnosi
method
describ
patient
usual
interstiti
pneumonia
associ
cytomegaloviru
infect
percutan
translumin
coronari
angioplasti
result
woman
histori
diabet
mellitu
admit
icu
hospit
due
acut
myocardi
infarct
percutan
translumin
coronari
angioplasti
perform
two
day
follow
icu
discharg
patient
becam
febril
nonproduct
cough
progress
dyspnoea
three
day
later
readmit
icu
due
sever
dyspnoea
type
respiratori
failur
patient
intub
admissioncxr
reveal
diffus
infiltr
lung
pleural
effus
patient
treat
intraven
piperacillintazobactam
ofloxacin
teicoplanin
remain
febril
improv
chest
ctscan
demonstr
confluent
opac
right
upper
middl
lobe
left
lower
lobe
well
airbronchogram
extens
right
pleural
effus
patholog
swell
pretrach
lymph
node
serolog
test
cmv
reveal
posit
igg
antibodi
igm
antibodi
present
open
lung
biopsi
reveal
distort
lung
parenchyma
moder
inflamm
patchi
fibrosi
subpleur
accentu
fibrot
area
consist
dens
collagen
focal
honeycomb
pattern
altern
area
rel
normal
alveolar
parenchyma
also
focal
alveolar
macrophag
accumul
smooth
muscl
prolifer
focal
subpleur
fatti
metaplasia
overal
pattern
consist
usual
interstiti
pneumonia
epitheli
type
ii
pneumocyt
show
atypia
abund
cytoplasma
larg
pleomorph
nuclei
harbour
intranuclear
inclus
consist
cmv
infect
despit
treatment
ganciclovir
patient
die
two
week
later
sever
ard
multipl
organ
failur
conclus
clinician
awar
cmv
associ
sever
bilater
pneumonia
cardiac
procedur
even
nontranspl
patient
correct
diagnosi
depend
clinic
awar
appropri
set
along
proof
viral
infect
object
mrsa
epidem
norway
steadili
grow
increas
report
case
sinc
last
year
signific
increas
mrsacas
nurs
home
report
august
sensit
method
mrsa
detect
introduc
refer
laboratori
central
norway
st
olav
hospit
period
observ
grow
incid
mrsa
throat
alon
combin
find
site
bodi
aim
present
studi
investig
import
includ
throat
swab
mrsa
screen
examin
occurr
new
patient
posit
mrsa
site
period
januari
b
period
august
octob
period
new
mrsa
detect
broth
use
first
posit
specimenset
new
patient
carriag
infect
includ
period
specimen
grown
select
mannitol
agar
contain
nacl
nacl
octob
oxacillin
mgl
wherea
period
b
specimen
grown
select
broth
contain
phenol
red
mannitol
aztreonam
mgl
ceftizoxim
mgl
isol
mrsa
verifi
pcr
detect
nuc
meca
gene
pcr
period
object
challeng
increas
demand
mrsa
surveil
declin
resourc
clinic
laboratori
requir
sensit
specif
screen
media
ensur
rapid
turnaroundtim
tat
notif
low
falseposit
rate
cost
mrsa
control
conclus
cfox
plate
costli
significantli
sensit
p
specif
p
msox
result
less
materi
labour
cost
tat
notif
appear
reduc
due
eas
work
directli
cfox
plate
result
use
breakpoint
r
mm
cefox
r
mm
cefox
r
mm
cefox
two
three
two
meca
posit
isol
test
fals
suscept
respect
five
four
six
meca
neg
isol
test
fals
resist
zone
edg
mcg
tablet
distinct
easier
read
aureu
atcc
follow
zone
diamet
found
mm
mm
mm
respect
aureu
atcc
mm
mm
mm
respect
conclus
three
cefoxitin
neosensitab
perform
high
accuraci
use
challeng
set
good
result
obtain
recent
evalu
mcg
paperdisk
cefoxitin
mcg
neosensitab
perform
slightli
better
mcg
zone
edg
easier
read
suggest
use
mcg
tablet
evalu
lipovitellinsaltmannitolagar
oxacillin
cefoxitin
disc
primari
screen
medium
methicillinresist
staphylococcu
aureu
boudewijn
k
lagrou
j
verhaegen
leuven
b
introduct
numer
primari
media
advoc
enhanc
detect
methicillinresist
staphylococcu
aureu
mrsa
recent
lipovitellinsaltmannitolagar
lsm
oxacillin
disk
describ
medium
detect
mrsa
isol
enhanc
due
product
lecithinas
result
enlarg
coloni
surround
zone
opacif
also
use
cefoxitin
disk
method
recent
describ
report
superior
oxacillin
disk
method
aim
evalu
perform
lsm
lg
oxacillin
disk
lg
cefoxitin
disk
lsmoc
select
differenti
primari
medium
detect
mrsa
screen
specimen
materi
method
screen
specimen
swab
nose
perineum
obtain
patient
popul
intens
care
unit
lsmoc
medium
compar
hous
method
use
colistinnalidix
acid
agar
cna
hors
blood
perform
parallel
inocul
aureu
isol
presumpt
identifi
coloni
morpholog
confirm
coagulas
tube
test
vitek
idgpc
testcard
methicillin
resist
lsmoc
medium
presumpt
detect
read
zone
inhibit
around
disk
confirm
disk
diffus
latex
agglutin
assay
object
uroquick
system
employ
detect
methicillinresist
metr
aureu
coagulaseneg
staphylococci
con
order
achiev
full
agreement
antibiot
suscept
result
obtain
refer
method
nccl
uroquick
system
optim
experiment
condit
inoculum
size
time
incub
antibiot
nacl
concentr
determin
aureu
con
respect
method
metr
staphylococci
includ
differ
speci
aureu
con
epidermidi
heterogen
express
resist
blactam
agent
screen
uroquick
system
aureu
atcc
meca
neg
aureu
atcc
meca
posit
use
qualiti
control
oxacillin
appropri
concentr
follow
nccl
breakpoint
ad
vial
contain
ml
suspens
strain
test
drugfre
vial
use
control
opportun
time
incub
instrument
print
result
growth
growth
curv
like
control
repres
suscept
resist
strain
respect
result
best
result
obtain
use
muellerhinton
broth
concentr
cellsml
aureu
con
aureu
test
grown
within
hour
incub
metr
phenotyp
correctli
detect
within
hour
strain
hour
respect
con
strain
grown
within
hour
incub
insuffici
growth
within
period
time
observ
strain
haemolyticu
metr
correctli
detect
within
hour
strain
grown
time
hour
respect
conclus
basi
present
find
uroquick
system
appear
use
rapid
detect
metr
staphylococci
excel
result
obtain
aureu
concern
con
result
suggest
differ
growth
rate
among
variou
member
group
incub
time
necessari
metr
detect
isol
respect
speci
must
analys
reach
gener
conclus
comparison
differ
techniqu
detect
methicillin
resist
staphylococci
evalu
card
akan
uysal
ankara
tr
laboratori
diagnosi
methicillin
resist
problem
everi
system
evalu
introduct
routin
laboratori
practic
studi
result
comparison
disk
diffus
oxacillin
mcg
disk
dd
oxacillin
agar
screen
oat
test
miniapi
staph
ast
system
biomerieux
vitek
ast
card
biomerieux
vt
detect
methicillin
resist
clinic
staphylococci
present
mic
valu
use
etest
ab
biodisk
use
refer
nccl
procedur
manufactur
recommend
use
differ
detect
methicillin
resist
dd
oat
etest
among
aureu
except
fals
suscept
oat
strain
dd
one
strain
randomli
select
methicillin
resist
methicillin
sensit
strain
studi
use
vt
strain
show
fals
resist
among
show
discord
oxacillin
screen
well
mic
detect
well
could
pass
advanc
expert
system
real
fals
posit
valid
appli
coagulas
neg
staphylococi
cn
epidermidi
cn
fals
neg
common
oat
recommend
nccl
one
strain
dd
strain
fals
resist
vt
valid
among
randomli
select
strain
epidermidi
cn
one
strain
fals
resist
strain
show
discord
oxacillin
screen
well
mic
detect
well
ommit
oxacillin
screen
well
high
antibiot
content
detect
resist
cn
fals
posit
strain
still
remain
antibiot
suscept
test
compat
aureu
isol
result
obtain
vt
show
system
adopt
routin
laboratori
practic
use
complementari
test
aureu
cn
case
discord
interpret
result
two
well
oxacillin
resist
comparison
oxacillin
resist
screen
agar
base
realtim
pcr
convent
cultur
rapid
detect
methicillinresist
ander
g
gei
gatermann
bochum
object
rapid
accur
identif
methicillinresist
aureu
mrsa
crucial
therapi
manag
infect
colon
patient
use
convent
cultur
techniqu
requir
prolong
incub
timeconsum
isol
procedur
follow
identif
suscept
test
accur
diagnosi
may
take
five
day
earli
point
time
report
mrsa
convent
method
hour
aim
studi
evalu
new
oxacillin
resist
screen
agar
base
orsab
pcrmethod
identif
mrsa
clinic
specimen
compar
convent
cultur
method
swab
variou
site
suspend
ml
nacl
equal
aliquot
use
three
method
method
orsab
oxoid
b
realtim
pcr
detect
meca
gene
aureusspecif
marker
incub
select
broth
c
convent
cultur
consist
blood
agar
plate
tryptic
soy
broth
contain
nacl
object
although
staphylococcu
aureu
aureu
rel
easi
cultiv
cultur
method
requir
h
incub
convent
identif
method
may
yield
falseposit
falseneg
result
standard
suscept
penicillinbind
protein
latex
agglutin
test
timeconsum
requir
coloni
isol
h
cultur
correct
identif
aureu
detect
meca
gene
base
molecular
method
consid
gold
standard
determin
methicillinresist
aureu
mrsa
mani
pcr
simultan
detect
aureu
specif
gene
target
meca
gene
develop
appli
direct
detect
mrsa
nonsteril
specimen
nasal
sampl
without
isol
step
comprehens
real
time
pcr
assay
target
aureusspecif
gene
meca
gene
within
singl
pcr
tube
reaction
use
one
coupl
primer
two
adjac
fluoresc
probe
establish
evalu
object
frequent
outbreak
staphylococcu
aureu
infect
worldwid
emphas
urgent
need
rapid
reliabl
detect
method
aureu
especi
hospit
set
commun
ultim
aim
studi
identifi
potenti
diagnost
marker
develop
dna
base
assay
use
microbiolog
laboratori
rapid
reliabl
detect
aureu
pure
cultur
also
directli
clinic
sampl
method
select
genet
target
diagnost
purpos
aureu
isol
obtain
differ
hospit
malaysia
fingerprint
use
rep
repetit
element
sequenc
primer
rep
fingerprint
marker
band
present
isol
clone
sequenc
primer
pair
amplifi
bp
fragment
oligonucleotid
probe
design
conserv
region
primer
probe
test
local
aureu
isol
atcc
valid
ubiqu
specif
molecular
assay
verifi
use
genom
dna
batteri
gramposit
gram
neg
bacteri
speci
abil
assay
detect
aureu
directli
clinic
sampl
also
test
pcr
membran
assay
compar
ubiqu
specif
rapid
result
rep
fragment
sequenc
univers
primer
determin
size
marker
bp
show
high
similar
gap
dehydrogenas
operon
aureu
genom
molecular
assay
develop
innov
primer
probe
success
none
non
aureu
speci
show
posit
signal
confirm
ubiqu
specif
pcr
assay
effici
detect
aureu
direct
clinic
sampl
membran
assay
requir
purifi
dna
term
rapid
assay
produc
result
hr
conclus
develop
simpl
rapid
molecular
assay
innov
primer
probe
specif
ubiquit
aureu
even
detect
aureu
directli
clinic
sampl
could
appli
microbiolog
laboratori
fast
diagnosi
aureu
infect
novel
achiev
made
studi
allow
faster
correct
identif
aureu
establish
effect
antibiot
therapi
therebi
control
prevent
futur
outbreak
develop
membran
base
assay
identif
staphylococcu
aureu
speci
level
detect
multipl
drug
resist
isol
object
incid
staphylococcu
aureu
infect
increas
recent
year
due
spread
multidrugresist
isol
convent
identif
base
biochem
characterist
determin
antibiot
resist
base
antibiot
suscept
pattern
identifi
aureu
rapid
effici
method
need
improv
rapid
direct
identif
bacterium
clinic
sampl
urin
would
use
earli
diagnosi
aureu
infect
clinic
microbiolog
laboratori
studi
incorpor
develop
singl
tube
pcr
system
multiplex
membran
base
assay
identif
aureu
detect
multipl
antibiot
resist
isol
directli
clinic
sampl
method
seventi
isol
aureu
differ
hospit
malaysia
studi
singl
tube
pcr
system
identif
aureu
detect
methicillin
gentamycin
erythromycin
vancomycin
resist
gene
carri
use
set
publish
primer
aureu
isol
directli
urin
sampl
boil
method
sensit
system
determin
serial
dilut
aureu
cultur
aliquot
dilut
subject
dna
isol
purifi
dna
use
templat
pcr
specif
system
verifi
use
panel
gram
posit
gram
neg
isol
membran
base
assay
develop
base
dnaprob
hybrid
techniqu
result
singl
tube
pcr
system
yield
product
bp
aureu
ident
fragment
bp
erythromycin
gentamycin
bp
methicillin
resist
gene
sequenc
show
homolog
none
isol
amplifi
vancomycin
resist
gene
assay
specif
aureu
none
gram
neg
posit
isol
amplifi
ident
fragment
sensit
level
achiev
urin
sampl
cfu
cycl
amplif
chemiluminesc
detect
hybrid
obtain
membran
base
assay
minimum
concentr
ng
probe
confirm
ident
aureu
detect
multipl
drug
resist
isol
conclus
studi
demonstr
practic
valu
sensit
rapid
specif
accuraci
molecular
base
method
diagnosi
therebi
treatment
aureu
infect
right
choic
drug
effici
genotyp
methicillinresist
staphylococcu
aureu
use
combin
binari
marker
singl
nucleotid
polymorph
object
staphylococcu
aureu
continu
signific
human
pathogen
sever
lineag
methicillin
resist
aureu
mrsa
common
agent
nosocomi
infect
recent
year
seen
appear
rapid
spread
mrsa
clone
capabl
caus
commun
acquir
infect
object
studi
develop
effici
aureu
genotyp
method
carri
use
realtim
pcr
technolog
method
design
provid
epidemiolog
fingerprint
also
allow
infer
clinic
relev
aspect
phenotyp
identif
lineag
genom
backbon
use
snp
combin
test
presenc
gene
exhibit
binari
variabl
method
basi
approach
design
genotyp
method
computeris
analysi
compar
sequenc
databas
order
identifi
minim
set
genet
polymorph
provid
desir
degre
resolv
power
analys
carri
use
comput
programm
minimum
snp
assembl
set
singl
nucleotid
polymorph
snp
empir
basi
maximis
simpson
index
divers
snp
interrog
use
allel
specif
pcr
real
time
format
kinet
pcr
object
base
biofilm
form
capac
staphylococcu
epidermidi
frequent
caus
foreignbodi
relat
infect
sever
specif
factor
mediat
primari
attach
accumul
character
order
analyz
concert
action
factor
method
situ
express
analysi
demand
aim
present
studi
establish
green
fluoresc
protein
gfp
base
report
gene
system
staphylococcu
epidermidi
result
therefor
clone
clontech
pasi
control
xyloseinduc
promotor
introduc
result
construct
epidermidi
howev
xylos
induct
signific
increas
fluoresc
intens
compar
uninduc
control
detect
find
may
attribut
ineffici
translat
initi
natur
shinedelgarno
sd
sequenc
inde
coupl
differ
sdsequenc
wellcharacter
epidermidi
gene
front
gfp
start
codon
crucial
impact
element
gfp
translat
initi
demonstr
wherea
strong
fluoresc
signal
obtain
presenc
hld
sd
sequenc
almost
signal
detect
sara
sd
sequenc
influenc
differ
sd
sequenc
transcript
translat
also
analys
realtim
transcript
semiquantit
western
blot
experi
construct
investig
almost
ident
gfp
transcript
level
found
regardless
sd
sequenc
present
contrast
western
blot
analysi
use
antigfp
antibodi
reveal
huge
differ
gfp
amount
correspond
respect
quantit
fluoresc
signal
calcul
halflif
epidermidi
h
importantli
express
interfer
biofilmposit
phenotyp
strain
conclus
conclus
use
appropri
sd
sequenc
optim
translat
initi
offer
attract
system
monitor
gene
express
epidermidi
bordetella
pertussi
fastidi
aerob
gramneg
coccobacillu
caus
classic
diseas
whoop
cough
clinic
manifest
pertussi
due
toxin
produc
organ
local
bacteri
invas
isol
blood
cultur
extrem
rare
knowledg
third
report
case
bordetella
pertussi
bacteraemia
case
report
immunocompromis
patient
patient
year
old
man
year
histori
multipl
myeloma
initi
treat
autolog
bone
marrow
transplant
current
treat
chemotherapi
due
diseas
progress
one
weak
treatment
vincristin
adriamycin
dexamethason
vad
develop
product
cough
fever
admit
medic
depart
admiss
creactiv
protein
mgl
wbc
count
chest
xray
normal
blood
cultur
initi
neg
treat
day
intraven
cefotaxim
suspect
bronchopneumonia
discharg
good
conditionth
patient
readmit
day
later
dri
cough
hoars
fever
creactiv
protein
mgl
wbc
count
chest
xray
normal
blood
cultur
neg
bronchopneumonia
suspect
given
intraven
penicillin
day
eventu
blood
cultur
first
admiss
reveal
growth
atyp
gramneg
rod
aerob
bottl
bacterium
identifi
bordetella
pertussi
sequenc
rrna
gene
patient
discarg
good
condit
treat
day
oral
clarithromycin
norway
experienc
outbreak
whoop
cough
sinc
report
case
annual
system
infect
may
occur
immunocompromis
host
growth
blood
cultur
may
slow
prolong
incub
recommend
result
patient
bacteri
infect
identifi
median
age
rang
acut
leukemia
common
follow
lymphoma
chronic
leukaemia
myeloma
neutropen
antibacteri
prophylaxi
site
infect
includ
respiratori
tract
bsi
includ
catheterrel
urinari
tract
skin
skin
structur
gastrointestin
tract
episod
monomicrobi
polymicrobi
gramposit
bacteria
account
monomicrobi
bsi
infect
overal
ie
polymicrobi
infect
also
includ
spectrum
gramneg
bacteria
account
monomicrobi
bsi
infect
overal
polymicrobi
infect
gramneg
compon
p
aeruginosa
singl
common
speci
isol
common
gramposit
coagulaseneg
staphylococci
aureu
viridan
group
streptococci
enterococcu
spp
common
gramneg
e
coli
p
aeruginosa
maltophilia
klebsiella
spp
background
previous
demonstr
procalcitonin
pct
valu
higher
ngml
associ
fungal
invas
infect
ifi
patient
persist
fever
five
day
empir
antibiotherapi
neutropen
phase
hematopoiet
stem
cell
transplant
hsct
object
analys
pct
independ
earli
diagnost
marker
ifi
high
risk
adult
patient
undergo
allogen
hsct
patient
method
pct
level
determin
febril
episod
develop
consecut
patient
receiv
allogen
hsct
episod
neutropen
period
within
second
third
phase
immun
recoveri
hsct
febril
episod
classifi
accord
final
diagnosi
fever
unknown
origin
microbiolog
clinic
document
infect
noninfecti
febril
episod
microbiolog
clinic
document
infect
classifi
possibl
probabl
proven
ifi
accord
eortcmsg
criteria
valu
pct
includ
classif
criteria
result
final
diagnosi
febril
episod
fever
unknown
origin
case
microbiolog
clinic
document
infect
noninfecti
fever
among
patient
document
infect
fulfil
ifi
criteria
possibl
probabl
proven
ifi
respect
eleven
ifi
case
occur
neutropen
phase
neutrophil
absolut
count
nac
case
nonneutropen
phase
hsct
mean
ngml
valu
pct
first
day
fever
among
neutropen
patient
patient
infect
ifi
n
possibl
ifi
n
probabl
ifi
n
proven
ifi
n
mean
valu
pct
first
day
fever
among
nonneutropen
patient
infect
ifi
n
possibl
ifi
n
probabl
ifi
n
proven
ifi
n
p
kruskalw
ic
conclus
nonneutropen
phase
allogen
hsct
high
pct
valu
first
day
fever
associ
signif
ifi
pct
monitor
could
earli
use
help
differenti
diagnosi
febril
episod
patient
high
risk
ifi
agrobacterium
radiobact
periton
patient
continu
ambulatori
periton
dialysi
object
present
agrobacterium
radiobact
periton
adult
continu
ambulatori
periton
dialysi
capd
method
periton
fluid
specimen
examin
cell
count
cultur
bactec
plu
cultur
vial
bactec
plu
becton
dickinson
centrifug
specimen
also
cultur
appropri
media
aerob
anaerob
microorgan
smear
perform
gram
stain
identif
bacterium
carri
standard
method
api
biomerieux
suscept
test
perform
disk
diffus
method
case
report
male
patient
age
year
final
stage
renal
failur
capd
month
defici
renal
function
admit
hospit
appear
cloudi
periton
dialys
effluent
nausea
patient
histori
three
episod
periton
caus
gram
neg
bacteria
klebsiella
pneumonia
pseudomona
aeruginosa
flavomona
oryzihabitan
acinetobact
johnsonii
patient
success
treat
ip
tobramycin
recov
complet
day
admiss
periton
analysi
show
neutrophil
patient
treat
empir
ip
tobramycin
forti
eight
hour
incub
periton
fluid
gram
neg
bacterium
isol
test
oxidas
catalas
posit
hydrolysi
test
esculin
posit
bacterium
identifi
agrobacterium
radiobact
bacterium
suscept
cefuroxim
ceftriaxon
ciprofloxacin
imipenem
tetracyclin
gentamicin
resist
ampicillin
trimethoprimesulfamethoxazol
cephalothin
tobramycin
patient
treat
cefuroxim
ip
three
week
recov
complet
conclus
agrobacterium
radiobact
microorgan
found
environ
particularli
sever
kind
soil
consid
plant
pathogen
rare
case
immunocompromis
patient
especi
patient
transcutan
cathet
implant
biomed
prothes
agrobacterium
radiobact
regard
caus
bacteramia
periton
erysipelothrix
rhusiopathia
introduct
e
rhisiopathia
rare
pathogen
found
worldwid
commens
wide
varieti
vertebr
invertebr
speci
major
reservoir
domest
swine
greatest
commerci
impact
infect
due
swine
erysipela
seriou
infect
human
extrem
rare
associ
cutan
infect
occup
exposur
clinic
manifest
includ
brain
abscess
osteomyel
chronic
arthriti
system
infect
often
complic
infect
endocard
mortal
rate
appear
higher
organ
report
rare
case
e
rhusiopathia
joint
infect
case
report
year
old
male
patient
long
term
treatment
rheumatoid
arthriti
present
clinic
isol
knee
sepsi
associ
rais
crp
wcc
knee
aspir
e
rhusiopathia
isol
cultur
broth
fail
grow
initi
cultur
media
system
manifest
direct
occup
exposur
report
repeat
knee
aspir
fail
grow
e
rhusiopathia
third
aspir
taken
arthroscopi
isol
organ
assum
soft
tissu
infect
e
rhusiopathia
led
bacteraemia
seed
rheumatoid
knee
joint
underw
prolong
treatment
six
week
cours
clindamycin
unfortun
low
grade
chronic
infect
persist
lead
complet
disorganis
joint
joint
replac
consid
discuss
report
interest
except
unusu
natur
pathogen
lack
system
symptom
histori
social
occup
exposur
explain
presenc
organ
diagnosi
e
rhusiopathia
problemat
essenti
ensur
effect
treatment
strain
resist
vancomycin
often
use
empir
treat
bacteraemia
due
gram
posit
organ
patient
immunocompromis
suffer
malign
diabet
mellitu
one
collagen
diseas
one
pulmonari
tuberculosi
one
itp
microbiolog
test
includ
combin
method
coloni
microscop
morpholog
use
acidfast
kinyounmodifi
stain
simpl
biochem
hydrolysi
test
casein
hydrolysi
gelatin
liquefact
decomposit
tyrosin
xanthin
hypoxanthin
antibiot
suscept
profil
suscept
cefamandol
tobramycin
result
high
degre
correspond
biochem
characterist
antibiot
suscept
pattern
note
strain
identifi
n
asteroid
biochem
suscept
pattern
criteria
patient
treat
either
cotrimoxazol
high
dose
imipenem
minocyclin
three
patient
die
two
suffer
lung
cancer
one
itp
object
fournier
gangren
seriou
skin
soft
tissu
infectiousnecrotis
process
perineogenit
area
affect
adult
usual
sixti
seventi
isol
flora
cultur
necrot
lesion
commonli
multimicrobi
although
idiopath
condit
consid
past
today
genitourinari
anorect
dermal
trigger
factor
identifi
patient
seri
system
host
debilit
disord
diabet
mellitu
chronic
alcohol
abus
malign
neoplasia
associ
condit
may
consid
risk
factor
suffer
diseas
studi
patient
fg
eight
uncontrol
dm
investig
risk
factor
clinic
sign
laboratori
find
prognosi
method
studi
fg
patient
hospit
gulhan
militari
medic
academi
haydarpasa
train
hospit
depart
gener
surgeri
servic
present
age
clinic
present
predispos
factor
microbiolog
test
manag
prognosi
studi
broad
spectrum
parenter
antibiot
earli
aggress
surgic
debrid
necrot
area
hiperbar
oxygen
therapi
appli
case
result
mean
age
fg
case
averag
time
begin
symptom
appli
hospit
day
promin
associ
diseas
diabet
affect
per
cent
patient
potenti
contribut
factor
includ
trauma
surgic
oper
three
case
fast
blood
glucos
level
level
diabet
patient
mgdl
respect
bacteri
cultur
result
reveal
singl
organ
one
organ
case
frequent
isol
bacteria
escherichia
col
streptococcu
pyogen
klebsiella
pneumonia
quantit
tissu
cultur
overal
mortal
rate
percent
howev
mortal
rate
among
diabet
per
cent
p
conclus
fournier
gangren
seriou
lifethreaten
disord
especi
diabet
patient
despit
earli
aggress
debrid
use
appropri
antimicrobi
therapi
relationship
uropathogen
escherichia
coli
host
compromis
statu
object
evalu
role
compromis
statu
play
uropathogen
e
coli
strain
set
virul
factor
ecor
phylogenet
group
patient
without
compromis
statu
method
e
coli
strain
patient
pyelonephr
neg
blood
cultur
urinari
bacteraemia
analys
ecor
phylogenet
group
virul
factor
vf
gene
papa
papgi
papgii
papgiii
fimh
afadrabc
sfafocd
hlya
iuta
fyua
kpsmii
ibea
trat
malx
pcr
antigen
associ
uti
determin
use
agglutin
microtechniqu
compromis
statu
obtain
medic
record
includ
immnunocompromis
andor
local
predispos
factor
urinari
tract
infect
result
patient
pyelonephr
urosepsi
compromis
pyelonephrit
strain
healthi
patient
belong
group
group
compromis
patient
group
group
group
urosepsi
strain
normal
patient
belong
group
group
compromis
patient
group
group
group
group
e
coli
strain
noncompromis
patient
associ
higher
virul
score
pyelonephr
virul
trait
urosepsi
strain
compromis
host
pyelonephr
virul
trait
urosepsi
despit
papgii
significantli
preval
pyelonephrit
strain
healthi
patient
vs
compromis
p
wherea
malx
papa
kpsmii
fyua
somewhat
preval
normal
peopl
pyelonephr
urosepsi
peopl
compromis
remain
trait
similari
distribut
strain
group
show
high
virul
score
mean
trait
follow
group
group
p
group
vs
other
conclus
e
coli
strain
normal
host
predominantli
ecor
phylogenet
group
harbour
great
number
virul
trait
consequ
show
high
virul
score
wherea
strain
phylogenet
group
poss
virul
trait
infect
patient
compromis
statu
howev
substanti
preval
group
strain
lot
virul
trait
among
compromis
host
could
explain
lack
associ
condit
reduc
virul
object
periton
import
complic
continu
ambulatori
periton
dialysi
capd
review
incid
etiolog
capdassoci
periton
method
total
periton
fluid
sampl
adult
patient
capd
examin
januari
octob
effluent
sampl
cultur
appropri
solid
liquid
media
min
centrifug
addit
ml
fluid
inocul
aerob
anaerob
vital
cultur
vial
biomerieux
marcyl
etoil
franc
enumer
wbc
done
use
standard
count
chamber
identif
microorgan
perform
use
standard
method
api
system
biomerieux
result
total
dialys
posit
two
posit
sampl
polymicrobi
gramposit
organ
account
infect
coagulas
neg
staphylococci
cn
commonest
gramneg
bacteria
found
posit
sampl
anaerob
bacteria
fungi
conclus
capdassoci
periton
commonli
caus
coagulas
neg
staphylococci
prompt
identif
caus
agent
essenti
appropri
manag
microbi
periton
patient
capd
object
report
unusu
case
periton
caus
n
sicca
continu
ambulatori
periton
dialysi
capd
patient
method
periton
effluent
specimen
examin
wbc
count
detect
microorgan
gram
stain
direct
smear
cultur
appropri
media
centrifug
also
inocul
bactec
cultur
vial
becton
dickinson
identif
microorgan
perform
standard
method
biochem
characterist
coloni
morpholog
api
nh
system
biomerieux
suscept
test
carri
disc
diffus
method
accord
nccl
perform
standard
case
report
femal
capd
patient
end
stage
renal
failur
admit
hospit
periton
effluent
turbid
start
capd
eleven
month
ago
suffer
system
lupu
erythematosu
year
corticosteroid
year
episod
periton
admiss
wbc
count
periton
fluid
neutrophil
decreas
second
third
day
respect
admiss
administ
cefazolin
gr
ip
afterward
mg
ip
next
day
gram
diplococci
intracellular
seen
direct
smear
gram
stain
two
periton
effluent
cultur
gram
diplococcu
oxidas
posit
strict
aerob
isol
coloni
white
opaqu
wrinkl
adhes
peak
nitrat
reduct
neg
api
nh
good
identif
strain
identifi
neisseria
spp
group
includ
speci
n
sicca
n
mucosa
subflava
strain
differenti
subflava
base
coloni
morpholog
n
mucosa
nitrat
reduct
strain
betalactamas
neg
resist
erythromycin
trimethoprimesulphamethoxazol
clindamycin
suscept
penicillin
cephalosporin
aminoglycosid
ampicillin
ciprofloxacin
tetracyclin
patient
treat
cefazolin
mg
ip
per
day
next
day
recov
complet
conclus
nonpathogen
neisseria
spp
caus
sever
diseas
immunocompromis
patient
first
case
report
capd
periton
neisseria
sicca
greec
third
world
wide
antibiot
resist
enterococci
faecal
sampl
cancer
patient
e
chinou
p
apostolakopoulo
e
skout
georgouli
p
golemati
athen
gr
object
aim
studi
determin
preval
antibiot
resist
isol
enterococci
fecal
sampl
oncolog
patient
method
total
strain
enterococci
isol
fecal
cultur
oncolog
patient
undergo
peripher
blood
stem
cell
transplant
pbsct
bone
marrow
transplant
bmt
one
year
fecal
sampl
inocul
bile
esculin
agar
plate
without
mgrlt
vancomycin
enrich
bileesculin
broth
supplement
mgrlt
vancomycin
identif
isol
bacteria
perform
standard
method
apistrep
system
suscept
test
carri
disk
diffus
method
accord
nccl
guidelin
etest
vancomycin
teicoplanin
patient
febril
diarrhoea
treat
antimicrobi
agent
stool
cultur
result
strain
isol
enterococci
strain
identifi
e
faecali
strain
efaecium
two
strain
enterococcu
sp
total
strain
found
resist
ampicillin
high
level
gentamycin
ciprofloxacin
tetracyclin
quinopristin
dalfopristin
isol
strain
sensit
vancomycin
teicoplanin
linezolid
isol
strain
efaecium
observ
multidrug
resist
sensit
glycopeptid
linezolid
quinopristin
dalfopristin
conclus
present
studi
indic
preval
vre
fecal
sampl
oncolog
patient
appear
low
ciprofloxacin
frequent
use
antimicrobi
agent
cancer
patient
less
activ
antibiot
test
gener
good
activ
glycopeptid
linezolid
test
show
promis
combin
therapi
requir
enterococc
infect
immunocompromis
patient
object
infect
major
caus
morbid
mortal
patient
undergo
highdos
therapi
subsequ
autolog
allogen
stem
cell
transplant
sct
despit
antimicrobi
prophylaxi
use
growth
factor
newer
antimicrobi
drug
method
compar
incid
earli
infecti
complic
autolog
sct
allogen
sct
recipi
singl
centr
period
januari
june
consecut
adult
patient
infect
occur
within
day
transplant
defin
earli
infect
fortytwo
patient
allograft
autograft
antimicrobi
prophylaxi
mainli
quinolon
fluconazol
acyclovir
trimethoprimsulfamethoxazol
result
within
first
day
patient
develop
febril
neutropenia
episod
infect
document
patient
patient
undergo
allogen
sct
tend
document
infect
compar
recipi
autolog
sct
vs
respect
p
frequent
infect
bacteremia
follow
urinari
infect
pneumonia
catheterrel
infect
pathogen
isol
febril
neutropenia
episod
mostli
gramposit
organ
follow
gramneg
rod
candida
spp
predomin
pathogen
coagulaseneg
staphylococcu
e
coli
aureu
infect
respons
death
transplant
within
day
patient
earli
mortal
associ
infect
allogen
sct
autolog
sct
p
conclus
febril
episod
frequent
complic
autolog
allogen
sct
gramposit
isol
remain
main
pathogen
patient
methicillin
resist
increas
glycopeptid
remain
choic
treat
infect
high
incid
febril
episod
bacteraemia
may
due
lack
efficaci
antimicrobi
prophylaxi
although
infect
rate
high
measur
taken
prevent
treat
infect
result
low
rate
mortal
infect
sct
patient
studi
report
local
microbiolog
find
necessari
support
antibiot
choic
prophylaxi
therapi
accur
report
area
microbiolog
document
infect
follow
peripher
blood
stem
cell
transplant
object
assess
isol
rate
bacteri
fungal
caus
agent
earli
late
infect
patient
underw
peripher
blood
stem
cell
transplant
pbsct
method
condit
preengraft
period
defin
earli
period
postengraft
period
one
year
defin
late
period
studi
perform
evalu
earli
late
infect
patient
underw
pbsct
autolog
allogen
singl
institut
patient
receiv
antibiot
prophylaxi
ciprofloxacin
acyclovir
fluconazol
tmp
smx
oral
hematopoiet
growth
factor
neutropenia
febril
patient
receiv
iv
imipenem
cefepim
plu
amikacin
ceftazidim
plu
amikacin
result
total
episod
microbiolog
document
infect
seen
patient
patient
experienc
least
one
febril
episod
microbiolog
document
infect
posttranspl
cours
episod
earli
period
late
period
earli
period
caus
organ
gram
posit
gram
neg
fungi
common
pathogen
coagulaseneg
staphylococcu
con
e
coli
earli
period
late
period
caus
organ
gram
posit
gram
neg
fungi
con
e
coli
also
commonli
isol
agent
period
total
microbiolog
document
cathet
infect
seen
earli
period
late
period
common
pathogen
con
cathet
relat
infect
resist
methicillin
detect
aureu
con
isol
suscept
pattern
gramneg
isol
percentag
suscept
test
antibiot
conclus
isol
rate
accord
previou
report
similar
percentag
gram
posit
gram
neg
isol
found
patient
underw
pbsct
remark
low
rate
viridan
group
streptococci
fungi
observ
spectrum
pathogen
detect
case
serv
basi
recommend
choic
empir
antimicrobi
treatment
regimen
therefor
studi
report
local
microbiolog
find
well
suscept
profil
necessari
suggest
local
microbiolog
surveil
known
empir
antimicrobi
therapi
start
institut
detect
human
polyomavirus
bkv
jcv
infect
pcr
assay
patient
haematopoiet
progenitor
cell
transplant
object
two
human
polyomavirus
bk
bkv
jc
jcv
common
popul
follow
primari
infect
virus
establish
latenc
renal
tissu
b
lymphocyt
adult
asymptomat
polyomaviru
carrier
polyomavirusrel
diseas
larg
associ
immunolog
impair
jcv
caus
agent
progress
multifoc
leukoencephalopathi
aid
patient
well
immun
compromis
host
patient
undergo
renal
bone
marrow
transplant
reactiv
polyomavirus
may
result
hemorrhag
cystiti
hc
lateonset
viral
hc
mainli
relat
bkv
reactiv
signific
caus
posttranspl
morbidityth
aim
studi
evalu
frequenc
clinic
implic
human
polyomavirus
infect
children
underw
hematopoiet
progenitor
cell
transplant
hpct
method
polyomaviru
dna
detect
plasma
urin
pcrbase
assay
viral
dna
extract
plasma
urin
sampl
digest
proteinas
k
purif
qiagen
column
accord
manufactur
protocol
primer
pair
amplifi
sequenc
bkv
genom
sequenc
jcv
genom
digest
pcr
product
prior
electrophoresi
use
discrimin
bkv
jcv
sequenc
result
regular
screen
polyomaviru
infect
perform
children
underw
hpct
bkv
detect
urin
children
serum
patient
jcv
detect
urin
patient
plasma
patient
frequent
clinic
manifest
probabl
relat
hpv
infect
hemorrhag
cystiti
howev
almost
hpv
posit
patient
asymptomat
conclus
conclus
demonstr
rapid
identif
viral
agent
may
allow
initi
effect
therapi
imper
polyomaviru
infect
follow
hematopoiet
stem
cell
transplant
monitor
herpesviru
dna
load
children
allogen
hematopoiet
stem
cell
transplant
ebv
cmv
may
suffici
calbican
isol
case
strain
cnonalbican
isol
blood
wound
infect
mix
microflora
includ
candida
spp
patient
previous
receiv
line
antimicrobi
therapi
pt
cnonalbican
wound
discharg
c
albican
c
nonalbican
isol
sputum
c
albican
c
nonalbican
isol
bronchoscop
materi
pt
clinic
radiograph
evid
pneumonia
preval
calbican
sputum
may
explain
materi
taken
less
sever
ill
patient
bronchoscopi
undertaken
critic
ill
patient
urin
colon
c
albican
c
nonalbican
pt
urinari
catet
nt
clinic
evid
urinari
infect
c
nonalbican
consist
c
glabrata
c
parapsilosi
c
krusei
cinconspicuanorvegensi
c
tropicali
kefyr
globosa
c
sake
c
lusitania
c
dubliniensi
strain
suscept
test
perform
often
isol
strain
follow
test
strain
c
albican
suscept
amphotericin
b
flucitozin
miconazol
intermedi
suscept
seen
ketokonazol
econazol
nystatin
resist
reveal
nystatin
comment
qnr
gene
still
infrequ
among
esblproduc
microorgan
occasion
found
qnr
harbour
esblproduc
enterobacteria
previous
describ
spain
case
qnr
enough
absenc
topoisomeras
mutat
produc
fluoroquinolon
resist
though
mutant
select
might
frequent
strain
harbour
qnr
effect
plasmid
encod
quinolon
resist
determin
p
stuartii
select
strain
clinic
resist
ciprofloxacin
wiegand
luhmerbeck
b
wiedemann
bonn
object
influenc
plasmid
encod
quinolon
resist
determin
qnr
e
coli
k
pneumonia
strain
differ
singl
target
gene
mutat
efflux
level
porin
pattern
alreadi
studi
none
strain
clinic
resist
ciprofloxacin
p
stuartii
strain
show
slightli
higher
ciprofloxacin
mic
natur
sensit
popul
studi
e
coli
k
pneumonia
strain
detect
qnr
three
differ
clinic
p
stuartii
isol
want
determin
influenc
qnr
speci
abil
select
ciprofloxacin
resist
mutant
method
qnr
transfer
p
stuartii
rifr
use
filter
mate
techniqu
qnrposit
strain
p
vulgari
donor
qnrposit
transconjugand
select
use
studi
mic
valu
determin
etest
accord
manufactur
instruct
mutant
select
use
inocula
cell
plate
lb
agarpl
contain
ciprofloxacin
concentr
mic
result
transconjugand
obtain
conjug
frequenc
mic
valu
present
tabl
mutant
prevent
concentr
determin
mic
strain
mutant
pick
show
normal
coloni
size
also
minor
subpopul
small
coloni
variant
scv
shown
stabl
antibiot
free
medium
least
three
passag
mic
valu
four
repres
coloni
type
per
strain
uniform
within
small
rang
median
valu
given
tabl
conclus
p
stuartii
combin
qnr
singl
mutat
event
lead
clinic
resist
thu
like
singl
quinolon
treatment
singl
step
mutant
select
speci
e
coli
klebsiella
spp
may
import
reservoir
qnr
resist
determin
role
clinic
set
remain
determin
evid
fluoroquinoloneresist
mechan
associ
efflux
pump
outer
membran
protein
omp
neisseria
gonorrhoea
j
yoo
b
kim
c
yoo
w
seong
seoul
kor
object
ciprofloxacin
resist
ngonorrhoea
korea
dramat
increas
although
known
mainli
caus
mutat
within
gyra
parc
fact
anoth
mechan
involv
resist
fluoroquinolon
well
known
organ
studi
design
investig
evid
anoth
mechan
relat
resist
ciprofloxacin
ngonorrhoea
method
mutant
deriv
parent
strain
isol
korea
obtain
sever
vitro
select
gc
agar
supplement
increas
concentr
ciprofloxacin
amino
acid
substitut
within
quinolon
resistancedetermin
region
qrdr
gyra
parc
determin
sdspage
gel
electrophresi
outer
membran
protein
omp
perform
result
signific
reduc
sensit
ciprofloxacin
observ
select
mutant
mic
ciprofloxacin
strain
increas
seven
elevenfold
higher
wild
type
strain
respect
mutant
deriv
show
resist
pen
te
cro
either
howev
observ
mutant
wt
reduc
sensit
azi
te
increas
sensit
spt
addit
cccp
proton
motiv
forc
uncoupl
mic
ciprofloxacin
strain
greatli
reduc
sequenc
analysi
gyra
demonstr
singl
mutat
except
strain
mutat
parc
mutant
strain
show
point
mutat
gyra
sdspage
analysi
omp
strain
reveal
remark
alter
express
protein
locat
rang
kda
also
analysi
show
thirti
spot
chang
amount
fivefold
interestingli
omp
strain
show
littl
chang
compar
wild
type
induc
two
kind
mutant
probabl
differ
fluoroquinolon
resist
mechan
although
one
mutat
gyra
strongli
suggest
main
caus
resist
ciprofloxacin
reduct
omp
increas
efflux
pump
omp
analysi
genet
analysi
method
suscept
studi
perform
use
microdilut
method
sensititr
r
follow
nccl
guidelin
etest
follow
manufactur
procedur
clonal
relationship
two
strain
rule
pulsedfield
gel
electrophoresi
mutat
alter
qrdr
gyra
parc
investig
pcr
sequenc
use
dideoxi
method
thermo
sequenasetm
dye
termin
sequenc
kit
automat
laser
fluoresc
dna
sequenc
result
first
ciprofloxacinresist
agalactia
strain
recov
octob
second
isol
septemb
strain
isol
urolog
patient
previous
treat
sever
time
ciprofloxacinth
two
ciprofloxacinresist
agalactia
isol
also
resist
tetracyclin
suscept
penicillin
vancomycin
erythromycin
clindamycin
quinupristindalfopristin
chloramphenicol
rifampicin
mic
valu
quinolon
strain
ciprofloxacin
mgl
norfloxacin
mgl
levofloxacin
mgl
mgl
sparfloxacin
mgl
mgl
moxifloxacin
mgl
mgl
clinafloxacin
mgl
mgl
respect
quinoloneresist
agalactia
isol
show
mutat
parc
well
addit
mutat
gyra
strain
show
wherea
strain
present
conclus
first
report
agalactia
quinolon
resist
strain
spain
whose
mechan
resist
mutat
parc
gyra
strain
isol
patient
treat
ciprofloxacin
clonal
relationship
observ
among
novel
gyrb
pare
mutat
detect
quinoloneresistancedeterminingregion
clinic
quinoloneresist
pseudomona
aeruginosa
ferreira
tr
walsh
mendo
aveiro
p
bristol
uk
object
aim
present
studi
character
mutat
occur
quinoloneresistancedeterminingregion
qrdr
region
gyra
gyrb
parc
pare
gene
clinic
ciprofloxacin
pefloxacin
resist
pseudomona
aeruginosa
isol
patient
hospit
central
portug
method
nucleotid
sequenc
pcramplifi
gyra
gyrb
parc
pare
fragment
determin
use
autom
dna
sequenc
biolog
sequenc
align
editor
bioedit
version
use
dna
amino
acid
sequenc
align
sequenc
obtain
compar
other
deposit
embl
genebank
result
dna
sequenc
analys
mutat
lead
amino
acid
chang
associ
fluoroquinolon
resist
nine
strain
harbour
mutat
thr
fi
ile
codon
gyra
silent
mutat
also
found
four
p
aeruginosa
strain
harbour
gyrb
mutat
occur
codon
lead
amino
acid
substitut
ser
fi
tyr
two
strain
show
mutat
codon
gli
fi
arg
also
lead
amino
acid
substitut
howev
compar
sequenc
gyrb
fragment
obtain
p
aeruginosa
silent
mutat
found
parc
four
strain
exhibit
amino
acid
substitut
ser
leu
codon
new
mutat
occur
codon
lead
amino
acid
substitut
asp
fi
glu
two
strain
silent
mutat
also
found
parc
qrdr
region
nucleotid
sequenc
par
e
gene
amino
acid
replac
found
chang
occur
codon
leu
fi
val
glu
fi
gln
ala
fi
pro
ala
fi
pro
gli
fi
val
gln
fi
two
replac
novel
codon
glu
gln
codon
ala
fi
pro
occur
strain
replac
occur
insid
highli
conserv
motif
egdsa
furthermor
silent
mutat
also
found
conclus
gyra
mutant
contain
substitut
show
higher
level
resist
fluoroquinolon
mutant
contain
differ
singl
point
mutat
novel
mutat
detect
gyrb
pare
gene
also
result
obtain
parc
par
e
gene
reveal
mutat
type
ii
topoisomeras
subunit
b
rare
use
singl
mutat
parc
gene
among
levofloxacin
suscept
clinic
isol
streptococcu
pneumonia
e
mateo
r
alonso
r
cisterna
vitoria
bilbao
e
object
levofloxacin
lvx
recommend
treatment
communityacquir
pneumonia
increas
multidrug
resist
streptococcu
pneumonia
incid
levofloxacin
resist
clinic
isol
pneumonia
rel
low
lvx
resist
requir
least
mutat
quinolon
resist
determin
region
qrdr
topoisomeras
iv
dna
gyras
purpos
studi
determin
preval
singl
qrdr
mutat
parc
gene
pneumonia
method
sixtynin
levofloxacinsuscept
pneumococci
mic
mgl
isol
microbiolog
servic
hospit
de
basuto
bilbao
spain
eight
isol
show
lvx
mic
mgl
isol
show
lvx
mic
mgl
use
pcrrflp
assay
screen
randomli
chosen
pneumococc
isol
levofloxacin
mic
mgl
isol
mic
mgl
mutat
known
confer
resist
parc
gyra
qrdr
region
parc
isol
suspect
mutat
amplifi
pcr
dna
sequenc
determin
result
strain
lvx
mic
mgl
strain
parc
chang
among
strain
lvx
mic
mgl
strain
parc
chang
four
isol
show
singl
parc
mutat
one
isol
show
doubl
parc
mutat
mutat
gyra
gene
detect
strain
conclus
fluoroquinolon
resist
among
pneumonia
remain
low
howev
increas
isol
contain
parc
mutat
observ
select
parc
mutat
could
relat
use
levofloxacin
treat
pneumonia
infect
mutat
parc
gyra
gene
among
levofloxacin
resist
clinic
isol
streptococcu
pneumonia
r
alonso
e
mateo
f
calvo
r
cisterna
vitoria
bilbao
e
object
incid
levofloxacin
resist
clinic
isol
pneumonia
rel
low
lvx
resist
requir
least
mutat
quinolon
resist
determin
region
qrdr
topoisomeras
iv
dna
gyras
purpos
studi
character
among
recent
clinic
isol
pneumonia
mutat
confer
resist
levofloxacin
method
twentyfour
levofloxacinresist
pneumococci
mic
mgl
isol
respiratori
sampl
analys
minim
inhibitori
concentr
cmi
levofloxacin
gatifloxacin
moxifloxacin
gemifloxacin
determin
agar
dilut
method
use
muellerhinton
agar
hors
blood
qrdr
region
parc
gyra
amplifi
pcr
dna
sequenc
determin
result
levofloxacin
resist
associ
combin
least
two
amino
acid
substitut
commonli
involv
parc
gyra
strain
three
strain
show
singl
parc
mutat
doubl
gyra
mutat
one
strain
show
substitut
parc
mutat
found
qrdr
gyra
strain
may
harbour
mutat
gyrb
gene
none
strain
suscept
gatifloxacin
twelv
twenti
isol
suscept
moxifloxacin
cmi
mgl
gemifloxacin
cmi
mg
l
respect
conclus
result
suggest
resist
levofloxacin
requir
least
two
substitut
amino
acid
within
qrdr
region
gyras
topoisomeras
iv
consider
crossresist
among
fluoroquinolon
associ
chang
mechan
quinolon
resist
p
aeruginosa
strain
efflux
pump
overexpress
b
henrichfreis
wiegand
b
wiedemann
bonn
object
aim
studi
determin
whether
addit
mechan
quinolon
resist
target
modif
via
mutat
protect
found
p
aeruginosa
pa
strain
effluxpump
overexpress
epo
method
levofloxacinresist
strain
pa
collect
german
hospit
epo
verifi
test
levofloxacin
lev
mic
use
broth
microdilut
without
effluxpump
inhibitor
epi
qrdr
gyra
parc
furthermor
mexr
intergen
region
mexr
mexa
ir
contain
share
operatorpromotor
region
mexamexboprm
mexr
amplifi
sequenc
also
screen
qnr
conduct
clonal
ident
investig
multiplelocu
variabl
number
tandem
repeat
analysi
mlva
result
phenotyp
genotyp
characteris
strain
shown
tabl
strain
whose
lev
mic
reduc
epi
wildtyp
wt
level
mgl
aminoacid
chang
gyra
parc
found
strain
two
chang
gyra
one
chang
parc
detect
strain
show
mutat
mexr
mutat
ir
exchang
e
strain
previous
describ
levsuscept
isol
qnr
detect
mlva
indic
clonal
relationship
among
strain
conclus
strain
nalb
mutat
observ
epo
phenotyp
strain
could
caus
nalc
overexpress
ep
contrari
usual
find
strain
correl
epo
target
mutat
found
analysi
sequenti
isol
pseudomona
aeruginosa
cystic
fibrosi
patient
repeatedli
treat
ciprofloxacin
mutant
prevent
concentr
minim
inhibitori
concentr
puls
field
gel
electrophoresi
j
blondeau
l
blondeau
c
william
saskatoon
glasgow
uk
object
mpc
measur
propens
antimicrobi
compound
select
resist
base
drug
concentr
requir
block
growth
firststep
resist
mutant
cystic
fibrosi
patient
cfp
frequent
infect
pseudomona
aeruginosa
pa
requir
repeat
cours
therapi
therapi
may
precipit
resist
test
sequenti
pa
isol
cfp
repeatedli
treat
cpx
mic
mpc
method
sequenti
isol
collect
period
pa
isol
test
cpx
levofloxacin
lfx
microbroth
dilut
accord
nccl
guidelin
mpc
test
billion
organ
appli
agar
plate
contain
drug
incub
hr
lowest
concentr
prevent
growth
mpc
pa
strain
compar
puls
field
gel
electrophoresi
pfge
use
spe
result
patient
isol
receiv
cours
cpx
mg
bid
patient
cours
period
collect
yr
mic
cpx
lfx
rang
lgml
lgml
respect
mpc
rang
lgml
lgml
lgml
lgml
respect
pfge
profil
isol
ident
differ
strain
cpx
therapi
result
increas
mpc
valu
lfx
mpc
valu
higher
cpx
everi
instanc
conclus
repres
first
report
mpc
test
sequenti
pa
isol
histori
avail
mpc
remain
constant
cpx
durat
organ
isol
mpc
lfx
high
beyond
achiev
sustain
drug
concentr
never
receiv
lfx
yet
mpc
valu
high
suggest
lfx
readili
select
quinolon
resist
pa
mpc
use
monitor
chang
suscept
guid
appropri
select
therapi
detect
quinolon
resistancemedi
gyra
mutat
fluoroquinolon
suscept
salmonella
live
vaccin
strain
preisler
p
heisig
hamburg
object
product
effect
vaccin
instead
develop
new
antibiot
promis
approach
circumv
rapid
develop
bacteri
resist
besid
attenu
salmonella
typhi
live
vaccin
strain
use
human
typhimurium
strain
tad
salmonella
vact
use
live
vaccin
strain
foodproduc
chicken
attenu
virul
achiev
random
mutagenesi
wildtyp
typhimurium
strain
follow
select
reduc
virul
epidemiolog
marker
vaccin
strain
includ
reduc
suscept
rifampicin
rifr
nalidix
acid
nalr
loss
tensid
toler
presum
associ
alter
membran
permeabl
marker
rtt
curious
vaccin
strain
retain
high
suscept
fluoroquinolon
macrolid
present
studi
aim
understand
molecular
basi
phenotyp
method
tad
salmonella
vact
character
determin
antibiot
suscept
pattern
gener
time
dnasupercoil
degre
dnasequ
entir
gyra
gene
well
quinolon
resistancedetermin
region
qrdr
remain
fluoroquinolon
target
gene
gyrb
parc
pare
encod
subunit
b
gyras
b
topoisomeras
iv
respect
result
compar
parent
tad
salmonella
vact
show
reduc
growth
rate
signific
chang
dna
supercoil
dna
sequenc
analysi
complet
gyra
gene
reveal
three
novel
mutat
affect
codon
trparg
glyala
seril
one
known
point
mutat
posit
aspgli
although
mutat
codon
known
mediat
quinolon
resist
vaccin
strain
highli
suscept
fluoroquinolon
like
sparfloxacin
ciprofloxacin
moder
resist
nalidix
acid
conclus
two
hypothes
might
alon
combinationexplain
phenotyp
least
one
novel
gyra
mutat
compens
fluoroquinolon
resist
mutat
increas
drug
accumul
result
inactiv
multidrug
efflux
pump
presum
associ
rtt
marker
allow
higher
accumul
fluoroquinolon
macrolidesin
cell
result
point
combin
mechan
therefor
provid
molecular
basi
understand
report
stabil
live
vaccin
vitro
field
identif
plasmidmedi
quinolon
resist
enterobacteri
isol
turkey
object
plasmidmedi
quinoloneresist
determin
qnra
identifi
recent
enterobacteri
isol
usa
china
thailand
korea
netherland
franc
strain
resist
nalidixicacid
produc
expandedspectrum
betalactamas
object
evalu
preval
qnr
gene
nalidixicacid
resist
enterobacteri
isol
recov
univers
hospit
istanbul
turkey
sinc
locat
mainland
europ
asia
method
pcr
primer
specif
qnralik
gene
use
screen
primer
specif
differ
esbl
gene
use
identifi
correspond
betalactamas
gene
matingout
assay
attempt
demonstr
transfer
qnr
determin
combin
primer
use
identifi
qnrsurround
sequenc
eightyeight
nalidixicacid
resist
enterobacteri
strain
isol
studi
among
esbl
produc
result
qnra
gene
identifi
two
esblposit
isol
esbl
strain
enterobact
cloaca
citrobact
freundii
isol
e
cloaca
isol
express
esbl
encod
plasmid
cotransf
nalidixicacid
resist
addit
resist
kanamycin
tobramycin
chloramphenicol
trimethoprim
sulfonamid
c
freundii
isol
possess
also
conjug
plasmid
harbour
qnra
gene
associ
gene
confer
also
resist
streptomycin
tobramycin
chloramphenicol
rifampin
sulfonamid
case
qnra
gene
locat
downstream
recombinas
gene
previous
identifi
qnraposit
isol
conclus
studi
emphas
qnra
gene
confer
resist
nalidix
acid
present
distantlyloc
european
countri
interestingli
qnra
gene
found
associ
gene
correspond
first
identif
latter
esbl
turkey
norfloxacin
altern
marker
decreas
suscept
fluorquinolon
salmonella
enterica
l
pez
gisaeu
pascual
sevil
e
object
treatment
failur
fluorquinolon
problem
case
salmonella
strain
show
resist
nalidix
acid
nal
ciprofloxacin
cip
mic
valu
increas
salmonella
strain
nal
resist
sever
author
propos
chang
ciprofloxacin
suscept
breakpoint
mgl
salmonella
enterica
vitek
system
extens
use
autom
suscept
system
nal
test
includ
lowest
cip
dilut
vitek
card
mgl
aim
studi
trace
nalidix
acid
resist
salmonella
enterica
isol
vitek
system
use
norfloxacin
mic
valu
marker
nalidix
acid
resist
materi
method
fortytwo
clinic
salmonella
enterica
isol
collect
julyaugust
suscept
test
achiev
use
card
vitek
system
method
southernrflp
analysi
also
perform
investig
basic
structur
detail
plasmid
contain
qnra
copi
number
qnra
determin
dot
blot
hybrid
transcript
studi
carri
use
total
rna
isol
transconjug
grown
absenc
presenc
ciprofloxacin
moxifloxacin
x
mic
result
qnra
locat
plasmid
similar
mobil
ident
southernrflp
four
plasmid
qnra
probe
hybrid
one
ecori
fragment
kb
mic
quinolon
transconjug
donor
ident
mic
transconjug
differ
parent
strain
vari
within
rang
qnra
copi
number
strain
time
higher
strain
time
higher
strain
differ
qnra
copi
number
e
coli
transconjug
observ
amount
qnra
transcript
least
greater
transconjug
transconjug
strain
without
quinolon
induct
differ
transcript
qnra
differ
transconjug
also
note
basal
level
induct
quinolon
doserespons
studi
induc
effect
ciprofloxacin
qnra
transcript
perform
transconjug
strain
maximum
effect
xmic
induct
ciprofloxacin
mic
transcript
qnra
increas
time
baselin
transconjug
strain
respect
induct
qnra
ciprofloxacin
time
higher
caus
moxifloxacin
transconjug
respect
conclus
regul
qnra
express
may
similar
four
strain
differ
qnra
copi
number
strain
contain
gene
transcript
analysi
reveal
ciprofloxacin
moxifloxacin
abl
induc
qnra
gene
ciprofloxacin
better
induc
moxifloxacin
use
norfloxacin
mcg
screen
disc
predict
fluoroquinolon
resist
streptococcu
pneumonia
c
rw
smyth
w
hryniewicz
g
kahlmet
e
sadowi
warsaw
pl
object
use
sensit
screen
disc
detect
antibiot
class
resist
becom
increasingli
import
nalidix
acid
disc
mcg
success
use
detect
fluoroquinolon
fq
resist
enterobacteriacea
haemophilu
spp
neisseria
spp
cefpodoxim
use
detect
esbl
recent
cefoxitin
detect
mrsa
compar
sensit
norfloxacin
mcg
ciprofloxacin
mcg
disc
detect
fluoroquinolon
resist
collect
fq
sensit
resist
streptococcu
pneumonia
method
collect
pneumonia
strain
poland
without
sweden
fluoroquinolon
resist
mechan
test
antibiot
disc
norfloxacin
mcg
ciprofloxacin
mcg
oxoid
uk
muellerhinton
agar
oxoid
uk
defibrin
sheep
blood
isosensitest
agar
oxoid
uk
defibrin
hors
blood
nad
use
muellerhinton
agar
investig
confluent
semiconflu
inoculum
isa
test
semiconflu
inoculum
ciprofloxacin
micvalu
etest
ab
biodisk
sweden
determin
isa
plate
incub
c
carbon
dioxid
h
measur
inhibit
zone
strain
exhibit
ciprofloxacin
micvalu
mgl
consid
part
wild
type
mic
distribut
defin
eucast
epidemiolog
cutoff
valu
wwweucastorg
result
strain
mic
mgl
reliabl
detect
method
disc
difficult
reliabl
separ
wild
type
distribut
strain
mic
mgl
irrespect
agar
inoculum
norfloxacin
mcg
disc
easili
distinguish
strain
mic
mgl
strain
mgl
ciprofloxacin
mcg
slightli
inferior
norfloxacin
disc
much
reliabl
ciprofloxacin
mcg
conclus
use
method
base
nccl
bsac
srga
methodolog
norfloxacin
mcg
ciprofloxacin
mcg
prefer
ciprofloxacin
mcg
detect
fluoroquinolon
resist
pneumonia
suggest
fluoroquinolon
resist
surveil
perform
one
disc
ciprofloxacin
micdetermin
perform
strain
identifi
screen
test
antibacteri
suscept
studi
ii
object
antibiot
lock
therapi
alt
recent
recommend
conserv
cathet
treatment
central
venou
cathet
cvc
relat
infect
perform
studi
investig
adequ
antibiot
concentr
antibiot
treatment
durat
alt
method
evalu
bacteri
kill
activ
vancomycin
teicoplanin
ciprofloxacin
rifampin
cefazolin
gentamicin
nafcillin
erythromycin
biofilm
aureu
epidermidi
effect
antibiot
lock
assay
exposur
antibiot
mgml
day
use
vitro
model
biofilm
polyurethan
pu
film
biofilm
bacteria
quantifi
determin
viabl
count
result
signific
biofilm
kill
achiev
cefazolin
nafcillin
gentamicin
erythromycin
time
interv
examin
object
pseudomona
aeruginosa
opportunist
pathogen
innat
resist
mani
antibiot
predominantli
infect
patient
defect
antibacteri
defens
ultrasound
current
use
medic
practic
diagnost
therapeut
purpos
recent
applic
ultrasound
drug
deliveri
mani
report
literatur
suggest
ultrasound
activ
potenti
make
effect
pharmacolog
agent
studi
investig
effect
ultrasound
smic
ceftazidim
phagocytosi
pseudomona
aeruginosa
atcc
separ
combin
method
suscept
bacteria
murin
macrophag
kill
examin
follow
exposur
ceftazidim
ultrasound
frequenc
mhz
power
output
w
bacteria
ad
macrophagecontain
polypropylen
tube
incub
centrifug
wash
macrophag
remov
adher
unphagocyt
organ
cell
lyse
distil
water
sampl
plate
incub
number
viabl
coloni
count
result
vitro
pretreat
bacteria
smic
antibiot
ultrasound
separ
result
enhanc
macrophag
phagocytosi
kill
organ
p
notabl
enhanc
effect
manifest
increas
nonopson
kill
follow
pretreat
bacteria
two
independ
variabl
combin
p
conclus
result
show
simultan
applic
ultrasound
ceftazidim
efficaci
inactiv
pseudomona
aeruginosa
improv
phagocyt
activ
physic
mechan
inactiv
ultrasound
alon
appear
transient
cavit
mechan
ultrasound
enhanc
antibiot
action
may
due
perturb
cell
membran
stress
respons
bacteria
mechan
synergist
effect
ultrasound
ceftazidim
unknown
mani
attempt
made
occurr
resist
wide
spectrum
antimicrobi
agent
clinic
isol
genu
acinetobact
object
aim
studi
determin
occurr
resist
antimicrobi
agent
acinetobact
clinic
isol
nd
nd
nd
n
n
n
n
n
n
n
n
n
inoculum
synerg
antagon
defin
decreas
increas
major
equal
cfuml
viabl
count
combin
h
compar
activ
agent
alon
object
nontyp
haemophilu
influenza
nthi
wellknown
major
respiratori
tract
pathogen
recent
shown
abl
invad
persist
insid
human
epitheli
cell
studi
analys
intracellular
vitro
activ
ampicillin
azithromycin
telithromycin
ciprofloxacin
moxifloxacin
nthi
method
confluent
normal
human
bronchial
epitheli
nhbe
cell
load
bacteria
per
epitheli
cell
h
extracellular
h
influenza
kill
gentamicin
intracellular
bacteria
incub
fresh
invas
medium
supplement
select
antimicrobi
agent
concentr
mgl
h
final
step
invas
medium
remov
number
intracellular
viabl
bacteria
determin
lysi
epitheli
cell
result
moxifloxacin
show
highest
bactericid
efficaci
intracellular
nthi
follow
ciprofloxacin
azithromycin
telithromycin
first
h
ampicillin
abl
influenc
intracellular
surviv
h
influenza
comparison
control
without
antibiot
compar
test
antibiot
moxifloxacin
effect
kill
intracellular
nthi
therefor
moxifloxacin
combin
high
extracellular
intracellular
activ
seen
import
tool
treatment
rti
antibiot
suscept
fusobacterium
necrophorum
strain
caus
seriou
infect
r
hannula
l
bevang
trondheim
n
object
f
necrophorum
caus
abscess
mainli
oropharynx
lemierr
syndrom
postangin
sepsi
rare
lifethreaten
diseas
young
previous
healthi
adult
longterm
antibiot
treatment
often
neededw
studi
suscept
pattern
f
necrophorum
avail
clinic
isol
hospit
januari
octob
method
four
bloodstream
isol
nine
clinic
isol
mainli
abscess
avail
testingth
bacteria
cultur
fastidi
anaerob
agar
faa
identifi
coloni
morpholog
microscop
morpholog
chartreus
fluoresc
lipas
posit
biochem
rapid
id
bacteria
suspend
brain
heart
broth
mcfarland
turbid
swab
pdm
agar
defibrin
hors
blood
etest
strip
biodisk
appli
dri
agar
surfac
plate
incub
anaerob
hour
read
result
strain
test
penicillinas
activ
nitrocephin
result
three
strain
resist
penicillin
produc
penicillinas
mic
valu
ciprofloxacin
gener
higher
antibiot
coloni
size
agar
plate
increas
compar
coloni
plate
suggest
growth
stimul
ciprofloxacin
etest
result
imipenem
show
high
mic
due
hazi
coloni
inhibit
zone
etest
result
indic
resist
penicillin
imipenem
f
necrophorum
strainsclindamycin
metronidazol
seem
good
therapi
alternativesm
valu
ciprofloxacin
high
ciprofloxacin
choic
therapi
doxycyclin
cefotaxim
might
use
second
line
therapi
mic
test
alway
perform
seriou
anaerob
infect
vitro
activ
variou
antibiot
alon
combin
colistin
methanesulfon
pseudomona
aeruginosa
strain
isol
cystic
fibrosi
patient
project
focus
analysi
associ
resist
antimicrobi
pathogen
bacteria
method
mic
estim
modif
standard
colorimetr
method
potenti
factor
pathogen
evalu
vitro
use
test
hydrophob
adher
xylen
motil
agar
product
biofilm
microtit
plate
assay
hsl
biosensor
c
violaceum
tumefacien
respons
oxid
stress
evok
hydrogen
peroxid
result
strain
demonstr
greatest
level
resist
addit
natur
resist
cefotaxim
isol
rang
resist
aminoglycosid
ciprofloxacin
cephalosporin
hand
strain
remain
suscept
meropenem
piperacillintazobactam
piperacillin
major
strain
manifest
hydrophil
charact
higher
zone
motil
show
isol
averag
mm
compar
one
mm
one
third
strain
produc
higher
amount
biofilm
quantifi
measur
absorb
solubil
crystal
violet
rest
isol
two
strain
produc
sampl
detect
four
isol
higher
biofilm
product
show
type
hsl
major
strain
manifest
higher
resist
hydrogen
peroxid
compar
rest
strain
group
strain
resist
aminoglycosid
ciprofloxacin
reveal
significantli
higher
number
hydrophob
strain
compar
sensit
one
associ
found
among
rest
test
paramet
data
obtain
studi
indic
resist
antimicrobi
pseudomona
spp
isol
alway
associ
chang
product
pathogen
factor
studi
synerget
action
dioxidin
isoniazid
structur
tubercl
bacillu
vitro
background
epidemiolog
aureu
rapidli
chang
mrsa
tradit
confin
institut
set
occurr
multidrug
resist
caus
concern
howev
even
concern
increas
preval
mrsa
commun
therapeut
option
infect
limit
dap
cyclic
lipopeptid
recent
object
quinolon
potent
bactericid
agent
mechan
kill
poorli
understood
one
interest
featur
repres
fact
anaerob
condit
growth
bacteria
inhibit
viabil
affect
similar
effect
observ
drug
associ
protein
synthesi
inhibitor
studi
evalu
quinolon
suscept
presenc
chloramphenicol
two
mutant
strain
previous
describ
int
j
antimicrob
agent
suscept
nalidix
acid
anaerob
environ
method
mutat
cotransf
insert
min
e
coli
map
transduct
perform
standard
method
wildetyp
strain
timekil
experi
aerob
anaerob
condit
carri
two
differ
quinolon
ciprofloxacin
nalidix
acid
alon
combin
chloramphenicol
mgl
follow
procedur
suggest
nccl
report
elsewher
antimicrob
agent
chemoth
result
transduct
reveal
phenotyp
origin
mutant
suscept
nalidix
acid
anaerob
condit
assess
time
kill
elong
cell
format
aerob
growth
gener
time
min
comparison
min
control
time
kill
experi
aerob
environ
reveal
two
transduct
also
suscept
ciprofloxacin
nalidix
acid
presenc
chloramphenicol
isol
exclud
duplic
within
week
sampl
collect
hour
hospitalis
patient
cystic
fibrosi
mic
determin
central
use
bsac
agar
dilut
method
interpret
bsac
criteria
logist
regress
model
fit
separ
penicillinnonsuscept
tetracyclin
erythromycinand
ciprofloxacinresist
penn
tetr
eryr
cipr
result
tabl
show
unadjust
resist
rate
final
model
penn
tetr
eryr
includ
centr
age
group
year
linear
function
final
model
cipr
includ
centr
age
group
year
categor
variabl
sex
specimen
type
sputumoth
care
set
gpnurs
homehospit
requir
model
isol
miss
data
n
exclud
penn
tetr
eryr
ireland
signific
linear
trend
fall
resist
odd
ratio
tabl
conclus
trend
resist
pneumonia
differ
ireland
uk
class
antimicrobi
resist
penicillin
tetracyclin
erythromycin
decreas
ireland
similar
extent
uk
trend
ciprofloxacin
resist
reason
differ
sought
influenc
age
resist
communityacquir
lower
respiratori
tract
isol
pneumonia
uk
ireland
object
examin
relationship
patient
age
antimicrobi
resist
pneumonia
method
lower
respiratori
tract
isol
streptococcu
pneumonia
collect
total
laboratori
uk
ireland
five
winter
isol
exclud
duplic
within
week
sampl
collect
hour
hospitalis
patient
cystic
fibrosi
mic
determin
central
use
bsac
agar
dilut
method
interpret
bsac
criteria
logist
regress
model
penicillinnonsuscept
tetracyclin
erythromycinand
ciprofloxacinresist
penn
tetr
eryr
cipr
fit
correct
age
year
collect
laboratori
result
age
unknown
patient
median
age
penn
tetr
eryr
model
age
group
categor
variabl
use
group
baselin
resist
least
group
greater
younger
older
patient
shown
odd
ratio
or
tabl
cipr
model
linear
function
age
or
correspond
median
age
within
age
group
shown
moxifloxacinresist
mxfr
mic
mgl
rare
logist
model
also
strongli
associ
age
mxfr
isol
cip
mic
mgl
patient
age
fisher
exact
p
none
patient
age
observ
resist
rate
isol
baselin
age
group
shown
tabl
conclus
patient
age
signific
predictor
resist
pneumonia
isol
young
elderli
patient
increas
risk
resist
pen
tet
eri
fluoroquinolon
resist
increas
linearli
age
resist
mxf
rare
uk
ireland
seen
isol
patient
age
oza
murchan
r
cunney
dublin
irl
object
aim
present
provid
updat
studi
investig
factor
affect
bacteraemia
caus
key
pathogen
isol
irish
hospit
studi
primarili
focus
pathogen
exhibit
antibiot
resist
result
use
suppli
time
feedback
contribut
laboratori
method
sampl
hospit
laboratori
particip
european
antimicrobi
resist
surveil
system
earss
provid
addit
inform
bloodstream
infect
aris
earss
pathogen
quarterli
basi
start
addit
inform
includ
patient
demograph
hospit
administr
data
risk
factor
primari
sourc
secondari
foci
inform
link
resist
data
isol
hospit
activ
denomin
data
use
calcul
rate
result
data
quarter
result
match
record
repres
hospit
laboratori
analys
dataset
data
receiv
quarter
present
preliminari
result
indic
infect
occur
younger
older
year
age
group
malign
identifi
third
patient
recent
surgeri
icustay
haemodialysi
particularli
associ
mrsa
bacteraemia
respiratori
tract
infect
common
sourc
pneumonia
bacteraemia
urinari
tract
e
coli
intraabdominalgastrointestin
tract
e
coli
enterococci
includ
vre
differ
predomin
sourc
aureu
infect
associ
differ
level
methicillinresist
skinsoft
tissu
low
proport
mrsa
cvc
medium
respiratori
tract
high
find
far
support
fact
hospit
function
influenc
bacteraemia
rate
result
treat
patient
differ
risk
factor
profil
analys
provid
surveil
programm
could
use
make
inform
target
infect
control
decis
anova
show
linear
relationship
resist
increas
per
quarter
p
suggest
increas
highli
signific
p
signific
trend
observ
resist
cephalosporin
isol
gentamicin
conclus
methicillin
resist
aureu
remain
import
public
health
problem
ireland
increas
past
five
year
although
increas
doubt
signific
ciprofloxacin
resist
e
coli
increas
significantli
sinc
surveil
began
studi
warrant
understand
reason
part
surveil
system
continu
appropri
analysi
data
trend
essenti
data
present
highlight
chang
profil
amr
ireland
time
antimicrobi
suscept
respiratori
bacteri
pathogen
among
children
greenland
littl
antibiot
resist
spite
high
antibiot
use
object
alaskan
nativ
preval
penicillinresist
pneumonia
isol
high
greenland
respiratori
tract
infect
children
frequent
antibiot
use
high
local
data
antimicrobi
resist
hardli
exist
greenland
object
studi
obtain
inform
method
populationbas
cohort
children
age
year
follow
sisimiut
greenland
twoyear
period
first
time
two
ampicillinresist
betalactamas
neg
isol
recov
high
rate
resist
found
clarithromycin
cotrimoxazol
remain
drug
test
ciprofloxacin
levofloxacin
moxifloxacin
azithromycin
telithromycin
amoxicillinclavulan
chloramphenicol
tetracyclin
gener
cephalosporin
highli
activ
suscept
strain
catarrhali
suscept
rate
rang
ampicillin
cotrimoxazol
amoxicillinclavulan
ceftriaxon
cefixim
telithromycin
azithromycin
ciprofloxacin
levofloxacin
moxifloxacin
mssa
activ
drug
suscept
teicoplanin
rifampin
cotrimoxazol
ceftriaxon
cefaclor
telithromycin
levofloxacin
conclus
antibiot
resist
among
communityacquir
respiratori
pathogen
circul
itali
rise
comparison
valu
describ
previou
nation
survey
global
telithromycin
levofloxacin
amoxicillinclavulan
ceftriaxon
activ
drug
incid
antibiot
suscept
pathogen
caus
sever
communityacquir
nosocomi
infect
itali
total
strain
test
erythromycin
non
suscept
erythromycin
pnsp
show
suscept
erythromycin
test
strain
highli
suscept
gener
cephalosporin
well
quinolon
haemophilu
influenza
total
isol
n
resist
ampicillin
total
isol
n
blactamas
neg
isol
blactamas
neg
howev
resist
ampicillin
blnar
isol
blactamas
posit
resist
amoxclav
blpacr
preval
invas
pneumonia
season
clear
peak
winter
percentag
penicillin
non
suscept
pneumonia
among
strain
display
season
preval
invas
penicillin
non
suscept
pneumonia
highest
children
year
younger
emphas
import
prudent
antimicrobi
use
antibiot
vaccin
age
group
proport
erythromycin
resist
among
penicillin
non
suscept
pneumonia
high
comparison
studi
done
mainli
europ
earss
pnsp
still
gener
highli
suscept
levofloxacin
cefotaxim
imipenem
problem
ampicillin
resist
among
isol
h
influenza
import
complic
blactamaseneg
strain
resist
ampicillin
mechan
perhap
elabor
alter
penicillinbind
protein
exot
pet
possibl
reservoir
ciprofloxacinresist
salmonella
typhimurium
infect
children
object
consid
highlevel
resist
ciprofloxacin
mgl
cipr
human
isol
salmonella
still
rare
europ
analys
molecular
characterist
cipr
strain
isol
seven
children
one
adult
order
explor
possibl
epidemiolog
relationship
two
cipr
strain
isol
parrot
snake
pet
anim
speci
report
reservoir
salmonella
sporad
transmit
human
method
strain
character
serotyp
phage
type
antimicrobi
suscept
test
without
efflux
pump
inhibitor
epi
pulsedfield
gel
electrophoresi
pfge
polymeras
chain
reaction
dna
sequenc
use
identifi
integronborn
gene
cassett
mutat
gyra
gyrb
parc
pare
gene
result
enterica
strain
serotyp
typhimurium
phage
type
variant
resist
multipl
antibiot
ampstrspctetcmpsul
includ
cip
mgl
one
except
gen
tmp
cipr
associ
case
mutat
gyra
gyrb
parc
moder
decreas
quinolon
efflux
gen
tmpresist
strain
carri
ca
kb
integron
dfrxii
cassett
gen
tmpsuscept
strain
contain
cassett
also
ca
kb
integron
use
xbai
pfge
profil
strain
indistinguish
use
blni
reveal
discret
subgroup
differ
isol
children
snake
identifi
sourc
infect
b
isol
children
adult
parrot
without
document
contact
c
gen
tmpsuscept
isol
child
contact
pet
snake
conclus
food
chain
common
rout
animaltohuman
transmiss
salmonella
may
resist
multipl
antibiot
includ
fluoroquinolon
present
studi
rais
possibl
exot
pet
anim
may
becom
reservoir
strain
may
transmit
especi
young
children
chang
antimicrobi
associ
resist
suscept
pattern
resist
load
consecut
uti
escherichia
coli
object
antimicrobi
resist
often
express
individu
resist
rate
speci
defin
drug
object
studi
present
altern
model
describ
resist
develop
escherichia
coli
urinari
tract
infect
systemat
categoris
suscept
fluoroquinolon
trimethoprim
ampicillin
cefadroxil
mecillinam
nitrofurantoin
use
methodolog
interpret
criteria
swedish
refer
group
antibiot
three
model
analys
associ
resist
present
resist
rate
drug
presenc
absenc
resist
drug
previous
describ
jac
suscept
pattern
chang
describ
chang
rank
order
pattern
number
differ
pattern
time
resist
load
express
transform
suscept
pattern
strain
numer
valu
suscept
pattern
sssssr
correspond
pattern
rssir
minimum
maximum
resist
load
respect
result
associ
resist
high
observ
period
exampl
trimethoprim
resist
ecoli
resist
sensit
ampicillin
versu
versu
five
common
yet
standard
present
studi
compar
outcom
cutoff
level
day
year
surveil
data
ecoli
saureu
materi
method
consecut
isol
e
coli
n
aureu
n
routin
suscept
test
laboratori
includ
duplic
identifi
exclud
base
uniqu
person
identif
number
speci
cutoff
time
day
first
isol
suscept
test
perform
recommend
swedish
refer
group
antibiot
chang
year
except
fluoroquinolon
norfloxacin
ciprofloxacin
nalidix
acid
effect
resist
rate
exclud
duplic
isol
di
small
despit
fact
almost
one
third
isol
exclud
day
exclus
algorithm
except
fluoroquinolon
resist
rate
e
coli
decreas
di
exclud
basi
day
increas
di
exclud
basi
day
resist
aureu
tend
decreas
duplic
exclud
independ
cutoff
time
conclus
e
coli
aureu
two
import
pathogen
common
resist
surveil
although
effect
resist
rate
exclus
duplic
isol
minor
statist
signific
present
studi
suggest
exclus
cutoff
match
timelin
ie
rate
present
yearli
figur
exclus
cutoff
day
furthermor
believ
effect
exclud
duplic
present
conjunct
present
surveil
data
data
suggest
e
coli
reinfect
infect
speci
day
first
incid
mainli
caus
new
less
resist
strain
wherea
patient
acquir
resist
strain
aureu
continu
colon
strain
haemophilu
influenza
antibiot
resist
greek
patient
object
h
influenza
repres
one
commonest
pathogen
communityacquir
respiratori
infect
recent
great
concern
worldwid
regard
increas
preval
betalactamas
produc
strain
increas
incid
resist
ampicillin
macrolid
emerg
ampicillin
resist
nonbetalactamas
produc
isol
blnar
well
isol
betalactamas
produc
strain
resist
amoxicillinclavulan
acid
blpacr
isol
test
betalactamas
product
well
suscept
ampicillin
amoxicillin
amoxicillin
clavulan
acid
ac
erythromycin
trimethoprimesulfamethoxazol
ciprofloxacin
moxifloxacin
disk
diffus
method
accord
standard
procedur
corval
type
extendedspectrum
betalactamas
tem
shv
esbl
produc
strain
multiresist
antimicrobi
blatem
gene
success
transfer
recipi
e
coli
strain
simultan
gene
code
resist
aminoglycosid
sulfonamid
gene
code
resist
aminoglycosid
chloramphenicol
blatempcr
amplif
reveal
gene
senteritidi
blatem
scorvallisbefor
enteritidi
suscept
antimicrobi
agent
test
studi
salmonella
reveal
resist
least
one
antimicrobi
agent
frequent
nalidix
acid
trimethoprimsulfamethoxazoleresist
nalidix
acid
combin
retain
suscept
ciprofloxacin
enteritidi
suggest
mutat
chromosom
gyraresist
ampicillin
senteritidi
could
explain
wide
distribut
plasmid
european
countri
includ
bulgariaselect
multiresist
blatem
produc
scorval
probabl
uniqu
countri
conclus
divers
resist
gene
wide
distribut
among
lead
caus
agent
human
salmonellos
bulgaria
gramposit
bacteria
diabet
foot
ulcer
resist
current
use
antibiot
greek
gener
hospit
object
evalu
microbiolog
efficaci
antibiot
patient
without
antibiot
pretreat
commun
acquir
pneumonia
cap
method
patient
hospit
cap
evalu
sensit
pathogen
erythromycin
eri
amoxicillin
amo
azythromycin
azi
gener
cephalosporin
ceph
cefotaxim
ceftriaxon
sputum
blood
bronchial
aspir
probe
receiv
within
first
day
hospit
analys
pathogen
patient
destruct
pneumonia
exclud
atyp
pathogen
investig
identif
sensit
test
perform
accord
nccl
respect
period
discdiffus
method
atb
express
biomerieux
patient
record
screen
evalu
possibl
antibiot
treatment
current
cap
hospit
record
contain
clear
statement
antibiot
pretreat
absenc
pretreat
exclud
analysi
pathogen
patient
without
antibiot
pretreat
compar
null
hypothesi
absenc
differ
antibiot
sensit
treat
nontreat
patient
test
result
number
etiolog
insignific
pathogen
increas
nontreat
group
ntg
antibiot
treat
group
tg
among
etiolog
signific
pathogen
frequenc
enterobacteriacea
spp
grow
ntg
tg
chang
pathogen
signific
avail
sampl
total
number
strain
sensit
amo
azi
significantli
higher
ntg
respect
tg
respect
drop
sensit
eri
ntg
tg
ceph
ntg
tg
respect
signific
investig
set
pathogen
well
sensit
could
shift
set
hospit
admiss
polici
facilit
entranc
auto
plant
employe
amo
azi
could
accept
empir
choic
antibiot
cap
ntg
hospit
patent
tg
preferenti
choic
ceph
eri
macrolid
without
antihaemophilu
activ
pose
suffici
microbiolog
efficaci
even
nontreat
patient
microbiolog
efficaci
antibiot
patient
differ
sever
score
communityacquir
pneumonia
object
evalu
microbiolog
efficaci
antibiot
patient
differ
sever
commun
acquir
pneumonia
cap
method
patient
hospit
cap
evalu
sensit
pathogen
erythromycin
eri
amoxicillin
amo
azythromycin
azi
gener
cephalosporin
ceph
cefotaxim
ceftriaxon
sputum
blood
bronchial
aspir
probe
receiv
within
first
day
hospit
analys
pathogen
patient
destruct
pneumonia
exclud
atyp
pathogen
investig
identif
sensit
test
perform
accord
nccl
respect
period
discdiffus
method
atb
express
biomerieux
modifi
fine
score
use
evalu
sever
pneumonia
pathogen
patient
sever
score
less
class
score
class
compar
null
hypothesi
absenc
differ
antibiot
sensit
patient
differ
sever
cap
test
result
lower
sever
group
lsg
predomin
pathogen
haemophilu
spp
higher
sever
group
hsg
drop
frequenc
streptococcu
spp
nonfer
gramneg
bacteria
staphylococcu
spp
increas
lsg
respect
hsg
nevertheless
avail
sampl
signific
differ
total
number
sensit
strain
sever
group
lsg
sensit
amo
eri
azi
ceph
hsg
amo
eri
azi
ceph
investig
set
pathogen
well
sensit
could
shift
set
hospit
admiss
polici
facilit
entranc
auto
plant
employe
conclus
fine
sever
score
could
predict
microbiolog
efficaci
antibiot
hospit
patient
cap
total
number
pathogen
sensit
amo
macrolid
without
antihaemophilu
activ
suffici
legitim
antibiot
fist
line
treatment
hospit
patient
cap
sensit
azi
margin
accept
ceph
provid
best
microbiolog
efficaci
object
mani
countri
nontyphoid
salmonella
lead
caus
foodborn
ill
human
salmonellosi
usual
selflimit
antimicrobi
treatment
recommend
sever
ill
fluoroquinolon
thirdgener
cephalosporin
drug
choic
concern
rais
recent
regard
poultri
major
sourc
fluoroquinoloneresist
salmonella
spp
surveil
compris
two
larg
eu
region
conduct
method
one
programm
caecal
sampl
randomli
taken
belgian
slaughterhous
chicken
rais
belgium
franc
netherland
caecal
content
bird
pool
provid
singl
sampl
per
flock
anoth
carcass
meat
sampl
collect
chicken
process
sever
process
plant
across
germani
total
salmonella
strain
isol
standard
suscept
test
ciprofloxacin
cp
nalidix
acid
na
well
nonquinolon
includ
ampicillin
cefotaxim
ct
chloramphenicol
ca
gentamicin
gm
streptomycin
tetracyclin
te
trimethoprimsulfadiazin
ts
perform
agar
dilut
resist
assess
applic
use
nccl
criteria
result
differ
serotyp
identifi
serotyp
preval
differ
strikingli
two
geograph
area
well
time
programm
resist
cp
absent
except
one
isol
mic
lgml
decreas
suscept
appar
deterior
indic
stabl
cp
valu
around
lgml
resist
na
among
serotyp
decreas
suscept
hadar
virchow
blockley
paratyphi
b
rel
frequent
contrast
resist
te
ts
amount
belgian
collect
germani
ca
resist
respect
gm
resist
exceed
programm
isol
thu
far
test
ct
suscept
none
resist
mic
lgml
conclus
resist
among
salmonella
spp
chicken
vari
nonquinolon
ct
consider
higher
rate
older
drug
resist
cp
particularli
import
treat
invas
salmonellosi
human
approach
zero
decreas
cp
suscept
vari
markedli
differ
serotyp
preval
differ
notabl
site
time
integron
class
antibiot
resist
enterobacteriacea
blood
stream
infect
danish
counti
n
norskovlauritsen
sandvang
hc
schonheyd
aarhu
copenhagen
aalborg
dk
object
determin
antibiot
resist
gene
cassett
associ
class
integron
enterobacteriacea
isol
blood
method
consecut
blood
isol
enterobacteriacea
n
counti
northern
jutland
investig
isol
express
resist
sulphonamid
n
examin
presenc
pcr
amplif
conserv
fragment
gene
cassett
insert
class
integron
pcr
amplifi
primer
locat
upand
downstream
recombin
site
amplicon
alloc
type
accord
restrict
fragment
length
polymorph
rflp
digest
mspi
hinfi
gene
cassett
identifi
sequenc
repres
type
result
resist
sulphonamid
express
isol
escherichia
coli
one
hundr
twentyf
posit
presenc
could
divid
rflp
type
resist
sulphonamid
express
isol
none
coli
twentythre
posit
presenc
could
divid
rflp
type
six
uniqu
seven
also
found
e
colia
total
distinct
type
one
three
gene
cassett
found
isol
four
type
account
isol
two
associ
e
colith
predomin
antibiot
resist
direct
toward
streptomycinspectinomycin
seven
distinct
gene
isol
trimethoprim
eight
distinct
gene
isol
six
isol
carri
gene
confer
resist
veterinari
antibiot
streptotricin
number
class
integron
carri
gene
confer
resist
antibiot
four
gentamicin
three
conspicu
low
conclus
presenc
class
integron
acquir
resist
sulphonamid
time
preval
e
coli
repres
enterobacteriacea
antibiot
resist
collect
isol
predominantli
direct
toward
streptomycinspectinomycin
trimethoprim
e
antibiot
clinic
use
long
time
background
recent
studi
unexpectedli
high
resist
rate
unrel
heavi
antimicrobi
consumpt
clinic
microbiolog
infect
volum
supplement
detect
commens
e
coli
popul
remot
rural
commun
bolivia
purpos
studi
analys
molecular
basi
drugresist
isol
collect
set
method
drugresist
e
coli
isol
collect
healthi
individu
subject
clonal
analysi
mean
rapd
isol
present
common
multidrug
resist
mdr
pattern
ampicillin
tetracyclin
chloramphenicol
trimethoprimsulfamethoxazol
atc
pattern
n
investig
natur
transfer
resist
determin
plasmid
profil
result
rapd
result
identifi
clonal
group
one
larg
preval
isol
intrafamili
clonal
cluster
often
observ
one
case
mdr
strain
detect
fecal
sampl
member
famili
subject
heterogen
resist
phenotyp
observ
within
clonal
group
underli
relev
role
transfer
resist
determinantsclon
plasmid
variabl
observ
mdr
isol
show
atc
resist
pattern
belong
preval
clonal
group
show
colicin
product
harbour
teta
gene
transfer
resist
determin
could
detect
strain
ii
belong
differ
clonal
group
harbour
conjug
plasmid
carri
teta
gene
link
betalactam
chloramphenicol
trimethoprimsulfamethoxazol
resist
determin
gene
involv
colicin
product
iii
belong
differ
clonal
group
show
colicin
product
harbour
tetb
gene
often
locat
conjug
plasmid
differ
restrict
profil
differ
carriag
resist
determin
conclus
clonal
plasmid
divers
suggest
presenc
mdr
isol
particular
set
due
mechan
complex
simpl
dissemin
singl
clone
singl
resist
plasmid
occasion
introduc
commun
object
zygomycosi
lifethreaten
diseas
increas
incid
immunocompromis
patient
sever
fungi
respons
infect
identif
speci
level
remain
difficult
convent
mycolog
techniqu
aim
studi
investig
use
rdna
sequenc
speci
identif
zygomycet
method
isol
mostli
clinic
origin
belong
order
mucoral
test
includ
speci
belong
genera
commonli
respons
zygomycosi
human
mycelium
grown
liquid
rpmi
medium
complet
genom
dna
extract
ctabchloroform
pcramplif
rdna
region
perform
primer
set
ttaagtccctgccctttgta
gagtcgagttgtttgggaatgc
amplif
strand
sequenc
fungal
dna
perform
sequenc
align
compar
clustalw
result
sequenc
ca
bp
obtain
analysi
show
speci
studi
except
absidia
corymbifera
homogen
similar
strain
within
given
speci
contrast
sequenc
variabl
genera
similar
speci
similar
allow
precis
identif
speci
level
particular
possibl
differenti
rhizopu
oryza
r
microsporu
discrimin
differ
mucor
spp
sequenc
corymbifera
heterogen
similar
strain
interestingli
none
studi
speci
own
univers
fungal
primer
sequenc
result
show
sequenc
region
reliabl
molecular
tool
identif
agent
zygomycosi
speci
level
strain
identifi
corymbifera
higher
number
isol
studi
molecular
data
obtain
promis
develop
new
diagnosi
method
zygomycosi
patient
object
cultur
infect
tissu
zygomycosi
often
neg
case
avail
diagnost
tool
histopatholog
demonstr
larg
nonsept
hypha
characterist
zygomycet
nevertheless
identif
genu
speci
level
possibl
convent
histopatholog
aim
studi
evalu
use
rdna
sequenc
speci
identif
tissu
mice
infect
variou
zygomycet
method
mice
infect
intraven
nine
differ
speci
order
mucoral
rhizopu
oryza
r
microsporu
var
rhizopodiformi
absidia
corymbifera
mucor
indicu
circinelloid
racemosu
rhizomucor
pusillu
cunninghamella
bertholletia
syncephalastrum
racemosum
differ
inocula
test
rang
sporangiosporesmous
mice
challeng
c
bertholletia
racemosum
receiv
mg
kg
hydrocortison
subcutan
infect
mice
sacrif
day
post
infect
brain
kidney
asept
remov
homogen
complet
genom
dna
extract
ctabchloroform
fungal
dna
pcramplifi
univers
fungal
primer
set
ttaagtccctgccctttgta
gagtcgagttgtttgggaatgc
amplif
strand
sequenc
fungal
dna
perform
sequenc
align
compar
clustalw
result
activ
infect
demonstr
presenc
hypha
brain
kidney
obtain
test
speci
except
racemosu
fungal
dna
amplifi
directli
tissu
eight
former
speci
furthermor
six
speci
sequenc
region
allow
identif
infect
strain
speci
level
technic
problem
impair
analysi
sequenc
c
bertholletia
racemosum
conclus
setup
anim
model
zygomycosi
common
speci
respons
infect
human
demonstr
extract
amplif
sequenc
fungal
dna
possibl
directli
infect
tissu
strain
cultur
liquid
rpmi
medium
dna
extract
mycelium
dneasi
plant
kit
qiagen
region
dna
pcr
amplifi
use
univers
fungal
primer
strand
sequenc
perform
sequenc
align
clustalw
intraand
interspeci
sequenc
similar
assess
align
sequenc
also
use
gener
phylogenet
tree
result
mycetomati
appear
homogen
speci
homolog
strain
except
one
strain
differ
significantli
rais
issu
identif
similarli
intraspeci
variat
found
c
lunata
e
jeanselmei
homolog
strain
l
senegalensi
l
tompkinsii
show
intraspeci
similar
similar
two
speci
contrast
p
romeroi
grisea
appear
heterogen
intraspeci
similar
respect
intergenera
interspeci
variat
import
except
p
romeroi
grisea
sequenc
homolog
genera
conclus
p
romeroi
grisea
heterogen
speci
wherea
within
speci
high
degre
sequenc
homolog
observ
result
show
sequenc
region
suitabl
tool
identif
black
grain
mycetoma
agent
usual
difficult
identifi
standard
phenotyp
method
rapid
diagnosi
pcp
resist
cotrimoxazol
use
realtim
pcr
object
compar
convent
microbiolog
stain
method
convent
pcr
realtim
pcr
method
diagnosi
pneumocysti
jiroveci
patient
suspect
pneumocysti
pneumonia
pcp
assess
posit
sampl
presenc
cotrimoxazol
cot
resist
mutat
method
eightyfour
sequenti
bronchoalveolar
lavag
sampl
patient
analys
methanamin
silver
giemsa
stain
method
store
subsequ
analys
pcr
bal
collect
period
realtim
pcr
design
dihydroptero
synthas
dhp
specif
p
jiroveci
enabl
sequenc
pcr
product
determin
resist
mutat
nucleotid
posit
convent
pcr
mitochondri
larg
subunit
rrna
describ
wakefield
et
al
lancet
also
perform
bal
result
stain
method
show
patient
pcp
realtim
pcr
convent
pcr
detect
p
jiroveci
sampl
posit
stain
method
posit
addit
posit
detect
pcr
methodolog
use
stain
method
gold
standard
sensit
specif
posit
predict
valu
neg
predict
valu
pcr
method
respect
mean
cycl
threshold
ct
valu
stain
posit
stain
negativepcr
posit
analysi
clinic
record
microbiolog
result
discrep
sampl
show
microbiolog
agent
found
pcp
like
clinic
diagnosi
posit
sequenc
resist
mutat
found
time
perform
differ
method
hour
hour
hour
stain
method
realtim
pcr
convent
pcr
sequenc
could
perform
directli
realtim
pcr
result
avail
one
work
day
conclus
realtim
pcr
pjiroveci
provid
rapid
sensit
specif
diagnosi
pcp
bal
sampl
addit
ct
valu
may
use
determin
amount
infect
use
method
target
dhp
gene
rapid
result
also
obtain
resist
cot
identif
trichosporon
mucoid
isol
use
test
direct
dna
sequenc
intern
transcrib
spacer
rdna
u
nawrot
pa
fonteyn
f
fauch
n
nolard
wroclaw
pl
brussel
b
object
identif
system
provid
distinguish
three
speci
publish
far
genu
trichosporon
aim
studi
investig
genet
homogen
strain
identifi
accord
trichosporon
mucoid
trichophyton
rubrum
rubrum
cosmopolitan
arthropophil
dermatophyt
caus
skin
nail
infect
antifung
drug
avail
clinic
use
target
four
molecul
includ
betaglucan
sterolalphademethylas
ergosterol
dnarna
synthesi
limit
select
effect
antifung
agent
combin
emerg
drug
resist
result
critic
need
develop
new
drug
direct
novel
molecular
target
present
studi
tri
character
gene
encod
betatubulin
protein
fungu
use
potenti
molecular
target
novel
drugsclin
isol
rubrum
cultur
liquid
medium
nucleic
acid
dna
rna
isol
obtain
myceli
mass
standard
method
sequenc
known
betatubulin
gene
fungi
align
pair
nt
primer
design
highli
conserv
region
use
mention
primer
amplifi
predict
molecul
use
genom
dna
well
cdna
trubrum
pcr
templatesbi
time
nucleotid
sequenc
new
gene
encod
polypeptid
amino
acid
nucleotid
sequenc
comparison
gene
data
bank
ncbi
nih
partial
dna
deduc
amino
acid
sequenc
reveal
signific
homolog
member
eukaryot
betatubulin
gene
amino
acid
sequenc
encod
protein
ident
sequenc
betatubulin
protein
fungiconsid
role
tubulin
protein
format
mitot
spindl
structur
cell
betatubulin
gene
may
appli
antifung
research
field
moreov
use
determin
molecular
action
drug
includ
mitot
spindl
structur
fungi
lead
metaphas
arrest
probabl
mechan
betatubulin
express
inhibit
well
definit
possibl
role
physiolog
function
rubrum
still
investig
c
krusei
c
glabrata
r
rubra
unidentifi
fungi
agent
detect
repeatedli
patient
patien
agent
isol
second
blood
cultur
differ
isol
first
one
case
result
correspond
well
result
detect
mannan
antigen
antimannan
antibodi
serum
patient
case
blood
sampl
posit
cultiv
possibl
caus
neg
cultiv
antifung
therapi
patient
could
supress
growth
yeast
blood
cultur
result
suggest
combin
pcr
detect
fungal
dna
proof
mannan
antigen
antimannan
antibodi
help
diagnost
fungal
blood
stream
infect
especi
patient
antimycot
therapi
work
support
grant
agenc
iga
mz
immunosuppress
host
earli
diagnosi
import
achiev
best
outcom
patient
howev
definit
proof
often
difficult
obtain
due
counterind
invas
procedur
serum
galactomannan
detect
consid
use
test
earli
diagnosi
follow
invas
aspergillosi
method
studi
evalu
specif
sensit
detect
galactomannan
gm
diagnost
ia
adult
patient
hospit
hematolog
unit
patient
consid
confirm
probabl
invas
aspergillosi
base
clinic
radiolog
data
serial
screen
aspergillu
gm
circul
antigen
evalu
use
doubl
sandwich
elisa
assay
platelia
aspergillu
biorad
franc
sera
test
posit
defin
accord
manufactur
recommend
result
among
patient
studi
present
confirm
ia
n
patient
probabl
ia
n
patient
seven
patient
posit
result
od
index
two
consecut
platelia
aspergillu
test
consid
galactomannan
posit
case
antigen
detect
sera
one
patient
confirm
ia
latex
agglutin
assay
galactomannan
posit
patient
probabl
ia
patient
without
ia
posit
antigenemia
sensit
specif
compar
larger
seri
circul
antigen
detect
control
group
compos
healthi
adult
gradual
rise
antigen
titer
consecut
sampl
strong
indic
infect
present
taken
account
interpret
result
conclus
detect
circul
aspergillu
galactomannan
antigen
sandwich
enzymelink
immunosorb
assay
elisa
one
promis
method
diagnos
ia
atrisk
patient
presenc
antigen
good
diagnost
valu
mainli
increas
titer
two
consecut
sera
sampl
repeat
neg
result
strong
argument
diagnosi
ia
inhibit
control
alway
necessari
pcr
human
sampl
barkham
v
rajagop
singapor
sgp
object
assess
need
inhibit
control
diagnost
pcr
human
serum
blood
cultur
bactalert
fan
media
method
dengu
rtpcr
perform
daili
month
rna
extract
serum
qiagen
viral
rna
minikit
pcr
kit
artu
gmbh
germani
includ
intern
control
everi
sampl
perform
lightcycl
roch
perform
inhous
multiplex
gel
base
pcr
assay
primer
aim
calbican
c
glabrata
ctropicali
c
parapsilosi
pcr
appli
without
dna
extract
supernat
bactalert
fan
bottl
left
stand
allow
charcoal
particl
settl
bottl
flag
posit
shown
contain
yeast
gram
stain
neat
doubl
dilut
salin
test
result
inhibit
control
posit
sera
test
artu
dengu
rtpcr
kit
mean
pcr
process
success
without
signific
inhibit
sampl
inhibit
detect
use
neat
broth
bactalert
fan
bottl
detect
dilut
conclus
inhibit
pcr
perform
sera
common
unnecessari
control
inhibit
pcr
supernat
bactalert
fan
bottl
subject
inhibit
howev
pcr
success
supernat
dilut
assay
use
sampl
known
contain
yeast
demonstr
gram
stain
absent
signal
would
suggest
inhibit
speci
recognis
primer
neg
result
might
delay
identif
speci
level
refin
antifung
chemotherapi
would
delay
diagnosi
candidaemia
data
support
view
inhibit
control
unnecessari
pcr
applic
valid
perform
adequ
furthermor
inhibit
consider
problem
bacteri
cultur
standard
practic
detect
report
inhibit
would
inconsist
make
inhibit
control
obligatori
nucleic
acid
test
briefli
eia
sandwich
style
system
use
rabbit
polyclon
antibodi
histoplasma
antigen
captur
plate
block
allow
dri
test
sampl
ad
allow
incub
wash
next
polyclon
antibodi
use
captur
contain
biotin
label
ad
follow
streptavidinhors
radish
peroxidas
incub
conjug
wash
benzidin
tmb
ad
substrat
reaction
stop
use
h
endpoint
optic
densiti
od
read
nm
result
intralaboratori
correl
good
singl
sampl
purifi
galactomannan
antigen
test
posit
day
one
neg
day
two
ssi
mvd
lab
interlaboratori
correl
excel
compar
result
lab
day
two
sampl
control
result
ident
result
interpret
accord
guidelin
result
express
eia
unit
eu
eu
neg
n
eu
weak
posit
n
eu
moder
posit
n
eu
high
posit
n
result
remain
within
categori
laboratori
conclus
excel
correl
result
support
feasibl
develop
histoplasma
antigen
eia
test
kit
use
refer
test
ssi
blind
subcultur
increas
margin
detect
fungaemia
highrisk
patient
u
hjort
hc
aalborg
dk
object
abil
detect
fungaemia
bacteriolog
blood
cultur
bc
media
autom
system
may
question
investig
retrospect
whether
blind
subcultur
day
increas
detect
fungaemia
bactalert
system
acceler
diagnosi
high
risk
patient
method
histor
cohort
studi
conduct
univers
hospit
affili
hospit
period
app
year
nov
dec
bc
subcultur
day
incub
patient
base
clinic
microbiolog
assess
believ
high
risk
fungaemia
adult
patient
bc
set
compris
one
standard
aerob
one
fan
aerob
one
standard
anaerob
bottl
bac
talert
system
aerob
bottl
vent
recept
incub
period
day
data
record
department
inform
system
result
bc
drawn
studi
period
confid
interv
ci
yield
growth
yeast
speci
c
albican
c
glabrata
c
parapsilosi
c
tropicali
c
krusei
yeast
speci
total
bc
select
subcultur
origin
patient
admit
icu
bc
ci
patient
turn
yeast
posit
howev
blind
subcultur
instrument
detect
yeast
bc
eight
bc
neg
blind
subcultur
one
bottl
detect
posit
bactalert
system
continu
incub
bc
growth
yeast
detect
first
three
day
incub
contrari
expect
found
time
detect
shorter
case
select
subcultur
group
ci
yeast
posit
bc
detect
within
day
compar
ci
subcultur
group
state
conclus
patient
believ
high
risk
thu
select
subcultur
group
prove
approxim
time
increas
rate
yeast
posit
bc
howev
blind
subcultur
day
disclos
quarter
yeast
posit
bc
group
due
limit
increas
detect
recommend
blind
subcultur
precaut
patient
high
risk
fungaemia
conclus
echinococcosi
parasitosi
present
big
problem
public
health
albania
base
data
incid
infect
consist
everi
year
parasit
affect
adult
children
well
women
infect
approxim
two
time
men
due
longer
exposur
domest
anim
parasit
clear
differ
urban
rural
area
term
preval
diseas
higher
reason
probabl
persist
migrat
popul
one
area
anoth
laboratori
diagnosi
echinococcosi
base
one
serolog
test
great
import
treatment
patient
evalu
immunocard
stat
immunoassay
detect
giardia
lamblia
cryptosporidium
parvum
specif
antigen
conclus
compar
microscopi
gold
standard
giardia
cryptosporidium
detect
sensit
specif
npv
antigentest
favour
rapid
assay
easi
perform
less
labourintens
low
ppv
could
explain
low
preval
pathogen
popul
overr
fals
posit
use
nonoptim
gold
standard
yersinia
outer
membran
proteinand
cell
wallspecif
antibodi
sera
healthi
adult
hungarian
sonnevend
k
al
uae
budapest
hun
object
aim
studi
investig
presenc
antiyop
igg
iga
antibodi
healthi
blood
donor
hungari
ie
countri
reportedli
low
incid
yersiniosi
compar
data
preval
cell
wallspecif
agglutinin
method
sera
healthi
hungarian
blood
donor
collect
decemb
januari
specimen
test
yopspecif
igg
iga
elisa
mikrogen
germani
sampl
also
subject
tube
agglutin
use
enterocolitica
pseudotubercolusi
iiiiiiivv
antigen
specimen
exhibit
agglutin
yersinia
antigen
also
test
brucella
salmonella
ob
od
antigen
result
sera
test
exhibit
posit
antiyop
reaction
igg
iga
class
boundari
figur
respect
iga
posit
boundari
sampl
also
posit
igg
object
enterocolitica
pseudotuberculosi
infect
manifest
enterocol
mesenter
lymphaden
reactiv
arthriti
erythema
nodosum
import
factor
pathogen
yersinia
associ
presenc
virul
plasmid
code
releas
protein
yersinia
outer
membran
protein
yop
detect
antibodi
protein
highli
specif
sensit
method
serolog
diagnosi
form
yersiniosi
aim
studi
use
enzym
immunoassay
elisa
combin
western
blot
assay
detect
antibodi
yop
pathogen
yersinia
strain
serodiagnosi
yersiniosi
method
total
number
sera
collect
equal
number
children
age
year
refer
probabl
case
yersiniosi
test
children
hospitalis
paediatr
clinic
univers
hospit
ioannina
nw
greec
period
object
human
viscer
leishmaniasi
hvl
endem
sever
foci
iran
ardebil
far
provinc
north
western
south
part
iran
region
sporad
viscer
leishmaniasi
iran
mediterranean
type
caus
agent
leishmania
infantum
main
reservoir
dog
method
studi
direct
agglutin
test
dat
compar
indirect
fluoresc
antibodi
test
ifat
diagnosi
viscer
leishmaniasi
patient
suspect
kalaazara
total
serum
sampl
collect
suspect
kalaazar
patient
mainli
kalaazar
endem
area
leishmania
infantum
antigen
studi
prepar
depart
parasitolog
school
medicin
isfahan
univers
medic
scienc
princip
phase
procedur
make
dat
antigen
mass
product
promastigot
leishmania
fetal
bovin
serum
trypsinizn
parasit
stain
coomassi
blue
fix
formaldehyd
human
serum
sampl
test
dat
well
ifat
linfantum
antigen
prepar
laboratori
result
sero
posit
rate
spr
dat
titer
ifat
titer
geometr
mean
reciproc
titer
gmrt
dat
ifat
therefor
titer
usual
consid
posit
dat
titer
regard
posit
ifat
coincid
two
test
conclus
result
show
simpl
local
laboratori
one
two
train
technician
quit
suffici
dat
serodiagnosi
serolog
survey
kalaazar
endem
area
accord
result
studi
seem
kala
azar
endem
area
clinic
symptom
viscer
leishmaniasi
particularli
among
children
dat
antibodi
titer
equal
good
indic
specif
treatment
kalaazar
evalu
three
serodiagnost
method
radioimmunoassay
indirect
haemagglutin
immunoelectrodiffus
human
hydatidosi
princip
subclass
specif
immunoglobulin
dorostcar
moghaddam
andalib
amrollahei
isfahan
ir
object
sever
techniqu
develop
serodiagnosi
hydatid
diseas
emphas
scientist
percentag
posit
result
depend
partli
techniqu
util
local
cyst
approxim
sera
patient
hydatidosi
give
fals
neg
reaction
rel
high
figur
necessit
use
comparison
sever
diagnost
techniqu
hydatidosi
present
studi
attemp
investig
solid
phase
radioimmunoassay
diagnosi
compar
indirect
heamagglutin
iha
immunoelectrodiffus
i
materi
method
sera
patient
clinic
confirm
hydatid
diseas
test
radioimmunoassay
ria
iha
i
patient
local
hepat
pulmonari
hepat
pulmonari
addit
sera
patient
clinic
confirm
hydatidosi
neg
iha
i
also
test
ria
control
sera
obtain
appar
healthi
blood
donor
result
present
studi
ria
iha
i
approxim
patient
clinic
suspect
hydatid
diseas
confirm
serologicali
sensit
three
method
similar
princip
subclass
specif
antihydatid
immunoglobulin
igg
high
level
specif
antiig
found
two
five
patient
studi
conclus
conclud
satisfactori
serodiagnosi
hydatid
diseas
ria
i
use
fuether
work
done
purif
hydatid
antigen
improv
sensit
radioimmunoassay
without
loss
specif
object
staphylococci
especi
staphylococcu
epidermidi
staphylococcu
aureu
import
pathogen
context
implant
medic
devic
infect
abil
establish
multilay
biofilm
surfac
foreign
bodi
significantli
contribut
pathogen
speci
polysaccharid
intercellular
adhesin
pia
synthes
icaadbc
encod
protein
mediat
biofilm
accumul
epidermidi
aureu
therefor
pia
appear
suitabl
antigen
novel
diagnost
tool
order
measur
humor
immun
respons
appropri
system
specif
detect
antipiaantibodi
demand
result
describ
develop
enzymelink
immuno
sorbent
assay
elisa
specif
detect
antipia
antibodi
human
sera
maxisorp
plate
nunc
coat
purifi
pia
use
piacoat
plate
igg
titer
detect
serum
rabbit
immun
purifi
pia
contrast
pre
immun
serum
lower
titer
detect
absorpt
antipia
antiserum
piaposit
epidermidi
lead
reduct
serum
reactiv
wherea
absorpt
pianeg
effect
demonstr
specif
test
confirm
competit
elisa
experi
purifi
pia
pneumococc
meningococc
capsul
polysaccharid
specif
inhibit
bind
antibodi
immobil
pia
use
elisa
serum
sampl
patient
endoprosthesisassoci
infect
due
clonal
independ
icaadbcand
piaposit
epidermidi
strain
antipiaantibodi
titer
rang
detect
contrast
collect
serum
sampl
patient
endoprosthesisrel
infect
due
icaadbcneg
epidermidi
healthi
blood
donor
igg
titer
conclus
due
widespread
presenc
icaadbc
pathogen
staphylococci
pia
appear
suitabl
antigen
novel
diagnost
tool
foreignbodi
infect
use
specif
elisa
antipiaigg
titer
patient
icaadbcposit
epidermidi
infect
significantli
higher
control
collect
measur
antipia
igg
appear
suitabl
tool
improv
diagnosi
staphylococc
foreignbodi
infect
object
aim
studi
continu
extend
previou
investig
main
ribotyp
determin
local
univers
hospit
present
survey
determin
preval
differ
ribotyp
c
difficil
strain
detect
distribut
type
three
hungarian
region
method
c
difficil
strain
isol
hungarian
laboratori
diarrhoeal
faec
inpati
outpati
presenc
toxin
gene
toxin
tcda
toxin
b
tcdb
actinspecif
adpribosyltransferas
cdta
cdtb
detect
pcr
szege
laboratori
ribotyp
strain
determin
pcr
ribotyp
method
arl
cardiff
result
total
ribotyp
detect
among
test
c
difficil
strain
ribotyp
distinct
previous
describ
type
suggest
new
type
common
type
hungari
ribotyp
ribotyp
uk
predomin
type
ribotyp
distribut
examin
ribotyp
differ
differ
hungarian
region
ribotyp
frequent
south
hungari
time
budapest
region
ribotyp
rare
west
hungari
detect
type
examin
period
west
hungari
budapest
region
frequent
type
ribotyp
respect
conclus
numer
differ
method
use
intern
studi
c
difficil
strain
differ
origin
comparison
therefor
difficult
frequent
appli
use
type
method
pcr
amplif
rrna
intergen
spacer
region
discrimin
reproduc
rapid
techniqu
determin
differ
type
c
difficil
present
survey
previou
studi
reveal
presenc
distribut
c
difficil
ribotyp
vari
countri
countri
also
depend
site
isol
period
test
strain
isol
shown
addit
region
differ
within
given
countri
work
support
hungarian
scholarship
grant
hungarian
nation
research
foundat
otka
element
clostridium
difficil
clinic
isol
p
spigaglia
v
carucci
f
barbanti
p
mastrantonio
rome
object
c
difficil
tetracyclin
resist
predominantli
due
tet
gene
gene
shown
carri
clinic
strain
c
difficil
wherea
element
environment
strain
c
difficil
two
element
relat
differ
integrationexcis
modul
copres
cell
aim
studi
examin
clostridium
difficil
clinic
isol
presenc
like
element
method
detect
tet
erythromycin
resist
gene
erm
b
integras
gene
int
marker
perform
pcr
well
analysi
genet
arrang
element
amplifi
fragment
use
probe
hybridis
assay
genom
dna
c
difficil
isol
digest
hindiii
nucleotid
sequenc
tet
gene
also
analys
antibiot
suscept
strain
assess
etest
method
result
eighteen
c
difficil
isol
posit
tet
int
signal
obtain
use
gene
probe
overlap
ten
isol
show
one
hybridis
band
either
kb
seven
isol
show
two
hybridis
band
kb
one
strain
two
banda
kb
indic
presenc
two
copi
like
element
heterogen
element
observ
etest
result
indic
isol
two
copi
tetracyclin
resist
element
resist
induc
resist
tetracyclin
wherea
isol
one
copi
resist
induc
resist
suscept
antibiot
three
isol
also
erm
b
posit
resist
erythromycin
band
obtain
use
tet
erm
b
probe
overlap
kb
indic
presenc
element
associ
gene
also
confirm
pcr
seven
differ
allel
identifi
sequenc
tet
gene
prototyp
strain
among
examin
present
studi
specimen
posit
c
difficil
tcdatcdb
toxin
posit
cpent
c
perfringen
gave
posit
test
result
c
difficil
c
perfringen
toxin
found
rel
small
number
enterotoxigen
c
perfringen
cpent
strain
strain
c
difficil
c
perfringen
suscept
metronidazol
occurr
c
perfringen
cpent
etiolog
agent
nosocomi
diarrhoea
known
poland
laboratori
found
suprisingli
signific
number
c
perfringen
enterotoxin
cpent
posit
stool
conclud
c
perfringen
potenti
caus
aad
poland
will
particip
instruct
collect
specimen
provid
dacron
swab
steril
empti
tube
envelop
place
tube
subject
ask
complet
short
questionnair
sexual
practic
medic
checkup
sexual
transmit
diseas
std
specimen
return
laboratori
within
h
c
trachomati
detect
use
previous
valid
inhous
pcr
method
tip
swab
cut
use
steril
scissor
place
microcentrifug
tube
pb
ph
ad
tube
vortex
swab
press
wall
tube
squeez
fluid
discard
use
steril
forcep
fluid
centrifug
rpm
min
supernat
discard
pellet
resuspend
pcr
buffer
contain
proteinas
k
incub
h
heat
inactiv
proteinas
k
ten
microlitr
treat
sampl
use
pcr
use
primer
c
trachomati
thirti
cycl
follow
min
min
use
amplif
final
anneal
min
min
amplifi
dna
run
agaros
gel
visual
ethidium
bromid
posit
neg
control
use
occas
result
csw
invit
particip
specimen
collect
none
awar
current
infect
c
trachomati
nine
specimen
posit
repres
infect
rate
seventi
per
cent
csw
report
usual
use
condom
client
level
infect
csw
hong
kong
rel
low
compar
countri
may
reflect
regular
condom
use
selfcollect
vagin
swab
anonym
screen
wellaccept
csw
mani
report
fear
stigmat
possibl
legal
repercuss
attend
std
clinic
effect
freez
wash
highspe
centrifug
outcom
bd
probetec
chlamydia
analysi
urin
sampl
g
lisbi
h
westh
hvidovr
dk
object
urin
sampl
chlamydia
trachomati
ct
analys
immedi
standard
procedur
freez
sampl
analysi
known
ctposit
ctneg
patient
sampl
valuat
impact
freez
wash
wash
unfrozen
sampl
well
impact
centrifug
frozen
sampl
xg
prior
analysi
method
urin
sampl
analys
freez
bd
probetec
system
remain
sampl
frozen
c
inclus
studi
carri
three
arm
investig
arm
frozen
posit
sampl
frozen
neg
sampl
thaw
reanalys
wash
clinic
microbiolog
infect
volum
supplement
arm
refriger
posit
neg
sampl
analys
without
wash
arm
frozen
posit
frozen
neg
sampl
thaw
analys
centrifug
xg
wash
test
effect
centrifug
xg
determin
whether
xg
effici
tradit
xg
sediment
ct
organ
due
cellular
lysi
caus
freezethaw
cyclu
intracellular
ct
found
extracellular
phase
might
sediment
complet
xg
intern
extern
qualiti
assess
c
trachomati
use
eia
molecular
method
c
trachomati
sexual
transmit
pathogen
caus
genit
tract
infect
men
women
clinic
symptom
may
absent
silent
delay
treatment
lead
seriou
consequ
infertil
uk
neqa
microbiolog
introduc
intern
eqa
scheme
detect
c
trachomati
eia
sinc
use
molecular
method
increas
clinic
laboratori
challeng
specimen
includ
distribut
object
summaris
result
intern
eqa
scheme
c
trachomati
compar
perform
eia
molecular
method
use
detect
c
trachomati
specimen
vari
ebml
consist
found
urin
sampl
method
total
posit
neg
ml
specimen
produc
vari
concentr
c
trachomati
strain
buffer
solut
bronidox
distribut
particip
panel
particip
instruct
examin
ml
specimen
presenc
c
trachomati
report
result
within
day
result
overal
detect
c
trachomati
posit
specimen
method
vari
detect
molecular
method
significantli
higher
eia
method
risk
differ
analysi
show
method
significantli
like
detect
c
trachomati
present
higher
concentr
analysi
specif
molecular
assay
indic
abbott
lcx
detect
bdprobeteet
detect
roch
method
detect
particip
use
bdprobetecet
less
like
give
posit
result
dilut
greater
wherea
abbott
lcx
less
like
give
posit
result
dilut
higher
roch
method
like
report
posit
result
less
concentr
specimensfals
posit
report
rare
neg
specimen
common
eia
user
object
optimis
evalu
use
autom
extract
apparatu
abbott
perform
realtim
pcr
use
realart
c
trachomati
tm
pcr
kit
abbott
rapid
sensit
detect
chlamydia
trachomati
ct
sperm
urin
specimen
franc
detect
ct
sperm
mandatori
assist
reproduct
techniqu
perform
justifi
need
valid
method
test
specimen
known
contain
pcr
inhibitor
method
autom
protocol
defin
apparatu
appli
extract
urin
sperm
previous
test
posit
coba
amplicor
test
roch
diagnost
kept
frozen
qualiti
extract
sperm
sampl
evalu
quantif
betaglobin
gene
inhous
realtim
pcr
sensit
ct
detect
evalu
sperm
sampl
spike
dilut
posit
clone
pcr
product
includ
pcr
kit
final
protocol
intern
control
pcr
kit
incorpor
sampl
tube
apparatu
order
control
whole
extract
protocol
extract
pcr
condit
evalu
prospect
studi
involv
clinic
specimen
sperm
n
urin
n
result
preliminari
experi
specimen
detect
posit
coba
amplicor
kept
frozen
found
posit
combin
autom
extract
protocol
realtim
pcr
extract
protocol
found
suitabl
either
crude
sperm
sperm
pellet
reproduc
qualiti
extract
apparatu
evalu
quantif
human
betaglobin
gene
sensit
detect
sperm
least
copymicrolitr
elut
volum
posit
control
prospect
studi
posit
specimen
detect
one
urin
sperm
inhibit
rate
sperm
pretreat
sampl
proteinas
k
sd
remov
inhibitor
whole
durat
process
includ
autom
extract
realtim
pcr
test
hour
least
sampl
conclus
apparatu
found
suitabl
conveni
rapid
autom
extract
dna
sperm
urin
specimen
detect
ct
realtim
pcr
simultan
isol
chlamydia
trachomati
neisseria
mycoplasma
genitalium
ureaplasma
urealyticum
urin
use
chlamcap
autom
sampl
prepar
system
base
magnet
particl
separ
object
chlamydia
trachomati
neisseria
gonorrhoea
infect
worldwid
public
health
problem
combin
estim
incid
million
case
c
trachomati
alon
approxim
mill
new
case
regist
everi
year
sexual
transmit
diseas
often
caus
one
microorgan
instanc
coinfect
c
trachomati
n
gonohorroea
may
high
certain
countri
nonchlamydi
nongonococc
urethrisi
mycoplasma
genitalium
ureaplasma
urealyticum
consid
microorgan
commonli
involv
genitalium
directli
implic
numer
genitourinari
tract
patholog
u
urealyticum
associ
acut
prostatati
preterm
deliveri
connect
pregnanc
method
present
new
system
chlamcap
simultan
sampl
prepar
dna
four
bacteria
mention
urin
sampl
follow
four
separ
pcr
amplif
use
specif
primer
new
method
bacteria
initi
adsorb
uniqu
coat
paramagnet
particl
magnet
separ
sampl
rapid
lysi
room
temperatur
releas
dna
adsorb
onto
magnet
particl
wash
robot
transfer
purifi
dna
microwel
pcr
analysi
result
c
trachomati
posit
urin
sampl
spike
n
gonorrhoea
genitalium
u
urealyticum
combin
four
differ
concentr
highest
concentr
approxim
cfuml
sampl
posit
c
trachomati
indic
presenc
bacteria
neg
interfer
captur
bacterium
sampl
four
speci
could
detect
moreov
increas
concentr
n
gonorrhoea
posit
effect
detect
speci
describ
interspeci
hitchhik
conclus
summari
result
obtain
demonstr
chlamcap
system
use
simultan
detect
std
speci
new
system
repres
solut
analysi
bacteria
frequent
involv
std
use
urin
sampl
could
import
contribut
reduc
preval
new
flexibl
autom
sampl
prepar
method
base
paramagnet
particl
isol
chlamydia
trachomati
urin
sampl
downstream
analysi
use
three
differ
naat
system
object
chlamydia
trachomati
lead
caus
sexual
transmit
diseas
worldwid
import
improv
diagnost
method
use
noninvas
sampl
collect
favor
increas
test
current
avail
method
swab
still
prevail
urin
sampl
mainli
due
higher
naat
inhibit
necess
centrifug
urin
sampl
method
method
avoid
centrifug
chlamcap
genpoint
norway
initi
develop
c
trachomati
autom
use
custom
tecan
miniprep
robot
system
dna
prepar
urin
sampl
multicentr
studi
present
urin
sampl
analys
c
trachomati
use
autom
chlamcap
system
combin
three
differ
naat
bdprobetec
tm
et
becton
dickinson
valid
inhous
taqman
pcr
coba
amplicor
roch
evalu
perform
use
result
produc
parallel
onsit
refer
dna
prepar
method
third
independ
method
use
resolv
discrep
result
new
method
bacteri
cell
initi
adsorb
uniqu
coat
paramagnet
particl
magnet
separ
urin
remov
naat
inhibit
substanc
lysi
rt
wash
robot
transfer
purifi
dna
resuspend
appropri
buffer
final
naat
recipi
result
bdprobetec
tm
et
sda
downstream
analysi
system
specif
obtain
sampl
prepar
wherea
sensit
obtain
bdprobetec
tm
et
chlamcap
respect
inhibit
observ
use
magnet
particl
inhous
develop
taqman
analysi
sensit
onsit
refer
sampl
prepar
chlamcap
respect
coba
amplicor
analysi
sensit
specif
use
coba
amplicor
chlamcap
procedur
dna
isol
respect
conclus
clear
improv
brought
new
autom
dna
prepar
method
help
promot
choic
urin
sampl
materi
allevi
need
physician
sampl
collect
final
compat
toward
divers
naat
potenti
dna
prepar
std
organ
neisseria
gonorrhoea
mycoplasma
genitalium
ureaplasma
urealyticum
enabl
develop
univers
autom
dna
prepar
platform
suitabl
std
laboratori
object
estim
efficaci
hepat
b
immunoprophylaxi
children
malign
diseas
materi
method
children
differ
malign
age
year
median
year
receiv
chemotherapi
includ
studi
patient
receiv
activ
immun
recombin
vaccin
engerix
b
hbvax
ii
scheme
month
mkg
patient
mkg
patient
patient
receiv
combin
immunoprophylaxi
specif
antibodi
hepatekt
mukg
scheme
month
along
hbvax
ii
month
mkg
vaccin
conduct
children
without
serolog
marker
hepat
b
first
day
diagnosi
malign
children
malign
receiv
specif
immunoprophylaxi
form
control
group
result
month
level
protect
antibodi
antihb
exceed
mmuml
titr
median
mmuml
children
receiv
mkg
vaccin
children
receiv
mkg
vaccin
g
titr
protect
antibodi
patient
receiv
combin
immunoprophylaxi
reveal
earlier
g
titr
median
antihb
month
accordingli
mmuml
mmu
ml
mmuml
contamin
hepat
b
group
specif
immunoprophylaxi
control
group
g
conclus
vaccin
children
malign
time
chemotherapi
redoubl
dose
combin
immunoprophylaxi
effect
quantif
serum
hbvdna
coba
taqman
diagnosi
monitor
prognosi
chronic
hepat
b
viru
infect
method
sera
individu
current
past
hbv
infect
chronic
hdv
infect
subject
unexpos
hepat
b
viru
test
coba
taqman
hbv
test
result
compar
find
coba
amplicor
hbv
monitor
test
roch
hous
real
time
pcr
result
taqman
test
correl
best
pcr
r
p
specif
high
taqman
test
neg
sampl
person
unexpos
viru
sampl
patient
low
level
viraemia
sensit
much
higher
pick
pcr
neg
monitor
neg
sampl
among
patient
diagnos
longterm
inact
hbsag
carrier
sampl
posit
level
rang
copiesml
wherea
sampl
neg
pcr
monitor
respect
low
hbv
viraemia
level
also
pick
patient
marker
past
infect
neg
compar
pcr
method
patient
hdv
infect
detect
hbvdna
maximum
copiesml
data
serial
sampl
patient
undergo
antivir
treatment
show
mani
individu
wrongli
classifi
virolog
respond
basi
non
detect
compar
method
fact
hbvdna
posit
exhibit
breakthrough
increas
therapi
coba
taqman
hbv
test
sensit
method
detect
quantif
hbvdna
serum
use
better
monitor
treatment
result
sequenti
sampl
test
method
predict
earlier
subsequ
breakthrough
respons
antivir
therapi
introduct
hbv
strain
classifi
seven
genotyp
design
ag
base
intergenotyp
nucleotid
diverg
exceed
complet
genom
hbv
genotyp
seem
characterist
geograph
distribut
major
greek
patient
chb
hbeag
hbeab
last
decad
greec
host
great
number
econom
immigr
aim
intent
assess
preval
hbvgenotyp
associ
hbeag
statu
evalu
two
commerci
hbsag
assay
lowend
sensit
hepat
b
surfac
antigen
j
van
helden
lentzen
object
develop
immunoassay
highest
possibl
sensit
detect
hbv
infect
commonli
encount
routin
clinic
set
major
challeng
manufactur
current
diagnost
sensit
commerci
hbsag
test
ngml
howev
fals
neg
result
still
obtain
may
due
presenc
hbsag
detect
limit
assay
could
occur
earli
acut
diseas
chronic
convalesc
phase
diseas
mutant
hbv
strain
alter
antigen
shown
affect
reactiv
antigen
commerci
hbsag
assay
incid
viral
variant
appear
limit
chronic
infect
individu
especi
medic
natur
induc
immun
pressur
method
present
studi
design
evalu
lowend
sensit
two
commerci
hbsag
immunoassay
bayer
advia
centaur
hbsag
assay
abbott
axsym
hbsag
assay
follow
materi
util
evalu
hbsag
assay
sensit
pei
standard
hbsag
aday
subtyp
one
bbi
hbsag
aday
sensit
panel
lowtit
mixedtit
panel
bbi
bcp
nabi
hbsag
seroconvers
panel
teragenix
hepat
b
precor
mutant
panel
result
bayer
advia
centaur
hbsag
assay
better
lowend
sensit
detect
presenc
hbsag
earlier
stage
abbott
axsym
hbsag
assay
thu
reduc
window
period
studi
result
also
indic
assay
detect
hbv
precor
mutant
result
summaris
tabl
conclus
improv
lowend
sensit
advia
centaur
hbsag
provid
clinic
import
advantag
routin
hbsag
test
eighteen
chronic
renal
failur
patient
creatinin
clearanc
patient
haemodialysi
receiv
three
dose
mcg
engerix
short
schedul
nonrespond
fourth
dose
administ
six
month
third
antibodi
hbsag
antihb
measur
immunoenzym
assay
assxym
abbott
diagnost
uil
antihb
two
month
first
dose
vaccin
consid
protect
result
fortythre
patient
vaccin
classic
schedul
seroconvert
uil
antihb
eleven
patient
chronic
renal
failur
hemodialysi
patient
vaccin
short
schedul
seroconvert
among
hemodialysi
patient
respons
rate
lower
patient
vaccin
short
schedul
p
nonrespond
seroconvert
fourth
dose
vaccin
conclus
chronic
renal
failur
patient
short
schedul
vaccin
hepat
b
less
effici
standard
schedul
schedul
may
indic
patient
time
receiv
vaccin
classic
schedul
data
indic
booster
dose
hbv
vaccin
need
chronic
renal
failur
patient
studi
hbv
vaccin
among
antihb
neg
hospit
health
care
worker
object
needl
stick
injuri
rare
accid
among
hospit
health
care
worker
hepat
b
viru
hbv
infect
one
main
infecti
agent
needl
stick
injuri
therefor
hbv
vaccin
strongli
recommend
hbv
exposur
risk
group
surveil
studi
mani
hcw
could
get
antihb
vaccin
analys
effect
hbv
vaccin
korean
hcw
method
survey
hospit
hcw
doctor
nurs
aidnurs
technician
previou
hbv
vaccin
histori
test
hbsag
antihb
titer
hbcab
igg
use
enzym
immunoassay
recommend
hbv
vaccin
accord
cycl
schedul
month
case
antihb
neg
hcw
result
person
show
antihb
neg
result
among
person
complet
finish
cycl
hbv
vaccin
programm
ratio
male
femal
posit
rate
antihb
cycl
respect
howev
antihb
titer
associ
vaccin
cycl
case
antihb
neg
person
previou
vaccin
histori
hbcab
also
neg
hbcab
neg
group
show
remark
higher
antihb
titer
compar
hbcab
posit
group
iuml
vs
iuml
though
antihb
format
rate
lower
hbcab
posit
group
vs
object
needl
stick
injuri
associ
hbv
rare
accid
among
hospit
healthcar
worker
hcw
preval
hbv
infect
report
korea
therefor
basic
data
preval
hbv
viral
marker
hbsag
hbsab
hbcab
vaccin
histori
health
care
worker
use
guidelin
hospit
infect
control
hcw
benefit
method
tri
survey
hcw
includ
doctor
nurs
aidnurs
technician
hcw
male
femal
particip
surveil
answer
previou
hbv
vaccin
histori
hbsag
hbsab
elecsi
roch
hbcab
igg
centaur
bayer
analys
enzym
immunoassay
result
posit
rate
hbsag
hbsab
respect
hbsag
hbsab
case
rang
hbsab
posit
rate
accord
occup
divis
divis
nurs
group
doctor
least
preval
hbsab
posit
group
respect
case
hbv
vaccin
histori
experienc
time
hbv
vaccin
hbsab
titer
iuml
popular
hbsab
posit
case
among
case
show
neg
hbcab
igg
hbsab
case
show
posit
hbcab
also
repres
posit
hbsab
test
conclus
preval
hbsag
hbsab
hcwa
korean
hospit
similar
gener
popul
korea
need
educ
announc
group
doctor
hbv
vaccin
hospit
hcw
expos
hbv
mainli
hbv
vaccin
howev
differ
found
vaccin
group
nonvaccin
group
hbsab
posit
suggest
korea
still
high
preval
area
hbv
infect
therefor
need
practic
hbv
vaccin
programm
hcw
case
hbv
exposur
needl
stick
injuri
shortterm
use
lamivudin
patient
sever
acut
hepat
b
seri
case
radulescu
tatulescu
turdean
v
zanc
clujnapoca
ro
object
limit
data
use
lamivudin
patient
acut
hepat
b
present
experi
use
lamivudin
seven
patient
sever
acut
hepat
b
shortterm
use
lamivudin
consid
base
almost
complet
viral
suppress
within
week
practic
issu
prompt
recoveri
drug
avail
method
noncompar
prospect
studi
use
lamivudin
sever
hepat
b
diagnosi
fulmin
hepat
b
establish
base
accept
criteria
clinic
sign
portal
encephalopathi
high
aminotransferas
level
prothrombin
level
less
sever
hepat
b
diagnos
upon
prolong
worsen
evolut
serolog
test
perform
hepat
b
surfac
antigen
ig
antibodi
hepat
b
core
antigen
also
hepat
c
lamivudin
dose
mg
per
day
introduc
sinc
hepat
sever
progress
support
treatment
patient
monitor
till
hospit
discharg
routin
followup
ensur
result
fulmin
hepat
b
develop
three
healthi
individu
year
two
case
year
liver
injuri
due
isoniazidrifampin
alcohol
abus
respect
one
sever
cholestat
hepat
b
occur
patient
three
month
surgeri
cholelitiasi
initi
lamivudin
astonish
clinic
recoveri
occur
six
case
aminotransferas
billirubin
level
decreas
quickli
patient
discharg
well
three
week
without
lamivudin
treatment
except
two
case
previou
liver
injuri
continu
treatment
month
drug
cessat
clinic
sign
biochem
test
suggest
rebound
aghb
seroconvers
document
three
patient
month
six
patient
well
normal
biochem
find
healthi
woman
develop
aggress
fulmin
hepat
due
strenuou
physic
effort
use
antiinflammatori
drug
onset
lamivudin
postpon
benefit
observ
die
liver
transplant
seven
day
treatment
lamivudin
conclus
shortterm
use
lamivudin
sever
hepat
b
induc
prompt
recoveri
sustain
serolog
respons
data
encourag
use
safe
drug
seem
effect
short
regimen
cover
period
hepat
failur
method
hbsag
test
done
vida
hbsag
hbsagultra
advia
centaur
hbsag
roch
axsym
hbsag
abbott
abbott
prism
hbsag
abbott
access
aghb
anali
hbv
surfac
antibodi
hbsab
hbv
e
antigen
antibodi
hbeag
hbeab
test
vida
hbv
core
antibodi
hbcab
access
anali
dna
extract
serum
amplif
done
real
time
pcr
primer
direct
precorecor
gene
hbvfor
analysi
sgene
sequenc
cycl
sequenc
done
primer
target
small
sgene
result
htx
patient
hbsag
hbv
dna
neg
hbcab
hbsab
posit
three
year
htx
elev
liver
test
found
repeatedli
serolog
investig
hav
hcv
cmv
hsv
ebv
neg
real
time
pcr
detect
high
load
hbvdna
none
mention
serolog
assay
abl
detect
hbsag
serum
htx
patient
howev
hbcab
hbsab
hbeag
well
hbeab
positiveth
hbv
small
surfac
antigen
sequenc
analys
cycl
sequenc
compar
ncbi
genbank
sequenc
reveal
presenc
multipl
missens
mutat
mutat
compar
found
major
hydrophil
loop
aa
antigen
part
small
surfac
antigen
conclus
viru
escap
detect
commerci
serolog
hbsag
assay
test
major
antibodi
use
assay
direct
small
surfac
antigen
bind
strongli
influenc
presenc
missens
mutat
crucial
loci
present
viral
dna
futur
serolog
assay
detect
hbsag
take
mutat
major
hydrophil
loop
account
attempt
detect
much
hbv
mutant
possibl
complet
genom
sequenc
phylogenet
related
hepat
b
viru
isol
iran
object
date
studi
carri
hepat
b
viru
hbv
complet
genom
sequenc
iranian
hbv
infect
patient
object
studi
investig
phylogenet
analysi
genom
organ
genotyp
character
hbv
strain
obtain
iranian
chronic
infect
subject
compar
hbv
genotyp
report
middl
east
countri
method
hbsagposit
sera
collect
five
iranian
chronic
hbv
carrier
complet
hbv
genom
amplifi
use
two
novel
primer
introduc
hind
iii
ecor
restrict
enzym
cleavag
site
hbv
fulllength
amplicon
clone
pcr
plasmid
sequenc
iranian
hbv
genom
sequenc
compar
human
hbv
genom
sequenc
align
achiev
use
clustalx
softwar
genet
distanc
estim
use
kimura
twoparamet
algorithm
phylogenet
tree
construct
neighborjoin
method
recombin
investig
use
simplot
bootscan
programm
webbas
genotyp
tool
viral
sequenc
result
result
show
five
strain
close
relat
nucleotid
similar
phylogenet
analysi
base
complet
genom
sequenc
reveal
stain
classifi
genotyp
gene
encod
correspond
subtyp
strain
nucleotid
length
bp
except
strain
uniqu
bp
insert
x
gene
intragenotyp
diverg
complet
genom
sequenc
iranian
strain
intergenotyp
genotyp
genotyp
middl
east
countri
hbv
gene
sequenc
analys
find
show
hbv
genotyp
subtyp
domin
result
show
saudi
arabia
isol
similar
iranian
isol
turkish
egyptian
yemeni
isol
rank
next
respect
conclus
first
report
fulllength
nucleotid
sequenc
genom
organ
investig
hbv
isol
iran
studi
reveal
hbv
genotyp
subtyp
present
iranian
infect
patient
uniqu
amino
acid
insert
x
gene
one
iranian
strain
detect
unpreced
length
bp
updat
middl
east
hbv
geograph
genotyp
distribut
map
depict
autochthon
sporad
acut
hepat
e
case
madrid
spain
introduct
hepat
e
viru
hev
infect
import
caus
epidem
acut
sporad
hepat
develop
countri
hev
consid
endem
western
europ
hepat
e
viru
hev
infect
rare
import
case
report
recent
autochthon
case
industri
countri
emerg
patient
never
travel
endem
area
aim
studi
describ
nine
autochthon
sporad
case
hev
infect
madrid
spain
method
june
septemb
nine
patient
acut
hepat
igg
antihev
antibodi
serum
specimen
detect
hospit
viral
marker
hav
hbv
hcv
neg
eia
assay
assxym
abbott
diagnost
igg
igm
antihev
antibodi
studi
eia
bioelisa
hev
igg
bioelisa
hev
igm
biokit
barcelona
spain
detect
rnahvc
dnahvb
perform
taqmanr
roch
diagnost
patient
increas
aminotransferas
level
symptom
acut
hepat
patient
question
epidemiolog
risk
factor
relat
hev
infect
travel
endem
area
contact
anim
result
antihev
igg
igm
antibodi
found
patient
seven
patient
male
two
femal
mean
age
year
mean
alt
valu
risk
factor
hev
infect
found
except
two
patient
one
work
slaughterhous
anoth
occasion
hors
rider
patient
deni
travel
endem
area
conclus
endem
area
hev
infect
frequent
found
young
adult
patient
older
report
author
given
anim
may
reservoir
hev
animaltohuman
transmiss
occur
think
two
patient
risk
factor
hev
infect
although
hev
infect
rare
nonendem
area
must
consid
diagnosi
acut
hepat
neg
viral
marker
hav
hbv
hcv
even
patient
never
endem
area
hev
infect
must
consid
emerg
countri
increas
immigr
geograph
situat
j
mossong
l
putz
patini
f
schneider
luxembourg
lux
object
prospect
seroepidemiolog
survey
carri
luxembourg
determin
antibodi
statu
luxembourg
popul
hepat
viru
hav
hepat
b
viru
hbv
one
object
survey
assess
impact
hepat
b
vaccin
programm
start
may
includ
catchup
campaign
adolesc
age
method
venou
blood
individu
screen
presenc
antibodi
hepat
viru
antigen
antibodi
hepat
b
surfac
antigen
hbsag
use
enzym
immunoassay
sampl
posit
hbsag
antibodi
test
antibodi
hepat
b
core
antigen
antihbc
use
chemiluminisc
microparticl
immunoassay
distinguish
individu
past
exposur
vaccin
natur
infect
result
estim
agestandard
antihav
seropreval
popul
four
year
age
seropreval
agedepend
highest
adult
immigr
portug
former
yugoslavia
agestandard
preval
antihbsag
antihbc
estim
respect
antihbsag
seropreval
exceed
found
cohort
target
routin
hepat
b
vaccin
programm
start
conclus
studi
illustr
young
peopl
luxembourg
suscept
hav
infect
hepat
b
vaccin
programm
substanti
impact
popul
immun
children
teenag
hepat
outbreak
school
observ
explos
sewer
system
object
hepat
classic
exampl
infect
transmit
fecalor
rout
preval
close
relat
socioeconom
statu
societi
show
moder
endem
primari
transmiss
rout
person
contact
hand
water
origin
outbreak
may
seen
method
result
studi
hepat
outbreak
observ
local
school
follow
explos
sewer
system
street
istanbul
sariy
septemb
investig
children
attend
school
live
home
around
hepat
clinic
first
case
seen
day
explos
age
distribut
children
mean
age
first
case
detect
octob
case
report
first
day
case
seen
day
water
sampl
taken
fecal
contamin
search
school
order
find
origin
canteen
toilet
also
search
student
check
find
new
case
teacher
student
educ
diseas
hygien
doctor
health
group
presid
continu
educ
provid
doctor
charg
throughout
outbreak
school
around
check
educ
cooper
directori
nation
educ
origin
research
also
perform
home
case
famili
inform
diseas
quarantin
precaut
iski
quickli
inform
subject
control
take
water
exampl
document
also
done
iski
conclus
dimens
outbreak
infecti
diseas
transmit
water
fecalor
metropoli
million
popul
may
great
countri
report
hepat
obligatori
origin
diseas
search
soon
report
case
isol
case
provid
hepat
vaccin
includ
nation
vaccin
programm
countri
seriou
risk
diseas
childhood
need
passiv
immun
contact
evalu
respect
also
outbreak
control
end
first
week
precaut
educ
school
popul
preval
antihav
antibodi
differ
age
group
spain
introduct
hepat
viru
hav
usual
spread
fecalor
rout
frequent
associ
poor
hygien
habit
condit
preval
hav
decreas
hygien
condit
improv
igg
antibodi
hav
last
year
frequent
lifetim
patient
suffer
hepat
seropreval
use
know
frequenc
contact
hav
groupw
studi
seropreval
igg
antibodi
hav
sera
nonselect
healthi
individu
obtain
order
know
seropreval
differ
age
group
evolut
seropreval
method
sera
sampl
obtain
sera
obatin
healthi
patient
studi
sera
group
organ
age
group
includ
sera
follow
group
patient
year
old
group
year
old
group
group
group
sera
studi
eia
hav
liaison
saluggia
itali
result
appear
tabl
patient
year
old
almost
patient
older
year
antihav
antibodi
patient
year
posit
sera
obtain
seropreval
chang
significantli
seropreval
group
much
lower
vs
vs
vs
seropreval
remain
group
comment
seropreval
antihav
antibodi
high
adult
individu
spain
decreas
fast
moment
seropreval
remain
around
patient
older
year
around
patient
year
becom
infrequ
young
adult
situat
shall
account
order
stablish
vaccin
protocol
hav
method
prospect
studi
elderli
year
patient
present
gener
practition
acut
hz
rash
week
person
demograph
data
regist
patient
pain
assess
use
visual
analogu
scale
qualiti
life
questionnair
blood
sampl
collect
baselin
one
week
later
analys
iga
igg
igm
pain
assess
initi
visit
subsequ
week
result
patient
includ
hz
could
serolog
confirm
signific
associ
found
titer
iga
igg
initi
visit
age
sever
durat
rash
signific
associ
report
pain
titer
antibodi
serolog
data
contribut
predict
occurr
phn
clinic
diagnosi
hz
made
gener
practition
serolog
confirm
case
titer
antibodi
correl
sever
durat
rash
howev
associ
intens
pain
neither
predict
durat
pain
herp
zoster
hospitalis
turkish
children
clinic
microbiolog
infect
volum
supplement
age
present
month
rang
month
year
establish
underli
diseas
childhood
herp
zoster
found
case
common
underli
diseas
lymphoma
patient
acut
lymphoblast
leukaemia
patient
histori
varicella
recal
case
interv
varicella
herp
zoster
rang
month
involv
dermatom
thorac
patient
servic
patient
sacral
patient
two
dermatom
involv
detect
two
children
two
children
experienc
mild
pain
erupt
without
requir
specif
therapi
case
herp
zosterassoci
complic
includ
pneumonia
hepat
keratoconjunct
note
none
patient
immun
varicella
mean
period
onset
rash
initi
acyclovir
treatment
day
rang
day
eighteen
case
receiv
intraven
acyclovir
treatment
five
patient
receiv
sequenti
parenteralor
acyclovir
treatment
wherea
one
patient
receiv
oral
treatment
acyclovir
treatment
discontinu
renal
toxic
one
child
mean
treatment
period
day
rang
day
patient
case
post
herpet
neuralgia
record
conclus
acyclovir
treatment
start
time
import
prevent
progress
diseas
acyclovir
treatment
effect
acyclovir
prophylaxi
seem
unnecessari
prevent
modifi
clinic
varicella
immunocompromis
children
varicella
immun
import
prevent
varicella
herp
zoster
object
herpesvirus
among
success
human
pathogen
inhibit
apoptosi
common
strategi
viral
pathogenesi
favor
viru
replic
may
contribut
oncogenesi
herp
simplex
virus
code
varieti
protein
cooper
block
apoptosi
trigger
viru
infect
nitric
oxid
potenti
toxic
signal
molecul
implic
wide
rang
divers
pathophysiolog
process
crosstalk
cell
destruct
protect
signal
pathway
activ
inhibit
modulatori
influenc
determin
possibl
role
apoptot
cell
death
andor
surviv
acylovir
effect
mechan
target
viral
dna
polymeras
act
chain
termin
first
phosphoryl
step
catalyz
viru
encod
thymidin
kinas
acyclovir
interact
cell
death
seem
import
post
treatment
cognit
functionsthat
may
encount
due
treatment
process
enceph
mening
case
method
cell
infect
ko
strain
uvinactiv
mock
strain
g
strain
uvinactiv
mock
strain
infect
cell
treat
non
apoptot
dose
acyclovir
lgml
respect
follow
hour
infect
cell
detect
hoechst
propidium
iodid
apoptosisnecrosi
cultur
supernat
griess
reagent
result
respons
significantli
higher
hsv
infect
cell
respons
higher
infect
cell
also
infect
cell
dose
acyclovir
apoptot
respons
higher
necrosi
respons
significantli
higher
infect
cell
lg
ml
conclus
studi
shown
signific
differ
hsv
apoptosisnecrosi
respons
assum
involv
acyclovir
dose
higher
lgml
may
trigger
necrot
pathway
infect
cell
compound
seem
caus
statist
signific
higher
respons
infect
cell
contrast
infect
result
deserv
studi
order
explain
effect
acyclovir
treatment
process
especi
cognit
function
clinic
evalu
signific
herp
virus
dna
amplif
central
nervou
system
neurolog
patient
patient
adult
children
year
male
femal
p
definit
clinic
diagnosi
hsvposit
patient
enceph
lymphocyt
mening
intracran
hemorrhag
tuberculosi
mening
neurolog
syndrom
group
patient
hivposit
cmvposit
patient
present
congenit
cmv
infect
hivposit
lymphocyt
mening
neurolog
syndrom
vzvposit
patient
children
clinic
postvaricella
enceph
posit
patient
child
year
exanthem
subitum
neurolog
manifest
convuls
correl
herp
virus
genom
amplif
csf
clinic
studi
patient
analys
clinic
signific
hsv
cmv
vzv
overal
correl
cmv
hsvposit
patient
respect
hivposit
p
pcr
highli
sensit
techniqu
although
case
result
obtain
difficult
relat
clinic
symptom
especi
tuberculosi
mening
cerebr
hemorrhag
fals
posit
crystal
structur
hcmv
analysi
interact
new
target
drug
discoveri
human
cytomegaloviru
dna
polymeras
compos
catalyt
subunit
accessori
protein
propos
act
process
factor
solv
crystal
structur
resolut
remark
structur
reveal
dimer
shape
like
cclamp
could
partial
surround
doublestrand
dna
monom
resembl
herp
simplex
viru
dimer
interfac
near
base
region
identifi
crystal
structur
connector
loop
analyt
ultracentrifug
gel
filtrat
measur
demonstr
also
form
dimer
solut
substitut
larg
hydrophob
residu
along
homodim
interfac
alanin
disrupt
dimer
decreas
dna
bind
addit
defin
individu
residu
crucial
interact
engin
sever
mutat
ctermin
region
connector
loop
substitut
alanin
greatli
impair
interact
pulldown
assay
longchain
dna
synthesi
identifi
residu
crucial
subunit
interact
use
isotherm
titrat
calorimetri
quantit
measur
bind
peptid
correspond
extrem
cterminu
found
peptid
correspond
last
residu
bound
specif
complex
dissoci
constant
approxim
lm
substitut
residu
complet
abolish
bind
peptid
thu
result
identifi
specif
side
chain
appear
crucial
interact
inform
structur
may
aid
ration
design
new
antihcmv
compound
act
disrupt
interact
develop
realtim
nasba
herp
simpl
viru
b
deiman
f
jacob
vermeer
c
schrover
van
strijp
boxtel
nl
object
aim
develop
evalu
herp
simplex
viru
assay
base
nasba
amplif
includ
realtim
detect
molecular
beacon
studi
perform
new
test
evalu
method
hsv
dna
isol
use
semi
autom
magnet
extract
method
nuclisen
minimag
intern
control
ad
sampl
prior
nucleic
acid
extract
primer
direct
polgen
region
hsv
genom
hsv
intern
control
amplifi
primer
set
assay
includ
three
molecular
beacon
probe
two
genotypespecif
molecular
beacon
probe
detect
hsv
hsv
specif
one
addit
beacon
detect
intern
control
amplif
reaction
perform
nuclisen
easyq
analys
allow
realtim
detect
result
hsv
hsv
ic
detect
one
reaction
use
threelabel
approach
coinfect
hsv
hsv
detect
use
serial
dilut
vitro
dna
hsv
detect
shown
copi
amplif
hsv
hsv
good
result
obtain
qcmd
panel
hsv
detect
geqml
lowest
concentr
genotyp
hsv
sampl
identifi
correctli
addit
hsv
detect
clinic
sampl
csf
swab
vzv
ebv
detect
assay
realtim
assay
hsv
csf
sampl
detect
within
approxim
hour
data
show
realtim
intern
control
hsv
assay
rapid
sensit
specif
qualit
assay
detect
hsv
hsv
one
reaction
use
standard
reagent
offer
consider
benefit
routin
set
clinic
manag
patient
hsv
infect
assay
bring
sameday
result
enabl
earli
accur
clinic
intervent
lead
better
patient
care
consider
overal
health
care
cost
save
develop
type
specif
base
glycoprotein
g
assay
identifi
infect
jamalidoust
f
fotouhi
chahooki
h
soleimanjahi
roostae
tehran
ir
object
herp
simplex
viru
main
caus
genit
herp
infect
preval
increas
worldwid
vari
wide
gener
higher
rate
develop
develop
countri
urban
rural
area
studi
preval
seroepidemolog
survey
hsv
prepar
prokaryot
system
recogn
asymptom
unknown
symptom
individu
method
iranian
isol
propag
hela
cell
line
viral
genom
extract
phenolchloroform
use
templat
nest
polymeras
chain
reaction
npcr
amplifi
gene
amplifi
gene
clone
clone
vector
sequenc
next
step
compet
ecoli
transform
construct
plasmid
result
white
coloni
select
presenc
ampicilin
xgal
iptg
recombin
plasmid
extract
purifi
larg
scale
restrict
enzym
analysi
kb
fragment
extract
purifi
lmp
gel
treat
bamhi
hindiii
enzym
isol
gene
subclon
appropri
site
plasmid
express
vector
protein
product
confirm
sdspage
western
blot
induct
iptg
use
polyclon
antibodi
result
gg
gene
confirm
sequenc
result
western
blot
analysi
reveal
glycoprotein
g
herp
simplex
viru
type
express
effici
prokaryot
system
conclus
pure
use
candid
antigen
instead
crude
whole
serolog
test
elisa
object
sever
genit
herp
may
reason
infertil
recurr
pregnanc
loss
ivf
failur
method
women
mean
age
sever
genit
herp
mean
recurr
per
year
includ
studi
test
cervic
sampl
cytokin
tnfalfa
ifngamma
serum
sampl
hladr
recurr
remiss
valaciclovir
treatment
dose
mg
per
clinic
microbiolog
infect
volum
supplement
day
control
group
ten
healthi
women
without
genit
herp
hsv
antibodi
g
serum
result
herp
recurr
local
level
tnfalfa
increas
twice
time
much
compar
remiss
control
ifngamma
time
time
time
hladr
time
p
decreas
time
less
valaciclovir
treatment
cervic
level
tnfalfa
decreas
hladr
p
conclus
high
level
inflammatori
marker
cervix
serum
sever
genit
herp
confirm
import
role
hsv
genit
inflamm
cervic
endometri
patholog
allow
consid
genit
herp
inflammatori
process
herp
simplex
viru
caus
agent
innoc
bystand
presenc
hsv
test
use
nest
pcr
method
nation
refer
laboratori
pragu
patient
case
immunocompet
adult
identifi
contain
anoth
etiolog
agent
follow
data
collect
sever
symptom
hospit
length
perman
neurolog
sequel
result
neuroimag
method
includ
eeg
clinic
cours
dual
infect
compar
imunocompet
adult
hospit
neuroinfect
total
result
case
hsv
dna
identifi
includ
dual
infect
mention
among
case
correspond
tickborn
enceph
agent
serolog
confirm
case
neuroborreliosi
case
purul
mening
patient
year
old
averag
age
show
substanti
neurolog
involv
entranc
examin
averag
hospit
period
dual
infect
day
longer
refer
patient
focal
neurolog
sequel
typic
hsv
enceph
confirm
case
show
normal
ct
result
patient
treat
acyclovir
least
day
despit
dual
infect
sever
entranc
neurolog
involv
treatment
show
posit
result
conclus
number
patient
suffer
dual
infect
underestim
reactiv
herp
virus
one
caus
dual
infect
sinc
dual
infect
addit
effect
desir
identifi
case
cure
caus
increas
evid
primari
cytomegaloviru
infect
otherwis
healthi
adult
r
manfredi
l
calza
f
chiodo
bologna
increas
avail
serologybiomolecular
assay
acut
cytomegalovirosi
c
allow
us
includ
assay
workout
fever
unknown
origin
fuo
immunocompet
adult
retrospect
survey
patient
p
diagnos
primari
c
refer
centr
fuo
associ
broad
spectrum
constitut
signssymptom
perform
sinc
year
p
age
year
femal
assess
fuoc
serolog
carri
workout
togeth
haematologicalbiochemistri
studi
assay
collagen
vascular
autoimmun
disord
thyroid
function
microbiolog
studi
mononucleosi
toxoplasmosi
hiv
communityacquir
respiratori
urinari
stool
pathogen
tuberculosi
p
underw
c
serolog
igmigg
search
minor
p
viral
dnaantigen
search
result
posit
igm
search
c
confirm
case
biomolecularantigen
assaysa
crossreact
ebv
serolog
found
p
igm
antibodi
titr
ebv
lower
rapidli
declin
month
followup
alter
leukocyt
count
differenti
alway
present
lymphocyt
subset
show
transient
imbal
cell
ratio
decreas
rate
absolut
number
cell
expans
subset
underli
signssymptom
includ
fever
p
associ
mononucleosislik
syndrom
p
usual
character
moder
lymphadenopathi
pharyngodinia
case
moder
elev
transaminas
present
hepatosplenomegali
confirm
ultrasonographi
p
fever
fatigu
anorexia
predomin
sign
symptom
normal
hepat
enzym
leukocyt
differenti
preced
disappear
lymphadenopathi
hepatosplenomegali
posit
c
igm
search
last
month
p
mean
time
month
discuss
primari
c
selflimit
diseas
whose
appar
increas
frequenc
probabl
attribut
easier
access
specif
laboratori
test
although
treatment
indic
otherwis
immunocompet
p
clinician
maintain
elev
suspicion
primari
c
fuo
concern
sinc
c
may
last
significantli
p
miss
diagnosi
risk
viciou
circl
appar
unexplain
diseas
need
examin
result
sampl
posit
novel
eia
assay
sensit
calcul
coincid
commerci
avail
eia
percentag
posit
reactiv
investig
group
follow
health
blood
donor
children
stdpatient
hivinfect
specif
assay
around
signific
differ
health
donorschildren
group
highest
risk
acquir
infect
artifici
mosaic
protein
use
studi
demonstr
signific
potenti
diagnost
reagent
new
eia
highli
specif
diagnost
assay
detect
activ
serum
specimen
may
use
tool
studi
epidemiologykshv
seropreval
russian
european
popul
low
among
health
donor
hivinfect
peopl
human
herp
viru
infect
pulmonari
hypertens
lung
transplant
candid
e
nicastri
c
vizza
cicalini
f
carletti
r
badagliacca
r
poscia
f
fedel
n
petrosillo
rome
object
human
herp
detect
biolog
sampl
patient
affect
kaposi
sarkoma
castleman
diseas
primaryeffus
bcell
lymphoma
recent
describ
pathogenesi
idiopath
pulmonari
arteri
hypertens
ipah
conduct
seropreval
studi
aim
detect
antibodi
among
popul
lung
transplant
candid
assess
antibodi
seropreval
among
pulmonari
hypertens
ph
patient
without
ipah
compar
nonph
patient
method
januari
februari
patient
refer
depart
cardiovascular
respiratori
scienc
univers
rome
la
sapienza
clinic
serolog
evalu
lung
transplant
consecut
enrol
studi
diagnosi
ph
base
intern
criteria
perform
assay
antibodi
direct
lytic
antigen
plasma
sampl
use
indirect
immun
fluoresc
assay
base
cell
line
sampl
reactiv
dilut
antilyt
test
consid
posit
result
thirtythre
patient
transplant
candid
signific
ph
mean
pulmonari
arteri
pressur
mmhg
sixteen
ipah
ramin
secondaryph
antibodi
detect
patient
three
patient
hiv
infect
ab
neg
differ
seropreval
found
ph
patient
patient
without
ph
particularli
among
patient
ph
one
patient
ipah
serolog
antibodi
wherea
patient
secondaryph
antibodi
among
patient
clinic
diagnost
evid
ph
five
patient
cystic
fibrosi
three
patient
interstiti
lung
diseas
antibodi
affect
idiopath
pulmonari
fibrosi
differ
seropreval
rate
report
neither
patient
cystic
fibrosi
patient
interstiti
lung
diseas
conclus
preval
rate
similar
found
italian
gener
popul
report
among
candid
lung
transplant
relationship
infect
ph
idiopath
secondari
shown
object
sinc
discoveri
kaposi
sarcoma
herpesviru
kshv
mani
question
aros
origin
transmiss
pathogenesi
kshv
orf
gene
use
defin
five
major
subtyp
ae
amino
acid
variabl
previou
report
orf
real
time
assay
method
analys
gene
phylogenet
cuban
german
ks
tissu
hiv
nest
pcr
sequenc
addit
studi
first
pbmc
specimen
cuban
asymptomat
sexual
contact
ks
patient
presenc
circul
kshv
dna
realtim
pcr
also
sequenc
whose
result
moreov
compar
kshv
viral
load
pbmc
ks
tissu
result
ten
pbmc
sampl
show
kshv
infect
nest
pcr
reinforc
kshv
sexual
transmit
phylogenet
character
reveal
major
german
sampl
belong
subtyp
c
n
n
previous
describ
european
kshv
strain
cuban
sampl
show
wide
rang
subtyp
includ
n
c
n
b
n
one
newli
describ
subtyp
e
subtyp
b
previous
report
african
genotyp
e
subtyp
recent
found
amerindian
brazil
ecuador
furthermor
realtim
pcr
detect
addit
patient
low
kshv
viral
load
pbmc
detect
nest
pcr
kshv
viral
load
ks
tissu
much
higher
pbmc
asymptomat
infect
patient
also
correl
among
kshv
antibodi
two
dna
amplif
method
conclus
subtyp
variabl
reflect
mix
ethnic
background
cuban
new
dna
amplif
assay
real
time
pcr
repres
reliabl
techniqu
identifi
individu
risk
develop
ks
lesion
well
follow
kshv
viral
load
therapi
object
plectasin
newli
discov
defensintyp
antimicrobi
peptid
amino
acid
isol
saprophyt
ascomycet
fungu
pseudoplectania
nigrella
plectasin
activ
sever
gramposit
bacteria
includ
drug
resist
strain
show
poor
activ
gramneg
bacteria
addit
plectasin
shown
activ
murin
pneumonia
periton
model
clinic
isol
streptococcu
pneumonia
peptid
dose
intraven
method
antimicrobi
activ
spectrum
assess
determin
minimum
inhibitori
bactericid
concentr
cationicadjust
muellerhinton
broth
use
nccl
guidelin
bactericid
activ
character
time
kill
experi
sever
concentr
result
purifi
plectasin
show
potent
activ
rang
gramposit
bacteria
mic
low
lgml
clinic
isol
pneumonia
includ
penicillin
tetracyclin
chloramphenicol
trimethoprim
resist
isol
plectasin
cidal
demonstr
mbc
equival
mic
rapid
kill
kinet
time
kill
experi
hour
incub
human
serum
plectasin
stabl
measur
elisa
antimicrobi
activ
conclus
plectasin
novel
antimicrobi
peptid
display
potent
antimicrobi
activ
gramposit
bacteria
includ
drug
resist
organ
peptid
rapidli
cidal
gramposit
bacteria
inact
toward
gramneg
bacteria
result
report
serum
stabil
well
vivo
anim
model
suggest
plectasin
may
potenti
system
therapeut
agent
gramposit
bacteria
vitro
evalu
peptid
deformylas
inhibitor
combin
aztreonam
determin
synergist
potenti
gramposit
gramneg
pathogen
preliminari
studi
demonstr
pdi
may
display
enhanc
activ
test
combin
gn
activ
agent
complet
lack
ant
either
gp
gn
pathogen
potenti
expand
spectrum
activ
agent
uniqu
mechan
action
pdi
warrant
investig
potenti
role
combin
therapi
antimicrobi
activ
nvp
recent
object
evalu
spectrum
potenc
lbm
formerli
nvp
test
intern
collect
common
bacteri
pathogen
compris
lbm
surveil
programm
lbm
first
member
peptid
deformylas
inhibitor
pdi
class
consid
clinic
trial
treatment
communityacquir
respiratori
tract
infect
seriou
infect
caus
antimicrobialresist
gramposit
cocci
method
nondupl
clinicallysignific
bacteri
isol
strain
collect
medic
centr
particip
global
surveil
programm
origin
north
america
europ
south
america
asia
geograph
area
isol
suscept
test
use
nccl
broth
microdilut
method
interpret
criteria
applic
lbm
compar
repres
agent
use
empir
direct
therapi
target
indic
speci
result
antimicrobi
activ
lbm
shown
tabl
antibiogram
characterist
collect
includ
oxacillinresist
sa
con
penicillinnonsuscept
spn
vancomycinr
ent
ampicillinr
hi
lbm
highli
activ
staphylococci
streptococci
enterococci
mcat
result
inhibit
mgl
well
inhibit
hi
strain
concentr
differ
note
activ
lbm
r
subset
sa
con
spn
ent
hi
antimicrobi
oxacillin
penicillin
ampicillin
macrolid
vancomycin
fluoroquinolon
region
differ
appar
compar
agent
activ
lbm
vari
geograph
sampl
conclus
lbm
display
broadspectrum
activ
common
gramposit
pathogen
includ
r
subset
region
differ
potenc
fastidi
gramneg
speci
hi
mcat
also
inhibit
lbm
class
antimicrobi
pdi
compound
exhibit
spectrum
activ
uniqu
mode
action
promis
signific
advanc
chemotherapi
baselin
assess
telavancin
activ
collect
gramposit
isol
includ
resist
phenotyp
object
akacid
new
member
polymer
biguanid
famili
disinfect
especi
develop
enhanc
antimicrobi
activ
class
significantli
less
toxic
paper
describ
wide
rang
biocid
activ
low
potenti
induct
resist
akacid
method
total
recent
clinic
isol
patient
document
infect
hospit
locat
austria
studi
organ
test
refer
method
includ
staphylococcu
aureu
conclus
studi
clearli
demonstr
excel
antimicrobi
properti
akacid
akacid
highli
activ
bacteria
includ
mycobacterium
spp
l
pneumophila
spore
fungi
without
affect
resist
profil
strain
properti
togeth
low
potenti
select
resist
make
akacid
promis
tool
battl
rise
resist
therapeut
failur
cu
x
clo
n
previous
characteris
thermal
stabil
coordin
geometri
rang
techniqu
includ
element
thermal
analysi
ir
epr
electron
reflect
spectra
screen
vitro
abil
inhibit
microbi
growth
modif
evidenc
ir
spectra
correl
presenc
dmbg
chelat
epr
electron
spectra
typic
squareplanar
surround
ni
ii
respect
distort
octahedr
one
cu
ii
abstract
resist
metal
complex
exhibit
mic
mcgml
studi
demonstr
among
multipl
biolog
activ
biguanidin
complex
combin
could
also
exhibit
effect
antimicrobi
properti
select
bacteri
strain
vitro
activ
human
intestin
anaerob
bacteria
nisin
e
wahlund
e
ce
nord
stockholm
object
nisin
new
bacteriocin
use
food
preserv
resist
nisin
associ
increas
resist
antibiot
nisin
use
anim
food
therefor
import
investig
nisin
impact
normal
human
intestin
microflora
aim
present
investig
studi
antimicrobi
activ
nisin
anaerob
bacteria
isol
normal
human
intestin
microflora
suscept
nisin
minimum
inhibitori
concentr
mgl
eleven
eggerthella
lentum
strain
show
high
suscept
nisin
minimum
inhibitori
concentr
mgl
nisin
agent
activ
lactobacilli
minimum
inhibitori
concentr
mg
l
peptostreptococci
except
one
strain
highli
suscept
nisin
mgl
bacteroid
fragili
strain
high
minimum
inhibitori
concentr
valu
nisin
mgl
fusobacteria
show
high
minimum
inhibitori
concentr
valu
nisin
mgl
three
strain
lower
minimum
inhibitori
concentr
valu
mgl
present
studi
show
nisin
good
activ
anaerob
gramposit
bacteria
less
activ
anaerob
gramneg
bacteria
isol
human
normal
intestin
microflora
vitro
activ
tigecyclin
compar
agent
enterococci
sweden
vitro
activ
garenoxacin
comparison
fluoroquinolon
isol
e
coli
p
aeruginosa
aureu
includ
genet
defin
fluoroquinoloneresist
mutant
heisig
p
heisig
hamburg
object
enhanc
research
activit
aim
overcom
increas
incid
fluoroquinolon
fq
resist
bacteri
pathogen
extend
spectrum
activ
gramposit
pathogen
result
develop
new
garenoxacin
grn
former
method
evalu
invitro
activ
comparison
levofloxacin
lvx
gatifloxacin
gat
ciprofloxacin
cip
mic
garenoxacin
grn
determin
suscept
isol
e
coli
p
aeruginosa
aureu
seri
isogen
mutant
carri
differ
combin
known
resist
mutat
affect
either
target
dna
gyras
topoisomeras
iv
well
multipl
drug
resist
mdr
efflux
pump
result
suscept
isol
lowlevel
resist
mutant
e
coli
mic
grn
cip
lgml
respect
thu
slightli
lower
activ
grn
highlevel
resist
mutant
e
coli
compar
cip
higher
lvx
gat
grn
mic
lgml
superior
test
fq
mic
lgml
suscept
resist
aureu
suscept
wildtyp
p
aeruginosa
grn
gat
compar
mic
lgml
higher
cip
lvx
mic
lgml
overexpress
mdr
efflux
pump
mexab
mexcd
mexef
similar
impact
fq
grn
increas
mic
serial
dilut
step
conclus
garenoxacin
promis
new
quinolon
deriv
combin
high
activ
gramposit
gramneg
pathogen
includ
clinic
relev
mutant
aureu
multipl
resist
mutat
h
sader
fritsch
stilwel
r
jone
north
liberti
usa
object
compar
activ
garenoxacin
grn
formerli
select
antimicrobi
worldwid
collect
enterobacteriacea
ent
grn
unlik
recent
market
fluoroquinolon
fq
lack
fluorin
posit
method
isol
consecut
collect
medic
centr
bloodstream
respiratori
urinari
skin
soft
tissu
infect
test
refer
broth
microdilut
method
accord
nccl
guidelin
grn
suscept
breakpoint
mgl
appli
comparison
purpos
result
result
major
organ
group
test
follow
grn
show
excel
activ
larg
collect
ent
mgl
isol
inhibit
mgl
vitro
activ
grn
similar
ciprofloxacin
cip
ent
speci
except
serratia
indoleposit
proteu
cip
slightli
activ
gener
grn
cip
show
higher
potenc
broader
spectrum
oral
administ
betalactam
tmpsmx
grn
also
highli
activ
e
coli
yersinia
enterocolitica
mgl
conclus
grn
vitro
activ
similar
commonli
use
fq
superior
list
oral
administ
antimicrobi
test
global
ent
isol
potenc
garenoxacin
new
desf
quinolon
test
communityacquir
respiratori
tract
infect
pathogen
worldwid
potenc
spectrum
garenoxacin
test
intern
collect
skin
soft
tissu
infect
pathogen
report
sentri
antimicrobi
surveil
programm
fritsch
h
sader
r
jone
north
liberti
usa
object
evalu
spectrum
potenc
garenoxacin
grn
novel
desf
quinolon
larg
intern
collect
gramposit
neg
bacteri
pathogen
caus
skin
soft
tissu
infect
ssti
compris
distinct
set
gramposit
cocci
gramneg
aerob
facult
bacilli
grn
potent
agent
test
sa
least
potent
gati
mgl
potent
either
cipro
levo
mgl
furthermor
grn
potent
fq
bh
viridan
group
streptococci
vg
potent
esp
grn
compar
cipro
levo
gati
ec
ksp
asp
less
activ
agent
psa
antimicrobi
suscept
nonenterobacteriacea
gramneg
organ
pseudomona
aeruginosa
test
novel
desf
quinolon
garenoxacin
sentri
antimicrobi
surveil
programm
h
sader
fritsch
stilwel
r
jone
north
liberti
usa
object
compar
antimicrobi
activ
garenoxacin
grn
select
antimicrobi
agent
nonenter
gramneg
organ
p
aeruginosa
collect
part
sentri
antimicrobi
surveil
programm
method
isol
consecut
collect
medic
centr
six
contin
bloodstream
respiratori
urinari
skin
soft
tissu
infect
test
nccl
broth
microdilut
method
grn
suscept
breakpoint
mgl
appli
comparison
purpos
result
result
major
organ
group
test
overal
grn
mgl
activ
ciprofloxacin
mgl
ceftazidim
mgl
piperacillintazobactam
mgl
amikacin
grn
activ
compound
test
result
result
summaris
tabl
fix
concentr
mgl
potent
inhibitor
unclassifi
blactamas
respons
ceftazidim
aztreonam
resist
speci
enterobacteriacea
includ
escherichia
coli
n
citrobact
freundii
n
klebsiella
pneumonia
n
enterobact
cloaca
n
morganella
morganii
n
great
major
isol
inhibit
mgl
either
antimicrobi
combin
inhibitor
inhibit
activ
tem
oxa
ceftazidimeresist
escherichia
coli
transform
express
enzym
reduc
mic
mgl
restor
activ
ceftazidim
aztreonam
mic
mgl
mgl
respect
isol
klebsiella
spp
express
shvesbl
fix
ratio
combin
ceftazidim
respect
demonstr
similar
inhibitori
activ
blactamas
produc
isol
howev
mic
gener
fold
higher
compar
achiev
ceftazidim
plu
mgl
fix
concentr
conclus
potent
inhibitor
wide
rang
blactamas
includ
shvesbl
restor
potent
activ
ceftazidim
aztreonam
ceftazidimeresist
isol
speci
enterobacteriacea
high
affin
pbp
enabl
uniqu
guanidinepyrrolidin
carbapenem
achiev
good
vitro
activ
mrsa
confirm
murin
infect
model
low
gc
content
journal
bacteriolog
genom
analysi
reveal
linear
dna
genom
base
pair
encod
put
orf
gene
encod
lysin
protein
identifi
standard
molecular
biolog
techniqu
util
clone
lysin
protein
result
bioinformat
analysi
bacteriophag
lysin
lysk
gene
indic
interrupt
intron
observ
confirm
rtpcr
result
cdna
found
encod
amino
acid
protein
lysk
gene
heterolog
overexpress
escherichia
coli
use
promot
lactococcu
lacti
use
nisininduc
promot
view
gener
cell
factori
lysin
product
result
zymogram
dead
staphylococc
cell
indic
activ
recombin
lysk
product
gener
case
exhibit
cell
wall
degrad
activ
coagulas
neg
staphylococci
mrsa
strain
vrsa
aureu
associ
bovin
infect
conclus
bacteriophag
lysin
clone
studi
exhibit
activ
drug
resist
aureu
thu
promis
candid
antimicrobi
elimin
problemat
aureu
strain
circumv
resist
betalactam
antibiot
staphylococcu
aureu
c
fuda
mobasheri
notr
dame
usa
object
emerg
methicillinresist
staphylococcu
aureu
mrsa
creat
challeng
treatment
nosocomin
infect
aureu
normal
produc
four
pbp
suscept
modif
blactam
antibiot
event
lead
bacteri
death
gene
product
meca
mrsa
penicillinbind
protein
pbp
design
refractori
action
avail
blactam
antibiot
furthermor
capabl
take
function
pbp
aureu
face
challeng
blactam
antibiot
basi
resist
inhibit
blactam
antibiot
studi
us
methodolog
appli
investig
three
cephalosporin
abri
antibiot
research
institut
vienna
sandoz
specif
develop
inhibit
mrsa
method
meca
gene
clone
express
e
coli
purifi
homogen
also
synthet
cell
wall
fragment
produc
studi
result
kinet
paramet
interact
typic
blactam
antibiot
evalu
manifest
resist
inhibit
avail
blactam
antibiot
attenu
microscop
rate
constant
acyl
elev
dissoci
constant
kd
two
factor
work
concert
result
drug
resist
abri
cephalosporin
develop
treatment
mrsa
exhibit
lower
kd
valu
ratio
approxim
one
two
order
magnitud
higher
blactam
document
bind
portion
cell
wall
outsid
activ
site
facilit
open
activ
site
close
conform
becom
predispos
modif
abri
antibiot
manifest
increas
compar
typic
blactam
antibiot
conclus
recent
emerg
variant
mrsa
resist
oxazolidinon
glycopeptid
antibiot
creat
challeng
treatment
certain
strain
aureu
disconcert
situat
clinic
studi
laboratori
provid
mechanist
detail
inhibit
result
abri
cephalosporin
demonstr
problem
present
uniqu
pbp
circumv
present
opportun
antibiot
design
background
tolevam
potassiumsodium
tolevam
novel
high
molecular
weight
nonantibiot
polym
develop
treat
clostridium
difficil
associ
diarrhoea
cdad
current
form
modifi
earlier
compound
tolevam
sodium
addit
potassium
prevent
anion
polym
exacerb
hypokalemia
bind
excret
intestin
potassium
stool
tolevam
sodium
shown
resolv
symptom
cdad
similar
efficaci
vancomycin
larg
phase
studi
tolevam
current
phase
develop
object
determin
safeti
toler
liquid
tolevam
given
four
differ
dose
level
g
g
g
g
healthi
male
volunt
method
random
doubleblind
placebocontrol
paralleldesign
multipl
dose
studi
consist
screen
period
day
treatment
period
week
followup
period
conduct
dose
group
subject
random
activ
drug
match
placebo
half
subject
dose
group
receiv
load
dose
singl
dose
equival
total
daili
dose
object
nchlorotaurin
nct
longliv
oxid
produc
human
leukocyt
inflamm
crystallin
sodium
salt
synthet
chemic
broad
spectrum
antimicrobi
activ
bacteria
fungi
virus
mild
activ
therefor
low
toxic
nct
thought
use
antisept
applic
differ
bodi
site
perform
three
clinic
phase
ii
studi
evalu
efficaci
toler
otiti
externa
epidem
keratoconjunct
chronic
leg
ulcer
purul
coat
method
aqueou
nct
mm
solut
appli
topic
day
three
indic
studi
design
random
test
nct
control
group
standard
medic
otiti
externa
epidem
keratoconjunct
studi
doubleblind
evalu
done
clinic
use
score
system
subject
object
symptom
microbiolog
result
nct
well
toler
indic
littl
burn
eye
minut
patient
like
sweat
significantli
less
burn
p
chloramin
purul
crural
ulcer
side
effect
granul
reepitheli
ulcer
appear
earlier
nct
group
p
nct
equal
effect
remov
purul
coat
stronger
antisept
chloramin
clinic
symptom
extern
otiti
decreas
day
earlier
test
group
control
group
treat
combin
polymyxin
b
neomycin
hydrocortison
p
regard
epidem
conjunct
sever
cours
caus
mainli
adenoviru
type
show
reduct
symptom
day
earlier
control
group
mock
treat
gentamicin
p
conclus
mild
antisept
nct
excel
toler
effect
infect
differ
bodi
site
endogen
amino
acid
deriv
toxic
allerg
side
effect
never
observ
appli
without
addit
advantag
nct
estim
promis
antimicrobi
agent
human
medicin
ertapenem
initi
antimicrobi
monotherapi
patient
typic
communityacquir
pneumonia
c
petrogiannopoulo
g
svouka
k
papamichael
deliousi
k
kanaki
p
papasava
n
kostako
zaharof
athen
gr
object
ertapenem
group
carbapenem
onceaday
parenter
alactam
antibiot
use
initi
antimicrobi
monotherapi
treatment
communityacquir
pneumonia
cap
aim
studi
evalu
clinic
respons
safeti
profil
ertapenem
method
studi
patient
femal
male
mean
age
rang
cap
prove
clinic
radiograph
blood
test
examin
blood
cultur
neg
sputum
cultur
posit
streptococcu
pneumonia
patient
klebsiella
pneumonia
patient
patient
reciev
gr
ertapenem
intraven
iv
daili
initi
antimicrobi
therapi
day
least
everyday
haematolog
biochem
test
made
order
evalu
clinic
respons
safeti
profil
ertapenem
clinic
improv
patient
switch
oral
antibiot
therapi
day
result
day
therapi
ertapenem
patient
clinic
haematolog
improv
concern
reduct
fever
wbc
crp
valu
common
drugrel
advers
experi
report
parenter
therapi
patient
treat
ertapenem
diarrhoea
infus
vein
complic
nausea
headach
liver
function
test
normal
treatment
conclus
data
provid
evid
efficaci
ertapenem
initi
antimicrobi
monotherapi
patient
cap
ertapenem
given
gr
day
iv
infus
gener
well
toler
overal
good
safeti
toler
profil
treatment
chronic
mrsa
infect
use
novel
aqueou
extract
allicin
rr
cutler
pd
josl
nj
bennett
london
rye
uk
allicin
recognis
main
bioactiv
agent
allium
sativum
garlic
compound
highli
activ
gener
unstabl
use
cold
aqueou
extract
method
obtain
novel
extract
allicin
report
stabl
highli
activ
vitro
methicillin
resist
staphylococcu
aureu
mrsa
due
nation
public
patient
long
stand
unresolv
mrsa
infect
request
agent
treatment
mrsa
commonli
relat
delay
closur
mani
chronic
acut
wound
associ
high
level
bacteria
tissu
also
toxin
secret
toxin
caus
local
necrosi
disrupt
delic
balanc
critic
mediat
cytokin
proteas
necessari
heal
progress
present
initi
find
three
patient
complet
cours
treatment
cours
consist
capsul
mg
per
day
spray
liquid
lg
ml
onto
affect
area
per
day
appli
cream
lg
ml
infect
area
daili
patient
screen
nasal
wound
mrsa
prior
treatment
patient
nose
wound
swab
mrsa
posit
prior
treatment
year
age
either
major
surgeri
long
term
skin
infect
lead
format
ulcer
infect
mrsa
two
mrsa
infect
commun
acquir
one
hospit
acquir
strain
isol
patient
test
vitro
susceptiblepati
report
improv
condit
week
treatment
infect
resolv
month
although
timescal
requir
treatment
may
longer
normal
requir
use
antibiot
initi
relief
weep
ulcer
pain
much
quicker
note
patient
receiv
unsuccess
treatment
antibiot
month
year
prior
treatment
possibl
reason
initi
relief
symptom
could
relat
report
activ
garlic
extract
neutralis
bacteri
exoenzym
vitro
could
account
find
patient
got
relief
symptom
mrsa
fulli
remov
lesion
site
object
target
recombin
betalactamas
trbl
design
degrad
betalactam
antibiot
residu
gastrointestin
tract
therebi
inhibit
emerg
resist
present
studi
chang
resist
rate
persist
differ
intestin
escherichia
coli
strain
follow
beagl
ampicillin
treatment
without
trbl
method
eighteen
laboratori
beagl
randomis
receiv
ampicillin
amp
ampicillin
trbl
amptrbl
placebo
pla
suscept
intestin
e
coli
isol
collect
treatment
test
antimicrobi
agent
nccl
disk
diffus
method
select
isol
type
use
pulsedfield
gel
electrophoresi
pfge
xbai
restrict
total
dna
result
vast
genet
heterogen
includ
differ
pfge
type
display
differ
resist
pattern
detect
beagl
harbour
averag
pfge
type
studi
share
sever
common
clone
although
number
resist
isol
increas
similar
resist
pattern
detect
treatment
group
singl
ampicillinresist
pfge
type
wide
spread
group
ampicillin
resist
found
pfge
type
differ
combin
coresist
proport
resist
isol
number
dog
carri
ampicillinresist
strain
treatment
higher
amp
group
amptrbl
pla
group
respect
new
resist
pfge
type
appear
extens
replac
previou
type
amp
group
case
previous
suscept
strain
acquir
resist
treatment
amptrbl
group
slight
increas
resist
due
enrich
resist
strain
dog
alreadi
carri
resist
pla
group
new
resist
pfge
type
appear
proport
remain
moder
conclus
trbl
seem
inhibit
select
pressur
preserv
genet
divers
intestin
e
coli
popul
increas
resist
due
select
heterogen
resist
strain
rather
emerg
resist
among
previous
suscept
strain
pharmacokineticspharmacodynam
antistaphylocc
drug
object
studi
releas
linezolid
polymethylmethacryl
pmma
bead
load
three
differ
concentr
antimicrobi
method
pmma
bead
prepar
load
surgic
simplex
p
radiopaqu
bone
cement
ww
linezolid
bead
place
continu
flow
chamber
ml
kreb
ringer
buffer
flow
mlh
h
antimicrobi
concentr
determin
triplic
disk
diffus
antimicrobi
bioassay
lower
detect
limit
mcgml
detect
time
cmax
tmax
per
cent
antimicrobi
recov
bead
calcul
result
result
list
tabl
mean
standard
deviat
three
valu
antimicrobi
greater
limit
detect
assay
present
linezolid
load
bead
elut
paramet
linezolid
similar
bead
contain
antimicrobi
object
polymethylmethacryl
pmma
use
local
antimicrobi
deliveri
treatment
prevent
bone
joint
infect
develop
vitro
assay
determin
releas
profil
antimicrobi
agent
pmma
studi
compar
vitro
releas
kinet
daptomycin
vancomycin
continu
flow
chamber
vivo
releas
rat
model
method
daptomycin
vancomycin
ww
load
powder
compon
pmma
liquid
monom
ad
mix
antimicrobi
load
pmma
form
mm
bead
allow
polymer
h
effect
pmma
compon
polymer
activ
daptomycin
vancomycin
determin
homogen
load
bead
ml
kreb
ringer
buffer
assay
buffer
antimicrobi
activ
vitro
antimicrobi
releas
kinet
determin
place
bead
chamber
contain
ml
kreb
ringer
buffer
mlh
kreb
ringer
buffer
flow
chamber
buffer
elut
system
collect
hourli
assay
antimicrob
use
bioassay
beadantimicrobi
test
triplic
vivo
antimicrobi
releas
kinet
perform
surgic
implant
singl
bead
bone
defect
proxim
left
tibia
rat
three
rat
daptomycin
load
bead
three
vancomycin
load
bead
sacrif
placement
bone
tissu
within
mm
bead
recov
homogen
ml
kreb
ringer
buffer
incub
h
assay
antimicrob
per
cent
releas
list
total
antimicrobi
detect
buffer
tissuetot
amount
antimicrobi
load
bead
result
daptomycin
vancomycin
load
pmma
bead
detect
immedi
polymer
pharmacokinet
result
shown
mean
concentr
tabl
conclus
peak
daptomycin
vancomycin
concentr
observ
vivo
approxim
threefold
peak
observ
vitro
daptomycin
load
pmma
produc
higher
antimicrobi
concentr
vancomycin
load
pmma
vitro
vivo
object
compar
pharmacodynam
daptomycin
vancomycin
kill
kinet
aureu
studi
fiveday
treatment
cours
wide
rang
ratio
area
curv
auc
mic
method
clinic
isol
aureu
mic
daptomycin
mgl
mic
vancomycin
mgl
expos
oncedaili
daptomycin
twicedaili
vancomycin
five
consecut
day
monoexponenti
concentrationtim
profil
simul
halfliv
h
daptomycin
h
vancomycin
rang
aucmic
ratio
h
antimicrobi
effect
express
intens
ieth
area
control
growth
curv
absenc
antibiot
timekillregrowth
curv
observ
presenc
antibiot
cumul
effect
treatment
determin
time
zero
time
effect
longer
could
detect
ie
time
last
antibiot
dose
number
antibioticexpos
bacteria
reach
least
logcfuml
valu
cutoff
level
use
determin
ie
result
daptomycin
vancomycin
bacteri
regrowth
follow
initi
kill
entir
rang
simul
aucmic
ratio
background
use
glycopeptid
febril
neutropenia
increas
follow
preval
gramposit
gp
infect
among
patient
withhold
empir
glycopeptid
treatment
ecolog
wise
stipul
result
increas
mortal
perform
systemat
review
metaanalysi
trial
assess
addit
antigp
treatment
febril
neutropenia
method
includ
randomis
trial
compar
one
antibiot
regimen
without
placebo
regimen
addit
antibiot
gp
infect
search
medlin
embas
cochran
librari
refer
confer
proceed
date
languag
age
public
limit
impos
two
review
extract
data
independ
rel
risk
confid
interv
estim
use
fix
effect
model
valu
favor
addit
antigp
antibiot
result
thirteen
trial
particip
includ
antibiot
gramposit
infect
includ
glycopeptid
studi
cephalotin
flucloxacillin
trimethoprimsulphamethoxazol
one
eleven
studi
randomis
patient
onset
febril
neutropenia
studi
randomis
patient
persist
fever
hour
signific
reduct
allcaus
mortal
seen
addit
antibiot
gramposit
infect
object
perform
nationwid
survey
defin
differ
practic
manag
febril
neutropenia
haematolog
unit
design
singl
round
audit
questionnair
sent
select
haematologist
haematolog
unit
uk
question
ask
regard
antimicrobi
chemotherapi
choic
antimicrobi
prophylaxi
manag
febril
neutropenia
result
respons
receiv
haematolog
unit
provid
care
patient
febril
neutropenia
febril
neutropenia
empir
treat
piperacillintazobactam
carbapenem
monotherapi
haematologist
overal
dual
therapi
ie
aminoglycosid
plu
piperacillimtazobactam
prescrib
haematologist
respons
initi
empir
therapi
occur
day
haematologist
may
add
glycopetid
vancomycin
teicoplanin
may
chang
carbapenem
glycopeptid
fortyeight
per
cent
haematologist
routin
add
convent
amphotericin
ongo
antibiot
persist
neutropenia
compar
use
liposom
amphotericin
granulocyt
colonystimul
factor
frequent
use
adjuv
manag
febril
neutropenia
haematologist
antifung
prophylaxi
fluconazol
prescrib
haematologist
follow
itraconazol
fortyseven
haematologist
use
antifung
prophylaxi
neutropen
patient
compar
use
antifung
patient
neutrophil
less
conclus
ration
use
antimicrobi
chemotherapi
manag
febril
neutropenia
adopt
studi
select
rct
compar
ciprofloxacin
aminoglycosid
combin
therapi
beta
lactam
treatment
febril
neutropenia
report
effect
mortal
andor
toxic
data
includ
analysi
studi
examin
quinolon
monotherapi
combin
quinolon
aminoglycosid
use
quinolon
outpati
set
start
treatment
quinolon
ciprofloxacin
exclud
data
extract
data
primari
secondari
outcom
extract
two
investig
object
aim
studi
evalu
frequenc
suscept
pattern
bacteri
pathogen
isol
blood
cultur
febril
neutropen
cancer
patient
hospit
anticanc
hospit
two
year
period
method
total
number
blood
cultur
examin
use
autom
bactalert
microbi
detect
system
aerob
fan
anaerob
fn
classic
subcultur
method
isol
character
speci
level
api
system
minim
inhibitori
concentr
perform
use
semi
autom
method
microscan
accord
nccl
recommend
investig
patient
neutropen
wbc
power
per
liter
fever
antimicrobi
antifung
therapi
time
blood
cultur
result
two
year
period
blood
cultur
perform
basi
physician
request
patient
hospit
two
oncolog
one
hematologist
ward
hospit
mean
length
neutropenia
day
pathogen
isol
blood
cultur
patient
among
bacteri
strain
isol
bloodstream
infect
gram
neg
strain
n
gram
posit
cocci
n
one
strain
l
monocytogen
one
strain
c
kruzei
group
gramneg
strain
e
coli
domin
increas
antibiot
resist
resist
amoxicillin
clavulan
acid
resist
ciprofloxacin
gramneg
rod
highli
suscept
imipenem
meropenem
piperacillintazobactam
group
gramposit
bacteria
glycopeptid
resist
strain
found
staphylococci
strain
suscept
methicillin
conclus
observ
rise
trend
number
gramneg
isol
antibiot
resist
gramneg
rod
empir
therapi
wide
rang
antibiot
febril
neutropen
cancer
patient
seem
optim
option
monitor
antibiot
suscept
bacteri
strain
still
requir
varicella
zoster
viru
vzv
frequent
associ
mild
hepat
rare
acut
liver
failur
immunolog
impair
signific
predispos
factor
object
report
yearsold
girl
acut
lymphoblat
leukemia
acut
fatal
liver
necrosi
vzv
infect
methodsresult
second
child
famili
neg
histori
vzv
diseas
vaccin
diagnos
six
month
ago
child
treat
accord
bfm
protocol
complet
remiss
time
admiss
three
week
dexamethason
mgrm
day
reinduct
child
first
admit
hematologyongolog
depart
sever
abdomin
pain
fever
elev
transaminas
next
day
cutan
lesion
appear
chest
face
suggest
vzv
infect
antivir
therapi
acyclovir
immedi
initi
two
day
later
patient
transfer
picu
sever
clinic
laboratori
deterior
high
fever
tachypnea
posit
chest
xray
right
low
lobe
consolid
pleural
effus
abdomin
distent
liver
enlarg
gross
haematuria
gi
bleed
vesicular
rash
chest
face
scalp
gener
petechia
echymos
patient
pancytopenia
mark
elev
hepat
enzym
bilirubin
hypoalbuminemia
sever
dissemin
intravascular
coagulopathi
continu
transfus
ffp
rbc
plt
cryoprecipit
child
intub
hour
progress
respiratori
neurolog
deterior
renal
failur
develop
assist
ask
liver
transplant
team
littl
girl
urgent
transfer
special
depart
emerg
liver
transplant
unfortun
two
day
transport
child
develop
deep
coma
sever
hypotens
die
vzv
antibodi
level
neg
vzv
dna
detect
liver
biopsi
blood
specimen
pcr
conclus
immunocompromis
children
potenti
threaten
infect
highli
contagi
chickenpox
mortal
vzvinduc
hepat
failur
high
patient
surviv
liver
transplant
use
procalcitonin
measur
diagnosi
febril
neutropenia
result
among
patient
bacteraemia
caus
gram
bacteria
pct
level
ngml
ngml
n
ngml
n
patient
bacteraemia
caus
cn
pct
level
ngml
n
ngml
n
aureu
pct
level
ngml
enterococcu
spp
pneumoniococcu
clostridium
perfingen
corynebacterium
acn
pct
level
ngml
conclus
bacteraemia
associ
cn
may
fail
elev
serum
procalcitonin
level
bacteraemia
associ
gram
bacteria
elev
significantli
studi
need
confirm
find
procalcitonin
measur
postsurg
neonat
guid
antibiot
manag
e
broadi
j
tong
c
davi
c
luca
c
william
glasgow
uk
measur
plasma
creactiv
protein
crp
becom
establish
mean
monitor
respons
antimicrobi
therapi
howev
rais
level
indic
inflammatori
process
gener
specif
signal
infect
could
result
tendenc
overprescrib
antibioticsin
adult
patient
procalcitonin
pct
measur
specif
differenti
infect
inflammatori
process
date
paediatr
data
especi
neonat
limit
aim
assess
potenti
pct
guid
infect
postsurg
neonat
object
leukocyt
count
erythrocyt
sediment
rate
esr
creactiv
protein
crp
often
obtain
patient
prosthet
joint
prior
arthroplasti
surgeri
evalu
valu
paramet
diagnosi
prosthet
joint
infect
pji
method
prospect
analys
preoper
leukocyt
count
esr
crp
level
patient
prior
revis
resect
knee
hip
arthroplasti
mayo
clinic
rochest
mn
januari
novemb
pji
defin
growth
microorgan
least
two
specimen
synovi
fluid
periprosthet
purul
acut
inflamm
histopatholog
evalu
presenc
sinu
tract
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
calcul
use
conting
tabl
result
preoper
blood
specimen
patient
prior
total
knee
n
hip
n
replac
analys
median
age
year
rang
year
male
primari
diagnosi
osteoarthr
n
inflammatori
joint
diseas
n
trauma
n
osteonecrosi
n
caus
organ
coagulaseneg
staphylococci
n
staphylococcu
aureu
n
enterococci
n
propionibacterium
acn
n
corynebacteria
n
viridan
group
streptococci
n
mycobacteria
n
gramneg
bacilli
n
three
infect
polymicrobi
cultureneg
patient
receiv
antimicrobi
treatment
month
prior
surgeri
object
neopterin
sensit
indic
activ
cellmedi
immun
reaction
thu
determin
neopterin
concentr
variou
bodi
fluid
diagnost
marker
varieti
infecti
diseas
lymphocyt
macrophag
involv
cell
mediat
immun
reaction
play
import
role
intracellular
bacteria
mycobacterium
tuberculosi
brucella
speci
aim
studi
compar
serum
neopterin
level
patient
activ
pulmonari
tuberculosi
patient
brucellosi
healthi
subject
method
thirtynin
patient
activ
pulmonari
tuberculosi
femal
male
mean
age
patient
brucellosi
femal
male
mean
age
healthi
subject
femal
male
mean
age
includ
studi
patient
anoth
infect
malign
autoimmun
diseas
surgic
intervent
recent
blood
transfus
includ
studi
serum
sampl
collect
patient
control
group
store
analys
neopterin
concentr
measur
elisa
accord
protocol
manufactur
ibl
hamburg
germani
result
mean
neopterin
level
nmoll
patient
activ
pulmonari
tuberculosi
nmoll
patient
brucellosi
nmoll
healthi
subject
respect
serum
neopterin
level
found
significantli
higher
patient
activ
tuberculosi
patient
brucellosi
compar
healthi
control
p
besid
differ
patient
activ
pulmonari
tuberculosi
patient
brucellosi
p
conclus
studi
show
neopterin
level
increas
patient
activ
pulmonari
tuberculosi
patient
brucellosi
neopterin
use
follow
patient
chronic
infecti
diseas
brucellosi
tuberculosi
object
recent
introduc
autom
gener
rna
dna
extract
system
enabl
throughput
sampl
less
hour
sever
studi
shown
suitabl
autom
extract
system
mani
differ
sampl
type
feed
molecular
diagnost
assay
method
unlink
surplu
specimen
clinic
routin
use
cross
contamin
studi
design
high
titer
sampl
interspers
neg
sampl
give
checkerboard
pattern
subsystem
diagnost
assay
use
studi
either
commerci
avail
homebrew
assay
valid
laboratori
routin
result
crosscontamin
observ
use
hiv
rna
log
copiesml
hcv
rna
log
iuml
polyomaviru
dna
log
copiesml
total
serum
plasma
sampl
process
rna
extract
use
lcx
hiv
hcv
rna
quantit
assay
agreement
coba
amplicor
monitor
hivhcv
assay
coextract
hivhcv
rna
serum
plasma
sampl
reveal
impair
lcx
assay
result
compar
monoextract
reach
agreement
manual
autom
extract
initi
posit
urin
sampl
coba
amplicor
ct
show
feasibl
extract
bacteri
dna
c
trachomati
genom
dna
extract
whole
blood
sampl
homebrew
type
reveal
agreement
manual
extract
autom
extract
viral
dna
hbv
serum
plasma
sampl
reveal
correl
coeffici
r
compar
manual
extract
replic
hbv
quantit
standard
test
homebrew
realtim
pcr
autom
extract
excel
linear
detect
rate
concentr
level
iu
ml
viral
dna
success
extract
spinal
fluid
urin
cell
cultur
supernat
bal
nasopharyng
wash
breast
milk
biopsi
leukocyt
bone
marrow
sampl
cmv
hsv
polyomavirus
jc
bk
test
homebrew
realtim
pcr
n
conclus
taken
togeth
studi
shown
provid
versatil
solut
autom
extract
viral
rna
dna
bacteri
genom
dna
differ
specimen
type
feed
differ
molecular
diagnost
assay
field
hepat
bc
hiv
sexual
transmit
diseas
transplant
hla
type
evalu
autom
extract
rna
dna
high
throughput
inhous
quantit
realtim
pcr
assay
k
beuselinck
j
van
elder
leuven
b
object
nucleic
acid
na
extract
becom
critic
labour
intens
step
na
base
diagnost
perform
na
base
diagnost
primarili
depend
na
extract
yield
puriti
amount
sampl
extract
recent
abbott
introduc
fulli
autom
gener
rna
dna
extract
system
use
magnet
microparticl
process
allow
extract
sampl
hour
method
studi
perform
frontend
extract
system
high
throughput
inhous
quantit
realtim
pcr
assay
hcv
hbv
cmv
ebv
analys
compar
manual
extract
plasma
serum
sampl
hcv
hbv
edtablood
sampl
cmv
ebv
autom
viral
load
assay
develop
excel
assay
intern
control
chemic
contamin
control
method
effect
evalu
new
dot
blot
assay
confirm
human
immunodefici
viru
type
infect
use
recombin
antigen
ravanshad
f
sabahi
f
mahboudi
roostae
kazemnejad
tehran
ir
dot
blot
assay
use
four
recombin
protein
correspond
human
immunodefici
viru
type
type
gene
product
develop
confirm
presenc
antibodi
sera
reactiv
screen
elisa
serum
sampl
test
obtain
healthi
seroneg
blood
donor
differ
categori
hivinfect
individu
asymptomat
hivinfect
aid
posit
reaction
defin
reactiv
gag
least
one
env
either
hiv
gene
product
neg
result
defin
reaction
antigen
indetermin
result
defin
reactiv
gag
env
alon
none
serum
sampl
healthi
seroneg
blood
donor
gave
posit
result
sampl
gave
indetermin
result
recombin
hiv
dot
blot
assay
identifi
seroposit
individu
high
degre
accuraci
none
hivseroposit
subject
neg
test
result
reactiv
antigen
demonstr
sensit
specif
distinguish
seroneg
seroposit
sera
seroneg
seroposit
sampl
test
commerci
avail
western
blot
develop
inhous
hiv
dot
blot
assay
accur
identifi
seroposit
seroneg
sampl
fewer
indetermin
result
commerci
western
blot
interpret
cdc
criteria
hepat
b
viru
dna
test
nestedpcr
pcrelisa
hybrid
captur
ii
blood
blood
product
purpos
studi
establish
nestedpcr
detect
hepat
b
viru
hbv
blood
blood
product
primer
pair
set
design
amplifi
bp
sregion
hbv
genom
first
pcr
bp
first
pcr
amplicon
rubisco
intern
control
second
pcr
assess
specif
pcr
result
sampl
test
crossreact
interfer
assay
case
hbv
spike
blood
product
immunogloubulin
coagul
factor
method
could
detect
hbv
dna
iuml
nestedpcr
compar
pcrelisa
hybrid
captur
ii
hcii
pcrelisa
show
sensit
hcii
specif
hcii
p
result
studi
show
nestedpcr
pcrelisa
could
use
equal
manag
hbv
detect
blood
blood
product
object
genu
flaviviru
compris
virus
mani
caus
sever
human
diseas
genom
flaviviru
singl
strand
rna
molecul
posit
polar
translat
larg
polyprotein
process
structur
nonstructur
protein
viral
cellular
proteas
virusencod
proteas
binari
complex
constitut
protein
cofactor
viral
proteas
play
critic
role
viru
replic
cycl
repres
one
main
target
antivir
therapi
member
flaviviru
genusth
aim
studi
develop
vitro
assay
use
proteas
sever
flavivirus
belong
differ
group
order
character
enzymat
properti
temperatur
ph
saltsensit
substrat
specif
method
sequenc
encod
viral
proteinas
locat
genom
flavivirus
proteinas
express
hexahistidinetag
recombin
protein
purifi
immobilizedmet
affin
chromatographi
enzymat
properti
character
vitro
use
bapna
chromogen
substrat
trypsinlik
proteas
result
proteas
moieti
flavivirus
success
produc
purifi
exhibit
activ
toward
bapna
effect
temperatur
ionic
strength
ph
enzymat
activ
determin
result
suggest
hydrophil
domain
necessari
proteolyt
activ
conclus
system
develop
allow
us
establish
screen
test
identifi
design
inhibitor
activ
antivir
drug
one
pathogen
flavivirus
lack
activ
proteas
assay
could
indic
slight
differ
flavivir
proteas
select
activ
diagnosi
dengu
infect
enzymelink
immunosorb
assay
revers
transcriptionnest
polymeras
chain
reaction
dri
urin
spot
filter
paper
j
pupaibool
n
jaimchariyatam
krajiw
k
arunyingmongkol
p
suandork
prommalikit
r
sittichai
nisalak
c
pancharoen
u
thisyakorn
w
kulwichit
bangkok
th
object
polymeras
chain
reaction
pcr
enzymelink
immunosorb
assay
elisa
serum
use
diagnosi
dengu
infect
howev
certain
area
world
readili
avail
storag
specimen
filter
paper
test
later
centr
attract
way
confirm
clinic
diagnosi
epidemiolog
studi
perform
pilot
studi
see
urin
spot
filter
paper
use
dengu
diagnosi
method
adult
children
admit
king
chulalongkorn
memori
hospit
suspect
dengu
infect
enrol
final
diagnosi
dengu
infect
base
standard
serum
elisa
assay
patient
neg
serolog
serv
control
urin
specimen
collect
twice
day
week
apart
spot
filter
paper
store
degre
minimum
day
test
rtnest
pcr
elisa
perform
extract
spot
elisa
criteria
urin
singl
igm
unit
primari
dengu
infect
singl
igg
unit
increas
igg
titer
second
titer
unit
secondari
dengu
infect
result
patient
enrol
specimen
analys
rtpcr
elisa
respect
result
summaris
tabl
primari
dengu
case
exclud
sensit
elisa
secondari
case
conclus
first
studi
use
dri
urin
sampl
filter
paper
dengu
diagnosi
studi
fresh
urin
spot
onto
filter
paper
laboratori
cross
contamin
possibl
realist
process
would
done
nearpati
basi
vastli
lower
likelihood
contamin
thu
better
result
rtpcr
collect
urin
less
invas
blood
especi
suitabl
children
method
would
highli
applic
epidemiolog
studi
dengu
outbreak
due
low
number
primari
case
endem
area
thailand
studi
elsewher
need
assess
util
urin
spot
case
rapid
sequenc
base
prototyp
assay
detect
high
risk
hpv
strain
cervic
sampl
background
human
papillomaviru
hpv
one
common
caus
sexual
transmit
diseas
result
estim
death
yearli
cervic
cancer
worldwid
type
found
anogenit
tract
least
consid
high
risk
hr
significantli
associ
progress
invas
cervic
cancer
effort
accommod
high
throughput
screen
hr
hpv
type
recent
develop
prototyp
hpv
assay
use
singl
base
dye
primer
profil
sbdpp
approach
present
studi
evalu
prototyp
assay
perform
patient
sampl
object
evalu
sbdpp
assay
detect
hr
hpv
strain
cervic
sampl
method
genom
dna
purifi
retrospect
cervic
sampl
use
feasibl
studi
fiftyfour
previous
type
success
digen
hybrid
assay
remain
sampl
yield
inconclus
result
assay
use
consensu
pcr
primer
sequenc
conserv
among
hpv
type
fragment
region
amplifi
presenc
intercal
dye
hpvposit
sampl
identifi
amplif
ct
valu
dissoci
curv
melt
profil
sequenc
rapid
sbdpp
protocol
analys
abi
genet
analyz
hr
hpv
type
identifi
uniqu
singl
base
distribut
profil
case
respect
cervic
sampl
posit
hpv
type
hpv
detect
concord
hpv
detect
concord
better
histolog
diagnos
cancer
highgrad
lesion
compar
lowgrad
lesion
sensit
hpv
detect
urin
similar
distil
water
conclus
studi
one
examin
presenc
hpv
urin
sampl
patient
refer
colposcopi
unit
high
hpv
typespecif
concord
cervic
urin
sampl
good
sensit
urin
detect
report
specimen
two
epitheli
cell
magnif
worth
process
expens
hpv
detect
method
report
support
possibl
selftest
hpv
use
urin
one
day
give
lowincom
group
specif
popul
like
young
adolesc
good
screen
altern
object
sever
diagnost
test
detect
sar
antibodi
serum
previous
evalu
includ
elisa
iift
assay
studi
evalu
novel
protein
chip
assay
coronaviru
protein
microarray
covpm
develop
detect
antibodi
multipl
coronavirus
includ
sarscov
compar
current
accept
commerci
avail
gold
standard
assay
euroimmun
sarscov
igg
indirect
immunofluoresc
test
iift
method
covpm
compris
sarscov
protein
protein
fragment
along
protein
addit
coronavirus
infect
human
cat
mice
cow
array
use
probe
select
previous
valid
challeng
sampl
human
sera
antibodi
sarscov
includ
sampl
patient
differ
date
sera
includ
sarscov
iggneg
neg
acut
sar
case
acut
sarscov
igg
posit
po
convalesc
case
conv
sarscovneg
patient
respiratori
ill
resp
healthcar
worker
hcw
sarscov
igg
po
neg
grid
covpm
probe
serumpati
react
fluoresc
label
antibodi
signal
detect
use
standard
microarray
scanner
scan
analys
two
reader
use
programm
develop
predict
natur
serum
result
sarscovpo
sera
read
posit
covpm
reader
sensit
conv
sera
read
covpm
po
one
reader
wherea
call
neg
inconclus
reader
interestingli
major
case
sarscov
po
sera
test
discrep
covpm
covpm
po
sampl
patient
later
date
hcw
acu
resp
sarscovneg
sera
covpmneg
specif
sarscov
antibodi
found
hcw
resp
other
inconclus
sarscov
po
sera
also
react
protein
suggest
concurr
prior
infect
coronaviru
sera
within
select
test
posit
western
blot
assay
conclus
covpm
appear
sensit
specif
method
detect
sarscov
antibodi
serum
ad
valu
abil
detect
antibodi
coronavirus
requir
evalu
preval
respiratori
virus
hospitalis
patient
rather
unclear
due
rather
larg
effort
revers
transcriptas
rt
pcr
method
poor
sampl
qualiti
mani
specimen
sensit
rapid
antigen
detect
test
mani
virus
diagnos
nucleic
acid
tetect
method
also
question
whether
acut
replic
virus
residu
genet
materi
detect
present
describ
result
studi
use
combin
cell
culturepcr
method
suitabl
detect
product
infect
differ
respiratori
virus
cultiv
total
nasopharyng
secret
bronchioalveolar
lavag
bal
children
hospit
local
paediatr
depart
adult
transplant
patient
human
larynx
epitheli
monkey
kidney
cell
abl
detect
also
slow
grow
virus
like
human
metapneumoviru
hmpv
method
also
abl
detect
parainfluenza
viru
rhinovirus
certain
extent
adenovirus
addit
influenzavirus
respiratorysyncyti
viru
rsv
adenovirus
detect
commerci
antigen
detect
assay
epidemiolog
respiratori
virus
western
austria
winter
season
reveal
parainfluenza
outbreak
confirm
sequenc
right
main
flu
season
rel
weak
rsv
season
mani
hmpv
isol
doubl
infect
indic
addit
sampl
also
test
exoticag
like
mimivirida
mimivirus
new
speci
describ
recent
water
amoeba
nearest
rel
appear
aquat
phycodnavirus
replic
mimiviru
similar
leginella
spp
also
replic
amoeba
suggest
occur
also
alveolar
cell
human
decid
test
patient
sampl
use
suicidepcr
protocol
disappointingli
enough
neither
detect
type
viru
respiratori
sampl
sampl
water
tank
contain
amoeba
speci
develop
realtim
nasba
respiratori
syncyti
viru
assay
b
deiman
f
jacob
c
schrover
vermeer
boxtel
nl
object
aim
develop
evalu
respiratori
syncyti
viru
assay
base
nasba
amplif
includ
realtim
detect
molecular
beacon
studi
perform
new
test
evalu
method
rsv
rna
isol
use
semi
autom
magnet
extract
method
minimag
intern
control
ad
sampl
prior
nucleic
acid
extract
primer
direct
fgene
region
rsv
genom
rsv
b
intern
control
amplifi
primer
set
one
gener
molecular
beacon
probe
design
detect
rsv
b
addit
beacon
design
detect
intern
control
amplif
reaction
perform
easyq
analys
allow
realtim
detect
result
use
serial
dilut
vitro
rna
hit
rate
realtim
rsv
assay
found
copi
isol
rsv
rsv
b
use
tissu
cultur
sampl
assay
sensit
approxim
isol
rsv
isol
rsv
b
cross
reactiv
observ
hmpv
hmpv
hmpv
hmpv
measl
realtim
assay
rsv
nose
swab
sampl
detect
within
approxim
hour
data
show
realtim
rsv
assay
rapid
sensit
qualit
assay
detect
rsv
use
standard
reagent
offer
consider
benefit
routin
set
clinic
manag
patient
rsv
infect
intrathec
synthesi
specif
antibodi
facial
nerv
palsi
j
bednarova
p
stourac
h
stroblova
sevcikova
brno
cz
object
accord
literatur
least
part
idiopath
facial
nerv
palsi
caus
herpet
virus
exampl
varicella
zoster
viru
ramsayhunt
syndrom
aim
studi
detect
intrathec
synthesi
specif
igg
antibodi
varicella
zoster
viru
patient
idiopath
facial
nerv
palsi
evalu
import
examin
establish
etiolog
diseas
subsequ
treatment
method
investig
cohort
patient
patient
diagnos
idiopath
facial
nerv
palsi
patient
diagnos
neuroborreliosi
nb
facial
nerv
palsi
part
clinic
symptom
serum
csf
sampl
analys
patient
use
diagnost
kit
human
compani
germani
varicellazost
viru
human
elisa
igg
antibodi
test
diagnost
kit
testlin
compani
clinic
diagnost
czech
republ
eia
borrelia
garinii
igg
detect
specif
igg
antibodi
intrathec
synthesi
evalu
specif
antibodi
index
ai
accord
method
result
intrathec
synthesi
igg
antibodi
varicella
zoster
viru
detect
patient
idiopath
facial
nerv
palsi
patient
neg
intrathec
antiborrelia
antibodi
synthesi
nb
subgroup
patient
neg
intrathec
antibodi
synthesi
varicella
zoster
viru
statist
signific
specif
antibodi
intrathec
synthesi
confirm
spearman
rank
coeffici
wilcoxon
test
conclus
statist
support
data
emphas
import
intrathec
synthesi
specif
antibodi
diagnost
method
patient
idiopath
facial
nerv
palsi
reveal
subgroup
patient
viral
ethiolog
thu
profit
specif
antivir
treatment
method
panel
prepar
pool
csf
specimen
panel
consist
code
specimen
neg
specimen
specimen
contain
cytomegaloviru
cmv
specimen
contain
hsv
type
concentr
vero
cell
specimen
contain
hsv
type
concentr
one
specimen
contain
hsv
concentr
artifici
inhibit
addit
fraxiparin
concentr
uml
panel
sent
laboratori
togeth
questionnair
concern
method
employ
clinic
microbiolog
infect
volum
supplement
result
laboratori
sent
result
one
laboratori
answer
questionnair
use
hous
pcr
one
laboratori
use
realtim
pcr
two
laboratori
monitor
inhibit
overal
specimen
correctli
report
posit
specimen
correctli
identifi
fals
posit
result
report
neg
specimen
particip
six
laboratori
assay
distinguish
hsv
type
differ
type
correctli
distinguish
specimen
contain
cmv
never
report
posit
remark
differ
assay
seem
influenc
vari
degre
inhibitori
factor
particip
report
specimen
contain
fraxiparin
posit
despit
inhibit
six
lab
use
qiaamp
dna
kit
qiagen
extract
one
lab
specifi
extract
method
five
laboratori
report
fraxiparin
contain
specimen
inconclus
inhibit
one
particip
monitor
inhibit
report
specimen
fals
neg
lab
use
qiaamp
dna
kit
qiagen
extract
result
second
qualiti
control
detect
hsv
csf
specimen
excel
strike
conclus
qualiti
control
differ
pcr
result
obtain
posit
specimen
artifici
inhibit
probabl
reflect
differ
dna
extract
method
use
rapid
diagnosi
herp
simplex
genit
infect
use
realtim
pcr
autom
extract
nucleic
acid
object
herp
simplex
viru
genit
infect
increas
last
year
sensit
specif
method
detect
herp
simplex
viru
type
herp
simplex
viru
type
import
diagnos
genit
infect
avoid
transmiss
aim
studi
show
short
experi
diagnosi
genit
infect
use
realtim
pcr
autom
extract
nucleic
acid
method
total
specimen
genit
ulcerationvesicl
endocerv
urethr
rectal
collect
patient
women
men
ask
begin
symptom
none
risk
factor
patient
follow
std
clinic
sevil
spain
sampl
collect
follow
manufact
rule
magnapur
use
extract
nucleid
acid
product
use
determin
genit
infect
use
lightcycl
realtim
pcr
roch
diagnost
system
lc
detect
posit
neg
control
use
case
result
total
sampl
posit
hsv
genit
lesion
vesicl
posit
endocerviv
swab
urethr
swab
posit
result
case
detect
case
case
patient
urethr
endocerv
swab
posit
genit
lesion
posit
hsv
posit
patient
primari
infect
conclus
magnapur
easi
effect
nontim
consum
method
autom
extract
nucleid
acid
direct
sampl
realtim
pcr
use
lc
allow
detect
genit
lesion
possibl
distinguish
two
type
studi
profit
sampl
diagnosi
herp
simplex
genit
infect
genit
ulcer
vesicl
human
epsteinbarr
viru
cytomegaloviru
viral
load
case
sudden
death
children
approach
realtim
pcr
assay
r
lvarezlafuent
mp
b
aguilera
ballestero
g
vallejo
j
mez
madrid
e
object
aim
work
determin
viral
load
three
ubiquit
virus
human
epsteinbarr
viru
ebv
cytomegaloviru
cmv
quantit
realtim
polymeras
chain
reaction
pcr
assay
paraffinembed
tissu
case
sudden
children
death
scd
virus
previous
detect
techniqu
serolog
viral
cultur
nest
pcr
method
qiaamp
dna
mini
kit
qiagen
use
extract
dna
paraffinembed
tissu
case
scd
accord
manufactur
protocol
dna
concentr
determin
read
optic
densiti
nm
two
blank
reaction
extract
togeth
set
ten
sampl
order
evalu
possibl
crossreact
detect
ebv
cmv
genom
quantit
realtim
pcr
carri
specif
set
primer
taqman
probe
betaactin
pcr
carri
intern
control
assur
qualiti
dna
sampl
suitabl
pcr
sampl
analys
duplic
one
virus
intern
control
result
viral
load
copieslg
dna
follow
patient
year
liver
spleen
cmv
spleen
neg
three
herpesvirus
lung
patient
year
cmv
liver
neg
three
herpesvirus
larynx
lung
patient
year
ebv
amygdal
cmv
amygdal
kidney
patient
month
newborn
neg
three
herpesvirus
lung
patient
month
spleen
neg
three
virus
lung
patient
year
amygdal
ebv
lung
patient
year
cmv
spleen
neg
three
virus
lung
patient
month
lymphoid
tissu
ebv
heart
conclus
shown
quantit
realtim
pcr
could
import
tool
diagnosi
viral
infect
scd
case
sinc
sensit
allow
us
find
presenc
pathogen
assay
detect
low
yield
emphasis
need
establish
viral
load
threshold
order
make
accur
interpret
presenc
herpesvirus
tissu
contribut
igg
avid
diagnosi
cmv
infect
p
koudouni
pagkal
g
triantafil
p
rozi
serr
gr
object
evalu
measur
cytomegaloviru
immunoglobulin
g
avid
distinguish
recent
cmv
infect
past
method
blood
sampl
taken
patient
attend
outpati
depart
hospit
gener
hospit
serr
symptom
sign
recent
cmv
infect
month
presenc
specif
cmv
antibodi
determin
use
microparticl
enzym
immunoassay
abbottaxsym
system
confirm
enzym
link
fluoresc
assay
suggest
nonacut
infect
sensit
specif
bioplex
cmv
igm
assay
increas
respect
ten
discrep
sampl
resolv
avid
test
result
sampl
low
igg
avid
sensit
cmv
igm
assay
bioplex
versu
vida
one
low
igg
avid
sampl
igm
neg
vida
bioplex
cmv
igm
assay
sampl
high
igg
avid
sensit
vida
bioplex
igm
assay
respect
conclus
bioplex
cmv
igm
assay
describ
sensit
specif
detect
cmv
igm
antibodi
exhibit
abil
detect
cmv
igm
specimen
contain
low
avid
igg
antibodi
biofilm
pathogenesi
antibiot
suscept
effect
atmospher
inoculum
size
staphylococcu
epidermidi
biofilm
densiti
dilut
fresh
tsb
use
seed
five
column
steril
flatbottom
polystyren
cell
cultur
plate
two
strain
per
plate
variou
concentr
steril
filter
vancomycin
tsb
ad
four
column
per
strain
tsb
alon
ad
remain
column
four
differ
repeat
experi
perform
give
result
dilut
eight
strain
control
lg
ml
vancomycin
set
lgml
set
lgml
set
set
compris
eight
replic
condit
plate
incub
hour
well
empti
pipett
wash
three
time
phosphatebuff
salin
air
dri
stain
crystal
violet
solut
ten
minut
rins
gentli
run
water
biofilm
densiti
measur
optic
densiti
nm
od
taken
posit
repeat
condit
combin
express
result
multipl
control
condit
statist
signific
assess
use
mannwhitney
test
p
taken
signific
result
five
eight
strain
show
statist
signific
increas
biofilm
densiti
presenc
low
vancomycin
concentr
result
biofilmposit
result
well
see
tabl
studi
shown
biofilm
densiti
strain
epidermidi
increas
presenc
low
concentr
vancomycin
unknown
whether
reflect
increas
biofilmform
abil
less
sensit
clone
within
popul
effect
cell
wall
organ
modul
gene
express
regul
biofilm
format
sigmab
common
mechan
staphylococcu
epidermidi
mediat
sigmab
depend
sara
transcript
object
altern
sigma
factor
sigmab
identifi
major
regul
biofilm
format
staphylococcu
epidermidi
wherea
aureu
minor
impact
sigmab
biofilm
format
could
observ
exclud
individu
behavior
epidermidi
investig
studi
influenc
sigmab
biofilm
format
sara
transcript
methicillin
suscept
clinic
isol
epidermidi
well
methicillin
resist
clinic
strain
method
mutant
variou
delet
within
sigb
operon
character
phenotyp
quantit
biofilm
assay
pia
specif
immunofluoresc
assay
transcript
analysi
gene
icaa
icar
sara
perform
use
quantit
realtim
pcr
result
mutant
dysfunct
sigmab
activ
display
decreas
biofilm
format
wherea
mutant
inactiv
antisigmafactor
rsbw
increas
biofilm
format
observ
transcript
analysi
reveal
icaa
transcript
downregul
sigmab
neg
mutant
icar
transcript
upregul
howev
observ
differ
icar
transcript
mutant
alway
reach
signific
level
indic
addit
sigmab
depend
regul
involv
regul
biofilm
express
except
mutant
inactiv
rsbw
epidermidi
display
signific
increas
icaa
transcript
congruent
strong
increas
biofilm
format
mutant
inactiv
antisigmafactor
display
minor
transcript
differ
analysi
sara
transcript
reveal
minor
differ
compar
respect
wild
type
similar
influenc
phenotyp
well
compar
transcript
regul
icar
icaa
altern
sigma
factor
sigmab
three
independ
genet
background
clinic
epidermidi
isol
suggest
regul
biofilm
format
sigmab
gener
featur
epidermidi
therefor
sigmab
depend
regulatori
pathway
could
promis
target
new
strategi
prevent
foreign
bodyassoci
infect
lack
signific
differ
sara
transcript
indic
sigmab
depend
sara
transcript
involv
observ
phenotyp
chang
foreign
bodi
infect
wild
type
staphylococcu
epidermidi
potenti
biofilm
format
antimicrobi
resist
b
parschalk
grisold
f
yassin
h
adametz
w
graning
e
presterl
vienna
graz
object
foreign
bodi
infect
fbi
due
staphylococcu
epidermidi
becom
major
clinic
problem
associ
consider
morbid
cost
biofilm
format
resist
multipl
antibiot
major
obstacl
success
treatment
aim
studi
test
staphylococcu
epidermidi
isol
patient
verifi
foreign
bodi
infect
abil
form
biofim
ii
suscept
standard
antibiot
compar
wild
type
staphylococcu
epidermidi
isol
skin
healthi
volunt
method
sixti
patient
verifi
fbi
evalu
hundr
twentynin
blood
cultur
isol
patient
fbi
isol
healthi
hospitalassoci
volunt
analys
identif
staphylococcu
epidermidi
done
use
routin
method
exclud
doubl
fbi
isol
genotyp
pfge
suscept
test
done
use
disk
diffus
method
accord
nccl
antimicrobi
agent
test
penicillin
oxacillin
erythromycin
clindamycin
gentamicin
amikacin
vancomycin
fosfomycin
fusid
acid
rifampicin
ciprofloxacin
trimethoprim
linezolid
biofilm
format
test
use
microtit
plate
biofilm
model
clinic
microbiolog
infect
volum
supplement
signific
fbi
strain
resist
penicillin
oxacillin
erythromycin
clindamycin
ciprofloxacin
trimethoprim
wild
type
staphylococcu
epidermidi
gener
suscept
clinic
isol
p
howev
control
resist
penicillin
erythromycin
resist
clindamycin
conclus
biofilm
format
present
extent
fbiassoci
wild
type
staphylococcu
epidermidi
strain
demonstr
potenti
skin
flora
caus
fbi
although
well
known
nosocomi
staphylococcu
epidermidi
resist
multipl
antibiot
wild
type
isol
show
alarm
resist
erythromycin
clindamycin
possibl
reflect
abund
use
macrolid
minor
infect
popul
object
biofilm
express
staphylococcu
epidermidi
major
virul
factor
attach
polymer
surfac
lead
reduc
suscept
antimicrobi
substanc
altern
sigma
factor
sigmab
import
regul
biofilm
format
epidermidi
howev
biofilm
format
influenc
addit
yet
uncharacter
regul
examin
studi
method
insert
biofilmneg
mutant
gener
biofilmposit
genet
background
epidermidi
identifi
arbitrari
pcr
transcript
icaadbc
locu
essenti
biofilm
format
well
inactiv
gene
investig
function
inactiv
gene
character
complement
studi
differ
environment
condit
result
insert
distal
end
orf
homolog
regulatori
gene
purr
bacillu
subtili
gene
upstream
purr
conserv
epidermidi
b
subtili
aureu
furthermor
two
addit
orf
homolog
b
subtili
aureu
locat
downstream
insert
site
within
purr
gene
epidermidi
b
subtili
aureu
highli
conserv
motif
homolog
consensu
sequenc
sigmab
depend
promot
identifi
upstream
sigmab
depend
transcript
could
demonstr
mutant
inactiv
sigb
transcript
biofilm
associ
gene
icaadbc
abolish
wherea
transcript
neg
regulatori
gene
icar
unaffect
complement
singl
gene
show
effect
wherea
complement
togeth
abl
restor
biofilm
format
high
osmot
condit
interestingli
standard
condit
use
biofilm
format
well
biofilm
induct
subinhibitori
concentr
ethanol
biofilm
format
observ
complement
mutant
conclus
identifi
two
new
regul
epidermidi
biofilm
format
design
biofilm
accumul
regul
b
barab
bara
b
act
posit
regul
icaadbc
transcript
independ
regulatori
gene
icar
barab
sigmab
depend
gene
locu
least
partial
respons
nacl
induct
biofilm
format
epidermidi
role
fur
transferrin
bind
protein
staphylococcu
epidermidi
vitro
vivo
biofilm
format
c
massonet
j
van
elder
leuven
b
object
determin
whether
gadph
transferrin
bind
proteintbp
regul
fur
play
role
biofilm
format
staphylococcu
epidermidi
method
biofilm
form
strain
epidermidi
isol
patient
proven
catheterrel
infect
use
rna
dna
isol
perform
describ
vandecasteel
et
al
biochem
biophi
re
commun
vitro
studi
bacteria
grown
overnight
bhi
rpmi
without
iron
frpmi
reincub
frpmi
frpmi
lm
fecl
frpmi
apotransferrin
iron
free
lgml
frpmi
holotransferrin
ironsatur
lgml
vivo
studi
subcutan
rat
model
use
sampl
quantifi
realtim
pcr
describ
vandecasteel
et
al
biochem
biophi
re
commun
result
growth
bacteria
express
fur
tbp
plankton
bacteria
higher
iron
deplet
medium
lower
iron
rich
medium
vitro
studi
iron
deplet
medium
show
statist
signific
anova
bonferonni
n
regul
fur
express
sessil
bacteria
comparison
plankton
bacteria
iron
rich
environ
variat
express
fur
sessil
plankton
bacteria
frpmi
holotransferrin
apotransferrin
express
fur
sessil
bacteria
comparison
plankton
bacteria
significantli
regul
frpmi
holotransferrin
regul
medium
apotransferrin
result
obtain
tbp
similar
vivo
express
fur
regul
begin
follow
increas
express
one
week
express
tbp
low
stay
constant
period
two
week
statist
signific
anova
bonferroni
n
conclus
accord
vitro
result
lack
iron
greater
impact
sessil
bacteria
plankton
bacteria
holotransferrin
apotransferrin
also
affect
express
fur
tbp
sessil
bacteria
investig
requir
vivo
result
show
fur
play
role
late
stage
biofilm
effect
iron
ironregul
gene
biofilmassoci
staphylococcu
epidermidi
result
vitro
result
show
ironlimit
environ
plankton
form
epidermidi
produc
siderophor
grow
slower
ironrich
environ
vitro
hour
observ
period
express
sirr
stay
constant
independ
iron
concentr
express
sita
sitb
sitc
hand
higher
medium
low
iron
content
medium
ad
iron
vitro
studi
also
indic
sirr
statist
anova
bonferroni
n
signific
higher
express
sessil
bacteria
compar
plankton
bacteria
express
sitc
significantli
anova
bonferroni
n
higher
sessil
bacteria
plankton
bacteria
ironlimit
medium
express
sitc
ironrich
medium
ident
form
vivo
anova
bonferroni
n
express
sirr
high
remain
stabl
time
period
two
week
sitc
sita
sitb
also
highli
express
two
week
time
period
conclus
constant
high
vivo
express
sitabc
regul
sirr
could
indic
role
gene
biofilm
growth
mode
vitro
result
show
ironregul
express
sitabc
express
sirr
vitro
ironregul
specif
regul
mechan
yet
known
role
virul
regul
gene
staphylococcu
epidermidi
biofilm
format
v
pinten
vandecasteel
r
merckx
j
van
elder
leuven
b
object
monitor
gene
express
staphylococcu
epidermidi
regul
loci
earli
vitro
vivo
biofilm
format
method
agra
rnaiii
sara
rsbu
rsbv
sigb
express
vitro
examin
min
inocul
nacl
plankton
n
sessil
n
bacteri
cultur
gene
express
vivo
biofilm
format
evalu
two
week
cathet
fragment
inocul
epidermidi
implant
subcutan
rat
describ
vandecasteel
et
al
biochem
biophi
re
commun
cathet
n
explant
min
implant
express
determin
taqmantm
realtim
pcr
describ
vandecasteel
biochem
biophi
re
commun
result
vitro
express
rsbu
first
gene
sigb
operon
signific
higher
sessil
plankton
bacteria
rel
express
level
rnaiii
sara
higher
plankton
sessil
bacteria
signific
differ
vitro
express
agra
sigb
rsbv
sessil
versu
plankton
bacteria
vivo
express
gene
reach
peak
level
h
implant
log
time
express
level
implant
subsequ
decreas
toward
lowest
level
h
agra
express
remain
stabl
whole
observ
period
express
rnaiii
sara
decreas
remain
thereaft
low
level
sigb
express
remain
high
level
whole
observ
period
wherea
express
rsbv
rsbu
increas
rsbu
express
significantli
higher
degre
sigb
operon
gene
conclus
contrast
aureu
sigb
operon
particularli
rsbu
seem
import
factor
epidermidi
biofilm
format
staphylococc
biofilm
target
linezolid
vancomycin
oxacillin
andor
lysostaphin
e
walencka
b
sadowska
rozalska
w
hryniewicz
b
rozalska
lodz
warsaw
pl
object
medic
deviceassoci
infect
frequent
caus
staphylococci
relat
biofilm
format
chemotherapi
infect
seldom
fulli
effect
due
high
biofilm
resist
number
altern
approach
antimicrobi
treatment
propos
aim
studi
activ
antibiot
monotherapi
combin
lysostaphin
toward
aureu
biofilm
method
aureu
mssa
clinic
mrsa
clinic
hvisa
use
plankton
cultur
biofilm
built
well
micropl
chamber
labtekii
chamber
slide
polyethylen
cathet
mic
linezolid
vancomycin
oxacillin
lysostaphin
plankton
bacteria
determin
accord
standard
nccl
bicbec
biofilm
inhibitoryerad
concentr
estim
mtt
assay
measur
activ
metabol
bacteria
surviv
singl
cyclic
dose
antimicrobi
antibiot
alon
combin
submic
lysostaphin
given
earlier
togeth
antibiot
integr
biofilm
treat
antimicrobi
also
examin
cathet
studi
visual
ttc
reduct
assay
chamber
labtekii
chamber
slide
stain
fitc
confoc
fluoresc
microscopi
result
demonstr
effect
lysostaphin
treatment
hour
biofilm
built
flat
surfac
well
micropl
chamber
labtekii
chamber
slide
also
cathet
extraand
intralumin
surfac
micbic
lysostaphin
mgl
mssa
mrsa
mgl
hvisa
respect
synergist
effect
submic
lysostaphin
oxacillin
observ
mssa
mrsa
biofilm
bicoxalin
drop
h
mgl
effect
demonstr
hvisa
strain
bicoxa
still
mgl
submic
lysostaphin
linezolid
vancomycin
given
cycl
therapi
effect
disrupt
mssa
mrsa
hvisa
mssa
mrsa
biofilm
respect
thu
lysostaphin
combin
antibiot
effect
prevent
biofilm
rebuild
bec
experi
last
day
conclus
studi
indic
staphylococc
biofilm
erad
could
achiev
treatment
lysostaphin
alon
combin
select
antibiot
howev
complet
biofilm
remov
need
cyclic
therapi
object
zinc
compound
use
silicon
latex
urinari
cathet
sluc
manufactur
studi
vitro
shown
zn
elut
sluc
determin
decreas
suscept
carbapenem
plankton
pseudomona
aeruginosa
effect
associ
oprd
loss
p
aeruginosa
abl
adher
efficaci
surfac
sluc
form
biofilm
object
studi
evalu
relev
phenomenon
p
aeruginosa
form
biofilm
sluc
clinic
microbiolog
infect
volum
supplement
method
biofilm
p
aeruginosa
grown
cm
sluc
segment
muellerhinton
broth
hour
bacteri
biofilm
detach
sonic
zn
accumul
biofilm
determin
induct
coupl
plasma
atom
emiss
spectrometri
icpa
sluc
segment
without
biofilm
use
control
studi
outer
membran
protein
omp
bacteri
biofilm
cell
disrupt
sonic
khz
two
minut
sonic
water
bath
omp
isol
sodiumlauryl
sarcosyn
insolubl
materi
protein
resolv
sdspage
omp
pattern
compar
express
plankton
bacteria
grown
muellerhinton
broth
supplement
zinc
chlorid
mg
znl
result
p
aeruginosa
sluc
biofilm
accumul
zn
zn
valu
reach
bacteri
biofilm
lgg
cathet
similar
obtain
control
lgg
cathet
p
aeruginosa
form
biofilm
lost
express
show
omp
profil
plankton
bacteria
presenc
zn
conclus
p
aeruginosa
sluc
biofilm
express
oprd
porin
respons
carbapenem
entri
p
aeruginosa
zn
elut
sluc
accumul
biofilm
divers
adhes
initi
biofilm
format
motil
abil
among
clonal
lineag
nosocomi
strain
pseudomona
aeruginosa
ap
fonseca
p
correia
af
fonseca
r
tenreiro
jc
sousa
porto
lisbon
p
object
object
studi
test
potenti
constraint
genotyp
sever
virul
paramet
examin
extent
phenotyp
divers
context
clonal
lineag
cl
among
nosocomi
strain
p
aeruginosa
method
combin
two
genom
type
system
minisatelliteprim
pcr
msppcr
enterobacteri
repetit
consensu
sequenc
pcr
ericpcr
use
discrimin
strain
collect
portugues
central
hospit
isol
differ
sourc
data
analys
use
bionumer
softwar
bacteri
adhes
polystyren
initi
biofilm
format
studi
grow
bacteria
lb
modifi
microtiterpl
assay
strain
screen
capac
adher
hydrophob
biomateri
silicon
hexadecan
csh
use
biphas
separ
method
opportunist
paeruginosa
also
screen
capac
swim
flagella
twitch
pili
test
run
triplic
result
combin
genotyp
phenotyp
analysi
reveal
extens
divers
paramet
within
cl
p
aeruginosa
strain
signific
differ
among
cl
howev
small
cluster
strain
rel
high
abil
found
one
specif
group
contain
strain
similar
worth
mention
group
strain
similar
low
abil
posit
correl
spearman
observ
p
csh
p
csh
p
twitch
p
strain
highest
adhes
valu
one
effici
initi
biofilm
produc
strain
behavior
lowest
valu
strain
highest
csh
also
one
effici
adhes
silicon
strain
lowest
adhes
two
paramet
conclus
result
suggest
extens
divers
name
wide
variat
virul
paramet
among
strain
within
cl
signific
differ
cl
virul
paramet
result
also
suggest
import
hydrophob
adhes
abil
abiot
surfac
import
twitch
biofilm
format
correl
abil
acknowledg
studi
support
caloust
gulbenkian
compar
studi
antibiot
suscept
level
clinic
strain
p
aeruginosa
plankton
adher
grow
biofilm
cell
background
besid
well
known
genet
antibiot
resist
pseudomona
aeruginosa
strain
grow
biofilm
medic
implant
respons
persist
infect
much
less
suscept
antimicrobi
agent
plankton
counterpart
recalcitr
could
due
selfaggreg
bacteri
adher
differ
substrata
gener
protect
exopolysaccharid
mathrix
limit
antibiot
diffus
biofilm
underexpress
porin
overexpress
multidrug
resist
pump
presenc
persist
surviv
presenc
antibiot
inhibit
growth
highlight
abovement
factor
investig
antibiot
resist
level
p
aeruginosa
plankton
cell
compar
cell
grow
biofilm
develop
central
venou
cathet
piec
imers
nutrient
broth
origin
experiment
model
includ
agar
mimick
biofilm
mathrix
studi
perform
p
aeruginosa
strain
isol
central
venou
cathet
relat
infect
patient
admit
cardiovascular
surgeri
strain
firstli
submit
antimicrobi
test
perform
standard
disk
diffus
method
strain
suscept
aminoglycosid
betalactam
quinolon
test
two
experiement
model
antibiot
suscept
bacteri
cell
includ
biofilm
form
liquid
solid
media
strain
also
studi
slime
product
cell
hydrophob
result
result
show
p
aeruginosa
cell
grow
biofilm
significantli
less
suscept
antibiot
doserespons
increas
mic
mbc
timedepend
manner
aspect
particularli
evidenc
statist
confirm
aminoglycosid
poorli
penetr
biofilm
due
polication
structur
major
test
strain
produc
high
amount
slime
evidenc
safranin
stain
biofilm
develop
glass
tube
wall
express
well
correl
presenc
bacteri
capsul
test
strain
exhibit
high
hydrophob
level
evidenc
decreas
absorb
valu
aqueou
phase
bacteri
cultur
presenc
paraxilen
also
abil
selfaggreg
rais
risk
colon
inert
materi
cathet
relat
persist
infect
biofilm
format
nosocomi
acinetobact
baumannii
strain
acinetobact
baumannii
import
nonocomi
pathogen
usual
found
variou
surfac
hospit
environ
biofilm
format
virul
factor
baumannii
studi
blood
isol
baumannii
studi
abil
form
biofilm
surfac
polystyren
ultrastructur
cell
wall
properti
biofilmformat
strain
evalu
method
total
baumannii
strain
isol
blood
cultur
differ
patient
intens
care
unit
select
abil
acinetobact
strain
form
biofilm
determin
polystyren
microtit
plate
use
brain
heart
infus
supplement
glucos
growth
medium
addit
transmiss
electron
microscopi
strain
perform
presenc
fimbria
cell
wall
thick
amorph
materi
cover
cell
describ
bacteria
result
biofilm
format
detect
baumannii
strain
ultra
structur
analysi
show
fimbria
found
isol
thickest
layer
amorph
materi
observ
around
biofilmposit
strain
conclus
biofilm
format
baumannii
strain
patient
bacteriemia
found
high
result
obtain
electron
microscopi
studi
suggest
amorph
materi
cover
bacteria
probabl
play
import
role
mainten
bacterium
hospit
environ
protect
defens
mechan
host
strain
enterobact
cloaca
isol
hospit
environ
abil
adher
cell
line
biofilm
form
bacteria
enterobact
cloaca
observ
etiolog
agent
nosocomi
infect
poland
especi
hospitalacquir
pneumonia
urinari
tract
infect
moreov
major
e
cloaca
strain
isol
patient
hap
hospit
icu
show
resist
ceftazidim
aim
studi
examin
virul
properti
like
adher
human
cell
line
form
biofilm
strain
e
cloaca
isol
patient
infect
colonis
strain
isol
bodi
surfac
german
cockroach
collect
hospit
examin
abil
adher
human
cell
line
done
accord
knutton
et
al
method
three
pattern
adhes
observ
aggreg
b
local
c
diffus
adhes
moreov
determin
activ
select
chemic
disinfect
bacteria
grow
plancton
form
evalu
mic
grow
biofilm
cathet
effect
work
solut
done
pattern
adhes
cell
line
vari
among
test
strain
aggreg
adhes
observ
among
strain
e
cloaca
colonis
patient
one
isol
infect
one
e
cloaca
strain
isol
surfac
cockroach
show
pattern
adhes
accord
statist
analysi
signific
number
ecloaca
strain
isol
cockroach
present
lack
adhes
cell
line
diffus
adhes
comparison
strain
collect
patient
total
e
cloaca
strain
show
mannosesensit
mechan
adher
cell
line
strain
colonis
patient
strain
caus
infect
strain
surfac
cockroach
strain
show
stronger
adhes
presenc
mannos
one
e
cloaca
strain
form
biofilm
cathet
major
test
strain
grow
day
cathet
resist
work
solut
potassium
persulf
glucoprotamin
sodium
dichloroisocyjanur
howev
e
cloaca
strain
caus
infect
resist
disinfect
work
solut
even
mic
valu
similar
mic
strain
patient
colonis
cockroach
studi
virul
marker
present
e
cloaca
hospit
strain
continu
develop
crystallin
proteu
mirabili
biofilm
foley
cathet
sd
morgan
dj
stickler
cardiff
uk
object
manag
mani
patient
undergo
longterm
bladder
catheteris
complic
encrust
blockag
cathet
problem
result
infect
ureas
produc
bacteria
organ
colon
cathet
ureas
induc
alkalin
condit
calcium
magnesium
phosphat
precipit
result
crystallin
biofilm
block
flow
urin
aim
studi
investig
earli
stage
biofilm
format
rang
cathet
type
method
laboratori
model
catheteris
bladder
suppli
urin
infect
proteu
mirabili
clinic
isol
encrust
cathet
model
fit
five
differ
type
cathet
incub
variou
period
time
block
cathet
remov
model
examin
scan
electron
microscopi
xray
microanalysi
use
follow
colon
cathet
bacteria
crystallin
materi
result
allsilicon
hydrogelco
latex
siliconeco
latex
cathet
acquir
layer
crystallin
materi
within
h
deposit
consist
predominantli
calcium
phosphat
subsequ
becom
colon
larg
number
bacilli
rapidli
develop
crystallin
biofilm
block
cathet
within
h
case
nitrofurazoneimpregn
allsilicon
cathet
although
initi
process
slower
crystallin
layer
first
observ
h
cathet
blockag
occur
h
triclosanimpregn
silicon
cathet
howev
show
littl
sign
encrust
biofilm
format
still
drain
urin
freeli
day
experi
termin
conclus
cathet
current
avail
longterm
bladder
manag
rapidli
colon
crystallin
p
mirabili
biofilm
triclosanimpregn
cathet
howev
abl
resist
encrust
biofilm
format
vitro
day
role
capsul
klebsiella
pneumonia
biofilm
format
c
struve
molin
ka
krogfelt
copenhagen
dk
object
k
pneumonia
import
opportunist
pathogen
frequent
caus
hospit
infect
k
pneumonia
cell
characterist
surround
pronounc
polysaccharid
capsul
proven
import
virul
factor
bacteria
abil
bacteria
form
biofilm
recogn
play
role
pathogen
mani
bacteri
speci
biofilm
bacteria
organis
microcoloni
embed
matrix
exocellular
polymer
substanc
ep
ep
consid
stabil
biofilm
structur
protect
bacteria
host
defenc
mechan
action
antibiot
studi
investig
clinic
microbiolog
infect
volum
supplement
role
polysaccharid
capsul
k
pneumonia
biofilm
format
method
geneclust
encod
synthesi
capsul
clone
sequenc
clinic
k
pneumonia
isol
isogen
noncapsul
mutant
construct
wildtyp
mutant
tag
chromosom
fluoresc
marker
grown
continu
flowcel
system
character
biofilm
format
use
confoc
laser
scan
microscopi
result
wildtyp
stain
found
form
thick
irregularli
shape
biofilm
biofilm
mainli
consist
loos
cluster
bacteria
lm
thick
although
biofilm
cover
substratum
open
area
also
present
within
bacteri
cluster
noncapsul
mutant
also
abl
form
biofilm
howev
architectur
differ
wildtyp
noncapsul
mutant
spread
confluent
thin
layer
cell
cover
substratum
vast
major
biofilm
less
lm
thick
occasion
thicker
bacteri
cluster
resembl
wildtyp
biofilm
phenotyp
observ
conclus
k
pneumonia
cell
abl
form
thick
biofilm
grown
continu
flow
system
polysaccharid
capsul
found
essenti
biofilm
format
per
se
absenc
significantli
affect
biofilm
develop
architectur
futur
studi
may
reveal
influenc
capsul
biofilm
resist
host
defenc
system
action
antibiot
object
klebsiella
bacilli
frequent
case
nosocomi
infect
associ
usag
urinari
cauti
intraven
cathet
crbsi
due
abil
biofilm
format
biomateri
aim
studi
correl
pathogen
properti
clinic
klebsiella
strain
capsul
type
adhesin
type
use
biomateri
degre
vitro
format
biofilm
structur
cathet
materi
method
clinic
klebsiella
strain
produc
sever
distinct
type
fimbria
test
isol
uti
blood
clinic
sampl
influenc
capsul
abil
biofilm
format
estim
use
uncapsul
mutant
capsul
variant
investig
urinari
catheterspolyvinyl
chlorid
nelaton
latex
foley
allsilicon
foley
venou
catheterpolyurethan
cavafix
test
vitro
biofilm
format
evalu
richard
method
assay
solubl
colourless
ttc
reduc
insolubl
red
formazan
electron
transfer
associ
activ
oxid
bacteri
metabol
precipit
intracellulari
assay
valid
electron
microscopi
result
investig
strain
show
abil
format
biofilm
cathet
hour
incub
strain
valu
fomazan
reduct
evalu
like
intermedi
strong
highest
level
biofilm
format
show
strain
venou
cathet
polyurethan
urinari
cathet
polyvinyl
chlorid
lowest
adhes
rate
observ
case
allsilicon
foley
cathet
capsul
strain
made
biofilm
weaker
uncapsul
strain
presenc
characterist
biofilm
structur
cathet
confirm
electron
microscopi
level
adhes
clinic
klebsiella
bacilli
biomateri
associ
chemic
type
cathet
capsul
absenc
lead
case
investig
strain
stronger
biofilm
format
surfac
biomateri
variou
kebsiella
strain
show
electron
microskopi
variou
structur
biofilm
correl
type
express
fimbria
degre
biofilm
format
observ
investig
object
biofilm
compos
surfaceattach
cell
excret
exopolymer
substanc
bacteri
biofilm
infect
particularli
problemat
sessil
bacteria
resist
antibiot
host
immun
respons
lead
therapeut
difficulti
object
studi
analys
capac
biofilm
format
e
coli
clinic
isol
caus
differ
urinari
tract
infect
cystitisct
pyelonephritispna
prostatitispt
method
total
uropathogen
e
coli
strain
cystiti
pyelonephr
prostat
analys
capac
vitro
biofilm
format
determin
bacteri
growth
minim
glucos
medium
stain
violet
crystal
wash
pb
cell
dissolv
dmso
plate
automat
read
spectrophotomet
strain
use
control
strain
experi
made
duplic
result
biofilm
format
note
strain
patient
ct
pna
pt
respect
abil
form
biofilm
significantli
frequent
pt
pna
strain
p
show
trend
significantli
frequent
ct
strain
p
differ
ct
pna
strain
regard
biofilm
product
note
p
pool
ct
pna
strain
togeth
biofilm
format
characterist
significantli
associ
strain
caus
pt
univari
multivari
analysi
ci
p
conclus
biofilm
format
significantli
preval
among
strain
e
coli
involv
acut
prostat
caus
urinari
tract
infect
biofilm
format
relev
promot
persist
prostat
infect
given
high
frequenc
biofilm
product
among
strain
caus
acut
prostat
treatment
patient
conduc
erad
microbi
biofilm
environment
maltos
glucos
concentr
regul
biofilm
format
enterococcu
faecali
j
huebner
kropec
koch
r
creti
freiburg
boston
usa
rome
object
biofilm
format
e
faecali
seem
play
import
role
number
enterococc
infect
littl
know
regard
underli
mechan
want
identifi
environment
signal
regul
biofilm
format
enterococcu
recent
identifi
genet
locu
involv
biofilm
format
e
faecali
biofilm
format
measur
use
polystyren
plate
assay
media
supplement
oligosaccharid
express
gene
measur
realtim
pcr
locu
sequenc
homolog
assess
use
blast
relat
programm
result
genet
locu
identifi
us
also
involv
maltos
uptak
metabol
express
gene
locu
regul
maltos
glucos
growth
medium
indic
nutrit
oligosaccharid
may
promot
inhibit
biofilm
format
wildtyp
strain
abl
produc
biofilm
medium
contain
either
glucos
maltos
two
mutant
one
transposon
mutant
one
delet
mutant
show
opposit
effect
transposon
mutant
show
reduc
biofilm
format
grown
medium
contain
glucos
delet
mutant
produc
biofilm
grown
glucos
unabl
form
biofilm
maltos
ad
growth
medium
sugarbind
transcript
regul
bopd
seem
bind
oper
upstream
bop
locu
consensu
bind
sequenc
shown
bind
maltos
repressor
malr
present
noncod
region
upstream
bopa
conclus
biofilmposit
phenotyp
wildtyp
strain
seem
facilit
colon
enterococci
gut
presenc
oligosaccharid
food
may
regul
biofilm
format
therefor
colon
enterococci
gastrointestin
system
biofilm
format
morpholog
group
streptococci
isol
patient
sepsi
necrotis
fasciiti
object
group
streptococci
may
caus
sever
sepsi
associ
multiorgan
failur
high
mortal
addit
primari
caus
necrot
fasciiti
object
studi
evalu
abil
form
biofilm
morpholog
biofilm
produc
ga
isol
blood
patient
sepsi
tissu
patient
necrot
fasciiti
method
twentysix
ga
isol
blood
cultur
patient
sepsi
bacteraemia
isol
tissu
patient
necrot
cellul
fasciiti
collect
isol
identifi
use
routin
method
frozen
bhi
broth
glycerol
test
abil
form
biofilm
isol
grown
microtit
plate
trypton
soya
broth
hour
examin
morpholog
biofilm
format
isol
either
examin
unfix
fix
glutaraldehyd
use
electron
microscop
scan
philip
esem
quantif
fix
glutaraldehyd
dy
crystal
violet
measur
mean
optic
densiti
od
use
routin
microtiterplateread
nm
wavelength
calcul
differ
frequenc
group
fisher
exact
test
calcul
differ
od
mannwhitneyutest
use
result
seventeen
isol
patient
sepsi
isol
fom
patient
necrot
fasciiti
form
biofilm
differ
signific
scan
electron
studi
confirm
biofilm
format
howev
look
somewhat
scarc
isol
necrot
fasciiti
biofilm
form
isol
od
isol
sepsi
significantli
higher
od
isol
necrot
fasciiti
versu
p
conclus
ga
isol
bloodstream
tissu
abil
form
biofilm
biofilm
blood
stream
isol
significantli
denser
biofilm
tissu
isol
surplu
opac
blood
stream
isol
confirm
scan
electron
microscopi
studi
reveal
scanti
look
morpholog
tissu
ga
isol
lesser
densiti
biofilm
ga
isol
tissu
might
import
pathogenesi
necrot
fascitii
probabl
facilit
rapid
spread
bacteria
within
tissu
inhibit
candida
growth
biofilm
format
polyurethan
fluconazol
adsorpt
g
donelli
francolini
v
ruggeri
e
guaglianon
piozzi
rome
object
recent
attempt
prevent
devicerel
infect
includ
sever
strategi
among
cathet
coat
antibiot
result
one
promis
howev
far
sporad
studi
design
prevent
fungal
colon
devic
presum
recent
describ
abil
candida
speci
form
biofilm
studi
report
vitro
experi
efficaci
coat
newli
synthes
polyurethan
antifung
drug
fluconazol
prevent
polym
colon
biofilm
format
candida
albican
method
polym
use
studi
three
synthes
urethan
polym
differ
function
group
sidechain
hydroxyl
group
primari
amino
group
tertiari
amino
group
fluconazol
adsorb
round
shape
disk
made
describ
polyurethan
kinet
fluconazol
releas
polym
either
contain
albumin
pore
form
agent
studi
keep
fluconazoleload
polymer
disk
water
increas
time
day
antifung
activ
polym
studi
kirbybau
test
scan
electron
microscopi
result
among
test
polym
hydrophil
one
abl
adsorb
higher
drug
amount
establish
hydrogen
bond
van
der
waal
interact
kinet
fluconazol
releas
polym
influenc
degre
polym
swell
water
result
significantli
improv
albumin
incorpor
polyurethan
increas
polym
poros
best
experiment
vitro
model
consist
hydrophil
polymer
disk
averag
weight
mg
impregn
mg
albumin
mg
fluconazol
candida
albican
growth
inhibit
evidenc
kirbybau
test
biofilm
format
polymer
surfac
observ
day
evidenc
scan
electron
microscopi
conclus
overal
data
obtain
newli
synthes
function
polyurethan
treat
albumin
load
fluconazol
seem
promis
perspect
develop
medic
devic
refractori
candida
colon
vitro
activ
caspofungin
candida
candidiasi
associ
format
biofilm
bioprosthet
surfac
intrins
resist
candida
albican
biofilm
commonli
use
antifung
agent
demonstr
object
studi
report
antifung
activ
two
concentr
caspofungin
c
albican
c
parapsilosi
biofilm
differ
age
matur
method
fifteen
strain
c
albican
ten
strain
suscept
fluconazol
vitro
five
strain
resist
antifung
agent
six
strain
c
parapsilosi
suscept
fluconazol
vitro
studi
antifung
activ
caspofungin
assess
look
signific
inhibit
metabol
activ
yeast
includ
biofilm
antifung
treatment
biofilm
obtain
vitro
silicon
cathet
result
caspofungin
use
mic
modifi
metabol
activ
yeast
whatev
candida
speci
matur
age
biofilm
use
therapeut
concentr
caspofungin
mgl
induc
signific
decreas
metabol
test
strain
c
albican
c
parapsilosi
independ
matur
age
biofilm
high
antifung
potenc
caspofungin
c
albican
biofilm
observ
independ
suscept
yeast
fluconazol
conclus
studi
demonstr
caspofungin
use
mic
effici
reduc
candida
biofilm
suggest
caspofungin
use
mgl
could
repres
good
candid
prevent
candidiasi
associ
silicon
medic
devic
result
also
suggest
fluconazol
resist
yeast
modifi
caspofungin
activ
effect
shorttim
desicc
biofilmassoci
bacteria
turetgen
ei
sungur
cotuk
istanbul
tr
object
microorgan
tend
form
biofilm
consist
cell
embed
highli
hydrat
extracellular
polymer
matrix
biofilm
may
respons
wide
varieti
nosocomi
infect
sourc
biofilmrel
infect
includ
surfac
cathet
medic
implant
dental
unit
water
line
type
devic
well
cool
tower
shower
head
biofilm
protect
inhabit
antimicrobi
agent
ph
alter
confer
protect
desicc
possibl
encount
desicc
natur
manmad
environ
evapor
flowingoff
system
shutdown
howev
biofilmassoci
bacteria
surviv
absenc
water
within
system
studi
surviv
heterotroph
bacteria
sulphat
reduc
bacteria
srb
amoeba
evalu
short
time
desicc
method
biofilm
allow
grow
day
stainless
steel
coupon
desicc
experi
coupon
taken
reactor
left
airdri
desicc
cell
rehydr
ml
steril
phosphat
buffer
hour
biofilm
remov
coupon
enumer
heterotroph
bacteri
count
sampl
plate
agar
day
postgat
medium
b
use
srb
cultur
amoeba
isol
biofilm
homogen
spread
nonnutri
agar
plate
overlaid
eschericha
coli
result
h
desicc
old
biofilm
srb
growth
seen
heterotroph
bacteri
growth
observ
wherea
old
biofilm
heterotroph
bacteri
growth
observ
h
howev
srb
growth
seen
h
signific
differ
found
zero
time
h
count
regard
heterotroph
bacteria
discuss
heterotroph
bacteria
locat
biofilmwat
interfac
wherea
anaerob
bacteria
nich
deeper
layer
biofilm
abil
pathogen
bacteria
surviv
within
cyst
amoeba
suggest
possibl
mechan
organ
evad
disinfect
spread
colon
new
environ
bacteri
resist
desicc
report
frequent
maxim
toler
microorgan
airdri
state
still
unknown
studi
show
diurnal
absenc
water
could
affect
biofilmassoci
microorgan
significantli
effect
food
preserv
oral
streptococci
biofilm
gener
biofilm
reactor
object
aim
laboratori
studi
evalu
influenc
preserv
sodium
benzoat
potassium
sorbat
sodium
nitrit
mix
speci
biofilm
gener
oral
streptococci
method
modifi
biofilm
reactor
bio
surfac
technolog
corp
bozeman
usa
use
build
biofilm
bovin
enamel
slab
be
mixtur
six
oral
streptococci
mutan
miti
orali
sangui
salivariu
sobrinu
investig
gener
biofilm
period
four
dayseight
slab
adher
biofilm
treat
one
follow
solut
one
minut
salin
neg
control
b
chlorhexidin
diglucon
chx
posit
control
c
sodium
benzoat
sb
potassium
sorbat
ps
e
sodium
nitrit
sn
treatment
four
slab
wash
salin
vitaldead
stain
conduct
adher
biofilm
slab
analys
situ
biofilm
thick
vital
use
confoc
laser
scan
microscopi
clsm
four
slab
biofilm
dispers
salin
coloni
form
unit
cfu
columbia
blood
agar
well
total
bacteri
count
use
dapistain
determin
result
biofilm
thick
differ
test
be
lm
averag
vital
neg
control
determin
posit
control
sodium
benzoat
potassium
sorbat
vital
measur
respect
treatment
sodium
nitrit
led
vital
mean
log
cfu
untreat
biofilm
determin
biofilm
treat
chx
treatment
sb
ps
mean
log
cfu
respect
biofilm
treat
sn
mean
log
cfu
determin
plate
effici
determin
follow
chronic
infect
caus
biofilmform
staphylococci
repres
seriou
medic
problem
higher
preval
nowaday
associ
frequent
use
artifici
implant
medic
devic
surfac
implant
facilit
adhes
bacteria
form
biofilm
knowledg
biofilm
format
dynam
fundament
understand
process
run
biofilm
layer
aim
studi
determin
mathemat
model
differ
biofilm
format
differ
condit
determin
minimum
time
condit
necessari
develop
homogen
matur
biofilm
layer
suitabl
antibiot
test
staphylococcu
epidermidi
biofilmposit
strain
use
studi
posit
control
strain
ccm
use
biofilm
grown
tissu
cultur
microtit
plate
strain
cultiv
differ
concentr
glucos
differ
temperatur
strain
cultiv
simultan
well
first
hr
data
collect
everi
hour
hr
everi
hr
cultiv
well
microtit
plate
stain
crystal
violet
biofilm
format
assess
spectrophotometr
data
process
multipl
analysi
covari
mancova
mathemat
model
evalu
regress
analysi
imag
analysi
visualis
biofilm
differ
stage
format
specif
dye
alcian
blue
acridin
orang
rylux
etc
also
use
test
strain
show
better
growth
biofilm
temperatur
nutrientrich
environ
model
simpli
describ
follow
first
sign
bacteri
adhes
visibl
hr
cultiv
first
homogen
thin
layer
visibl
hr
hr
biofilm
layer
cca
thicker
hr
biofilm
layer
seem
matureth
chang
thick
evid
time
cultiv
longer
hr
part
biofilm
layer
start
detach
biofilm
becam
unhomogen
regress
model
nutrient
temperatur
condit
show
also
differ
influenc
format
biofilm
antibiot
test
biofilm
cultiv
hr
suffici
object
biliari
stent
common
treatment
palliat
malign
obstruct
jaundic
howev
stent
occlus
due
sludg
adhes
remain
import
clinic
problem
understand
mechan
occlus
present
work
dealt
studi
bacteriolog
characterist
bile
sampl
method
taken
patient
extra
hepat
cholestasi
biliari
decompress
also
bile
sampl
sludg
materi
patient
present
recurr
jaundic
due
late
stent
blockag
process
microbiolog
transmiss
electron
microscop
studi
tem
bacteriolog
analysi
includ
isol
identif
variou
bacteri
speci
well
detect
bglucouronidas
sever
esteras
activ
isol
speci
result
bacteriolog
analysi
disclos
wider
preval
monomicrobi
gram
neg
isol
gram
posit
isol
among
patient
tem
examin
sludg
materi
reveal
presenc
cluster
gram
neg
bacteria
embed
amorph
matrix
visual
microcoloni
bacteri
growth
confin
morophotyp
case
bacteriolog
analysi
confirm
tem
result
show
frequent
isol
speci
escherichia
coli
ecoli
samonella
arizona
arizona
klebsiella
speci
enteroboct
although
arizona
isol
blockag
stent
abund
produc
elabor
enzym
yet
record
longest
patenc
durat
among
block
tudi
stent
tem
notic
biofilm
matrix
chang
accord
type
bacteria
detect
biofilm
matrix
arizona
case
shown
fenestr
look
thick
etectron
dens
compar
matrix
e
coli
case
latter
show
clealr
thin
matrix
electron
lucent
detect
fibr
mostli
thin
conclus
present
work
confirm
pivot
role
gram
neg
bacteria
stent
blockag
therefor
antibiot
gram
neg
bacteria
mandatori
hour
endoscop
retrogad
cholangiopancreatographi
ercp
also
current
studi
highlight
relat
type
microorgan
morpholog
form
biofilm
matrix
may
import
underli
factor
stent
blockag
durat
patenc
lethal
biofilm
format
biliari
stent
h
krogh
johansen
n
copenhagen
dk
object
medic
implant
wide
use
varieti
clinic
treatment
frequent
becom
colonis
opportunist
bacteria
form
biofilm
devic
surfac
describ
medic
problem
old
alcohol
man
biliari
stent
insert
intraand
extrahepat
bile
stasi
probabl
caus
cystic
process
pancreat
head
block
flow
method
cm
long
teflon
coat
polyurethan
biliari
stent
insert
endoscop
common
bile
duct
antibiot
prophylaxi
treatment
use
patient
discharg
healthi
condit
day
result
two
week
insert
biliari
stent
patient
readmit
sepsi
sever
abdomin
pain
increas
liver
enzym
ultrasound
scan
reveal
intrahepat
bile
stasi
larg
inflam
abscess
pancreat
head
fistula
abscess
common
bile
duct
blockag
lumen
stent
stent
replac
two
cm
long
stent
patient
treat
ampicillin
metronidazol
gentamicin
day
ampicillin
suscept
e
coli
cultur
blood
day
patient
discharg
healthi
condit
three
week
second
stent
insert
patient
admit
emerg
septic
shock
treat
ceftriaxon
netilmicin
metronidazol
hour
intens
treatment
patient
die
e
coli
k
oxytoca
cultur
blood
pancrea
stent
pulsedfieldgelelectrophoresi
perform
e
coli
cultur
two
septic
episod
pattern
indic
bacteria
escap
brief
antibiot
treatment
probabl
biofilm
format
conclus
case
underlin
need
antibiot
prophylaxi
bile
stent
insert
infect
area
continu
antibiot
therapi
patient
medic
implant
experi
septic
episod
clinic
microbiolog
infect
volum
supplement
